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Abstract 
Osteolysis, and subsequent aseptic loosening, is the leading cause of 
revision in total hip replacements. The biological response to ultra-high 
molecular weight polyethylene (UHMWPE) wear debris is known to trigger 
the release of several inflammatory mediators such as tumour necrosis 
factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 
(IL-8), leukotriene B4 (LTB4) and prostaglandin E2 (PGE2); all of which are 
involved in the signalling cascade that triggers the differentiation of 
osteoclasts and begins osteolysis. UHMWPE has undergone modifications 
such as cross-linking (to reduce the volume of wear debris produced) and 
antioxidant doping (to neutralise free radicals produced by irradiative 
crosslinking and prevent oxidative embrittlement). Previous studies at the 
University of Leeds, using peripheral blood mononuclear cells (PBMNCs) 
cultured on wear particle containing agarose gel, have shown that 
antioxidant doped, highly cross-linked UHMWPE may reduce the production 
of osteolytic cytokines in comparison to highly cross-linked UHMWPE. This 
model has limitations; namely donor heterogeneity associated with the use 
of PBMNC’s in addition to the use of a 2D model for what is a 3D in vivo 
environment. The aims of this study were to develop a novel 3D model in 
which mononuclear phagocytes and wear particles were encapsulated within 
a gel and to use the model to compare the cellular production of osteolytic 
cytokines when treated with highly cross-linked UHMWPE and antioxidant 
doped, highly cross-linked UHMWPE wear debris.  
Three different cell types (PBMNC’s, U937 human histiocytes and RAW 
264.7 murine macrophages) and two gel types (agarose and type I rat tail 
collagen) were investigated during the development of the 3D model. It was 
found that the use of RAW 264.7 murine macrophages and UHMWPE wear 
debris simultaneously trapped inside a collagen gel matrix was the most 
promising model. A large volume of sterile highly cross-linked UHMWPE 
wear debris (with and without antioxidant doping) was generated using pin-
on-plate (POP) multidirectional wear simulator rigs for use in the 3D model. 
RAW 264.7 murine macrophages were cultured with both unfractionated 
UHMWPE wear debris, or a filtered, critical size range (0.1 – 1 µm) of 
UHMWPE wear debris. RAW 264.7 murine macrophages cultured in the 3D 
model with unfractionated UHMWPE wear debris showed no difference in 
oxidative stress levels or TNF-α, IL-1β, IL-6, KC (CXCL-1 – a murine 
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homologue of IL-8), LTB4 and PGE2 levels produced in response to highly 
cross-linked UHMWPE wear debris with and without antioxidant doping 
compared to the cells only controls. Similarly, RAW 264.7 murine 
macrophages cultured in the 3D model with a critical size range (0.1 – 1 µm) 
of UHMWPE wear debris showed no difference in oxidative stress levels or 
TNF-α, IL-1β,  IL-6, KC, LTB4 and PGE2 levels when treated with highly 
cross-linked UHMWPE wear debris with and without antioxidant doping 
compared to the cells only controls. RAW 264.7 murine macrophages were 
also stimulated with LPS in the 3D model and then treated with Protein 
Kinase C (PKC) inhibitors (Calphostin C and Bisindolylmaleimide I), 5-
lipoxygenase (5-LO) inhibitors (MK 886 and REV 5901), Cycloxygenase 
(COX) inhibitor (Indomethacin) and antioxidants (α –tocopherol and 
pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)) after 
three hours. RAW 264.7 murine macrophages treated with both PKC 
inhibitors and both antioxidants showed reduced levels of TNF-α and IL-6 
when compared to the LPS only control. All inhibitors and antioxidants 
reduced the production of IL-1β when compared to the LPS only control. 
Cells treated with Calphostin C exhibited a reduced production of LTB4 and 
PGE2 when compared to the LPS only control. 
Microscopy images of RAW 264.7 murine macrophages cultured in the 
novel 3D model incubated with 0.1 – 1 µm antioxidant doped, highly cross-
linked UHMWPE wear debris and FluoSpheres® showed that the RAW 
264.7 murine macrophages sequestered the UHMWPE wear debris in the 
perinuclear lysosomes, indicating attempted phagocytosis, which is 
consistent with the previous studies.  
Overall, the RAW 264.7 murine macrophages cultured in the novel 3D 
model largely failed to produce inflammatory and osteolytic cytokines, 
chemokines and mediators in response to the UHMWPE wear debris 
generated in this study. However the novel model showed some promise by 
demonstrating the link between vitamin E and PKC in reducing the 
production of inflammatory and osteolytic mediators as shown in previous 
studies. The novel culture model requires further work to produce a more 
accurate in vitro representation of the 3D periprosthetic environment for use 
in future studies.  
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Chapter 1 
Introduction 
1.1 Biomaterials 
Williams (1999) defines a biomaterial as a “nonviable material used in a medical 
device, intended to interact with biological systems” (Williams, 1999). Biomaterials, 
such as metals, ceramics or polymers, range extensively in their use and their 
exposure to the body, from hours to decades. It is important that a biomaterial should 
be biocompatible.  Williams (1999) defines biocompatibility as “the ability of a material 
to perform with an appropriate host response in a specific application” (Williams, 
1999). The biocompatibility of individual biomaterials varies according to their 
application but general qualities include: resistance to thrombogenicity, resistance to 
infection, lack of immunogenicity and lack of toxicity. The biological reactivity of the 
biomaterial varies depending on the application; for example, a hydroxyapatite coated 
femoral stem would be expected to interact with the surrounding femoral bone to 
encourage bone growth in order to fix the stem in place whereas a pacemaker would 
be expected to remain inert and have no chemical or biological reactivity. A lack of 
adverse biological reactivity is the general expectation of all biomaterials. Examples of 
the applications of biomaterials include: stents, dental implants, vascular grafts, breast 
implants and joint replacement prostheses.   
1.2  Joint replacements 
Synovial joints, such as the hip and knee, may become damaged, e.g. the 
development of osteophytes, micro-fractures and loss of cartilage (Man and 
Mologhianu, 2014), and lose function with age or disease. The pain from such 
damage can be managed with analgesics and physiotherapy however, ultimately, in 
order to restore function to a joint damaged beyond repair; the joint must be replaced 
with a biomaterial implant. Joint replacement surgery removes the damaged joint and 
replaces it with a synthetic biomaterial implant made from either metal, polymer or 
ceramic materials or a combination of these. The purpose of a joint replacement is to 
replace the damaged or missing bone and cartilage tissue with synthetic biomaterial 
alternatives and thus restore function to the joint. A joint implant must have the 
following qualities: biocompatibility (as defined above, Section 1.1), full joint 
functionality and no rapid degradation (low friction, low wear). In terms of biological 
reactivity, joint replacements must remain inert whilst in place unless using 
hydroxyapatite coated stems, which are used to encourage bone growth onto the 
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stem in place of cementation. According to the National Joint Registry (NJR), a total of 
232,241 joint replacement surgeries were carried out both privately and on the 
National Health Service (NHS) during 2017 (Table 1.1) (National Joint Registry, 2017). 
There are a number of different types of total joint replacements which include: hip, 
knee, ankle, elbow and shoulder. The most common types of total joint replacements 
are the hip and knee with 107,506 and 125,188 surgeries completed respectively in 
2017 (Table 1.1) (National Joint Registry, 2017).  
Table 1.1  The number of joint replacement surgeries performed both privately and on 
the NHS in 2017; according to the NJR (National Joint Registry, 2017).  
Joint NHS Independent 
Hip 68,162 39,344 
Knee 70,690 44,498 
Ankle 743 171 
Elbow 805 44 
Shoulder 6187 1597 
Total 146,587 85,654 
 
1.3  Hip replacements 
1.3.1  Hip anatomy 
The hip is a ball and socket synovial joint, which connects the lower limbs to the torso, 
supports the weight of the upper body whilst moving or stationary, has a role in 
posture and allows several types of movement: flexion, extension, adduction, 
abduction, internal and external rotation (Traina, De Fine and Affatato, 2012). The hip 
joint (Figure 1.1A) is composed of a rounded femoral head at the femoral epiphysis 
(Figure 1.1B) which sits in the acetabular cup, a socket formed by the convergence of 
the ilium, ischium and pubis bones of the pelvis (Figure 1.1C). The femoral head is 
covered in hyaline cartilage except for the fovea and the acetabular cup is lined with a 
rim of fibrocartilage known as the labrum. Cartilage, connective tissue consisting of 
chondrocytes which secrete extracellular matrix components such as collagen and 
proteoglycans, undergoes compression upon loading (Anderson and Johnstone, 
2017) and prevents bone interfaces meeting directly thereby reducing friction. The 
proteoglycans contained within the cartilage can attract and bind water molecules 
which confers compressibility on the cartilage tissue. Additionally, the interface 
between the femoral head and the acetabular cup contains the synovial bursae, the 
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synovial membrane filled with synovial fluid, which lubricates the joint; allowing 
movement and preventing friction  (Molini et al., 2011). The whole hip joint is itself 
surrounded by a fibrous membrane, the capsule, which protects the joint. The 
intracapsular ligaments, which reinforce the hip joint, are attached to and form part of 
this protective capsule: these consist of the iliofemoral, ischiofemoral and pubofemoral 
ligaments (Molini et al., 2011). Additionally, the ligamentum teres physically joins the 
femoral head and acetabular cup together (Navarro-Zarza et al., 2012). 
 
 
A) 
 
B) 
 
C) 
 
D) 
Figure 1.1  Anatomical diagrams of the hip joint adapted from Grays Anatomy: A) 
depicts the hip joint as found in vivo with the femoral head encased in the 
acetabular cup and capsule (composed of the iliofemoral and pubocapsular 
ligament) anterior view, B) depicts the hip joint as found in vivo with the femoral 
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head encased in the acetabular cup and capsule (composed of the ischiofemoral 
ligament) posterior view, C) depicts the femoral epiphysis and D) depicts the 
pelvis showing the convergence of the ilium, ischium and pubis bones to form the 
acetabulum (Gray, 2019a, 2019b, 2014a, 2014b).  
1.3.2  Diseases and injuries of the hip 
There are a multitude of conditions (Table 1.2) that can lead to the need to replace the 
hip joint with an artificial implant. Many are the result of age and deterioration over 
time. It should be noted that 88% of all hip replacements performed in 2016 were as a 
result of osteoarthritis (National Joint Registry, 2017). However, there are also some 
conditions that can affect patients of any age. Severe damage of the hip is debilitating 
and extremely painful for patients of any age. Initially, conditions may be managed 
with a variety of analgesics, such as paracetamol, and non-steroidal anti-inflammatory 
drugs (NSAIDs), such as ibuprofen and naproxen, alongside physiotherapy (Zhang et 
al., 2016). Additionally, corticosteroids, such as hydrocortisone, may be injected into 
the joint to reduce inflammation and relieve pain (Zhang et al., 2016). However, once 
these treatments begin to fail and pain levels increase, mobility decreases and the 
condition begins to severely impact upon the patient’s quality of life, the patient may 
undergo hip replacement surgery, whereupon the affected joint is replaced with a 
synthetic biomaterial implant that mimics the mechanical activity and natural 
morphology of the joint.  
Table 1.2  NJR data for 2016 indicating the reasons for hip replacement surgery and 
the percentage of patients associated with each (National Joint Registry, 2017).  
Reason for surgery % of total patients 
Osteoarthritis 88 
Femoral neck fracture 8 
Avascular necrosis 2 
Hip dysplasia/congenital dislocation 1 
Inflammatory arthropathy 1 
Chronic trauma 1 
Metastatic cancer/malignancy 1 
Previous surgery (non-trauma) <1 
Perthes disease <1 
Slipped Upper Femoral Epiphysis 
(SUFE) 
<1 
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Failed hemiarthroplasty <1 
Skeletal dysplasia <1 
Previous infection <1 
Previous arthrodesis <1 
Other 1 
Total (%) 100 
1.3.3  Types of hip replacement 
There are three types of hip replacement surgery that may be performed: hip 
resurfacing, hemi-arthroplasty and total hip replacement (THR). THR replaces both 
bearing surfaces with biomaterial implants, i.e. both the femoral head and the 
acetabular cup, whereas the hemi-arthroplasty only replaces one bearing surface and 
a hip resurfacing replaces the acetabular cup and caps the femoral head rather than 
replacing it fully.  
THR is carried out by first dislocating the hip in order to remove the femoral head and 
neck. The acetabulum is then reamed to remove any osteophytes present, and (if 
using a cemented cup) the subchondral plate. The acetabulum is then lined with a 
synthetic biomaterial cup, often an insert within a cup, which may or may not be 
cemented into place. The medullary canal of the femur is opened up and a synthetic 
biomaterial femoral stem is implanted down the centre; either cemented or fixed 
biologically. The synthetic biomaterial femoral head is then attached to the stem (Petis 
et al., 2015). 
For a THR, there are four different types of fixation: cemented, uncemented, hybrid 
and reverse hybrid. A cemented THR consists of both a cup and stem cemented in 
place using polymethylmethacrylate (PMMA) whereas in an uncemented THR neither 
the cup or stem is cemented in place. Instead, they are either roughened, porous or 
coated with hydroxyapatite to promote bone growth up to and onto the implanted 
components to achieve biological integration (Tonino, Thèrin and Doyle, 1999). A 
hybrid THR consists of a cemented femoral stem coupled with an uncemented 
acetabular cup whereas a reverse hybrid THR consists of an uncemented femoral 
stem coupled with a cemented acetabular cup.  
A hip resurfacing consists of a large cap, which covers the surface of the femoral head 
and is fixed in place with cement, and a matching material cup which lines the 
acetabulum. Until recently, hip resurfacing devices were only available with metal on 
metal (MOM) bearings; typically comprised of cobalt chromium alloy. However, 
recently, ceramic on ceramic (COC) hip resurfacings have been developed and are 
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beginning to become available clinically (Khan et al., 2018). The hip resurfacing 
surgical procedure preserves bone stock, as it removes less femur to accommodate 
the cap, and was thought to be useful for patients under 60 years of age with healthy 
bone as it allowed for further revision surgeries later on. Additionally, the large femoral 
cap of the hip resurfacing reduces the likelihood of dislocation (Mont et al., 2006). 
DePuy issued a recall of their MOM resurfacings, articular surface replacement (ASR), 
in 2010 due to early failure rates and very few MOM hip resurfacings are currently 
performed (Silverman, Ashley and Sheth, 2016).  
1.3.4  Materials used in hip replacements 
A THR can consist of five possible material combinations: ceramic on ceramic (COC), 
ceramic on metal (COM), ceramic on polyethylene (COP), metal on metal (MOM) and 
metal on polyethylene (MOP) (National Joint Registry, 2017). The femoral stem is 
made from metal with a metal or ceramic head whereas the acetabular cup can be 
made from metal, ceramic or polymer. MOP is the most common combination of 
materials used and therefore the present day gold standard; representing 87.1% of all 
cemented primary THRs and 30.4% of all primary THRs (National Joint Registry, 
2017). 
1.3.4.1 Metals 
Metal alloys,  a mixture of two or more elements of which one is a metal, are typically 
used in an orthopaedic context as pure metals are usually too soft, too brittle and too 
reactive, i.e. susceptible to corrosion. Creating metallic alloys allows the desirable 
characteristics of several metals or other elements to be combined into one optimal 
material. Initially, stainless steel was used, as in the original Charnley implant 
(Charnley, 1961), however, at present, cobalt chromium is the most common metal 
alloy used in hip implants; in particular femoral stems. Other metals, such as titanium, 
aluminium and vanadium, can be also found in metal femoral stems; these metals are 
too soft for use as a bearing surface (Moretti et al., 2012). There is some debate as to 
whether wrought or cast metal alloys are better. Studies show that wrought alloys 
have increased tensile and fatigue strength, corrosion resistance and are lower 
wearing than cast alloys (Devine and Wulff, 1975; Medley et al., 1996). The carbon 
content of metal alloys used in orthopaedics can also be varied; high (>0.2%) or low 
(<0.07%). Higher carbon content increases the hardness but reduces the ductility and 
increases the brittleness of the metal (Milosev et al., 2009). As a result, metal-on-
metal THA’s have a very low wear rate; typically around 0.01 mm per year (Milosev et 
al., 2009). 
1.3.4.2 Ceramics 
Ceramics are crystalline, inorganic materials. Ceramics are typically hard and strong 
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materials however their brittleness and inability to deform leads to an increased risk of 
fracture; particularly if there are any imperfections present on the ceramic surface or 
within the bulk structure (Traina et al., 2013). Ceramics are the material closest to 
native bone in terms of their structure, high compression strength and inability to bend 
(Hannouche et al., 2005). Ceramics produce very low volumes of wear debris; for 
example, a 12 year study by Jazrawi et al. (1999) found that ceramic on ceramic 
THA’s had an average wear rate of 0.016 mm per year. There are two types of 
ceramic orthopaedic materials: alumina and zirconia. Zirconia is no longer currently 
used by itself however it is mixed with alumina to form a composite material, zirconia 
toughened alumina (ZTA) (Willmann, 1998). 
1.3.4.3 Polymers 
Polymers are the least hard material used in orthopaedic implants; they are less 
resistant to deformation than metals or ceramics. However, polymers exhibit a high 
level of toughness; they are able to absorb energy and exhibit plastic deformation 
before fracture occurs because they are viscoelastic and therefore ductile, which 
means they have the propensity to creep, i.e. deform over time due to mechanical 
stress (Bracco et al., 2017). Polymers used in an orthopaedic context are typically 
chemically inert, i.e. they do not react directly with any chemical species in the body. 
The most common type of polymer used in orthopaedic implants is ultra-high 
molecular weight polyethylene (UHMWPE) which is commonly used in the acetabular 
cup component of THR’s (Charnley, 1961; Ingham and Fisher, 2005). Metal-on-
polyethylene THA’s have a higher wear rate than MOM or COC; typically around 0.02 
mm per year (Milosev et al., 2009). 
1.3.5  Failure and revision of hip replacements 
There are a number of reasons why a hip replacement may fail (Table 1.4) and it is 
often a combination of these that leads to eventual revision surgery. The revision rates 
for all types of hip replacement gradually increases over time post-implantation (Table 
1.3).  
Table 1.3  Revision rates of primary hip replacements up to 13 years post-
implantation (National Joint Registry, 2017).  
Year(s) post-implantation of primary Revision rate (%) 
1 0.78 
  3 1.56 
5 2.41 
7 3.47 
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10 5.21 
11 5.47 
13 6.83 
 
In the UK, there were 97, 341 revision surgeries performed between 2003 and 2016 
(National Joint Registry, 2017). The most common reason for revision surgery was 
aseptic loosening which accounted for 50.1% of all revision surgeries between 2003 
and 2016 (Table 1.4) (National Joint Registry, 2017). Dislocation/subluxation and pain 
tended to be the causes for early revisions whereas aseptic loosening tended to be 
responsible for revisions performed later (National Joint Registry, 2017). The risk of 
further revision surgeries once a revision has been performed is increased compared 
to revision rates for primary replacements (Table 1.5) (National Joint Registry, 2017). 
Table 1.4  Reasons for primary hip revisions between 2003 and 2016 according to the 
National Joint Registry 14th Annual Report. Note that the percentages do not add 
up to 100% as revisions are often multifactorial and the reasons for them not 
mutually exclusive (National Joint Registry, 2017).  
Reason for revision Percentage of 
revisions (%) 
Aseptic loosening 50.1 
Pain 20.5 
Lysis 15.4 
Dislocation/subluxation 15.2 
Implant wear 14.1 
Periprosthetic fracture 10.1 
Other indication 7.6 
Malalignment 5.6 
Implant fracture 3.6 
Infection 3.5 
Head-socket (size) mismatch 0.8 
Adverse reaction to particulate 
debris 
11.0 
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Table 1.5  Post-implantation re-revision rates following first revision hip replacement 
(National Joint Registry, 2017). 
Year(s) post-implantation of revision Re-revision rate (%) 
1 4.95 
3 8.98 
5 11.74 
 
1.4 Inflammation, osteolysis and aseptic loosening 
Any biomaterial, such as a THR, is perceived by the body as a threat and elicits a 
foreign body response whereupon the immune system attempts to eject or neutralise 
the foreign matter. This process can cause problems for the biocompatibility of joint 
replacements and can lead to their failure.  
The body can respond to a foreign body in two ways: the innate and adaptive immune 
responses. The innate immune response is non-specific but is able to respond 
immediately whereas the adaptive response is specific to the foreign body 
encountered but occurs after several days. A foreign body is defined as any material, 
biological or synthetic, that is non-self; for example, bacteria, viruses and fungi as well 
as medical implants and scaffolds. The response to the joint replacement is also size 
dependent: the response to the bulk implant and large wear debris (>10 µm) differs 
from the response to smaller wear debris (0.1 – 10 µm) and ions. 
1.4.1 Innate immune response: inflammation  
The innate immune system responds to a THR by initiating inflammation which 
proceeds in four stages: initial events, cellular invasion, tissue remodelling and 
resolution.  
Initial events 
When the THR is implanted, the surgery breaches the skin and mucosal epithelia and 
triggers inflammation. Initially platelets and the complement system are activated 
which initiated vasodilation. The products of the complement system (complement 
proteins such as C5a) attract neutrophils and mononuclear phagocytes to the implant 
site.  The mononuclear phagocytes secrete pro-inflammatory cytokines, such Tumour 
Necrosis Factor – Alpha (TNF-α), Interleukin-1β (IL-1β) and Interleukin-6 (IL-6), and 
chemokines, such as Interleukin-8 (IL-8) (Nich, Goodman and Hospital, 2014). 
Chemokines attract more leukocytes to the implant site whereas cytokines stimulate 
vasodilation during cellular invasion and activate leukocytes (Janeway et al., 2001).  
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Cellular invasion 
The permeability of the local blood vessel walls increases, which allows the 
extravasation of leukocytes, such as monocytes and neutrophils, and plasma, 
containing complement proteins, from the blood to the periprosthetic tissue. A 
decreased blood flow rate and the upregulation of adhesion molecules, such as 
Lymphocyte Function-associated Antigen 1 (LFA-1), allows the transient adhesion of 
leukocytes to the blood vessel walls. Extravasation and diapedesis then occur – this is 
where the leukocytes move from the blood vessels into the affected tissue. 
Complement proteins, proteins complementary to phagocytes that are carried in the 
plasma, coat the foreign material in a process called opsonisation and mark it for 
destruction by phagocytosis (Janeway et al., 2001). Phagocytes recognise the 
opsonised foreign material as non-self and attempt to phagocytose it. Additionally, in 
order to aid the destruction of the foreign body, neutrophils undergo a process called 
oxidative burst; the release of highly reactive oxygen species to aid chemical 
destruction.  
However, THR’s are non-biodegradable and cannot be destroyed by phagocytosis. 
This results in the continuous activation of macrophages as they continue to release 
cytokines to recruit further leukocytes to the implant site. The macrophages become 
frustrated as they are unable to phagocytose the implant and fuse together to form 
foreign body giant cells; multi-nucleated cells with large vacuoles. The foreign body 
giant cells coalesce together to form granulomatous tissue which encapsulates the 
THR from the rest of the body (Anderson, Rodriguez and Chang, 2008). Necrosis of 
the local tissue may occur when macrophages adhere to the implant and destroy the 
tissue surrounding it. Additionally, necrobiosis can occur if macrophages become 
epitheloids which secrete enzymes to destroy the surrounding extracellular matrix 
(Craig et al., 2017).  
Tissue remodelling 
The body attempts to heal the implant site by remodelling the tissue. Cytokines 
produced by macrophages attract mesenchymal and endothelial cells to the implant 
site. Endothelial cells revascularise the implant site which allows the infiltration of 
other cell types to the affected area. The extracellular matrix is reformed by collagen 
and proteoglycans produced by the mesenchymal cells. Granulation tissue, i.e. fibrous 
connective tissue, then forms to encapsulate the implant which is later replaced by 
scar tissue during fibroplasia (Anderson, Rodriguez and Chang, 2008).  The scar 
tissue exhibits abnormal biomechanical and biological properties (i.e. it is stiffer and 
less elastic) and possesses a disordered matrix.  
Resolution 
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Finally, the body attempts to extrude, resorb, integrate or encapsulate the material to 
return to its normal state. Extrusion and resorption are not possible for a THR as 
implantation is too deep and the implant is not biodegradable respectively. Some 
integration is possible with hydroxyapatite coated titanium alloy femoral stems 
(Tonino, Thèrin and Doyle, 1999) which allows bone to grow up to and onto the 
implant to biologically fix it in place. Encapsulation is the usual resolution for THR’s. 
The body compromises and tolerates the presence of the implant by “walling” the 
implant off from the rest of the body with fibrotic scar tissue which increases in 
thickness over time (Ingham and Fisher, 2000). 
1.4.2 Adaptive immune response 
The adaptive immune system requires several days in order to respond specifically to 
the foreign body. For pathogens, once the macrophage has phagocytosed the 
pathogen, it presents the foreign antigens on its surface and migrates to the lymph 
node. Here, the now antigen-presenting cell attaches the foreign antigen to the major 
histocompatibility complex (MHC) II and presents them to the T-cell receptors 
(Janeway et al., 2001). This presentation stimulates the clonal expansion of T-helper 
cells with foreign antigen specific receptors and T-helper cells release cytokines, 
which stimulate the production of antibodies against the foreign antigen by B cells 
(Janeway et al., 2001). Antibodies allow the specific targeting of the foreign material 
by their specific antigens and label them for destruction by phagocytosis. A small 
number of memory B cells remain that are primed to produce the necessary antibody 
to the foreign antigen, allowing a more rapid and effective response upon reinfection 
(Janeway et al., 2001). As an implant expresses no antigens, it is unaffected by the 
adaptive immune response except in cases where metal THR’s induce an allergic 
response. 
1.4.3 Allergic Response 
Nickel (Ni) and chromium (Cr) ions from metal THR components may induce a type IV 
hypersensitivity reaction (Granchi et al., 2012) through interaction with peptides in the 
body to form antigens. These antigens form a complex with MHC II and the adaptive 
immune response proceeds, producing antibodies against the metal ions. Targeted 
cells are destroyed by CD4+ T cells and continued macrophage activation forms 
foreign body giant cells and granulomatous tissue which can result in the formation of 
pseudotumours (Bergschmidt, Bader and Mittelmeier, 2012).    
1.4.4 Biological response to wear particles and ions  
In addition to the body responding to the bulk implant, the body will also produce an 
immune response to the wear particles shed by the implant. The biological response 
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to wear debris varies based on the type of material the wear debris is composed of 
and the size of the wear particles. 
1.4.4.1 Metals 
Metal THR’s generate wear debris but are also susceptible to galvanic corrosion 
(Tipper et al., 2005). Different metals establish an electrochemical potential difference; 
rapidly corroding the more reactive metal, which sheds metal ions into the surrounding 
tissue. Wear debris may be generated when a metal-on-metal contact point occurs, 
which results in rapid wear if there is a size mismatch between components or the 
angle between components is sub-optimal. Metal wear particles can also release 
further metal ions into the surrounding tissue (Brown, Fisher and Ingham, 2006). Metal 
wear particles are typically below 100 nm and so do not typically induce inflammation 
or osteolysis, both of which are size-dependent, but their size allows them to be taken 
up passively by surrounding cells via endocytosis and pinocytosis (Brown, Fisher and 
Ingham, 2006). Cobalt chromium alloys are the most common metal used in THR’s 
and release both cobalt (Co) and chromium (Cr) ions. Although necessary for cellular 
function, cobalt ions at high concentrations (328.5 parts per billion in patient blood 
levels) become cytotoxic; they cause swelling and oxidative stress in the mitochondria 
and abnormal changes in the nuclear envelope (Goode et al., 2012). Additionally, at 
high concentrations, both cobalt and chromium (136 parts per billion in patient blood 
levels) ions are genotoxic and can cause DNA damage (Brown, Fisher and Ingham, 
2006). DNA damage can generate mutagenic cells and may lead to cancer if the 
mutagenic cells are not apoptosed; mitochondrial oxidative stress impacts apoptosis. 
Metal wear particles may also lead to the formation of pseudotumours; an inflamed 
tissue mass, consisting of local soft tissue necrosis, granulomatous tissue and the 
presence of macrophages and lymphocytes, surrounding the implant (Pandit et al., 
2008a). There is significant patient variation in the pseudotumour symptoms 
experienced; some may go unnoticed and be detected only through routine imaging or 
some may cause high levels of damage and pain, resulting in a revision of the THR 
(Pandit et al, 2008b). Pseudotumour formation may be related to metal 
hypersensitivity (Granchi et al., 2006).  
1.4.4.2 Ceramics 
Ceramic THR’s have lower wear rates and produce lower volumes of wear debris than 
metal or polymer THR’s (Dorlot, Christel and Meunier, 1989). Ceramic wear debris 
appears to be well tolerated by the body (Niche et al., 2003). Ceramic wear debris has 
been shown to be less cytotoxic (Germain et al., 2003), is less likely to stimulate the 
production of osteolytic cytokines (Catelas et al., 1999) and induce less inflammation 
in the periprosthetic tissue (Nizard et al., 1992).  
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1.4.4.3 Polymers 
UHMWPE wear particles vary greatly in size; from several millimetres to nanometres. 
Large particles, >10 µm, are walled off by foreign body giant cells and granulomatous 
tissue (Ingham and Fisher, 2000). The majority of UHMWPE wear debris was 
previously found to be between 0.1 – 10 µm, which is within the phagocytosable size 
range, and able to be engulfed by the local macrophages (Green et al., 1998; 
Matthews et al., 2001). However, a more recent study by Richards et al. (2008), 
analysing tissue samples from seven failed Charnley hip prostheses, have found the 
majority of UHMWPE wear debris to be between 0.1 – 0.99 µm. As UHMWPE is 
chemically inert, the macrophages are unable to digest the wear particles and 
inflammation persists. Particles between 0.1 – 1 µm activate macrophages which then 
participate in the downstream signalling cascade that results in osteolysis and aseptic 
loosening. A review by Dumbleton et al. (2002) analysed several publications 
regarding the link between UHMWPE wear rates and osteolysis and found the 
threshold necessary for osteolysis to occur is a wear rate of more than 0.1 mm per 
year. The activated macrophages continuously attempt to phagocytose the material 
and continue to produce pro-inflammatory cytokines and chemokines which result in 
an influx of further macrophages. The continued release of pro-inflammatory and 
osteolytic cytokines, such as TNF-α, IL-1β and IL-6, and other inflammatory 
mediators, such as prostaglandin E2 (PGE2), results in the activation of osteoclasts 
and stimulates osteoclasts to resorb the bone surrounding the implant, i.e. osteolysis 
(Ingham and Fisher, 2005). Osteolysis loosens the fixation between the prosthesis 
and the surrounding bone , i.e. aseptic loosening, which leads to implant failure and 
revision surgery.  
Tipper et al. (2000) carried out a retrieval study on 18 failed acetabular cups; failure 
was caused by osteolysis and aseptic loosening. This study showed that the majority 
of UHMWPE wear debris retrieved was between 0.1 – 0.5 µm and that large particles 
(>10 µm) made up the minority of the particle numbers despite representing a large 
volume of the total particles (Tipper et al., 2000). Green et al. (1998) found that 
Ceridust® particles between 0.3 and 10 µm were the most biologically active and 
stimulated the production of inflammatory cytokines, TNF-α, IL-1β and IL-6, in murine 
peritoneal macrophages. Similarly, Matthews et al. (2001) found that Ceridust® 
particles between 0.1 – 1 µm stimulated the highest production of inflammatory 
cytokines; TNF-α, IL-1β, IL-6, Granulocyte-Macrophage Colony-Stimulating Factor 
(GM-CSF) and Prostaglandin E2 (PGE2) in human peripheral blood mononuclear cells 
(Matthews, Green, et al., 2000). Additionally, higher volumes of particles to cell 
numbers (100:1 and 10:1) produced more inflammatory cytokines in PBMNC’s than 
1:1 and 0.1:1 particle volumes to cell numbers ratios (Green et al., 1998; Matthews et 
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al., 2000b). However, Liu et al. (2015) found that nanometre sized UHMWPE 
particles, unlike micrometre sized UHMWPE particles, did not induce significantly 
elevated inflammatory and osteolytic cytokines and chemokines (TNF-α, IL-1β, IL-6 
and IL-8) in PBMNC’s after 12 and 24 hours.  
Bone remodelling  
Bone remodelling is a normal process in the body; occurring constantly. Bone 
remodelling is a two stage process: firstly, old bone is resorbed by osteoclasts and 
secondly, new bone is formed by osteoblasts. This process is mediated by osteocytes 
which release hormones into the bone microenvironment and detect strain. Bone 
remodelling also controls the calcium serum levels in the body. Bone remodelling can 
be affected by how the skeleton is loaded; increased loading leads to increased bone 
formation and decreased loading leads to increased bone resorption (Proff and 
Römer, 2009). Additionally, factors such as age, gender and disease can affect the 
balance of bone formation versus resorption. A common example of this is 
osteoporosis as described in Section 1.3.2.1.  
Osteoclastogenesis 
Osteoclasts are derived from myelopoietic progenitor cells, which are originally 
derived from haematopoietic stem cells (HSC’s), through a four stage process; 
commitment, differentiation, multinucleation and activation (Yavropoulou and Yovos, 
2008). The myelopoietic progenitor cell initially forms a granulocyte-macrophage 
colony forming unit (GM-CFU) (Menaa, Kurihara and Roodman, 2000). The first stage, 
commitment, begins with the promotion of an osteoclastic lineage via various 
transcription factors within the GM-CFU; such as PU.1 (Laslo et al.,  2006), 
Microphthalmia-associated transcription factor (MITF) and c-FOS (Miyamoto et al., 
2001). The surrounding microenvironment, consisting of osteoblasts and stromal cells, 
plays a vital role in osteoclastogenesis also. Cell-to-cell contact between the pre-
osteoclast cells and surrounding microenvironment is essential for the various 
signalling pathways involved during osteoclastogenesis. Local macrophages initially 
produce macrophage colony stimulating factor (M-CSF) which allows the 
preosteoclast cells to enter the cell cycle so they may proliferate – the production of 
M-CSF is upregulated by TNF-α and IL-1 during inflammation (Weir et al., 1996). The 
second stage, differentiation, is triggered by the production of Receptor Activator of 
Nuclear factor Kappa-B Ligand (RANKL) by bone cells, osteoblasts, osteoclasts and 
osteocytes, which is also upregulated by TNF-α and IL-1 (Wei et al., 2005), which 
binds to the Receptor Activator of Nuclear factor Kappa-B (RANK) receptor expressed 
on the surface of the pre-osteoclast. This triggers an intracellular signalling cascade 
which results in the expression of osteoclastic genes such as Cathepsin K 
(Matsumoto et al., 2004) and Tartrate-Resistant Acid Phosphotase (TRAP) (Kim et al., 
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2005). This process is regulated by osteoprotegerin (OPG) which binds to RANKL and 
inhibits the differentiation of osteoclast precursor cells (Yavropoulou and Yovos, 
2008). The third stage, multinucleation, is triggered by the binding of RANKL to the 
RANK receptor on a preosteoclast. Two RANK positive (RANK+) mononuclear cells 
fuse and the RANKL signal is transferred; propagating the signal. The now 
binucleated cell becomes the master fuser cell and fuses with another RANK+ cell; 
continuing the multinucleation process (Kim, Day and Morrison, 2005; Vignery, 2005; 
Kim and Kim, 2006). The final stage, activation, is established through the creation of 
two polarised structure within the cell membrane; the ruffled membrane and the 
sealing zone; an actin ring-like structure which isolates the bone resorption 
environment from the general extracellular space. Cell-extracellular matrix adhesion is 
facilitated by integrins, αvβ3 and RGD, which are also expressed and bind to 
osteopontin and bone sialoprotein (Teitelbaum, 2006).  
Osteolysis and aseptic loosening 
Chemokines attract the newly-formed osteoclasts which migrate to the site of bone 
resorption (Han et al., 2014). The osteoclasts then bind to the bone; the osteoclastic 
cell membrane contains integrins, αvβ3 and RGD, which can bind to osteopontin and 
sialoprotein expressed on the surface of bone. Once the bone resorption pit has been 
separated from the surrounding environment, H+ ions (Holliday et al., 2005) and 
various digestive enzymes are secreted by osteoclasts, such as Cathepsin K (a 
collagenase I enzyme) (Costa et al., 2011) and matrix metalloproteinases (Inada et 
al., 2003). The combined effect of acidifying the bone resorption pit (via H+ ions) and 
digesting the bone matrix enzymatically results in the dissolution of bone in the 
resorption pit. This process occurring around a prosthesis results in the loosening of 
the fixation of the prosthesis, i.e. aseptic loosening, and will ultimately result in the 
revision of the implant. 
1.5  Ultra-high molecular weight polyethylene 
UHMWPE was developed as a bearing material with a metal femoral head by 
Charnley in 1962. Metal on polyethylene THR’s are the present day gold standard. 
1.5.1  Chemical, mechanical and physical properties of UHMWPE 
Ultra-high molecular weight polyethylene (UHMWPE) is linear homopolymer of 
ethylene, i.e. it contains only one type of monomer repeated in a linear chain (Figure 
1.2 A and B). There are four types of polyethylene: low density polyethylene (LDPE), 
linear low density polyethylene (LLDPE), high density polyethylene (HDPE) and 
UHMWPE. UHMWPE differs from other types of polyethylene by its molecular weight; 
LDPE and LLDPE are typically <50,000 g.mol-1 and HDPE is typically around 200,000 
- 16 - 
g.mol-1 whereas UHMWPE ranges between 2 and 6 million g.mol-1; for example, GUR 
1020 UHMWPE has a molecular weight of around 2 million g.mol-1 and GUR 1050 
UHMWPE has a molecular weight of around 5 million g.mol-1 (Kurtz, 2004a). The 
hydrocarbon polymer chain is capable of rotating around the carbon-carbon bonds to 
form ordered crystalline sheets known as lamellae and disordered amorphous 
regions; both of which are linked by tie molecules (Figure 1.2C). The lamellae are 
typically between 10 and 50 nm thick and between 10 and 50 µm long (Kurtz et al., 
1999) with spaces of approximately 50 nm between (Bellare, Schnablegger and 
Cohen, 1995). The higher the degree of crystallinity, the greater its mechanical 
properties, i.e. creep resistance, high elasticity, higher yield strength and higher 
fatigue strength (Brach Del Prever et al., 2009).  
A)  
 
B)   
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C) 
Figure 1.2 Polymerisation of UHMWPE:A) polymerisation of monomer to form linear 
homopolymer, B) polymerisation of ethylene to form UHMWPE and C) Physical 
structure of UHMWPE showing ordered crystalline lamellae, disordered 
amorphous regions and tie molecules. 
Polymers, such as UHMWPE, behave in a temperature dependent manner and as 
such are defined by their glass transition temperature (Tg), melting temperature (Tm) 
and flow transition temperature (Tf) measured using differential scanning calorimetry 
(DSC) (Table 1.6). Tg is defined as the temperature at which the polymer become 
brittle, Tm is defined as the temperature at which most crystalline regions of the 
polymer have melted and Tf is defined as the temperature at which the polymer 
becomes liquid and flows. Because UHMWPE has a molecular weight of over 500,000 
g.mol-1, the chain entanglement prevents this and UHMWPE exhibits no flow transition 
temperature (Kurtz, 2004a). Additionally, the increased molecular weight affects the 
mechanical properties of UHMWPE. UHMWPE demonstrates increased abrasive 
wear resistance and impact strength (Table 1.6) (Kurtz, 2004a). 
Table 1.6 Table of the mechanical and chemical properties of UHMWPE (Edidin and 
Kurtz, 2000; Kurtz, 2004a) 
Mechanical and chemical properties UHMWPE 
Mw (g.mol-1) 2 -6 million 
Tg (°C) -160 
Tm (°C) 125 - 138 
Poissons ratio 0.46 
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Specific gravity 0.932 – 0.945 
Tensile modulus of elasticity (GPa) 0.8 – 1.6 
Tensile yield strength  (MPa) 21 - 28 
Tensile ultimate strength (MPa) 39 – 48 
Tensile ultimate elongation (%) 350 - 525 
Impact strength (Izod) >1070 – no break 
Degree of crystallinity (%) 39 - 75 
 
1.5.2  Manufacturing of UHMWPE  
UHMWPE is synthesised and manufacturing in a three stage process: polymerisation, 
consolidation and machining with specific details of each process being proprietary to 
each company (Kurtz, 2004b). In the first stage, ethylene gas is passed over a 
titanium tetrachloride catalyst in the presence of hydrogen gas in a reaction known as 
the Ziegler process (Birnkraut, 1991). This process was first developed at the Max-
Planck Institute and commercialised by Ruhrchemie (changed to Hoechst and now 
known as Ticona) in the 1950’s. The types of UHMWPE resin produced this way are 
designated type 1 (GUR 1020), type 2 (GUR 1050) and type 3 (1900H). Each resin 
differs by the size and morphology of its particles (Kurtz, 2004b). Each resin also 
differs, according to the standards ASTM F648 and ISO5834-1, by the mass of trace 
impurities present (types 1 and 2 contain less than type 3). Type 3 1900H UHMWPE 
is no longer produced, although stockpiling means Biomet are still machining implants 
from this resin. This material was not used in this study and will not be elaborated on 
further. Labelling type 1 and 2 resins follows a particular format. For example, GUR 
1020 is broken down as follows: G (granular) U (UHMWPE) R (Ruhrchemie) 1 (weight 
of resin) 0 (presence or absence of calcium stearate) 2 (Mw average) 0 (Hoechst 
internal code designation). Calcium stearate was an additive until the late 1990’s to 
act as a residual catalyst scavenger. (Kurtz, 2004b) 
The UHMWPE resin produced is then consolidated by one of four methods: 
compression moulding, ram extrusion, hot isostatic pressing and direct compression 
moulding. Because UHMWPE does not flow, standard thermoplastic processing 
methods, i.e. melting, are unable to be used. Consolidation works by thermally 
activating polymer chains (high temperature) and increasing the proximity of the 
polymer resin particles (high pressure) over time to allow neighbouring polymer chains 
to entangle (self diffusion). Compression moulding uses a press to create sheets, 
although these are then often turned into rods and other shapes, whereas ram 
extrusion feeds powder into a heated mantle and is then extruded by a hydraulic ram 
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to create rods. GUR 1020 is typically compression moulded whereas GUR 1050 is 
typically ram extruded although this is not always the case. Hot isostatic pressing of 
ArComTM UHMWPE involves creating a cylinder of UHMWPE using cold isostatic 
pressing following by sintering in a furnace whilst in a sealed argon pouch. Direct 
compression moulding, rather than pressing into a sheet, pressed the resin into its 
final shape, e.g. an acetabular cup, so no machining step is needed. Each 
consolidation method produces slight differences in morphology, mechanical and 
material properties but there is no consensus at present as to which method is 
superior (Kurtz, 2004b). 
The UHMWPE material is then machined, e.g. into an acetabular cup (Kurtz, 2004b). 
The material is milled and turned followed by roughing and finishing. Occasionally, the 
material is preshaped or preformed to save time on this step (Kurtz et al., 1999). 
Machining may leave macroscopic asperities on the surface of UHMWPE which 
contribute to the initial difference in surface roughness between a UHMWPE 
acetabular cup and a metal femoral head. Initial wear rates in MOP THR’s remove the 
macroscopic asperities on the UHMWPE surface whereas long term wear is controlled 
by the microscopic asperities on the metal surface  (Cooper, Dowson and Fisher, 
1993).    
1.5.3  Sterilisation and long term storage of UHMWPE 
Once the UHMWPE orthopaedic components have been manufactured and 
machined, they are then packaged and sterilised. Sterilisation is carried out in order to 
eliminate any biological contamination that could lead to infection or early implant 
failure. Initially, UHMWPE components were gamma irradiated (25 – 40 kGy) in air in 
gas permeable packaging (Isaac, Dowson and Wroblewski, 1996). This method was 
discontinued due to the oxidation degradation of the polymer during long term storage, 
caused by persistent free radicals, which result in the loss of mechanical properties of 
the polymer (Jahan et al., 1991; Premnath et al., 1996). Gamma irradiation of 
UHMWPE is now carried out in barrier packaging to block gas diffusion. The 
packaging is first evacuated of existing air and then be backfilled with an inert gas 
such as argon or nitrogen or simply placed under vacuum (with or without an oxygen 
scavenger). This minimises oxidative degradation whilst in long term storage. Some 
crosslinking of UHMWPE occurs when irradiated which may result in lower wear rates 
of components sterilised this way when compared to other methods (McKellop et al., 
1999). UHMWPE components may also be sterilised with ethylene oxide or gas 
plasma in gas permeable packaging to allow the sterilising medium contact with the 
polymer. Ethylene oxide is highly toxic and therefore effective at eliminating bacterial, 
fungal and viral contamination. Similarly, gas plasma, either peracetic acid or 
hydrogen peroxide eliminates biological contamination (Feldman and Hui, 1997). Both 
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methods work by diffusing into the surface layers of the polymer and then diffuse out 
again. Neither method binds the molecules to the surface of the polymer and so do 
not change the properties of the polymer nor have a negative effect in vivo. As with 
manufacturing methods, there is a lack of consensus as to which sterilisation method 
is superior.  
UHMWPE orthopaedic components are then stored in their packaging until implanted. 
In Europe, this shelf life has been standardised to no more than 5 years whereas in 
the USA there is no standard for the maximum shelf life (Kurtz, 2004c). 
1.5.4 Assessing the mechanical performance of UHMWPE 
1.5.4.1 Generation of wear debris 
In order to assess the mechanical performance of different UHMWPE materials, 
UHMWPE wear debris can be artificially generated using hip simulators or wear 
simulator rigs. A hip simulator is a rig that uses implant components, both the femoral 
stem head and acetabular cup, and carries out cycles of movement, based on typical 
walking gait and the kinetics and kinematics experienced within the hip joint, 
accelerated over a shorter period of time. Several years of use of an implant can be 
simulated in a matter of weeks; one million cycles is typically equivalent to one year of 
activity. This method produces clinically relevant wear debris due to anatomically 
accurate mechanics and the use of implant components (Barbour, 1999; Tipper et al., 
2006). Simpler wear simulator rigs, such as pin on plate (Lancaster et al., 1997; 
Galvin et al., 2006), pin on disc, ring on flat or crossed cylinders (Affatato et al., 2008), 
use a simplified, but still multidirectional, set up under kinematic conditions based on 
those experienced within the hip joint to produce clinically relevant wear debris. It is 
possible to use either a smooth or rough plate in the rig – a smooth plate is 
representative of the clinical in vivo situation as it mimics the surface roughness of the 
implant whereas a rough plate is artificially scratched in order to increase friction and 
therefore the amount of wear debris produced.  The wear debris produced is clinically 
relevant in both cases however the amount of biologically active wear debris produced 
i.e. between 0.1 – 10 µm in size is increased when a rough counterface is used (Endo 
et al, 2001; Ingram et al., 2004). Additionally, the pin and plate are submerged in 
lubricant. This can be a number of different things such as water or cell culture 
medium (typically RPMI 1640 cell culture medium), which can contain 25% (v/v) FBS 
and/or sodium azide. The lubricant is designed to mimic the natural synovial fluid 
present in the joint and therefore provide as close to natural a lubrication regime as 
possible. The use of cell culture medium supplemented with FBS is considered the 
most accurate as it mimics the protein corona found on wear debris retrieved from 
periprosthetic tissue. The body naturally coats the UHMWPE wear debris in a layer of 
proteins from the extracellular tissue fluid and this affects how the body interacts with 
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and responds to the particles (Scholes and Unsworth, 2006). Sodium azide is used in 
mechanical studies to prevent infection in the lubricant however it is highly toxic to 
cells so debris created in this way cannot be cultured with cells.  
1.5.4.2 Wear debris isolation 
Once UHMWPE wear debris is generated, it must then be isolated from the lubricant 
in which it has been produced (or from cadaveric periprosthetic tissue or synovial 
fluid) (Wolfarth et al., 1997) (ASTM F561) in order to characterise it in terms of size 
and volume distribution using field emission gun scanning electron microscopy 
(FEGSEM). The presence of lipids, proteins and salts in the lubricant or natural 
tissue/fluid would make characterisation incredibly difficult and therefore the particles 
must be isolated. The tissue or lubricant/synovial fluid must first be digested either 
chemically using acidic (hydrochloric (Margevicius et al., 1994) or nitric acid) or basic 
conditions (sodium or potassium hydroxide) (Baxter et al., 2009) or enzymatically 
(using Proteinase K) (Baxter et al., 2009), papain, protease or collagenase (Campbell 
et al., 1996) in order to remove any proteins present. It is useful to be able to digest 
periprosthetic tissue and synovial fluid because clinically relevant material is directly 
yielded from a patient or animal model however the volume of particles recovered is 
poor which is a severe limitation. There is significant variation in the effectiveness of 
the different digestion methods available. Enzymatic methods are typically less 
efficient than chemical methods as they do not digest and remove all the tissue 
present, and by extension; all the lipids, proteins and salts, in the sample. Of the 
chemical methods, sodium or potassium hydroxide and nitric acid appear to be the 
most effective (Baxter et al., 2009) however care must be taken with the 
concentrations used in order to preserve the surface morphology of the particles and 
not destroy the polycarbonate filters used for filtration. Both chemical and enzymatic 
methods of isolation are time consuming as the chemicals can require several days to 
work effectively. Tipper et al. (2000) selected potassium hydroxide as the most 
efficient chemical digestion step and developed the remainder of the isolation method 
used in this study (Tipper et al., 2000). Upon completion of protein digestion with 
potassium hydroxide, Tipper et al. (2000) used a mixture of chloroform and methanol 
to extract any lipids present via chemical separation. Tipper et al. (2000) then used 
ice-cold ethanol to precipitate any remaining proteins before diluting with ultrapure 
water, centrifuging and filtering the supernatant into the requisite sizes prior to imaging 
using FEGSEM and analysis using Image proPlus. This method has been in 
continuous use at the Institute of Medical and Biological Engineering at the University 
of Leeds (Howling et al., 2001; Richards et al., 2008).  
1.5.5  Clinical, wear and biological performance of virgin UHMWPE in hips 
UHMWPE produces the greatest volume of wear debris in comparison to metal and 
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ceramic materials as it is typically articulated against metal or ceramic components; 
both of which are considerably harder than a comparatively soft polymer therefore the 
increased friction leads to the production of wear debris. Typical in vitro wear rates for 
virgin (i.e. non-cross-linked) UHMWPE are around 50 mm3 per million cycles (Endo et 
al., 2002). In vivo wear rates vary greatly; between 2 to 226 mm3.year-1 (Martell, 
Berkson and Jacobs, 2000). It is widely believed that UHMWPE wear debris is 
responsible for osteolysis, and in turn aseptic loosening, which is the cause of 50% of 
all revision surgeries (National Joint Registry, 2017). 
Friction based wear between articulating joint prostheses components is influenced by 
factors such as angle of implantation, femoral head size vs. acetabular cup size (size 
mismatching the components) (Brown, Fisher and Ingham, 2006), surface roughness 
(rougher surfaces create more wear debris) (Kurtz et al., 1999) and differences in 
materials used, i.e. metal vs. polyethylene (difference in toughness and difference in 
surface roughness). Studies on wear debris production in MOP hip implants have 
shown that wear debris produced in the short term is caused by macroscopic 
asperities (imperfections) on the UHMWPE component surface and wear debris 
produced in the long term is caused by microscopic asperities on the metal 
component surface (Cooper, Dowson and Fisher, 1993). A retrieval study of 
UHMWPE wear debris from Charnley prostheses showed that virgin UHMWPE wear 
debris ranged in size between 0.1 µm and >1000 µm and particles over 10 µm formed 
the largest volume of particles however most particles were within the range of 0.1 – 
0.5 µm (Tipper et al., 2000). Tipper et al. (2000) found that the retrieved particles 
displayed a range of morphologies including platelet-like, fibril-like, small granules and 
aggregated particles.  Other studies have confirmed that virgin UHMWPE wear 
particles are typically between 0.1 and 1.0 µm in size (Wu, Peng and Tipper, 2013). 
1.6  Modifications and optimisations of UHMWPE material 
There are a number of modifications to UHMWPE that can improve their functionality 
and longevity in a joint replacement. The most common modifications include cross-
linking and antioxidant doping.  
1.6.1 Cross-linking 
In order to reduce the volume of wear particles produced by UHMWPE in vivo, 
UHMWPE can be cross-linked using gamma irradiation in an inert atmosphere (such 
as nitrogen or argon). This radiolytically breaks the carbon and hydrogen bonds; 
creating alkyl free radicals which recombine and crosslink the polymer chains to one 
another (via covalent bonds) creating a network (Figure 1.3). Cross-linking improves 
the material’s resistance to wear thus generating lower volumes of wear particles 
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compared to non cross-linked material. The level of radiation can be varied to acquire 
different levels of cross-linking; common doses include 10 MRad, 8 MRad, 5 MRad 
and 2.5 MRad although this varies between companies and is often proprietary 
(Galvin et al., 2006). UHMWPE is described as moderately cross-linked at 2.5 MRad 
whereas UHMWPE is described as highly cross-linked with a radiation dose of 
between 5 and 10 MRad. 
 
 
Figure 1.3 Covalently linked UHMWPE polymer chains to form a network; UHMWPE 
chains shown in blue and covalent bonds shown in red. 
Cross-linked UHMWPE produces a smaller volume of wear debris, typically an 80% 
reduction, than virgin UHMWPE i.e. UHMWPE that has not been cross-linked or 
modified in any way (Popoola et al., 2010). The wear particles themselves are also 
smaller, which are more biologically active compared to the larger particles produced 
by virgin UHMWPE (Endo et al., 2001). The volume of cross-linked UHMWPE wear 
debris is significantly decreased compared to virgin UHMWPE (35 mm3 per million 
cycles and 50 mm3 per million cycles) (Endo et al., 2002). A study by Galvin et al. 
(2006) shows that as the level of crosslinking increases (0 MRad, 5 MRad and 10 
MRad), the wear factor (against smooth plates) decreases (the wear factors are 2.2 
mm3.Nm-1, 1.8 mm3.Nm-1 and 0.6 mm3.Nm-1 respectively); As crosslinking, decreases 
the wear rate of UHMWPE, it follows that the osteolytic potential of the wear debris 
may also be decreased, as it takes longer to reach a sufficient threshold volume in the 
periprosthetic tissue although it must be noted than the threshold volume for cross-
linked UHMWPE is not yet known. Despite this difference in size, there is currently no 
consensus on the difference in biological activity of wear debris from virgin UHMWPE 
and cross-linked UHMWPE (Bracco and Oral, 2011). The alkyl free radicals produced 
by cross-linking can cause oxidative damage to the polymer structure and the material 
can continue to degrade whilst in storage and when implanted. The alkyl free radicals 
react with oxygen from the air and begin a cascade of oxidation reactions; producing 
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highly reactive species such as peroxyradicals (Table 1.7) which form carbonyl 
species such as ketones, esters and carboxylic acids. These can cause chain 
scission, which degrades the polymer’s mechanical integrity. The polymer becomes 
brittle, oxidative embrittlement, and the fatigue strength is reduced through loss of 
crystallinity (Sutula et al., 1995; Collier et al., 1996; Oral et al., 2006; Costa and 
Bracco, 2009). One solution to neutralise any residual free radicals in the cross-linked 
polymer is post irradiation melting. The polymer is heated to above its melting point to 
release free radicals which may then recombine. However, post-irradiation melting 
negatively affects the mechanical properties of UHMWPE by causing a loss in 
crystallinity and reducing fatigue strength. Another method of free radical 
neutralisation is annealing where the polymer is heated below its melting point. 
However, this too, has significant issues associated with it; such as an increased 
weakness of the polymer to oxidation when in air and failure to remove the free 
radicals so oxidation still occurs (Wang et al., 2006).  
Table 1.7 Common reactive oxygen species and their chemical structures; all of which 
are possible to produce when alkyl free radicals react with oxygen from the air. 
Reactive oxygen species Chemical structure 
Oxygen ●O2 
Superoxide anion ●O2- 
Peroxide ●O22- 
Hydrogen peroxide H2O2 
Hydroxyl radical ●OH 
Hydroxyl anion OH- 
1.6.2 Antioxidants 
As an alternative to remelting or annealing, which result in a loss of crystallinity and 
fatigue strength, it is possible to dope the polymer with antioxidant compounds, such 
as vitamin E, to dispel free radicals from cross-linked UHMWPE (Bracco and Oral, 
2011). As cross-linking increases the potential life of a THR by reducing the volume of 
wear debris produced so does antioxidant doping by reducing the amount of free 
radical present in the polymer structure and minimising aging and oxidative 
embrittlement during storage and implantation. 
An antioxidant prevents oxidation by itself being oxidised and neutralising oxidising 
agents, as they are reducing agents, and free radicals. Antioxidants neutralise free 
radicals, reactive species with an unpaired electron, and terminate further chain 
reactions, i.e. preventing propagation.   
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There are currently only two types of antioxidant doped, cross-linked UHMWPE 
clinically available – vitamin E and hindered phenol cross-linked UHMWPE. However 
there are a number of alternative antioxidants currently at various stages of research 
such as polyphenols, nitroxides, hindered amines, lanthanide compounds and 
anthocyanins.  
Vitamin E 
Vitamin E is a natural antioxidant and prevents against free radical induced oxidative 
damage in the cell membrane. Vitamin E is an essential vitamin in the human body; 
deficiency results in serious neurological and neuromuscular symptoms such as nerve 
and muscle lesions and retinal abnormalities (Sokol, 1993). Vitamin E is known to 
prevent oxidant-induced inflammation (Conner and Grisham, 1996) and has a 
beneficial effect on cardiovascular diseases such as atherosclerosis (Singh, Devaraj 
and Jialal, 2005). There are eight different types of vitamin E – tocopherols (α, β, γ 
and δ) and tocotrienols (α, β, γ and δ). α –tocopherol is the most common in nature 
and is the type used as an orthopaedic UHMWPE stabiliser (Brigelius-Flohé and 
Traber, 1999). An α-tocopherol molecule consists of two parts (Figure 1.4A): the 
chroman head, the fused ring structures with the functional phenol group, and the 
phytyl tail, the long saturated or unsaturated aliphatic linear structures (Burton, 1990). 
Synthetic vitamin E, rather than natural, is used to dope orthopaedic UHMWPE and 
both naturally occurring and synthetic vitamin E are safe for human consumption. 
(Bracco and Oral, 2011). Vitamin E is synthesised industrially from the intermediates 
trimethylhydroquinone (TMHQ) and isophytol (Figure 1.4B) (Mercier and Chabardes, 
1994). Synthetic vitamin E was first used as a stabiliser for polyolefins (i.e. alkenes) in 
the 1980’s (Adamirova, 1982). The use of synthetic vitamin E in UHMWPE acetabular 
cups for orthopaedic use was first approved by the FDA in 2007; followed by tibial 
trays for use in knees in 2008 (Oral and Muratoglu, 2009). The American Society for 
Testing and Materials also produced a standard for vitamin E doped UHMWPE for 
orthopaedic use in 2007 (ASTM F2695-12). There are now a number of vitamin E, 
cross-linked UHMWPE orthopaedic products clinically available; such as Vivacit-E® 
produced by Zimmer Biomet. 
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A) 
 
B) 
Figure 1.4 Vitamin E (α-tocopherol) molecular structure (A) and industrial synthesis 
(B) (adapted from Sheppard et al., 1993). 
Vitamin E is used in medical grade UHMWPE (at a clinical dose of 1000 ppm (Bladen 
et al., 2013a)) as a stabiliser because its antioxidant activity prevents oxidative 
degradation of the polymer caused by residual free radicals that are trapped within the 
structure from the sterilisation (gamma irradiation) and crosslinking (ionising radiation) 
processes. The role of vitamin E in UHMWPE is twofold: it confers oxidative 
resistance onto the material (i.e. it prevents oxidative damage by itself being oxidised) 
and it also preserves or improves the mechanical properties of the material such as 
fatigue strength; maintaining wear resistance through prevention of oxidative 
embrittlement. Vitamin E achieves its anti-oxidant activity by itself being oxidised. It 
can react with peroxy and alkyl macroradicals in a cyclic manner which results in the 
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regeneration of the tocopherol radical. The tocopherol radical can then go on to react 
over and over again thus only a small amount of vitamin E is required for doping 
UHMWPE to achieve an antioxidant effect (Bracco and Oral, 2011).  
Vitamin E can be added to UHMWPE in two different ways: blending and diffusion. 
Blending involves adding vitamin E to the UHMWPE powdered resin, which is then 
consolidated and irradiated in order to sterilise and crosslink the polymer. Since 
vitamin E is present during the crosslinking process, it can also react with the alkyl 
free radicals generated and reduce the crosslinking efficiency (Oral et al., 2005). 
Diffusion involves adding vitamin E to the polymer at a later stage. The UHMWPE is 
first consolidated and then irradiated (to sterilise and crosslink). After these processes 
are complete, the material is then soaked in a solution of vitamin E at a high 
temperature. It is then homogenised, by heating the polymer below its melting point in 
an inert gas, to ensure that the vitamin E is distributed beyond the surface and 
throughout the material. However it is not clear whether the distribution of vitamin E is 
even throughout the material or how far vitamin E has diffused into the polymer. Since 
vitamin E is not present during the crosslinking process, the crosslinking efficiency is 
not reduced however the polymer is not protected from free radical damage during 
sterilisation and crosslinking. Diffusion results in higher concentrations of vitamin E 
present in the polymer, as it is not lost through reaction with free radicals, which 
affords the polymer greater oxidative protection in the long term (Oral et al., 2007). 
There are concerns that the vitamin E added to the polymer, whether blended or 
diffused, may leach out in vivo and, if so, the effects of free vitamin E in the joint is 
unknown. There are two possibilities of how this may occur: vitamin E may leach from 
either the bulk material or the wear particles. Studies have shown that, under 
manufacturing conditions, no vitamin E leaches from the material; suggesting vitamin 
E is not leaching during the manufacturing process. However studies show that 
vitamin E does leach out of the material in water at physiological temperatures (Oral et 
al., 2008; Costa and Bracco, 2009) so it is plausible that some vitamin E may leach 
from the implant material when in the body. Although the studies show that even when 
implants are treated harshly (boiled in hexane) to remove as much vitamin E as 
possible, they still exhibit improved oxidative resistance (compared to unstabilised 
UHMWPE) and low wear volumes. This suggests some vitamin E is retained in the 
material even under extreme circumstances and is able to act sufficiently as an 
antioxidant. This is supported by the tocopherol radicals ability to regenerate itself with 
every oxidation reaction cycle, therefore only a small of vitamin E is required to confer 
oxidative resistance onto the material (Bracco and Oral, 2011). Studies have not yet 
taken place to evaluate whether vitamin E leaches from wear particles and, if so, 
therefore there is a need to carry out such studies as wear particles could be a 
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significant source of free vitamin E in the body. It would also be useful to compare the 
quantity of vitamin E that leaches from the bulk material to that leached from wear 
particles to establish which (if any) is the primary source of free vitamin E in the body.  
Studies at the University of Leeds have shown that the presence of vitamin E does not 
significantly affect the wear rate and wear particle size of virgin UHMWPE. It does 
however affect the inflammatory potential of wear particles; significantly lower levels of 
TNF-α are released (Bladen et al., 2013a). There is speculation that the 
immunogenicity and inflammatory potential of vitamin E wear particles may be 
different in comparison to virgin UHMWPE. The oxidative state of vitamin E wear 
particles may also be different. These potential differences may influence the 
response in vivo to the wear particles therefore this will require further study (Bracco 
and Oral, 2011). Many studies (Teramura et al., 2009; Vaidya et al., 2011) claim that 
vitamin E itself reduces wear particle production however, in actuality, it is the 
crosslinking of UHMWPE that results in reduced wear particle production due to 
mechanical strengthening of the polymer; crosslinking the polymer chains increases 
the polymer’s toughness. Studies that compare virgin and cross-linked UHMWPE 
clearly show this relationship; as discussed above, cross-linked UHMWPE produces 
80% less wear debris than virgin UHMWPE (Popoola et al., 2010). It is important 
therefore that the materials used in each study are carefully considered. Gowland 
(2014) compared the wear rates of GUR 1050 XL (10 MRad) and GUR 1050 XL (10 
MRad) VE (1000 ppm) and found no significant difference; 2.5 mm3.Nm-1 and 1.9 
mm3.Nm-1 respectively. Vitamin E does, however, prevent oxidative damage, which, in 
turn, preserves the mechanical properties of the polymer, such as ultimate tensile 
strength, elongation at break, work to failure and stress factor range at fatigue crack 
inception (Bracco and Oral, 2011).  
In vitro studies with vitamin E doped UHMWPE have shown that vitamin E exhibits 
anti-inflammatory properties, therefore vitamin E may also exhibit such effects in vivo. 
Studies by Bladen et al. (2013b) showed that vitamin E (either alone - at doses of 500 
mg.ml-1- or contained in UHMWPE wear debris – GUR 1050 containing vitamin E at 
1000 ppm) reduced the production of inflammatory and osteolytic cytokines and 
chemokines, TNF-α, IL-1β, IL-6 and IL-8, in PBMNC’s compared to virgin UHMWPE 
wear particles (Bladen et al., 2013a; Bladen et al., 2013b). Since UHMWPE wear 
particles cause a sustained inflammatory response in periprosthetic tissue, it is 
possible that the inclusion of vitamin E into the UHMWPE material may mitigate this 
response through the reduction in production of osteolytic mediators therefore 
potentially decreasing osteoclastogenesis. The lack of osteoclastogenesis could 
therefore, potentially, reduce the risk of osteolysis and aseptic loosening. The 
reduction in osteolysis potentially may lead to a longer implant lifetime in the patient; 
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taking orthopaedics one step closer to creating a prosthesis that lasts the lifetime of 
the patient. This is supported by studies that show that vitamin E has a direct effect on 
osteoclasts although the effect itself is not clear as there is evidence of both 
beneficial, such as the inhibition of osteoclast formation, and deleterious effects, such 
as the upregulation of osteolytic cytokines gene expression, on osteolysis (Roodman, 
2012). Bladen et al. (2013b) cultured PBMNC’s and U937 human macrophages with 
vitamin E (500 mg.ml-1) and cell viability was assessed after 24 hours using the ATP-
lite cell viability assay; vitamin E did not affect cell viability except at high 
concentrations (3mM and 2 mM for PBMNC’s and U937 cells respectively) (Bladen et 
al., 2013b). These studies suggested that vitamin E itself is biocompatible and that 
vitamin E wear debris is better tolerated than virgin UHMWPE on a cellular level. 
Hindered phenols 
Hindered phenols are complex molecules with multiple phenol groups which often 
contain one or more ring structures and several branches. A common example of a 
hindered phenol compound used to stabilise medical grade UHMWPE is 
pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (Figure 1.5) used 
by DePuy Synthes Joint Reconstruction. Hindered phenols as antioxidant additives in 
orthopaedic implants are currently in clinical use in total knee replacements (TKR) 
(AOX 7.5 – 8 MRad) and  in development for THR’s (10 – 11.5 MRad).   
 
Figure 1.5 Structure of pentaerythritol tetrakis (3,5-di-tert-butyl-4-
hydroxyhydrocinnamate). 
In vitro studies have shown that pentaerythritol tetrakis (3,5-di-tert-butyl-4-
hydroxyhydrocinnamate) is cytotoxic to U937 human histiocytes and human peripheral 
blood mononuclear cells (PBMNC’s), even at low concentrations; with LC50 (lethal 
concentrations that killed 50% of the cells) at 100 µM and 300 µM, respectively. 
Pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate) elicited reduced 
TNF-α production in LPS stimulated U937 human histiocytes, however it was less 
effective than vitamin E or europium (III) chloride (a lanthanide salt) at reducing TNF-α 
production and had no effect on TNF-α production from LPS stimulated PBMNC’s 
(Bladen et al., 2013b). These in vitro studies suggest that pentaerythritol tetrakis (3,5-
di-tert-butyl-4-hydroxyhydrocinnamate) may have some anti-inflammatory activity, 
certainly not to the same extent as vitamin E, however this requires further study into 
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other inflammatory mediators and pathways of inflammation to verify this. These 
studies also suggest that hindered phenols, such as pentaerythritol tetrakis (3,5-di-
tert-butyl-4-hydroxyhydrocinnamate), may have reduced biocompatibility as they may 
exhibit cytotoxic effects. It is not known if hindered phenol compounds are capable of 
leaching from UHMWPE, and therefore into the body, so elution studies must also be 
carried out to determine whether free hindered phenol compounds could leach from 
the implant into the body and, if so, what biological effects they would have. 
In vivo animal studies by King et al. (2010), carried out in rats (over 26 weeks) and 
rabbits (over 12 weeks), assessed the biocompatibility of GUR 1020 highly cross-
linked AOX material (containing hindered phenol; Poly-phenol of tetrakis[3-(3,5-di-tert-
butyl-4-hydroxyphenyl) propionate]. Haematoxylin and eosin staining of periprosthetic 
muscle (rabbit) and subcutaneous tissue (rat) after 26 weeks showed no adverse 
effects on the normal periprosthetic tissue architecture (King, Arscott and Narayan, 
2009). This, however, does not conclusively suggest biocompatibility for this material 
as haematoxylin and eosin stains cellular structures rather than highlighting any 
change in viability. More specific in vivo animal and human studies are required to 
comment more conclusively on biocompatibility. Studies by Green et al. (2012) used 
mouse calvarial models to demonstrate that the GUR 1020 highly cross-linked AOX 
material exhibits a similar osteolytic potential to current clinical UHMWPE orthopaedic 
materials; suggesting that there may be no improvement in the incidence of osteolysis 
with the use of hindered phenol UHMWPE materials (Green et al, 2012).  
Studies by Narayan et al. (2009) investigated the effect of hindered phenols, 
Pentaerythritol tetrakis [3-(3,5-di- tert-butyl-4-hydroxyphenyl) propionate], Octadecyl-
3,5-di-tert-butyl-4- hydroxycinnamate, and Isooctyl-3,5-di-tert-butyl-4-
hydroxycinnamate, on the wear rate of cross-linked UHMWPE. It was found that 
increasing the amount of hindered phenol present, from 0 to 0.1%, resulted in an 
increased wear rate (from around 1 mg per million cycles to around 5 mg per million 
cycles) due to a reduction in crosslinking as the hindered phenol was blended rather 
than diffused. However this effect could be overcome by increasing the radiation dose 
to increase the level of cross-linking (Narayan et al., 2009). The interfering effect of 
blended antioxidants on the crosslinking process is already known therefore further 
studies should be carried out on diffused hindered phenol UHMWPE materials.  
Lanthanide compounds 
Lanthanide compounds are already in use as stabilisers for polyvinyl chloride (PVC) 
(Peng et al., 2003; Zheng et al., 2005). Lanthanides form complexes with oxygen in 
high coordination numbers (Gallardo et al., 2011a). Lanthanides have no biological 
role in vivo however they are classified as having low toxicity (McGill, 2005).  
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Pennekamp et al. (2009) suggest that europium may have an anti-inflammatory effect 
on periprosthetic tissue, based on their initial study using murine macrophages 
(Pennekamp et al., 2009). This is promising, however, there is a need to do further 
study in human cells to validate this claim. Some lanthanides, such as cerium and 
yttrium (oxide nanoparticles), have been found to have an antioxidant effect on 
neurons. This is also promising, however it is necessary to confirm this effect in 
periprosthetic tissue and the joint capsule (Schubert et al., 2006).  
A pilot study examining the effects of europium (II) stearate on the mechanical 
properties of UHMWPE was carried out by Gallardo et al. (2011a). GUR 1050 
UHMWPE powder was blended with europium (II) stearate (375 ppm and 750 ppm), 
compression moulded and irradiated at 35 kGy. The study showed that the addition of 
europium (II) stearate at both concentrations reduced the loss of mechanical integrity 
(ultimate load, ultimate displacement and work to failure) of the polymer under 
accelerated aging conditions (Gallardo et al., 2011a) . However fatigue strength, the 
mechanical property most affected by crosslinking, was not assessed. Additionally, 
the addition of europium (II) stearate resulted in a statistically significantly lower 
oxidation index after accelerated aging than that of virgin UHMWPE. Europium (II) 
stearate is a reducing agent and is therefore capable of acting as an antioxidant 
through the oxidation of the europium ion from Eu2+ to Eu3+. However, the study did 
not examine cross-linked materials which are the most up-to-date form of clinically 
available UHMWPE for orthopaedic purposes and where antioxidants are more likely 
to be used to reduce the oxidative damage caused by free radicals. This study did not 
attempt to make any erroneous claims about the effect of the antioxidant on the wear 
rate of the material as some studies often do.  
Gallardo et al. (2011b) carried out a further study with europium (III) stearate 
specifically examining its antioxidant ability. The study characterised the quantity and 
nature of the oxidation products, hydroxides, ketones and carboxylic acid, from 
irradiated and non-irradiated UHMWPE doped with europium (III) stearate at 0, 375 
and 3750 ppm after accelerated aging using fourier transform infrared (FTIR) 
spectroscopy. The concentration of both hydroperoxides and ketones increased over 
time in all materials however significantly higher concentrations were found in non-
doped UHMWPE compared to doped UHMWPE. It seems the presence of europium 
(III) stearate significantly reduces the rate of oxidation of the material and therefore 
slows the increase in concentration of oxidation products (Gallardo et al., 2011b). The 
authors speculated that lanthanides may interact with carboxylate anions and thus 
stabilise UHMWPE – it is possible that europium is capable of coordinating to carbonyl 
anions as ligands in the same way as oxygen, thereby reducing their availability in the 
material for the continuation of the oxidation cycle. The study also suggested that the 
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stearate chains may be acting symbiotically with the europium to prevent oxidation as 
the IR spectra showed a change in structure over time with oxidation however a 
change in structure is not sufficient to claim an antioxidant role. The study did not 
account for cross-linked UHMWPE – the materials were gamma irradiated for 
sterilisation purposes, however the irradiation dose could have caused some 
crosslinking, which could have caused an unknown effect on the mechanism of 
oxidation.  
Bladen et al. (2013b) carried out cytotoxicity studies on europium (II) and (III) chloride 
using U937 human histiocytes and PBMNC’s. Europium chloride was not cytotoxic to 
either cell types except at high concentrations (2.5 mM and 1 mM, respectively). 
Similarly, both cell types when stimulated with LPS and treated with europium chloride 
produced reduced levels of inflammatory cytokines, notably TNF-α, in comparison 
with LPS stimulation alone. This study suggests that lanthanide salts are not cytotoxic 
and may be well tolerated in vivo therefore further animal and human studies are 
required to validate this  (Bladen et al., 2013b).  
Hindered amine light stabilisers 
Hindered amine light stabilisers (HALS) are complex molecules containing multiple 
amine groups and cyclic ring structures (both aromatic and non-aromatic). They often 
contain triazine aromatic rings and piperidine rings . 
Initial studies by Gjisman et al. (2010) showed that, compared to vitamin E, HALS did 
not affect crosslinking efficiency, as the amine form of the antioxidant compounds 
does not react with the polymer or alkyl radicals. HALS are converted into nitroxides 
which are then capable of free radical scavenging. The nitroxide radical is capable of 
regeneration, therefore only a small amount of HALS is needed. These authors 
showed that a small amount (500 ppm) of HALS compound is as effective an 
antioxidant as vitamin E at three times the concentration (1500 ppm). The authors 
suggest that HALS compounds should not leach from implanted UHMWPE, due to 
their lack of solubility in water and indeed no diffusion of the compounds from low 
density polyethylene (LDPE) was found after 10 months (Malik, Hrivik and Tomova, 
1992), although further testing is required to conclusively assess this (particularly in 
vivo as hydrophobic compounds can reside in fatty tissue). Moreover, this should be 
assessed in UHMWPE as LDPE is not used in an orthopaedic context and therefore 
has less clinical relevance. There is no information currently on the biocompatibility of 
HALS – either in vitro or in vivo therefore further study is required to investigate their 
biocompatibility and suitability in vivo; in particular, a joint environment context 
(Gijsman, Smelt and Schumann, 2010).  
Polyphenols 
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A natural source of antioxidants that could be used for oxidative stabilisation of cross-
linked UHWMPE is polyphenols. Polyphenols are molecules with multiple phenol 
groups i.e. aromatic rings with an alcohol moiety (Figure 1.6A). Some examples of 
naturally occurring polyphenols include gingerol (ginger), curcumin (cumin) and 
resveratrol (wine).  
A study by Fu et al. (2013) studied two examples of polyphenols, gallic acid (Figure 
1.6A) and dodecyl gallate (Figure 1.6B), which may be promising alternative 
antioxidant stabilisers for medical grade UHMWPE. Gallic acid and dodecyl gallate, an 
ester of dodecanol and gallic acid, both delayed the onset of oxidation of UHMWPE 
compared to vitamin E, at lower concentrations; 0.05 wt% for gallic acid and dodecyl 
gallate compared to 0.1% for vitamin E. The authors claimed that polyphenols 
provided a greater oxidative stability than vitamin E. The authors suggested that 
vitamin E experienced phenol loss, which reduced its effectiveness. In terms of 
mechanical properties, gallic acid and dodecyl gallate, did not influence the tensile 
strength of cross-linked UHMWPE, whereas vitamin E improved it. The presence of 
gallic acid or dodecyl gallate however, ensured that the mechanical properties were 
not affected by aging. Additionally, the presence of gallic acid and dodecyl gallate in 
UHMWPE were found to have no effect on wear rate. UHMWPE with gallic acid and 
dodecyl gallate was found to have a higher crosslinking density compared to vitamin E 
cross-linked UHWMPE, therefore gallic acid and dodecyl gallate did not interfere with 
the crosslinking process and therefore its efficiency. Finally, the biocompatibility of 
cross-linked UHMWPE doped with gallic acid and dodecyl gallate was tested by 
growing chondrocytes onto both materials – cells were found to adhere, spread and 
proliferate successfully; indicating biocompatibility (Fu et al., 2013). Further studies 
are required to verify biocompatibility; in particular in response to wear debris 
generated from such polyphenol materials. Detailed wear studies are required to 
assess the wear profiles of these materials – in terms of particle size and volume 
distribution and morphology as these are important factors in determining a biological 
response to the wear debris.  
A) 
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Figure 1.6 A) The general structure of phenol molecule, B) the structure of gallic acid 
(left) and dodecyl gallate (right). 
Nitroxides 
There is some interest in the use of nitroxide compounds as alternative antioxidant 
stabilisers for medical grade UHMWPE. Nitroxides, also called amine oxides, are 
charged (zwitterionic) nitrogen centred molecules with one oxygen and three alkyl 
chains bound (Figure 1.7A). Compounds of interest for stabilising orthopaedic 
UHMWPE include 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) (Figure 1.7B) and 4-
hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL) (Figure 1.7C) (Chumakov, 
2009). 
A) 
B) C) 
Figure 1.7  The general structure of nitroxide compounds (A) and the 
individual structures of TEMPO (B) and TEMPOL (C). 
 In vitro studies by Bladen et al (2013) showed that a solution of TEMPO (10 mM in 
ethanol) was cytotoxic (even at low concentrations – 200 µM and 300 µM, 
respectively) to U937 human histiocytes and human peripheral blood mononuclear 
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cells (PBMNC’s). The toxicity could not be attributed to ethanol, as ethanol was only 
present in a very low concentration, which was significantly below its cytotoxicity level. 
TEMPO did appear to cause a reduction in TNF-α production in LPS stimulated U937 
human histiocytes; approximately 75% less than LPS alone. This, however, was less 
than other antioxidants tested such as vitamin E; approximately 95% less than LPS 
alone. TEMPO did not reduce the amount of TNF-α produced or exhibit any anti-
inflammatory effects in LPS stimulated PBMNC’s. The study by Bladen et al. (2013b) 
showed that, although an antioxidant may perform well in terms of material properties, 
it is vital to consider the biological effects of such antioxidants before approving their 
use in medical grade UHMWPE; particularly if the compounds are capable of leaching 
from the implant into the body (Bladen et al., 2013b). 
Anthocyanins 
Anthocyanins are a well-known class of naturally occurring antioxidants. They consist 
of a conjugated dual heteroaromatic ring system covalently attached to a 
functionalised benzene ring (Figure 1.8). They also contain a sugar molecule in the 3 
position. There are hundreds of different anthocyanins and they are found naturally in 
a wide variety of different plants such as blueberries, blackcurrants and beetroots. 
Anthocyanins are responsible for the colouration of the plants they are found in and 
their colour depends on the pH of the environment they are in.  
Research is ongoing into the use of anthocyanins as alternative antioxidants to 
stabilise orthopaedic UHMWPE. Research is in the early stages and there are 
currently only two existing patents for anthocyanin doped UHMWPE (He et al., 2012, 
2013). He et al. (2012) performed a study on the wear rates and oxidation of 
anthocyanin doped UHMWPE acetabular cups in comparison to vitamin E doped 
UHMWPE acetabular cups. Two types of anthocyanin compounds were used to dope 
UHMWPE (antho-B – sourced from bilberries – and antho-G – sourced from grapes). 
The addition of both types of anthocyanins to the polymer showed no impact on 
 
Figure 1.8 Anthocyanin general structure (* may be any alkyl group or hydrogen). 
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physical and mechanical properties. Both anthocyanins and vitamin E doped 
UHMWPE showed no oxidation after 2 and 4 weeks of accelerated aging. Both 
anthocyanin doped UHMWPE cups showed lower wear rates than vitamin E doped 
UHMWPE at lower concentrations (1.3-1.4 mm3 per million cycles and 6 mm3 per 
million cycles respectively– antho-B was present at 125 ppm and antho-G was 
present at 40 ppm compared to vitamin E at 500 ppm (He et al., 2009). However, what 
is not clear from the study is whether the materials used were cross-linked and, if so, 
whether they were cross-linked to the same as extent as a clinical material would be. 
Additionally, the level of crosslinking may need to be increased if an antioxidant is 
blended with the polymer as this can impair the crosslinking process – this is true of 
vitamin E, which requires a higher dose of radiation to compensate. It was not 
therefore clear whether the characteristics of the anthocyanin and vitamin E doped 
materials were consistent, and therefore directly comparable. Anthocyanins may be a 
promising alternative antioxidant for use in stabilising UHMWPE for orthopaedic use. 
They are likely to be biocompatible as anthocyanins are naturally occurring 
antioxidants and are contained in food, such as beetroot (they are the source of purple 
colour), which is regularly consumed by humans with no ill effects. However, there 
may be drawbacks similar to blended vitamin E as the patents specify a method which 
includes anthocyanins with UHMWPE powder before crosslinking and, since the 
anthocyanins are present during the crosslinking procedure, they may impede the 
crosslinking process and reduce efficiency in the same way as vitamin E. Further 
study evaluating crosslinking density to verify the effect on crosslinking efficiency is 
required. There is no research data on the bulk implant material and the nature of 
wear particles produced from anthocyanin stabilized cross-linked UHMWPE at the 
present time. It is unknown how this material would fare on a systemic level in vivo 
and on a cellular level in vitro so further study is needed into this potentially promising 
orthopaedic material to establish its biological reactivity. 
1.6.3 Other modifications 
There are a number of alternative modifications currently in development for 
UHMWPE to improve mechanical properties and wear resistance.  One such group of 
alternative materials are UHMWPE composites such as UHMWPE/graphene oxide 
nanocomposites (Puertolas and Kurtz, 2016; Suñer et al., 2018), UHMWPE-
hyaluronan (<5%) microcomposites (James et al, 2016), UHMWPE homocomposites 
(Siskey et al, 2016) and UHMWPE hydroxyapatite composites (Puertolas and Kurtz, 
2016). Another such group is phospholipid polymer grafter highly cross-linked 
UHMWPE (Kyomoto, Moro and Ishihara, 2016). These are all still in development and 
undergoing further testing before clinical release. As such, these modifications will be 
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discussed no further in this introduction however it is helpful to acknowledge them in 
the context of UHMWPE modifications. 
1.7  In vivo and in vitro modelling 
The inflammatory and osteolytic potential of UHMWPE; both as a bulk material and 
particulate matter can be modelled in vivo and in vitro.  
1.7.1  In vivo modelling 
The in vivo response to UHMWPE is typically measured using animal models to both 
the bulk material and its particulate matter. Long term clinical studies in humans do 
also yield data although the return of data is typically over a much larger time frame 
(years or decades rather than weeks or months).  
1.7.1.1  In vivo implantation of bulk material 
In terms of assessing the biological response to the bulk UHMWPE material, the 
material can be implanted subcutaneously or alternatively a full joint replacement can 
be implanted into the animal. 
Several studies in animals have been carried out to verify the biocompatibility of 
vitamin E doped UHMWPE in an orthopaedic setting. Jarett et al. (2010) performed 
extensive animal studies on vitamin E doped UHMWPE. Vitamin E doped UHMWPE 
(GUR 1050 virgin material obtained from Orthoplastics, which was then gamma 
irradiated at 100 kGy and then soaked in vitamin E for 120 hours to provide two 
different doses of 1.4% and 0.7% by weight) was implanted subcutaneously in rabbits 
and vitamin E doped UHMWPE acetabular cups were implanted into a canine model 
to establish the effect of the material on bone and periprosthetic tissue. These studies 
showed that periprosthetic tissue histology was normal in the canine model and the 
subcutaneous implantation of the material resulted in a normal fibrous encapsulation 
response in the rabbit models (there was some initial inflammation, although this was 
consistent with a standard response to a foreign body) (Jarrett et al., 2010). These 
animal studies implied that vitamin E UHMWPE is well tolerated in the body in an 
orthopaedic setting as no adverse effects were observed in either rabbit or canine 
models. However, it is imperative that such biocompatibility data be established in 
humans as the response to chemical compounds can vary between species. These 
studies are useful because they assess the whole body and localised response to the 
bulk material but fail to account for the response to wear debris (unless the 
periprosthetic tissue is harvested from a joint implantation study). This study used 
UHMWPE materials with a clinically relevant dose of vitamin E (0.7% by weight) and a 
higher than clinical dose (1.4% by weight); both of which were tolerated by the rabbit 
and canine models.  
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1.7.1.2  In vivo injection or implantation of particulate matter 
The biological response to UHMWPE wear debris can be observed by implanting or 
injecting the wear debris, suspended in water or a water-ethanol solution (Jarrett et 
al., 2010), into an animal model and, after several weeks, harvesting the animal 
tissues for histology. 
The anti-inflammatory properties of vitamin E may reduce the incidence of osteolysis 
in vivo which is corroborated by studies by Bichara et al. (2014). Bichara et al. (2014) 
implanted the vitamin E cross-linked UHWMPE (0.8 % vitamin E by weight, 100 kGy 
gamma irradiation) wear debris (generated from clinical material obtained from 
Biomet) periostally in a mouse calvarial model. Bichara et al. (2014) showed a 
reduction in osteolysis in a mouse calvarial model when vitamin E cross-linked 
UHMWPE was compared to cross-linked UHMWPE with no antioxidant (Bichara et al., 
2014). Further study is required however into in vivo human biocompatibility. As 
vitamin E doped UHMWPE was only approved for clinical use in 2007, there is no long 
term clinical performance data; such studies are still ongoing. Over time, such data 
will reveal how well tolerated vitamin E doped UHMWPE is in vivo in an orthopaedic 
context as well as any additional effects such as anti-inflammatory effects and their 
implications. This is useful for gaining an understanding of what the 3D in vivo whole 
body response is to UHMWPE debris however, since it is an animal model, it is less 
relevant than a human model and somewhat harder to interrogate for specific qualities 
such as cytokine production. This requires an in vitro model.  
Jarett et al. (2010) injected vitamin E (pure and solubilised) into the knees of rabbits, 
in order to replicate any elution or leaching of vitamin E from the implant material. This 
study showed that the tissue histology was normal in response to solubilised vitamin E 
in the rabbit models (Jarrett et al., 2010). This study implied that vitamin E, unbound to 
polyethylene, would be well tolerated in the body in an orthopaedic setting as no 
adverse effects were observed in the rabbit models. However, it is imperative that 
such biocompatibility data be established in humans as the response to chemical 
compounds can vary between species.  
1.7.2  In vitro modelling 
The in vitro response to UHMWPE is typically measured using animal or human 
primary cells or cell lines – these can be cultured with or on the bulk material or in the 
presence of UHMWPE wear debris. 
1.7.2.1  In vitro modelling of response to bulk material 
Studies often culture animal or human primary cells or cell lines on a tablet of 
UHMWPE bulk material in order to establish biocompatibility and cytotoxicity data. 
This helps gain an understanding of how cellular qualities such as viability are affected 
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by cells growing on the bulk material but this situation is much less clinically relevant 
than subcutaneous implantation as it is only a flat 2D model. Moreover, it, again, fails 
to account for the impact wear debris has. 
Wolf et al. (2002) grew L929 murine fibroblasts onto thin sheets of vitamin E doped 
UHMWPE and showed that vitamin E doped UHMWPE did not have a cytotoxic effect 
on the cells or affect their behaviour in terms of proliferation, mitochondrial activity or 
membrane integrity although the study did show a reduction in cell adhesion and 
spreading (Wolf, Lederer and Muller, 2002). The growth of cells onto the acetabular 
cup of the prostheses is not directly relevant to the biocompatibility of this material as 
it is unlikely that cells will colonise the interior of the implant and the growth of tissue 
here would not be beneficial. It is perhaps more important to assess the response of 
relevant cells to the wear debris generated from the material and any free vitamin E 
that may arise from material elution. Additionally, whilst fibroblasts are a relevant cell 
type in terms of periprosthetic tissue, it is also important to establish biocompatibility in 
other relevant cells, such as macrophages and osteoclasts. Furthermore, 
biocompatibility must be established in a human primary cell source as well as cell 
lines (as the behaviour may differ between the two types of cells). It is also important 
to use human cells as these may differ from animal cells in their response to vitamin E 
UHMWPE and such material will ultimately be in humans not animals.  
A further study by Wolf et al. (2007) did indeed use human cell lines to test for 
biocompatibility with vitamin E doped UHMWPE. Cells were grown on ‘tablets’ of 
vitamin E doped UHMWPE. A fibroblastic cell line (HF-SAR) was used in addition to 
the GSJO cell line (established from a medullary thyroid carcinoma). The studies 
showed no negative impact on the human cell lines in terms of proliferation, 
mitochondrial activity and morphology (and where applicable, adherence and 
spreading) (Wolf et al., 2007). Whilst it is positive that human cell lines experienced no 
negative impact from growth on vitamin E doped UHMWPE compared to unstabilised 
UHMWPE, it is important to assess the biocompatibility of the wear debris generated 
from this material. Any significant biological response to joint implants tends to arise 
from wear debris, not the bulk implant itself, as the implant tends to be walled off from 
the rest of the body by a fibrous capsule whereas wear debris can travel away from 
the joint site (depending on size).  
1.7.2.2  In vitro modelling of response to particulate matter 
The cellular response to wear debris can be modelled by culturing representative cell 
types with clinically relevant wear debris. The cellular response to metal and ceramic 
wear debris is studied by directly culturing the cells of interest with the wear debris in 
cell culture medium. Both metal and ceramic particles are significantly denser than 
water therefore the wear particles sink to the bottom of the well and are in direct 
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contact with the cells in 2D culture on the base. Unlike metal or ceramic wear debris, 
UHMWPE wear debris cannot be directly cultured with cells. Polyethylene is less 
dense than water so wear debris floats on top of the cell culture medium in the well 
plates thus never coming into contact with the cells growing on the base of the well 
therefore simple 2D culture is inappropriate for assessing cellular response to 
UHMWPE wear debris. There are a number of adapted methods that can be used to 
culture cells with UHMWPE wear debris such as rotation culture models, inverted 2D 
culture models and gel encapsulation models. 
Rotation culture models 
Matsusaki et al. (2007) cultured U937 human histiocytes with polyethylene wear 
debris in a continuously rotating culture flask (Matsusaki et al., 2007). This method 
would not be suitable for adherent cell types, such as macrophages and fibroblasts, 
which are commonly used in in vitro studies of polyethylene so this method is limited 
in its application. Additionally, a rotation culture is not clinically representative as the 
periprosthetic tissue fluid is not experiencing continual rotary forces in vivo. 
Inversion culture models 
Inversion culture model, or cover slip method, involves suspending UHMWPE wear 
debris in the relevant cell medium and cells are cultured on to a cover slip which is 
then inverted over the medium so the cells are in contact with the debris floating on 
the top. Matthews et al. (2000b) cultured human PBMNC’s with model Ceridust® 
polyethylene particles using the inverted culture method. PBMNC’s were seeded onto 
a glass cover slip and allowed to adhere before inverting over an IVF dish containing 
medium with Ceridust® fractionated into the following mean sizes: 0.21 µm, 0.49 µm, 
4.3 µm, 7.2 µm and 88 µm. The viability was assessed using the MTT viability assay 
and the output of osteolytic mediators (IL-1β, IL-6, TNF-α, GM-CSF and PGE2) was 
assessed using ELISA. Matthews et al. (2000b) found that there was significantly 
increased osteolytic mediator production in response to the model particles in 
particular the particles with a mean size of 0.21 µm  and 0.49 µm which was 
consistent with the earlier findings of Green et al. (1998) that particles of a critical size 
range (0.1 – 10 µm) are necessary to activate macrophages. However the results 
were highly variable due to donor heterogeneity – this is the cost of using primary cells 
which, although they are more representative, demonstrate significant variability 
between donors.  The inversion method is a reasonable method for evaluating specific 
in vitro responses such as viability and cytokine output as it is easy to set up and use 
and produces results consistent with existing literature. However, the inversion 
method is a flat 2D model and does not fully represent the 3D clinical environment. It 
is also costly in terms of the IV dishes required.  
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Gel encapsulation models 
The agarose gel encapsulation model has been developed and used at the University 
of Leeds for two decades - the UHMWPE wear debris is encapsulated within an 
agarose gel matrix, the relevant cells are seeded on top of the gel and the outputs are 
measured as required. 
The first iteration of this model was a 2D model developed by Green et al. (1998) – 
Ceridust® model polyethylene particles and GUR 1120 resin powder were added to 
the agarose gel and, once the gel plugs were placed into the well plates, the well plate 
was centrifuged at 800 g. This centrifugation brought the polyethylene particles to the 
surface of the gel, creating a 2D monolayer upon which C3H primary murine 
peritoneal macrophages were seeded, in direct contact with the particles. This model 
effectively traps the wear debris and, as the particles are at the surface of the gel in a 
monolayer, the cells do not have to penetrate the gel in order to access the debris. 
This model was 2D rather than 3D, as the particles were centrifuged into a monolayer, 
which is not clinically representative of the in vivo periprosthetic environment. 
Additionally, Green et al. (1998) used primary mouse cells which are less 
representative as they are not human.  
The agarose gel encapsulation model was also used by Liu (2012). Liu (2012) 
removed the centrifugation step and instead relied upon the low density of 
polyethylene to allow the UHMWPE wear debris to rise to the surface of agarose gel. 
Additionally, Liu (2012) used human PBMNC’s, which contain macrophages (in 
addition to lymphocytes which make up the majority of the cell fraction obtained from 
donated blood) and are more representative than murine peritoneal macrophages. 
However, PBMNC’s are primary human cells and therefore require a human donor for 
each experiment that they are used for. The donor is often different each time as it is 
unethical to extract multiple samples from the same donor over a short time frame. 
This results in significant donor variation so it is difficult to establish a reliable 
response over multiple studies. Liu (2012) found it difficult to establish a significant 
donor response to the UHMWPE wear debris – the levels of cytokines produced were 
very low and often not significantly different from the controls. Additionally, this model 
is 2D when the periprosthetic environment is 3D and some cells do not remain on the 
surface of the agarose gel and thus lack contact with the UHMWPE particles; some 
travel down the sides of the gel or underneath it. This issue cannot be solved by 
trapping the cells with the particles simultaneously within the agarose gel as agarose 
gelation is temperature dependent and requires a high temperature (>60°C) to plate it 
out in its liquid phase (even for low temperature gelling agarose), which would 
adversely affect any cells present (Liu, 2012).  
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Gowland (2014) also used the agarose gel model adapted by Liu (2012) with some 
further modifications. The number of PBMNC’s used was increased from 1 x 105 to 2 x 
105 cells per well. The gel plug volume was increased from 200 µl to 300 µl to 
accommodate a greater wear debris volume. The agarose concentration was 
decreased from 1% (w/v) to 0.4% (w/v) to facilitate cell penetration of the gel. 
However it should be noted that agarose gel lacks cell attachment sites so cells would 
not naturally penetrate the gel. Finally, the volume of particles used was increased 
from 100 µm3 per cell to 500 µm3 per cell to maximise the number of particles in the 
critical size range for macrophage response: 0.3 – 1.0 µm (Green et al., 1998). 
Gowland (2014) also briefly trialled a human macrophage cell line – U937 – to 
overcome the issues associated with PBMNC’s. Matthews et al. (2001) conducted a 
study of three different human macrophage cell lines – U937, Monomac-1 and THP-1, 
to assess which is the most appropriate for assessing cytokine release in response to 
UHMWPE wear debris. Matthews et al. (2001) found that only U937 cells behaved in 
reliable, reproducible manner. U937 human histiocytes are the closest human cell line 
equivalent to PBMNC’s. However the use of U937 cells is not straightforward. U937 
human histiocytes are a cell line so donor variation is no longer an issue however 
U937 human histiocytes are a suspension culture therefore they must be chemically 
transformed using phorbol-12-myristate-13-acetate (PMA) in order to become true 
macrophages – both adherent and activated. Additionally they lack the sensitivity of 
murine macrophage lines such as RAW 264.7 cells (Matthews et al., 2000c). 
Ultimately Gowland (2014) returned to using PBMNC’s for the remainder of his work.  
1.8  Aims and objectives 
1.8.1  Hypothesis 
It is hypothesised that a 3D in vitro model can aid with determining whether the 
presence of antioxidants, such as vitamin E and hindered phenols, in UHMWPE can 
reduce osteolytic cytokine production in macrophages exposed to the particulate wear 
debris. 
1.8.2  Aims 
The aim of this study was to develop a novel 3D in vitro model with which to 
investigate the cellular response to highly cross-linked, antioxidant doped UHMWPE 
wear debris in order to assess the effect of antioxidant doping on osteolytic cytokine 
production.  
1.8.3  Objectives 
• To test the viability of three different types of cells (PBMNC’s, U937 human 
histiocytes and RAW 264.7 murine macrophages) in two different types of gels 
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(agarose and type I collagen) using ATP-liteTM luminescence detection assay in 
order to develop a novel in vitro model to measure cellular responses to 
UHMWPE wear debris.  
• To measure the TNF-α output of three different types of cells (PBMNC’s, U937 
human histiocytes and RAW 264.7 murine macrophages) in two different types 
of gels (agarose and type I collagen) in response to model polyethylene 
particles using ELISA in order to develop a novel in vitro model to measure 
cellular responses to UHMWPE wear debris.  
• To generate UHMWPE wear debris from both highly cross-linked UHMWPE 
and highly cross-linked, antioxidant doped UHMWPE using single and six 
station wear simulator rigs.  
• To isolate and characterise the generated wear debris using field emission gun 
scanning electron microscopy (FEGSEM) and analyse the data using ImageJ in 
order to assess the size and volume distribution. 
• To assess the cellular output of osteolytic cytokines and chemokines (TNF-α, 
IL-1β, IL-6 and KC) and inflammatory mediators (LTB4 and PGE2) in response 
to generated UHMWPE wear debris using ELISA; both the full unfiltered range 
of particles and particles that have been filtered into the critical size range of 
0.1-1 µm known to activate macrophages.  
• To assess intracellular reactive oxygen species production in response to 
generated UHMWPE wear debris using the cellular reactive oxygen species 
detection assay; both the full unfiltered range of particles and particles that 
have been filtered into the critical size range of 0.1-1 µm known to activate 
macrophages.  
• To assess the cellular output in terms of osteolytic cytokine and chemokine 
production (TNF-α, IL-1β and IL-6) and inflammatory mediators (LTB4 and 
PGE2) in response to LPS-stimulated cells treated with inflammatory pathway 
inhibitors (indomethacin, bisindolylmaleimide I, calphostin C, MK 886 and REV 
5901) and antioxidants (vitamin E and pentaerythritol tetrakis (3,5-di-tert-butyl-
4-hydroxyhydrocinnamate)) using ELISA in order to elucidate the pathway of 
any anti-inflammatory effects from doping orthopaedic UHMWPE with 
antioxidants. 
• To image particle sequestration (of fluorescein treated six station generated 
particles and model FluoSphere® particles) in the novel in vitro model using 
Lysotracker red to co-localise the particles with the lysosomes inside the 
macrophage cell line and Hoechst to assess whether particles from antioxidant 
doped UHMWPE materials are retained about the nucleus as shown previously 
by Gowland (2014) with GUR 1050 XL wear debris. 
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Chapter 2 
Materials and methods 
2.1  Materials 
The general materials used throughout this study are detailed throughout Chapter 2. 
2.1.1  Chemicals and reagents 
The general chemicals and reagents used throughout this study are listed in Table 
2.1.   
Table 2.1  General chemicals and reagents used throughout this study. 
Name Supplier Storage and 
preparation 
7X-PF detergent ICN 
Biomedicals 
Inc, Ohio, 
USA 
Stored at room 
temperature (25°C). 
10X Minimum Essential 
Medium (MEM) 
Sigma Aldrich, 
Dorset, UK. 
Stored at 4°C. 
ATP-liteTM Luminescence 
ATP detection assay kit 
Perkin Elmer, 
Cambridge, 
UK. 
Stored at 4°C. 
Bovine Serum Albumin 
(BSA) 
Sigma Aldrich, 
Dorset, UK. 
Stored at 4°C 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, 
Dorset, UK. 
Stored at room 
temperature (25°C) and 
passed through a 0.2 
µm filter unit prior to 
use. 
Distilled deionised water 
(dH2O) – ELGA Reservoir 
75 L still 
ELGA, High 
Wycombe, 
UK. 
Stored at room 
temperature (25°C). 
Dulbecco’s Modified Eagles 
medium (DMEM) 
Sigma Aldrich, 
Dorset, UK. 
Stored at 4°C. 
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Dulbecco’s phosphate 
buffered saline solution 
(without calcium and 
magnesium) (DPBS) 
Sigma Aldrich, 
Dorset, UK. 
Stored at room 
temperature (25°C). 
Ethanol - 70% (v/v) ThermoFisher 
Scientific UK, 
Loughborough
, UK. 
Stored at room 
temperature (25°C) and 
mixed with distilled 
water (7:3). 
Fairy liquid detergent (15 – 
30% anionic surfactants 
and 5 – 15% nonanionic 
surfactants) 
Proctor and 
Gamble, 
Weybridge, 
UK. 
Stored at room 
temperature (25°C). 
Foetal Bovine Serum (FBS) Seralab, 
Haywards 
Heath, UK. 
Stored at -20°C. 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid 
(HEPES) (1 M) 
Bio-Whittaker, 
Lonza, 
Verviers, 
Belgium 
Stored at room 
temperature (25°C). 
Human TNF-α uncoated 
ELISA kit – 20 x 96 well 
plates 
Diaclone, 
Besancon 
Cedex, 
France 
Stored at 4°C. 
L-glutamine Sigma Aldrich, 
Dorset, UK. 
Stored at -20°C. 
Lipopolysaccharide (LPS) - 
from E. coli 
Sigma Aldrich, 
Dorset, UK. 
Stored at 4°C and stock 
solution prepared by 
adding 1 ml DPBS to 1 
mg vial of lyophilised 
powder and frozen at -
20°C until use. 
Low melting point agarose Sigma Aldrich, 
Dorset, UK 
Stored at room 
temperature (25°C).  
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Lymphoprep Fresenius 
Kabi Norge 
AS for Axis 
Shield PoC 
AS, Oslo, 
Norway 
Stored at room 
temperature (25°C). 
Mouse IL-1β uncoated 
ELISA kit -10 x 96 well 
plates 
ThermoFisher 
Scientific UK, 
Loughborough
, UK. 
Stored at 4°C. 
Mouse IL-6 uncoated 
ELISA kit – 10 x 96 well 
plates 
ThermoFisher 
Scientific UK, 
Loughborough
, UK. 
Stored at 4°C. 
Mouse TNF-α uncoated 
ELISA kit – 10 x 96 well 
plates 
ThermoFisher 
Scientific UK, 
Loughborough
, UK. 
Stored at 4°C. 
Penicillin/Streptomycin Sigma Aldrich, 
Dorset, UK. 
Stored at -20°C. 
Phorbol-12-myristate-13-
acetate (PMA) 
Cayman 
Chemical, UK 
Stored at -20°C. 
Reconstituted by 
dissolving 1 mg powder 
in 1 ml DMSO. 
Rat Tail Collagen Type I, 
>2mg.ml-1 Chloroform 
Treated 
First Link Ltd, 
Wolverhampto
n, UK. 
Stored at 4°C. 
RayBio® Mouse KC ELISA 
kit – 1 x 96 well plate 
RayBio®, 
Georgia, USA. 
Stored at -20°C. 
R&D® Parameter ™ LTB4 
assay – 1 x 96 well plate 
R&D® 
Systems, 
Minneapolis, 
USA. 
Stored at -20°C. 
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R&D® Parameter ™ PGE2 
assay – 1 x 96 well plate 
R&D® 
Systems, 
Minneapolis, 
USA. 
Stored at -20°C. 
Roswell Park Memorial 
Institute medium (RPMI) 
1640 medium 
Sigma Aldrich, 
Dorset, UK. 
Stored at 4°C. 
Sodium azide Sigma Aldrich, 
Dorset, UK 
Stored at room 
temperature (25°C). 
Sodium hydroxide (NaOH) 
pellets 
ThermoFisher 
Scientific UK, 
Loughborough
, UK. 
Stored at 25°C. 
Sulfuric acid (H2SO4) - 1 M Sigma Aldrich, 
Dorset, UK. 
Stored at room 
temperature (25°C). 
Trypan blue Sigma Aldrich, 
Dorset, UK. 
Stored at room 
temperature (25°C) and 
passed through a 0.2 
µm filter unit prior to 
use. 
Trypsin (0.5% (v/v)) in 
ethylenediaminetetraacetic 
acid (EDTA) 
Sigma Aldrich 
Ltd, Dorset, 
UK 
Stored at -20°C. 
TWEEN-20 (Polysorbate-
20) 
Sigma Aldrich, 
Dorset, UK. 
Stored at room 
temperature (25°C). 
Ultrapure water Baxter 
Healthcare, 
Zurich, 
Switzerland. 
Stored at room 
temperature (25°C). 
Vacuum grease Dow Corning, 
Michigan, 
USA. 
Stored at room 
temperature (25°C). 
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Virkon solution – 1% (w/v) DuPont, 
Stevenage, 
UK. 
Stored at room 
temperature (25°C) and 
prepared by adding 5 
scoops of virkon 
powder to 5000 ml of 
distilled water. 
 
2.1.2  Consumables 
The general consumables used throughout this study are listed in Table 2.2. 
Table 2.2  General consumables used throughout this study. 
Item Size Supplier 
Blue paper roll N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Cell scraper N/A Greiner Bio-One, 
Kremsmunster, 
Germany. 
Cryovial 1 ml ThermoFisher Scientific 
UK, Loughborough, UK. 
Dish sponge N/A Tesco, Cheshunt, UK. 
Falcon tubes 50 ml Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Filter units 0.2 µm Merck Millipore Ltd, 
Cork, Ireland. 
Flat bottomed tissue 
culture plates  
48 and 96 well Corning, New York, USA 
and Nunc, Denmark. 
Foil N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Glass cover slips 22 x 22 mm Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
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Needles Various sizes Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Nitrile gloves Medium Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Nunc maxisorp 
plates 
96 well Nunc, Denmark 
Nunc uncoated F 
plates 
96 well Nunc, Denmark 
Plastic bijoux N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Plastic petri dishes Various sizes Sterilin Ltd, Newport, UK. 
Plastic pipette tips 1000 µl, 200 µl and 
20 µl 
Starlab, Milton Keynes, 
UK. 
Plastic serological 
pipettes  
5 ml, 10 ml and 25 
ml 
Sarstedt, Numbredt, 
Germany. 
Plastic syringes  1 ml, 2 ml, 5 ml, 10 
ml, 20 ml and 50 ml 
Appleton Woods, 
Birmingham, UK. 
Plastic universals N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Plate seals N/A Perkin Elmer, 
Cambridge, UK. 
Polycarbonate filter 
papers  
10 µm, 1 µm, 0.1 
µm and 0.015 µm 
pore sizes 
Whatman, Maidstone, 
UK. 
Sepmate tubes 50 ml Stem Cell Technologies, 
Vancouver, Canada. 
Sodium heparinised 
collection test tubes  
14 ml Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
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Sterile plastic pots  60 ml, 150 ml and 
250 ml 
ThermoFisher Scientific, 
Hemel Hempstead, UK. 
Tissue culture flask 75 cm2 Corning, New York, USA 
and Nunc, Denmark. 
Toothbrushes N/A Morrisons, Bradford, UK. 
Vacuum seal bags 30 cm x 10 cm Westfield Medical Ltd, 
Radstock, UK. 
Weighing boats Various sizes Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
White optiplates 96 well Perkin Elmer, 
Cambridge, UK. 
Wide bore pipette 
tips 
1000 µl Starlab, Milton Keynes, 
UK. 
 
2.1.3  Equipment 
The general equipment used throughout this study is listed in Table 2.3. 
Table 2.3  General equipment used throughout this study. 
Name Model Supplier 
Balance GR200 A & D Instruments Ltd, 
Oxford, UK. 
Balance  GX 2000 EC Sartorius, Epsom, UK. 
Centrifuge Harrier 15/80 Sanyo, Watford, UK. 
Class I laminar flow 
cabinet 
N/A Bassaire, Southampton, 
UK 
Class II safety 
cabinet 
Heraeus 85 Heraeus Instruments, 
Hanau, Germany 
Fluorescence 
microscope 
Zeiss Axio Imager M2 Carl Zeiss, Oberkochen, 
Germany. 
Freezer (-20°C) N/A Labcold, Basingstoke, 
UK. 
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Freezer (-80°C) N/A Labcold, Basingstoke, 
UK. 
Fridge N/A Labcold, Basingstoke, 
UK. 
Fumehood N/A Whiteley, Hants, UK. 
Gilson pipettes – 
1000 µl, 200 µl, 20 
µl and 2 µl 
N/A Thermo Scientific, Hemel 
Hempstead, UK. 
Glass Duran bottles 
(500 ml and 1 L) 
N/A Fisherbrand, 
Loughborough, UK. 
Glass filtration 
equipment 
N/A Sartorius, Epsom, UK. 
Glass petri dish N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Glass universals N/A Glassware Stores, 
School of Molecular and 
Cellular Biology, 
University of Leeds. 
Haemocytometer N/A Optik Labor, 
Friedrichshofen, 
Germany. 
Ignitor N/A Fisher Scientific UK, 
Loughborough, UK. 
Incubator  MCO-20AIC Sanyo, Watford, UK. 
Light microscope  Olympus CK40-SLP Olympus Optical Co. Ltd, 
London, UK. 
Metal spatula N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Metal tweezers N/A Fisher Scientific UK, 
Loughborough, UK. 
Microwave  KM19W Proline, UK 
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Mr Frosty N/A Sigma Aldrich, Dorset, 
UK. 
Orbital shaker PSU-10i Fisher Scientific UK, 
Loughborough, UK. 
Oven N/A Genlab, Widnes, UK. 
Pipette boy N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Plate reader Hidex plate chameleon Hidex, Turku, Finland. 
Plate reader Multiskan spectrum Thermo Scientific, Hemel 
Hempstead, UK. 
Scissors N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Sonicating water 
bath 
N/A VWR, Lutterworth, UK. 
Thermometer N/A Fisher Scientific UK, 
Loughborough, UK. 
Vacuum pump N/A KNF, Neubauer, 
Germany. 
Vacuum sealer N/A Hulme-Martin Ltd, 
Woking, UK. 
Vacuum tubing N/A Cole-Parmer Instrument 
Co Ltd, London, UK. 
Vortex mixer Topmix FB15024 ThermoFisher Scientific 
UK, Loughborough, UK. 
Wash bottle N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Water bath N/A Grant Instruments 
Limited, Cambridge, UK. 
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White plastic 
filtration disc 
N/A Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
 
2.1.4  Cell lines 
The general cell lines used throughout this study are listed in Table 2.4.   
Table 2.4  General cell lines used throughout this study. 
Cell line Species Origin Supplier 
RAW 264.7 Mouse Ascites of an 
induced tumour 
by intraperitoneal 
injection of 
Abselon 
Leukaemia Virus. 
European 
Collection of 
Animal Cell 
Cultures. 
U937 Human Histiocytic 
lymphoma 
European 
Collection of 
Animal Cell 
Cultures. 
 
2.1.5  Primary cells 
The primary cells used in this study are listed in Table 2.5.   
Table 2.5  Primary cells used throughout this study. 
Primary cell 
type 
Species Origin Supplier 
Peripheral Blood 
Mononuclear 
Cells (PBMNCs) 
Human Blood Individual donors 
 
2.1.6  Particles 
The general particles used throughout this study are listed in Table 2.6.   
Table 2.6  General particles used throughout this study. 
Item Supplier 
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0.2 µm FluoSpheres® Carboxylate-
Modified Microspheres – yellow-
green fluorescent (505/515) 
Invitrogen Life Technologies Ltd, 
Paisley, UK. 
Ceridust® 3615 resin Hoescht, Germany. 
 
2.2  Methods 
The methods used throughout all chapters of this study are described below.  
2.2.1  Equipment sterilisation 
Throughout the course of this study, it was necessary to sterilise various equipment 
and disinfect work surfaces to ensure a sterile working environment. The methods 
used to do so are detailed below. 
2.2.1.1  Aseptic technique 
Prior to use, the interior surfaces of the class II safety cabinet were sprayed with 1% 
Virkon (w/v) followed by 70% ethanol (v/v). All items that entered the cabinet were 
sprayed with 70% ethanol (v/v). After use, the cleaning process was repeated and the 
cabinet was disinfected with UV light for one hour prior to shut down.  
2.2.1.2  Glassware and plastic-ware sterilisation 
All glassware and plastic-ware was washed with fairy liquid and warm water and 
scrubbed using a toothbrush. The glassware and plastic-ware was then rinsed with 
distilled water followed by ultrapure water. The glassware was then sterilised using dry 
heat sterilisation and the plastic-ware was sterilised using moist heat sterilisation.  
2.2.1.3  Dry heat sterilisation 
All equipment to be sterilised was wrapped in foil after being washed thoroughly and 
air dried. Equipment was then placed into a hot air oven at 190°C for 4 hours. Items 
were left to cool before being removed from the oven.  
2.2.1.4  Moist heat sterilisation 
Items unable to undergo dry heat sterilisation, for example plastic and solutions in 
glass bottles, were autoclaved. After being washed thoroughly with detergent and air 
dried, items were sealed in medical packaging and autoclaved at 15 psi and 121°C for 
20 minutes. Items were left to cool before being removed from the autoclave.  
2.2.1.5  Filter sterilisation 
Solutions, such as DMSO and Trypan blue, were filter sterilised using a 0.22 µm 
sterile filter unit in a sterile class II safety cabinet prior to use. Solutions were drawn up 
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into a 10 ml syringe, the filter unit was attached and the solution was passed through 
into a sterile universal.   
2.2.2  Microscopy 
The methods used to carry out bright field and fluorescence microscopy are detailed 
below.  
2.2.2.1  Bright field 
For cell culture observation and counting, an optical Olympus CK040-SLP microscope 
was used. Köhler illumination was used to view the samples.  
2.2.2.2  Fluorescence 
A Zeiss Axio Imager M2 fluorescence microscope was used to image fluorescently 
stained cells and particles in collagen gel. The channels used were: 461 nm (Hoechst; 
blue), 521 nm (Fluorescein; green) and 590 nm (Lysotracker red; red). 
2.2.3  General reagents and solutions preparation 
The preparation of the general reagents and solutions used throughout this study are 
described below. Reagents and solutions specific to particular chapters are described 
in the relevant methods of Chapters 3, 4 and 5.  
2.2.3.1  Cryopreservation medium  
Cryopreservation medium for RAW 264.7 murine macrophages was prepared by 
combining 14 ml DMEM with 4 ml FBS (20% (v/v)) and 2 ml DMSO (10% (v/v)). The 
cryopreservation medium was heated to 37°C prior to use and stored at 4°C between 
uses for up to one month. 
2.2.3.2  Dulbecco’s Modified Eagles Medium cell culture medium 
Cell culture medium for RAW 264.7 murine macrophages was prepared by combining 
500 ml DMEM with 100 U.ml-1 penicillin and 100 µg.ml-1 streptomycin, 2 mM L-
glutamine and 10% (v/v) FBS. Aliquots of 100 U.ml-1 penicillin and 100 µg.ml-1 
streptomycin, 2 mM L-glutamine and 10% (v/v) FBS were stored at -20°C and 
defrosted using a water bath at 37°C. Complete DMEM was heated in a water bath at 
37°C for 30 minutes before use and stored in the fridge at 4°C between uses for up to 
one month.  
2.2.3.3  Ethanol 
A 10 L stock of 70% (v/v) ethanol was prepared by adding 3 L distilled water to 7 L of 
ethanol. 
2.2.3.4  Lipopolysaccharide 
Stock solution preparation 
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A mass of 1 mg of LPS powder was reconstituted with 1 ml DPBS to produce a 1 
mg.ml-1 stock solution. This was stored at -20°C between uses and defrosted in a 
water bath at 37°C when required.  
Working solution preparation 
A working solution of LPS was prepared by adding 4 µl of LPS stock (4000 ng) to 20 
ml medium (either DMEM or RPMI 1640) to give a final working concentration of 200 
ng.ml-1. 
2.2.3.5  Nutrient broth 
Nutrient broth powder, 13 g, was weighed out and added to 1 L of distilled water in a 
sterile glass Duran bottle. The bottle was agitated to dissolve the powder. The bottle 
was then autoclaved to sterilise the nutrient broth. 
2.2.3.6  Roswell Park Memorial Institute 1640 cell culture medium 
Cell culture medium for PBMNC’s and U937 human histiocytes was prepared by 
combining 500 ml RPMI 1640 cell culture medium with 100 U.ml-1 penicillin and 100 
µg.ml-1 streptomycin, 2 mM L-glutamine and 10% (v/v) FBS as per Section 2.2.3.2.  
2.2.3.7  Sodium hydroxide (1.94 M) 
Sodium hydroxide pellets (7.76 g) were weighed out and added to a 100 ml glass 
Duran bottle. The pellets were dissolved in 100 ml ultrapure water. This solution was 
then sent to autoclave (121°C and 15 psi for 20 minutes). 
2.2.3.8  Trigene  
A 5 L stock of 1% (w/v) Trigene was prepared by combining 50 ml of Trigene with 5 L 
distilled water.  
2.2.3.9  Virkon  
A 5 L stock of 1% (w/v) Virkon was prepared by mixing 50 g of Virkon powder with 5 L 
distilled water.  
2.2.3.10 Wear simulator rig lubricant 
FBS was added to RPMI 1640 cell culture medium to create a 25% (v/v) solution in a 
sterile, aseptically cleaned class II cell culture cabinet. This was prepared either the 
day before or on the day of the wear test in which it was used and was stored in a 
sterile plastic pot in the fridge at 4ºC until use.   
2.2.4  Isolation of primary cells 
The full procedure to isolate PBMNCs from donated human whole blood is detailed 
below. The blood used herein was collected as per the Faculty of Biological Sciences 
Ethics Committee approval (BIOSCI 10-018). All donors were healthy and were 
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between 24 and 60 years of age. Each donor provided informed consent prior to 
donation.  
2.2.4.1  Solution preparation 
RPMI 1640 cell culture medium 
RPMI 1640 cell culture medium was prepared as described previously in Section 
2.2.3.6. 
RPMI 1640 transport medium 
Transport medium for PBMNCs was prepared by combining 500 ml RPMI 1640 
medium with 2 ml of 100 U.ml-1 penicillin and 100 µg.ml-1 streptomycin and 80 µl 1M 
HEPES. RPMI 1640 transport medium was heated in a water bath at 37°C for 30 
minutes before use and stored in the fridge at 4°C between uses for up to one month.  
2.2.4.2  Tissue harvesting 
Approximately 30 ml of whole blood was taken by venepuncture of an anonymous 
donor using a 21 G butterfly needle. The donated blood was stored in sodium 
heparinised collection tubes at room temperature (25°C) until use later that day. 
2.2.4.3  Achiever tracking 
The blood was recorded and tracked from whole blood donation to PBMNC isolation 
to disposal using the Achiever tissue tracking system (Leeds Teaching Hospital NHS 
Trust and University of Leeds) as specified by the Human Tissue Authority and 
Faculty of Biological Sciences Ethics Committee Approval (BIOSCI 10-018).  
2.2.4.4  Isolation of Peripheral Blood Mononuclear Cells from whole blood tissue 
PBMNC isolation was carried out in an aseptically cleaned class II safety cabinet. The 
blood was mixed by gently inverting the tubes. All vials of blood were pooled in a 
sterile 150 ml pot (approximately 40 ml blood per sample overall) and were 
immediately diluted 1:1 with RPMI 1640 transport medium and swirled gently to mix. 
Lymphoprep was pipetted carefully through the filter hole into each Sepmate tube until 
the filter was covered (approximately 15 ml). Whole blood (between 10 and 15 ml per 
tube) was then layered over the lymphoprep in each tube. The Sepmate tubes were 
then centrifuged at 12000 g and brake speed 4 for 10 minutes at room temperature 
(25°C). The top layer of each Sepmate tube was poured into fresh falcon tubes; 
leaving behind the red blood cells below the filter. The PBMNC’s were washed with 
RPMI 1640 transport medium and centrifuged at 150 rcf for 10 minutes at brake speed 
4 at room temperature (25°C). This was repeated twice more. Finally the cell pellets 
were resuspended in complete RPMI 1640 cell culture medium and combined. The 
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cells were counted using the Trypan blue exclusion assay as described in Section 
2.2.8.3.  
2.2.5  Cell line culture and maintenance 
2.2.5.1  Resurrection of cell lines 
RAW 264.7 murine macrophages 
A cryovial of RAW 264.7 murine macrophages, containing approximately 1 x 106 cells, 
was taken from storage in liquid nitrogen at -196°C and defrosted rapidly (2 to 5 
minutes) in a water bath at 37°C. Complete DMEM cell culture medium (8 ml) was 
added to a Corning T75 tissue culture flask followed by the addition of the cells and 
cryopreservation medium contained in the cryovial (1 ml). The cryovial was rinsed with 
a further 1 ml of complete DMEM cell culture medium, which was also added to the 
tissue culture flask to give a final volume of 10 ml medium inside the flask. The cells 
were observed using light microscopy to confirm their presence and then the flask was 
placed inside an incubator at 37°C and 8% (v/v) CO2 in air overnight. After 
approximately 12 hours, the flask was observed again using light microscopy to 
confirm cell adherence. The existing medium in the tissue culture flask was replaced 
with 10 ml fresh complete DMEM cell culture medium in order to remove any remains 
of cryopreservation medium. The flask was placed in the incubator at 37°C and 8% 
(v/v) CO2 in air for a further 48 hours. 
U937 human histiocytes 
A cryovial of U937 human histiocytes (containing approximately 1 x 106 cells) was 
prepared as described above. Complete RPMI 1640 cell culture medium (8 ml) was 
added to a universal in addition to the contents of the cryovial (1 ml) and the medium 
used to rinse the cryovial (1 ml) to give a final volume of 10 ml medium. The universal 
was then centrifuged at 150 rcf for 10 minutes in order to separate the cells from the 
cryopreservation medium. The supernatant was discarded and the cell pellet was 
resuspended in 10 ml of fresh complete RPMI 1640 cell culture medium. The cells and 
medium were then transferred to a sterile Nunc T75 tissue culture flask. The flask was 
observed using light microscopy as above and placed at a 45° angle inside an 
incubator at 37°C and 5% CO2 (v/v) in air overnight.  
2.2.5.2  Transformation of U937 human histiocytes using Phorbol-12-Myristate-
13-Acetate 
Phorbol-12-Myristate-13-Acetate (PMA) powder (1 mg) was dissolved in 1 ml DMSO 
to create a 1 mg.ml-1 stock. A volume of 1 µl of stock PMA was added to 1 ml of DPBS 
to create a 1 µg.ml-1 stock. A volume of 100 µl of the diluted stock solution (1 µg.ml-1) 
was added to 10 ml of complete RPMI 1640 cell culture medium and suspended, non-
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transformed U937 human histiocytes in a tissue culture flask to create a 10 ng.ml-1 
working solution. This was carried out after a medium change (as described below in 
Section 2.2.5.3) to ensure the transformation medium was fresh. The tissue culture 
flask was then laid flat and incubated at 37°C and 5% (v/v) CO2 in air for 24 hours. 
After 24 hours, cell morphology was inspected using light microscopy to confirm 
transformation; transformed cells displayed fibroblastic morphology rather than 
rounded. 
2.2.5.3  Medium change of cell lines 
RAW 264.7 murine macrophages and transformed U937 human histiocytes 
Occasionally, it was necessary to change the medium rather than passage cells in 
order to maintain cell numbers prior to use. This was achieved by simply aspirating 
the existing medium and replacing it with 10 ml fresh complete cell culture medium 
and returning the tissue culture flasks to the incubator at 37°C and 8% (v/v) (RAW 
264.7 murine macrophages) or 5% (v/v) (U937 human histiocytes) CO2 in air. 
Non-transformed U937 human histiocytes 
The existing U937 human histiocytes and medium were removed from the tissue 
culture flask and placed into a sterile universal, which was centrifuged at 150 rcf for 10 
minutes at room temperature (25°C). The supernatant was discarded and the cell 
pellet was resuspended in 10 ml fresh complete RPMI 1640 cell culture medium. This 
was then transferred back into the existing tissue flask. The flask was then incubated 
at 37°C in 5% (v/v) CO2  in air overnight at a 45° angle.  
2.2.5.4  Passage of cell lines 
RAW 264.7 murine macrophages 
Following resurrection, the cells were regularly observed using a light microscope to 
check their confluency, i.e. how much of the observable space was covered with cells 
expressed as a percentage. Once the confluency was 70% or more, the RAW 264.7 
murine macrophages were passaged. RAW 264.7 murine macrophages were 
passaged at a lower confluency than other cell types (typically >80%) because they 
are a semi-adherent cell type. This means they can change phenotype and become a 
suspension cell type if they become overcrowded. Passaging was achieved by first 
replacing the existing medium with fresh medium. The cells were then detached 
physically from the tissue flask base using a cell scraper. The base was scraped back 
and forth from the back of the flask to the front and then in reverse. The medium 
became cloudy as the cells were detached and their detachment was confirmed using 
a light microscope. The detached cells were visible as free floating rounded up cells in 
the medium. The resultant cell:medium mixture was then divided between tissue 
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culture flasks in the ratio 1:2. Fresh medium was then added to each flask until each 
flask contained 10 ml complete cell culture medium. The flasks were then replaced in 
the incubator at  37°C and 8% (v/v) CO2 in air overnight. 
Non-transformed U937 human histiocytes 
Passaging was achieved by placing the existing suspension cells and medium from 
the tissue culture flask into a sterile universal, which was centrifuged at 150 rcf for 10 
minutes at room temperature (25°C). The supernatant was discarded and the cell 
pellet was resuspended in 10 ml fresh complete RPMI 1640 cell culture medium. This 
was then split 1:3 with each flask having a total volume of 10 ml medium. The flasks 
were then incubated at 37°C in 5% (v/v) CO2 in air overnight.  
Transformed U937 human histiocytes 
The existing medium was removed from the tissue culture flask and discarded. A 
volume of 3 ml of trypsin (0.5%(v/v)) in EDTA was added to the tissue culture flask 
such that the monolayer of cells attached to the surface was covered. The tissue 
culture flask was incubated at 37°C and 5% (v/v) CO2 in air for 10 minutes. The flasks 
were then gently tapped and inspected under a light microscope to confirm 
detachment of the cells. The cells and trypsin were removed from the tissue culture 
flask and placed into a sterile universal. A volume of 10 ml of fresh complete RPMI 
1640 cell culture medium was added to the universal. The universal was then 
centrifuged at 150 rcf for 10 minutes at brake speed 4 at room temperature (25°C). 
The supernatant was discarded and the cells were resuspended in 10 ml of fresh 
complete RPMI 1640 cell culture medium. The cells were not split amongst further 
flasks but instead went on to be used immediately.  
2.2.5.5  Cryopreservation of cell lines 
Cells were passaged as described in Section 2.2.5.4 and counted using Trypan blue 
exclusion assay as described in Section 2.2.8.3. The cells were then centrifuged at 
150 rcf for 10 minutes at brake speed 4. The supernatant was discarded and the cell 
pellet was resuspended in cryopreservation medium made with either DMEM or RPMI 
1640 culture medium according to the cell line used. Frozen cell stocks were created 
by adding 1 ml of cryopreservation medium to 1 x 106 cells in a cryovial. The cryovial 
was then placed into a controlled rate freezer (Mr Frosty) at -80°C for 24 hours. After 
24 hours, the cryovial was moved to permanent storage in liquid nitrogen at -196°C.   
2.2.5.6  Disposal of cell lines 
All cell containing waste was disposed of by adding 1% (w/v) Virkon solution, 
incubating at room temperature (25°C) for 30 minutes followed by disposal into the 
waste water system. 
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2.2.6  Particle preparation 
Both Ceridust® and FluoSpheres® were used as model particles throughout this 
study in addition to artificially generated UHMWPE wear debris. The preparation of all 
types of particles to be seeded with cells are detailed herein.  
2.2.6.1  Ceridust® 
Ceridust 3615® resin (Hoechst, Germany) is a low molecular weight polyethylene 
powder which is commercially available and often used to used to initially model 
cellular response to polyethylene particles in place of clinically relevant wear debris in 
cases where yields may be low and thus particle stock is limited. Ceridust 3615® resin 
is known to induce the production of inflammatory cytokines associated with osteolysis 
in both human (Matthews et al., 2000a; Matthews et al., 2001) and murine (Green et 
al., 1998) macrophage cells. In this study, Ceridust 3615® resin was filtered into three 
different size ranges (>10 µm, 1 – 10 µm and 0.1 – 1 µm) to assess the inflammatory 
response to defined particle sizes as size is known to be an important factor for the 
production of inflammatory cytokines by macrophage cells (Green et al., 1998).  
Preparation 
A mass of 100 mg of Ceridust® was weighed out. In a sterile environment, the 
Ceridust® was placed in a sterile glass petri dish. A volume of 1 ml of either RPMI 
1640 medium (for use with U937 human histiocytes and PBMNCs) or DMEM (for use 
with RAW 264.7 murine macrophages) was added drop-wise and used to blend the 
particles. Further volumes of medium (1 ml at a time drop-wise) were added until the 
particles were fully blended and a final volume of 20 ml was achieved. The particles 
and medium mixture was placed into a sterile glass universal. The universal was then 
sonicated for 40 minutes. 
Filtration 
Polycarbonate filter papers (10 µm, 1 µm and 0.1 µm pore sized) were rinsed with 
70% (v/v) ethanol and air dried then weighed. The filtration equipment was cleaned 
and sterilised in an oven at 190°C. The filtration equipment was set up in a sterile 
class II safety cabinet and then Ceridust® suspension was filtered sequentially 
through the 10 µm, 1 µm and 0.1 µm filters. The filter papers were then left to air dry 
overnight in the class II safety cabinet, in order to evaporate any moisture present 
which may affect mass readings, and then weighed again. The mass of Ceridust® for 
each size range (>10 µm, 1 - 10µm and 0.1 - 1 µm) was calculated: 𝑀𝑎𝑠𝑠 𝑜𝑓 𝐶𝑒𝑟𝑖𝑑𝑢𝑠𝑡 𝑔=  𝑀𝑎𝑠𝑠 𝑜𝑓 𝐶𝑒𝑟𝑖𝑑𝑢𝑠𝑡 𝑎𝑛𝑑 𝑓𝑖𝑙𝑡𝑒𝑟 𝑝𝑎𝑝𝑒𝑟 𝑎𝑓𝑡𝑒𝑟 𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑛𝑑 𝑎𝑖𝑟 𝑑𝑟𝑦𝑖𝑛𝑔 𝑔−𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑦 𝑓𝑖𝑙𝑡𝑒𝑟 𝑝𝑎𝑝𝑒𝑟 𝑝𝑟𝑖𝑜𝑟 𝑡𝑜 𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑔) 
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The filter papers were then cut into small pieces and placed in 10 ml of medium as 
before. The suspensions were stored at -20°C between use and, when required, 
defrosted and sonicated for 40 minutes prior to use.  
The particle dose for Ceridust® was calculated as follows. Each experiment required a 
dose of 100 µm3 particles.cell-1. The final cell seeding density chosen was 1 x 105 
cells.ml-1. These quantities are used to calculate the required volume of particles.ml-1: 
1 x 105 cells.ml-1 x 100 µm3 particles.cell-1 = 1 x 107 µm3 particles.ml-1 
The relationship between density and volume was then used to calculate the mass of 
particles needed per well: 
Mass = Volume x Density 
 (1 x 107 µm3) x (1 x 10-6 µg. µm-3) = 10 µg particles per well 
This mass was then used to calculate the volume of the prepared Ceridust® 
suspension required to encapsulate in either agarose or collagen gel.  𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑝𝑒𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 (6 𝑟𝑒𝑝𝑒𝑎𝑡𝑠)𝑀𝑎𝑠𝑠 𝑜𝑓 𝑐𝑒𝑟𝑖𝑑𝑢𝑠𝑡 𝑜𝑛 𝑓𝑖𝑙𝑡𝑒𝑟 𝑝𝑎𝑝𝑒𝑟  𝑥 100= % 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑡𝑜 𝑢𝑠𝑒 
for example - 0.06 mg/14.7 mg x 100 = 0.41% 
therefore 0.41% of 5 ml (20.5 µl) of the >10 µm Ceridust® suspension was used. 
2.2.6.2  FluoSpheres® 
FluoSpheres® (Invitrogen Life Technologies Ltd, Paisley, UK) are latex particles that 
are commercially available in a variety of sizes and with a variety of fluorescent tags. 
FluoSpheres® are known to induce an inflammatory response in human PBMNCs 
(Richards, 2008; Liu, 2012). For this study, 0.2 µm FluoSpheres® Carboxylate-
Modified Microspheres  yellow-green fluorescent (505/515) were used.  
The volume of FluoSpheres® required per ml was calculated as follows: 
1 x 105 cells.ml-1 x 100 μm3 particles.cell-1 = 1 x 107 μm3 particles.ml-1  
The total volume of the stock FluoSpheres® was then divided by the volume of 
FluoSpheres® required in order to yield the dilution factor: 
1.905 x 1010 μm3/1 x 107 μm3 = 1905 
Therefore 1/1905th of the total volume of FluoSpheres® (1 ml) was required per well, 
i.e. 0.5 μl.  
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2.2.6.3  Single and six station pin-on-plate multidirectional wear simulator rig 
generated UHMWPE wear debris 
Polycarbonate filter papers (10 µm, 1 µm and 0.1 µm pore sized) were rinsed with 
70% (v/v) ethanol and air dried then weighed. The filtration equipment was cleaned 
and sterilised in an oven at 190°C. The six station wear test lubricants to be used 
were removed from storage at -20°C, allowed to defrost at room temperature (25°C) 
and sonicated for 40 minutes. The filtration equipment was set up in a sterile class II 
safety cabinet and then each six station pin-on-plate (POP) wear test serum (GUR 
1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE) was filtered 
sequentially through the 10 µm, 1 µm and 0.1 µm pore sized polycarbonate filters. The 
polycarbonate filter papers were then left to air dry overnight in the class II safety 
cabinet and the 0.1 µm pore sized polycarbonate filter paper was weighed again. The 
mass of UHMWPE wear debris for the size range 0.1 - 1 µm was calculated: 𝑀𝑎𝑠𝑠 𝑜𝑓 𝑈𝐻𝑀𝑊𝑃𝐸 𝑤𝑒𝑎𝑟 𝑑𝑒𝑏𝑟𝑖𝑠 𝑔=  𝑀𝑎𝑠𝑠 𝑜𝑓 𝑈𝐻𝑀𝑊𝑃𝐸 𝑤𝑒𝑎𝑟 𝑑𝑒𝑏𝑟𝑖𝑠 𝑎𝑛𝑑 𝑓𝑖𝑙𝑡𝑒𝑟 𝑝𝑎𝑝𝑒𝑟 𝑎𝑓𝑡𝑒𝑟 𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑔−𝑀𝑎𝑠𝑠 𝑜𝑓 𝑓𝑖𝑙𝑡𝑒𝑟 𝑝𝑎𝑝𝑒𝑟 𝑝𝑟𝑖𝑜𝑟 𝑡𝑜 𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑔) 
Once dry, the filter papers were then cut into small pieces and placed in 1 ml of 
medium. The suspensions were used immediately with sonication for 40 minutes prior 
to use.  
The mass of particles required per condition was calculated:  𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑝𝑒𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 (12 𝑟𝑒𝑝𝑒𝑎𝑡𝑠)𝑀𝑎𝑠𝑠 𝑜𝑓 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒𝑑 𝑤𝑒𝑎𝑟 𝑑𝑒𝑏𝑟𝑖𝑠 𝑖𝑛 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛  𝑥 100= % 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑡𝑜 𝑢𝑠𝑒 
for example - 0.12 mg/88.8 mg x 100 = 0.14% 
therefore 0.14% of 20 ml (28 µl) of the single station POP generated GUR 1020 XL 
AOX suspension was used. 
2.2.7  Preparation of gels 
The methods used to prepare both the agarose and collagen gels used in this study 
are described below.  
2.2.7.1  Agarose gel preparation 
A stock solution of 2% (w/v) agarose was prepared which was then used to prepare 
the final 0.4% (w/v) agarose gel solution. The preparation of both is detailed below.  
Stock agarose gel preparation – 2% (w/v) 
A mass of 6 g of low melting point agarose powder was added to 30 ml of medium 
(either DMEM or RPMI 1640 depending on the cell type to be seeded within it) in a 
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sterile glass Duran bottle. The contents were then mixed and the glass Duran bottle 
underwent moist heat sterilisation as described in Section 2.2.1.4.  
Working concentration agarose gel preparation – 0.4% (w/v) 
The glass Duran bottle containing 2% (w/v) agarose gel stock was heated in the 
microwave until molten (approximately 1 minute). Stock agarose gel (2 ml) was added 
to preheated (37°C) medium (8 ml) – either DMEM or RPMI 1640 medium – to create 
a 10 ml stock solution. Gels were prepared in 48 well plates as follows. A volume of 
200 µl of the 0.4 % (w/v) agarose gel was pipetted into either Corning Co-Star (for 
RAW 264.7 murine macrophages) or Nunc coated 48 well tissue culture plates (for 
U937 human histiocytes and PBMNCs). The gels were left to set at room temperature 
(25°C) for 10 to 15 minutes, sealed with a plastic film cover and stored at 4°C until 
use. 
2.2.7.2  Type I rat tail collagen 
Initially 80% (v/v) type I rat tail collagen gel was added to a sterile universal followed 
by 10% (v/v) 10X MEM which was added slowly to avoid generating bubbles and 
mixed gently. The mixture was not aspirated in order to avoid the generation of 
bubbles. A peach/orange colour was observed. Once the collagen and 10X MEM was 
mixed, 1.94 M sodium hydroxide was added drop-wise to the gel in order to begin the 
pH dependent process of setting the gel until a light pink colour was achieved. Finally, 
4.2% (v/v) cells/medium/particles was added to the gel; again pipetted carefully into 
the gel mixture and mixed gently. A volume of 200 µl gel was added to each well of a 
Corning CoStar 48 well tissue culture plate and the plate was placed into the incubator 
until set (approximately 10 to 15 minutes). This volume was kept the same as that of 
agarose gel in order to generate gels of the same depth in the 48 well plates. This 
process was repeated for each batch. Finally, a volume of 1 ml complete DMEM was 
added to each well and the plates were incubated at 37°C and 8% (v/v) CO2 in air.  
Working example 
To create 3 ml of collagen gel for use in vitro, 2.4 ml (80% (v/v)) of type I rat tail 
collagen gel was added to a sterile universal followed by 300 µl (10% (v/v)) 10X MEM 
and mixed gently. Once the collagen and 10X MEM were mixed, 1.94 M sodium 
hydroxide was added drop-wise to the gel until a light pink colour was achieved. 
Finally, 126 µl (4.2% (v/v)) cells/medium/particles was added to the gel and mixed 
gently. A volume of 200 µl gel was added to each well of a Corning 48 well tissue 
culture plate and the plate was placed into the incubator until set.  
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2.2.8  Biochemical assays 
Below are detailed the methods of the general biochemical assays used throughout 
this project: ATP-liteTM luminescence ATP detection assay, ELISA and Trypan blue 
exclusion assay.  
2.2.8.1  ATP-liteTM luminescence ATP detection assay 
Adenosine triphosphate (ATP) is one of many markers of cell viability as it is present 
in healthy, metabolically active cells in abundance but declines when cells are 
undergoing apoptosis or necrosis. The ATP-liteTM luminescence ATP detection assay 
utilises the reaction of D-luciferin with ATP and oxygen, catalysed by luciferase, to 
produce detectable luminescence. This light is detected by a scintillation counter and 
is proportional to the amount of ATP present in the sample.  
𝐴𝑇𝑃 + 𝐷 − 𝐿𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝑂! !"#$%&'()&!"!!  𝑂𝑥𝑦𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝐴𝑀𝑃 + 𝑃𝑃𝑖 + 𝐶𝑂! + 𝑙𝑖𝑔ℎ𝑡 
This assay was chosen in place of the traditional colorimetric MTT assay as previous 
studies at the University of Leeds (Lee, 2016; Smith, 2016) have shown that the 
reduction reaction required for the MTT assay is disrupted by collagen gel, which 
causes the formazan product to turn brown instead of purple. As the MTT assay relies 
on a general reduction reaction, this is easily interfered with by the presence of other 
redox reagents.  
ATP-liteTM luminescence ATP detection assay kit components 
The components of the ATP-liteTM luminescence ATP detection assay kit are listed in 
Table 2.7.  
Table 2.7  List of ATP-liteTM luminescence detection assay kit components. 
ATP-liteTM 
luminescence 
detection assay kit 
components 
Supplier Storage 
Mammalian cell lysis 
solution (MCL) 
Perkin Elmer, 
Cambridge, UK. 
Stored at 4°C. 
ATP-liteTM substrate Perkin Elmer, 
Cambridge, UK. 
Stored at 4°C. 
ATP-liteTM substrate 
buffer 
Perkin Elmer, 
Cambridge, UK. 
Stored at 4°C. 
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Preparation of ATP-liteTM substrate 
ATP-liteTM substrate solution was prepared by adding 25 ml ATP-liteTM buffer solution 
to pre-weighed, lyophilised ATP-liteTM substrate, divided into 5 ml aliquots and frozen 
at -20°C until use. The aliquots were defrosted in a water bath at 37°C when required. 
ATP-liteTM luminescence detection assay procedure 
The supernatant was removed and 50 µl of MCL was added to each well. The plate 
was then placed on the orbital shaker for 5 minutes at 700 rpm at room temperature 
(25°C). Following this, 50 µl of ATP-liteTM substrate was added to each well in the 
dark. The plate was wrapped in foil and placed on the shaker as before. The contents 
of each well were then transferred to the corresponding wells of a white optiplate. The 
plate was checked for bubbles and any present were removed with a sterile needle. 
The plate was then sealed with a clear plastic cover, wrapped in foil and read using a 
Hidex plate chameleon plate reader; initially dark adapting each plate for 10 minutes 
prior to measuring luminescence output. On day 0, the assay was performed 2 hours 
post seeding to allow for cells to adhere to the tissue culture plate. 
Adapted procedure for agarose and collagen gels in 48 well tissue culture plates 
The manufacturers instructions were adapted in order to allow the reagents to fully 
penetrate the agarose and collagen gels. The volumes of MCL and ATP-lite substrate 
were increased four-fold from 50 µl to 200 µl. The shaking times were increased four 
fold from 5 minutes to 20 minutes. The contents of each well were therefore increased 
to 400 µl rather than 100 µl. Only 100 µl from each well was transferred to the white 
optiplate and measured. To account for this, the luminescence counts were multiplied 
by four during statistical analysis.  
2.2.8.2  Enzyme Linked Immunosorbent Assay 
A variety of both human and murine enzyme linked immunosorbent assays (ELISAs) 
were carried out during this study overall. The general kits used are detailed in the 
materials section of this chapter (Section 2.1.1) whereas the specific reagents 
associated with each kit are detailed in Tables 2.8, 2.9, 2.10, 2.11 and 2.12 below. In 
addition, a general method for both human and murine kits is described below and 
any details specific to a particular inflammatory cytokine or mediator tested are listed 
separately. Where the kit used differed significantly from the general method 
described, the specific method associated with a particular kits use is described in full.  
General assay components 
Human 
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Table 2.8  Human TNF-α ELISA kit reagents, storage and preparation instructions. 
Reagent Storage and preparation 
Human TNF- α capture 
antibody 
Stored at 4°C and prepared 
by adding 100 µl of capture 
antibody to 10 ml of coating 
buffer. 
Human TNF-α standard 
(800 pg.ml-1) 
Stored at 4°C and prepared 
by reconstituting with 0.87 ml 
of RPMI 1640 cell culture 
medium and inverted to mix. 
Biotinylated anti-hTNF-α 
detection antibody 
Stored at 4°C and 
reconstituted with 550 µl of 
reconstitution buffer prior to 
use. A volume of 100 µl of 
reconstituted biotinylated anti-
hTNF-α detection antibody 
was added to 5 ml of 
secondary antibody buffer.  
Streptavidin-HRP Stored at 4°C and prepared 
by adding 150 µl of vortexed 
streptavidin-HRP to 10 ml 
streptavidin-HRP diluent in a 
glass universal. 
TMB substrate Stored at 4°C. 
Reconstitution buffer Stored at 4°C and prepared 
by adding 0.09% (v/v) sodium 
azide to 1X PBS. 
Coating buffer Stored at 4°C and prepared 
by decanting 1X PBS into a 
sterile glass Duran bottle. 
Wash buffer Prepared by adding 0.05% 
(v/v) TWEEN-20 to 1X PBS. 
Not stored after use. 
Blocking buffer Stored at 4°C and prepared 
by adding 5% (v/v) BSA to 1X 
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PBS. 
Standard dilution buffer RPMI 1640 medium was 
used as the standard dilution 
buffer. 
Secondary antibody 
dilution buffer 
Stored at 4°C and prepared 
by adding 1% (v/v) BSA to 1X 
PBS. 
HRP-dilution buffer Stored at 4°C and prepared 
by adding 1% (v/v) BSA and 
0.1% (v/v) TWEEN-20 to 1X 
PBS. 
 
Mouse 
Table 2.9  Murine TNF-α, IL-1β and IL-6 ELISA kit reagents, storage and preparation 
instructions. 
Murine TNF-α uncoated 
10 x 96 well ELISA kit 
components 
Supplier Storage and 
preparation 
Anti mouse TNF-α/IL-1β 
/IL-6 Capture antibody 
ThermoFisher 
Scientific UK, 
Loughborough, UK 
Stored at 4°C and 
prepared by diluting 
1:250 with 1X coating 
buffer. 
mTNF-α (1000 pg.ml-1)/IL-
1β (1000 pg.ml-1)/IL-6 
(500 pg.ml-1)standard  
ThermoFisher 
Scientific UK, 
Loughborough, UK 
Stored at 4°C and 
prepared by 
reconstituting with 
DMEM and inverted to 
mix. 
ELISA diluent  ThermoFisher 
Scientific UK, 
Loughborough, UK 
Stored at 4°C and 
prepared by diluting 1:5 
in deionised water.   
Biotinylated anti-mTNF-
α/IL-1β/IL-6 detection 
antibody 
ThermoFisher 
Scientific UK, 
Loughborough, UK 
Stored at 4°C and 
prepared by diluting 
1:250 in ELISA diluent. 
The detection antibody 
was allowed to 
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reconstitute for 10 – 30 
minutes with gentle 
swirling prior to use. 
Streptavidin-HRP ThermoFisher 
Scientific UK, 
Loughborough, UK 
Stored at 4°C and 
prepared by diluting 
1:250 in ELISA diluent.  
TMB substrate ThermoFisher 
Scientific UK, 
Loughborough, UK 
Stored at 4°C. 
Coating buffer ThermoFisher 
Scientific UK, 
Loughborough, UK 
Stored at 4°C and 
prepared by diluting 
1:10 with deionised 
water 
Wash buffer N/A Prepared by adding 
0.05% (v/v) TWEEN-20 
to DPBS and stored at 
4°C for up to one 
month. 
Stop solution – Sulfuric 
acid 1 M 
Sigma Aldrich, 
Dorset, UK. 
Stored at room 
temperature (25°C). 
 
General assay procedure 
Detailed below are the methods used to carry out quantitation of human and mouse 
TNF-α, IL-1β and IL-6 ELISA after stimulation with particles and/or controls. 
Human  
A volume of 100 µl of diluted capture antibody was added to each well of a 96 well 
Nunc maxisorp plate. The plate was sealed and incubated at 4°C overnight. The cover 
was then removed and the plate was washed by aspirating the plate, filling each well 
with wash buffer and aspirating the wells again. This procedure was repeated once 
more. A volume of 100 µl of blocking buffer was then added to each well and the plate 
was sealed again and incubated at room temperature (25°C) for 2 hours. Following 
this incubation, the plate was washed a further three times as described previously. 
The plates were typically used immediately and thus preparation for storage was not 
necessary. During the previous incubation, the reagents were brought to room 
temperature (25°C) before use. The standards were added to the plate (100 µl per 
well) in serial dilution at the following concentrations: 800 pg.ml-1, 400 pg.ml-1, 200 
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pg.ml-1, 100 pg.ml-1, 50 pg.ml-1, 25 pg.ml-1 and 0 pg.ml-1. The samples were also 
added to each well - 100 µl per well. Standards and zeros were included in duplicate 
alongside duplicated cell culture supernatant samples. Once all standards and 
samples were added to the plate, 50 µl of dilute detection antibody was then added to 
each well and the plate was sealed and incubated at room temperature for 3 hours. 
After the incubation, the plate was washed as above twice. Following washing, 100 µl 
of dilute streptavidin-HRP was added to each well. The plate was sealed and 
incubated at room temperature for 30 minutes. The plates were then washed twice. A 
volume of 100 µl of TMB substrate was added to each well and the plates were sealed 
and wrapped in foil. The plates were incubated in the dark for between 5 and 15 
minutes. After approximately 10 minutes, 100 µl of 1 M sulfuric acid (stop reagent) 
was added to each well. The plate was then read immediately using the Multiskan 
plate reader at 450 nm and 630 nm. The 630 nm readings were subtracted from the 
450 nm readings prior to analysis. 
Mouse 
The plates of supernatant and the murine TNF-α/IL-1β/IL-6 ELISA kit components 
were defrosted at room temperature (25°C). The ELISA reagents were prepared as 
detailed above (Table 2.9). A volume of 100 µl of diluted capture antibody was added 
to each well of a Corning CoStar 96 well plate. The plates were sealed and incubated 
overnight at 4°C. Following this, the wells were aspirated and washed 3 times with 
wash buffer. The plate was then blotted dry and all wells were blocked with 200 µl 
ELISA diluent. The plate was sealed and then incubated at room temperature for 1 
hour. The standard was prepared as described in Table 2.9. The plate was then 
aspirated and washed once as before. A serial dilution of the standard was performed 
within the plate in order to generate a standard curve. A volume of 100 µl of each 
sample or each standard were added to the relevant wells. The plate was sealed and 
incubated at room temperature for 2 hours. The detection antibody was prepared as 
described above. The plate was aspirated and washed 3 times. A volume of 100 µl of 
detection antibody was added to each well and the plate was sealed and incubate at 
room temperature (25°C) for one further hour. Streptavidin-HRP was prepared as 
described above. The plate was aspirated and washed three times. A volume of 100 
µl of Streptavidin-HRP was added to each well. The plate was then sealed and 
incubated at room temperature (25°C) for 30 minutes. The plate was then aspirated 
and washed five times. A volume of 100 µl TMB substrate was added to each well. 
The plate was sealed and wrapped in foil. The plate was incubated for 10 – 15 
minutes after which 50 µl of stop solution (1 M sulfuric acid) was added to each well. 
The contents of the well plate were then immediately read at 450 and 570 nm using a 
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Multiskan plate reader. The 570 nm readings were subtracted from the 450 nm 
readings prior to analysis.  
TNF-α 
Human 
A serial dilution of the TNF-α standard was performed within the plate in order to 
generate a standard curve from the following concentrations: 800 pg.ml-1, 400 pg.ml-1, 
200 pg.ml-1, 100 pg.ml-1, 50 pg.ml-1, 25 pg.ml-1, 12.5 pg.ml-1 and 0 pg.ml-1 (i.e. RPMI 
cell culture medium only).  
Mouse 
A serial dilution of the TNF-α standard was performed within the plate in order to 
generate a standard curve from the following concentrations: 1000 pg.ml-1, 500 pg.ml-
1, 250 pg.ml-1, 125 pg.ml-1, 62.5 pg.ml-1, 31.25 pg.ml-1, 15.625 pg.ml-1 and 0 pg.ml-1 
(i.e. DMEM cell culture medium only).  
IL-1β 
A serial dilution of the IL-1β standard was performed within the plate in order to 
generate a standard curve from the following concentrations: 1000 pg.ml-1, 500 pg.ml-
1, 250 pg.ml-1, 125 pg.ml-1, 62.5 pg.ml-1, 31.25 pg.ml-1, 15.625 pg.ml-1 and 0 pg.ml-1 
(i.e. DMEM cell culture medium only).  
IL-6 
A serial dilution of the IL-6 standard was performed within the plate in order to 
generate a standard curve from the following concentrations: 500 pg.ml-1, 250 pg.ml-1, 
125 pg.ml-1, 62.5 pg.ml-1, 31.63 pg.ml-1, 15.81 pg.ml-1, 7.41 pg.ml-1 and 0 pg.ml-1 (i.e. 
DMEM cell culture medium only).  
  KC 
Table 2.10  Murine KC ELISA kit reagents, storage and preparation instructions. 
Murine KC coated 1 x 96 
ELISA kit component 
Storage and preparation 
KC 96 well microplate 
coated with anti-mouse KC 
Stored at 4°C for one 
month. 
Wash buffer concentrate 
(20X) – 25 ml 
Diluted 20 ml of wash 
buffer with 400 ml 
deionised water to prepare 
a 1X solution, Stored at 
4°C for one month. 
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Standard protein (Mouse 
KC x 2 vials) 
Stored at -80°C for one 
week. Each vial was 
diluted with 400 µl 1X 
assay diluent to prepare a 
50 ng.ml-1 standard 
solution. This was further 
diluted to a 150 pg.ml-1 by 
adding 3 µl of 50 ng.ml-1 
standard solution to 997 µl 
1X assay diluent. 
Detection antibody (KC) x 
2 vials 
Each vial was diluted with 
100 µl 1X assay diluent. 
This was then diluted 
further (1:80) with 1X 
assay diluent prior to use. 
Stored at 4°C for five days. 
HRP-Streptavidin 
concentrate (200X) – 200 
µl 
Diluted 50 µl of HRP-
Streptavidin concentrate 
with 10 ml 1X assay 
diluent. Not stored. 
TMB one step substrate 
reagent – 12 ml 
Not stored. 
Stop solution – 0.2 M 
sulfuric acid – 8ml 
Not stored. 
Assay diluent (5X) – 15 ml Diluted with 60 ml 
deionised water. Stored at 
4°C for one month. 
The plates of supernatant and the murine KC ELISA kit components were defrosted at 
room temperature (25°C). The ELISA reagents were prepared as detailed above 
(Table 2.10). Each cell culture supernatant sample was diluted prior to use: 33 µl 
sample was added to 67 µl assay diluent. A serial dilution of the KC standard was 
performed within the plate in order to generate a standard curve from the following 
concentrations: 150 pg.ml-1, 60 pg.ml-1, 24 pg.ml-1, 9.6 pg.ml-1, 3.84 pg.ml-1, 1.54 
pg.ml-1, 0.614 pg.ml-1 and 0 pg.ml-1 (i.e. DMEM cell culture medium only).  A volume 
of 100 µl of each diluted sample or each standard were added to the relevant wells. 
The plate was sealed and incubated at room temperature (25°C) for 2.5 hours with 
gentle shaking. The plate was aspirated and washed four times. A volume of 100 µl of 
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detection antibody was added to each well and the plate was sealed and incubate at 
room temperature (25°C) for one further hour with gentle shaking. The plate was 
aspirated and washed four times. A volume of 100 µl of Streptavidin-HRP was added 
to each well. The plate was then sealed and incubated at room temperature for 45 
minutes with gentle shaking. The plate was then aspirated and washed four times. A 
volume of 100 µl TMB substrate was added to each well. The plate was sealed and 
wrapped in foil. The plate was incubated for 30 minutes with gentle shaking after 
which 50 µl of stop solution (1 M sulfuric acid) was added to each well. The contents 
of the well plate were then immediately read at 450 and 570 nm using a Multiskan 
plate reader. The 570 nm readings were subtracted from the 450 nm readings prior to 
analysis.  
  LTB4 
Table 2.11  Murine LTB4 ELISA kit reagents, storage and preparation instructions. 
Murine LTB4 coated 1 x 96 ELISA kit 
component 
Storage and preparation 
LTB4 (coated with rabbit anti-chicken 
polyclonal antibody) 96 well microplate 
Stored at 4°C for one month. 
LTB4 conjugate – 1 vial (6 ml) Stored at -20°C for one month. 
LTB4 standard – 1 vial Stored at -20°C for one month. 
Reconstituted with deionised water to 
create a 50 ng.ml-1 stock solution, 
Primary antibody (chicken polyclonal) 
solution -1 vial (6 ml) 
Stored at 4°C for one month. 
Calibrator diluent – 1 vial (21 ml) Stored at 4°C for one month. 
Wash buffer concentrate 25X – 1 vial (21 
ml) 
Diluted 20 ml wash buffer concentrate 
with 500 ml deionised water. Stored at 
4°C for one month. 
Colour reagent A -1 vial (12 ml) stabilised 
hydrogen peroxide 
Stored at 4°C for one month. Mixed with 
colour reagent B in equal volumes 
immediately prior to use. 
Colour reagent B – 1 vial (12 ml) 
stabilised chromogen, 
tetramethylbenzidine. 
Stored at 4°C for one month. Mixed with 
colour reagent B in equal volumes 
immediately prior to use. 
Stop solution – 1 vial (11 ml) 2N (1M) Stored at 4°C for one month. 
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sulphuric acid 
Adhesive plate sealers x 4 N/A 
A serial dilution of the LTB4 standard was performed within the plate in order to 
generate a standard curve from the following concentrations: 2500 pg.ml-1, 833 pg.ml-
1, 278 pg.ml-1, 92.6 pg.ml-1, 30.9 pg.ml-1, 10.3 pg.ml-1 and 0 pg.ml-1 (i.e. calibration 
diluent only).  A volume of 50 µl of each standard and sample was added to the 
corresponding wells of the microplate (n=3). A volume of 50 µl of primary antibody 
solution was added to each well (except the non-specific binding wells). A volume of 
100 µl of calibrator diluent was added to the non-specific binding well. The plate was 
then sealed and incubated at room temperature (25°C) with shaking at 500 rpm for 
one hour. A volume of 50 µl of conjugate was added to each well. The plate was then 
sealed and incubated at room temperature (25°C) with shaking at 500 rpm for 3 hours. 
The plate was then aspirated and washed four times then blotted. A volume of 200 µl 
of substrate solution (colour reagents A and B) was added to each well and the plate 
was wrapped in foil. The plate was incubated at room temperature (25°C) for 30 
minutes. A volume of 100 µl of stop solution was added to each well. The contents of 
the well plate were then immediately read at 450 and 570 nm using a Multiskan plate 
reader. The 570 nm readings were subtracted from the 450 nm readings prior to 
analysis. 
  PGE2 
The components for the PGE2 ELISA were the same as the LTB4 ELISA in Table 2.11 
with any different components outlined in Table 2.12. 
Table 2.12  Murine PGE2 ELISA kit reagents, storage and preparation instructions. 
Murine PGE2 coated 1 x 96 ELISA kit 
component 
Storage and preparation 
PGE2 (coated with goat anti-mouse 
polyclonal antibody) 96 well microplate 
Stored at 4°C for one month. 
PGE2 standard Stored at -20°C for one month. 
PGE2 conjugate Stored at 4°C for one month. 
 
A serial dilution of the PGE2 standard was performed within the plate in order to 
generate a standard curve from the following concentrations: 2500 pg.ml-1, 1250 
pg.ml-1, 625 pg.ml-1, 313 pg.ml-1, 156 pg.ml-1, 78 pg.ml-1, 39 pg.ml-1 and 0 pg.ml-1 (i.e. 
calibration diluent only). The assay was carried out as per the LTB4 ELISA method.  
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2.2.8.3  Trypan blue exclusion assay 
Cell numbers were assessed by adding a 90 µl sample of cells/medium from an 
existing tissue culture flask to 10 µl of trypan blue in a sterile bijou. A volume of 20 µl 
of the resultant mixture was pipetted underneath the cover slip of a Neubauer 
haemocytometer and all the cells in the grid were counted. The number of cells was 
calculated as follows: 
No. of cells per ml = No. of cells counted x 10/9 x (1 x 104) 
*Dilution factor = 1 x 104 
** 10/9 = correction for dilution factor when adding trypan blue to cell suspension 
2.2.9  Statistical analysis 
All data where n>1 was analysed using one-way or two-way ANOVA as appropriate 
(Statplus) and the Tukey-Kramer post-hoc test at a significance level p<0.05 
(Microsoft Excel). The 95% confidence limits were also displayed on the subsequent 
graphs. 
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Chapter 3 
Development of a novel 3D in vitro model for measuring cellular 
responses to model polyethylene particles  
3.1  Introduction 
There is a need for a 3D method for modelling in vitro responses to UHMWPE wear 
debris as there is currently no working 3D model, only 2D models. A 3D model is more 
representative of the periprosthetic in vivo environment than a 2D model. The model 
needs to be simple to use and reliable in terms of inflammatory cytokine release. 
Significant time and resources were used in previous 2D studies to attempt to yield a 
consistent level of cytokine release from cells with particles in agarose gel. The cell 
types used, i.e. PBMNCs, have issues, such as donor heterogeneity and supply, 
associated with them so a more reliable and easy to use cell type should be chosen. 
The agarose gels used by previous 2D studies is not naturally found in the 
periprosthetic environment and lacks cell attachment sites therefore the gel type could 
be improved. The use of a gel must be continued to achieve a 3D culture model as 
UHMWPE wear debris floats in cell culture medium if not trapped in a gel matrix. 
However, it is possible to use inverted cell culture methods successfully to create a 2D 
cell-particle model.  
This study aimed to develop a novel 3D in vitro model by testing an alternative cell 
type – RAW 264.7 murine macrophages – alongside the existing PBMNCs and U937 
human histiocytes in addition to testing a new gel type – type I rat tail collagen – 
alongside the existing agarose gel. RAW 264.7 murine macrophages are a cell line 
derived from the ascites of an induced tumour by intraperitoneal injection of Abselon 
Leukaemia Virus. RAW 264.7 murine macrophages are a semi-adherent cell type; in 
culture, some cells are adherent and some cells are in suspension. As they are a cell 
line, there is no issue with donor supply or variation. The cells also do not require 
chemical transformation. RAW 264.7 murine macrophages are not human cells which 
is not ideal, as animal cells may behave differently in response to UHMWPE wear 
debris than human cells, however this is somewhat mitigated by the simplicity of both 
their use and their ability to generate vast cell numbers quickly without the need for a 
human donor. Furthermore, Matthews et al. (2000) compared the responses of 
primary murine macrophages and a human histiocyte cell line (U937) to UHMWPE 
wear debris and suggested that murine macrophages were an appropriate cell type for 
use in modelling cellular responses to UHMWPE wear debris. Additionally, as RAW 
264.7 murine macrophages are a cell line, their use is less representative of the in 
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vivo environment as the behaviour of cell lines in culture will differ from primary cells in 
the periprosthetic environment. However, primary cells, such as PBMNCs, introduce 
problematic donor variation so a compromise must be made. Type I rat tail collagen 
gel was chosen as the material for the gel as it has previously been successfully used 
to model neural cell responses to metal wear debris (Lee, 2016). Type I rat tail 
collagen gel includes cell attachment sites; making it more appropriate for 3D culture 
models than agarose. Collagen also uses a pH dependent gelling mechanism, rather 
than the temperature dependent gelling mechanism of agarose, and therefore does 
not affect the viability of any cells encased within it, so both wear debris and cells can 
be encapsulated within the gel simultaneously. Additionally, type I rat tail collagen is 
more representative of the 3D in vivo environment, i.e. the extracellular matrix which 
typically consists of collagen, elastin and proteoglycans to support the local cells, 
experienced by the macrophages in the body.  
3.2  Aims and objectives 
3.2.1  Aims 
The overall aim of this chapter was to develop a 3D in vitro model to assess the 
cellular responses to model polyethylene particles in order to provide a more accurate 
representation of the periprosthetic environment in comparison to earlier 2D models.  
3.2.2  Objectives 
The objectives of this chapter were as follows: 
• To determine the working seeding density of a number of different cells (RAW 
264.7, U937 and PBMNC’s) in both gel types (agarose and type I rat tail 
collagen) using the ATP-liteTM luminescence detection assay. 
• To investigate the effect of changing gel type on cell viability of a number of 
different cells (RAW 264.7, U937 and PBMNC’s) using the ATP-liteTM 
luminescence detection assay. 
• To assess the TNF-α release of each different cell type (RAW 264.7, U937 and 
PBMNC’s) in both gel types (agarose and type I rat tail collagen) in response to 
model polyethylene particles (Ceridust®) and FluoSpheres® using ELISA.  
• To assess the suitability of RAW 264.7 murine macrophages and U937 human 
histiocytes for use in an inverted 2D in vitro model using cell viability (ATP-liteTM 
luminescence detection assay) and TNF-α release (ELISA) as indicators. 
3.3  Materials 
The materials used throughout Chapter 3 are detailed below. 
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3.3.1  Chemicals and reagents 
All chemicals and reagents used throughout Chapter 3 are listed in Chapter 2, Section 
2.1.1. 
3.3.2  Consumables 
All consumables used throughout Chapter 3 are listed in Chapter 2, Section 2.1.2.  
3.3.3  Equipment 
All equipment used throughout Chapter 3 is listed in Chapter 2, Section 2.1.3.  
3.3.4  Cell lines and primary cells 
All cell lines and primary cells used throughout Chapter 3 are listed in Chapter 2, 
Sections 2.1.4 and 2.1.5, respectively.  
3.3.5  Particles 
All particles used throughout Chapter 3 are listed in Chapter 2, Section 2.1.6.  
3.4  Methods 
The specific experimental methods used throughout Chapter 3 are described below. 
General methods can be found in Chapter 2, Section 2.2.   
3.4.1  Determining working cell seeding densities of RAW 264.7 murine 
macrophages in 48 well tissue culture plates 
The agarose method of culturing cells in 3D with polyethylene wear debris in 48 well 
tissue culture plates used at the University of Leeds was developed using PBMNC’s at 
a density of 1 x 105 cells in 1 ml of cell culture medium (Green et al., 1998). This 
seeding density was later increased to 2 x 105 cells in 1 ml of cell culture medium as 
the centrifugation step was removed and the cells were presumed to penetrate the gel 
(Gowland, 2014). Additionally, Gowland (2014) used U937 human histiocytes at a 
seeding density of 2 x 105 cells.ml-1 in agarose gel in 48 well tissue culture plates. The 
seeding density of RAW 264.7 murine macrophages in 2D was determined by 
carrying out a cell viability assay in 48 well tissue culture plates in order to suggest a 
suitable range of seeding densities to assess in 3D.  
RAW 264.7 murine macrophages were cultured, passaged and counted as described 
in Chapter 2, Section 2.2.5.4. Cells were seeded into 48 well tissue culture plates at 
densities of 1 x 103, 5 x 103, 1 x 104, 5 x 104 and 1 x 105 cells.ml-1. Each well 
contained 1 ml medium. Cells plus DMSO (200 µl.ml-1) positive controls and medium 
only negative controls were included (n=6). Plates were incubated at 37°C and 8% 
(v/v) CO2 in air. Plates were assessed using the ATP-liteTM viability assay on days 0, 
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1, 2, 3 and 5 as described in Chapter 2, Section 2.2.8.1. The results were analysed 
statistically using two-way ANOVA and the Tukey-Kramer post-hoc test as described 
in Chapter 2, Section 2.2.9. 
3.4.2  Determining cell viability and TNF-α release of PBMNC’s, RAW 264.7 
murine macrophages and U937 human histiocytes following model particle 
treatments in agarose and collagen gel 
The viability of PBMNC’s, U937 human histiocytes and RAW 264.7 murine 
macrophages in both agarose and collagen gels was assessed over three days. The 
viability was assessed up to day 3, as the chosen cell type was only used for 24 hours 
as a maximum in the chosen gel type in later work therefore extending the viability 
assay significantly beyond this time frame was redundant.  
3.4.2.1  Cell viability of PBMNC’s, RAW 264.7 murine macrophages and U937 
human histiocytes in agarose and collagen gel 
RAW 264.7 murine macrophages and U937 human histiocytes, transformed (i.e. 
treated with PMA to become adherent and chemically activated macrophages) and 
non-transformed (i.e. untreated cells in a suspension culture), were cultured, 
passaged and counted as described in Chapter 2, Section 2.2.5.4 and 2.2.8.3 
respectively. PBMNC’s (donor 2) were isolated as described in Chapter 2, Section 
2.2.4. Agarose gels (0.4% (w/v)) were prepared in 48 well tissue culture plates as 
described in Chapter 2, Section 2.2.7.1. Cells were seeded on top of the agarose gels 
at densities of 1 x 104, 5 x 104 and 1 x 105 cells.ml-1. Cells were assembled in collagen 
gels as described in Chapter 2, Section 2.2.7.2. Cells were seeded at densities of 1 x 
104, 5 x 104 and 1 x 105 cells.ml-1. Each well contained 1 ml of medium (DMEM for 
RAW 264.7 murine macrophages and RPMI 1640 cell culture medium for PBMNCs 
and U937 human histiocytes). Cells plus DMSO (200 µl.ml-1) acted as the positive 
control and a medium only negative control was included (n=6). All conditions were 
assessed using the ATP-liteTM viability assay on days 0, 1 and 3 as described in 
Chapter 2, Section 2.2.8.1. The results were analysed statistically using two-way 
ANOVA and the Tukey-Kramer post-hoc test as described in Chapter 2, Section 2.2.9. 
RAW 264.7 murine macrophage viability was assessed in agarose gels both with and 
without a rinse step. A rinse step was included to remove any cells that had not 
penetrated the agarose gel and therefore would not be exposed to particle treatments 
in subsequent studies. For those assessed with a rinse step, this involved changing 
the medium in all wells 12 hours post seeding and then performing the ATP-liteTM 
viability assay as described in Chapter 2, Section 2.2.8.1.  
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3.4.2.2  TNF-α release from PBMNC’s, RAW 264.7 murine macrophages and 
U937 human histiocytes following model particle treatments in agarose and 
collagen gel 
RAW 264.7 murine macrophages and U937 human histiocytes (transformed and non-
transformed) were cultured, passaged and counted as described in Chapter 2, Section 
2.2.5.4 and 2.2.8.3 respectively. PBMNC’s (donor 2) were isolated as described in 
Chapter 2, Section 2.2.4. Agarose gels (0.4% (w/v)) were prepared with particle 
treatments as described in Chapter 2, Section 2.2.7.1. Collagen gels were prepared 
with cells and particle treatments as described in Chapter 2, Section 2.2.7.2. The 
following particle treatments were prepared as described in Chapter 2, Section 
2.2.6.1: >10 µm Ceridust®, 1 – 10 µm Ceridust®, 0.1 -1 µm Ceridust® and 0.2 µm 
FluoSpheres® at volumes of 100 µm3 particles per cell. Cells were seeded on top of 
the agarose gels at a density of 1 x 105 cells.ml-1. Each well contained 1 ml of medium 
(DMEM for RAW 264.7 murine macrophages and RPMI 1640 cell culture medium for 
PBMNCs and U937 human histiocytes). Cells plus LPS (200 ng.ml-1) acted as a 
positive control and cells only acted as a negative control for ELISA (n=4). Cells plus 
DMSO acted as a positive control and medium only acted as a negative control for cell 
viability (n=6). The plates were assessed at 12 and 24 hours post seeding using the 
ATP-liteTM viability assay as described in Chapter 2, Section 2.2.8.1. Prior to 
performing the ATP-liteTM viability assay, the supernatants from each plate were 
placed in the corresponding wells of a Nunc F uncoated plate and were frozen at -
80°C until required for ELISA. When ELISA was performed, the required supernatants 
were defrosted at room temperature (25°C). Subsequently, ELISA was performed on 
supernatants in duplicate for TNF-α quantification as described in Chapter 2, Section 
2.2.8.2. The results were analysed statistically using two-way ANOVA and the Tukey-
Kramer post-hoc test as described in Chapter 2, Section 2.2.9.  
3.4.3  Determining working cell seeding densities of RAW 264.7 murine 
macrophages and U937 human histiocytes in 96 well tissue culture plates 
for use in inverted 2D culture 
Previous studies at the University of Leeds cultured PBMNC’s with polyethylene wear 
debris in a novel inverted 2D model. PBMNCs are seeded at a density of 2 x 104 cells 
in 200 µl of cell culture medium on the base of a 96 well tissue culture plate and 
medium containing polyethylene particles is loaded on top of the cells. The plate is 
then carefully inverted, allowing the particles floating on the surface of the medium to 
come into contact with the cells seeded on the base of the plate. During the present 
study, RAW 264.7 murine macrophages and U937 human histiocytes were trialled in 
this novel inverted 2D model. A seeding density of 1 x 104 in 200 µl of cell culture 
medium was recommended for cell lines and this was verified by performing cell 
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viability assays of both cell types in 96 well tissue culture plates at a variety of cell 
seeding densities over five days.  
RAW 264.7 murine macrophages and U937 human histiocytes were cultured, 
passaged and counted as described in Chapter 2, Section 2.2.5.4 and 2.2.8.3 
respectively. Cells were seeded into 96 well tissue culture plates at densities of 5 x 
103, 1 x 104, 5 x 104, 1x 105 and 5 x 105 cells.ml-1 (n=6). Each well contained 200 µl 
medium (DMEM for RAW 264.7 murine macrophages and RPMI 1640 cell culture 
medium for U937 human histiocytes). Cells plus DMSO (200 µl.ml-1) positive controls 
and medium only negative controls were included (n=6). Plates were incubated at 
37°C and 5% (U937 human histiocytes) or 8% (RAW 264.7 murine macrophages) 
(v/v) CO2 in air. Plates were assessed using the ATP-liteTM viability assay on days 0, 
1, 2, 3 and 5 as described in Chapter 2, Section 2.2.8.1. The results were analysed 
statistically using two-way ANOVA and the Tukey-Kramer post-hoc test as described 
in Chapter 2, Section 2.2.9.  
3.4.4 Determining TNF-α release from RAW 264.7 murine macrophages and 
U937 human histiocytes following particle treatments in an inverted 2D 
culture model 
RAW 264.7 murine macrophages and U937 human histiocytes, transformed (i.e. 
treated with PMA to become adherent and chemically activated) and non-transformed 
(i.e. untreated cells in a suspension culture),  were cultured, passaged and counted as 
described in Chapter 2, Section 2.2.5.4 and 2.2.8.3 respectively. Using a pipette, 1 x 
104 cells in 100 µl medium was slowly and carefully placed into the centre of each well 
of a 96 well tissue culture plate. The plates were then incubated at 37°C and 5% 
(RAW 264.7 murine macrophages) or 8% (U937 human histiocytes) (v/v) CO2 in air 
for 3 hours to allow the cells to adhere to the tissue culture plate. After 3 hours, the 
medium was removed and replaced with 150 µl medium per well containing particle 
treatments, prepared as described in Chapter 2, Section 2.2.6.1, as follows: >10 µm 
Ceridust® particles, 1 – 10 µm Ceridust® particles, 0.1 – 1 µm Ceridust® particles 
and 0.2 µm FluoSpheres®. Cells plus LPS (200 ng.ml-1) acted as a positive control 
and cells only acted as a negative control for ELISA (n=4). Cells plus DMSO acted as 
a positive control and medium only acted as a negative control for cell viability (n=6). 
The plates were then deliberately inverted – neither too quickly or slowly – and the 
medium was then held in place by surface tension. Since polyethylene is less dense 
than water, the particles float at the surface of the medium, which was in contact with 
the monolayer of cells when the plate was inverted. The plates were then incubated at 
37°C and 5% (RAW 264.7 murine macrophages) or 8% (U937 human histiocytes) 
(v/v) CO2 in air. The cells were assessed at 12 and 24 hours post particle exposure 
using the ATP-liteTM viability assay as described in Chapter 2, Section 2.2.8.1. Prior to 
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performing the ATP-liteTM viability assay, the supernatants from each plate were 
placed in the corresponding wells of a Nunc F uncoated plate and were frozen at -
80°C until required for ELISA. When ELISA was performed, the required supernatants 
were defrosted at room temperature (25°C). Subsequently, ELISA was performed on 
supernatants in duplicate for TNF-α quantification as described in Chapter 2, Section 
2.2.8.2. The results were analysed statistically using two-way ANOVA and the Tukey-
Kramer post-hoc test as described in Chapter 2, Section 2.2.9. 
3.5  Results 
The viability of PBMNC’s, U937 human histiocytes and RAW 264.7 murine 
macrophages at different seeding densities (1 x 104 cells.ml-1, 5 x 104 cells.ml-1 and 1 
x 105 cells.ml-1) was assessed over three days in agarose and collagen gels. The 
ability of PBMNC’s, U937 human histiocytes and RAW 264.7 murine macrophages to 
produce the inflammatory cytokine, TNF- α, in response to model debris in both 
agarose and collagen gels was assessed using ELISA at 12 and 24 hour time points. 
ATP-liteTM luminescence detection assays were also carried out at these time points 
to assess cell viability and the results reported alongside ELISA analysis. Cells were 
seeded at 1 x 105 cells.ml-1 and particles were seeded at 100 µm3 per cell.  The 
following conditions were examined : >10 µm Ceridust® 1 -10 µm Ceridust®, 0.1-1 µm 
Ceridust®, 0.2 µm FluoSpheres®, cells only, medium only (for ATP-liteTM 
luminescence detection assay only), cells plus DMSO (200 µl.ml-1) (for ATP-liteTM 
luminescence detection assay only) and cells plus LPS (200 ng.ml-1). Cells plus LPS  
was included as a positive control as LPS is known to produce an intense cytokine 
response (Cho et al., 2002). The cells only condition acted as the negative control.  
Viability and ELISA data was analysed using ANOVA and the Tukey-Kramer post-hoc 
test. Error bars, using 95% confidence intervals, were displayed on the resultant 
graphs. It should be noted that, as 100 µl of supernatant from the total 1 ml volume 
was used for each ELISA – the results represent 1/10th of the volume of cytokine 
produced. Since this is the same for all experiments, the results have not been 
multiplied upwards.  
3.5.1  Cell viability and inflammatory response of PBMNCs to model particles in 
agarose and collagen gels 
The viability of PBMNC’s was assessed in both agarose and collagen gels over three 
days using the ATP-liteTM luminescence detection assay. PBMNC’s were cultured with 
model particles, Ceridust® and FluoSpheres®, in agarose and collagen gel. The 
viability was measured at 12 and 24 hours using the ATP-liteTM luminescence 
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detection assay. The supernatants at these time points were then used to assess the 
levels of TNF-α cytokine released using ELISA.  
3.5.1.1  Cell viability and response of PBMNCs to model particles in agarose 
gels 
The viability of PBMNC’s (donor 2) at three seeding densities (1 x 104, 5 x 104 and 1 x 
105 cells.ml-1) in agarose gel was assessed at days 0, 1, 2 and 3 using the ATP-liteTM 
luminescence detection assay. Isolated PBMNC’s were then cultured with Ceridust® 
and FluoSpheres® model particles in agarose gel. Cells were seeded at 1 x 105 
cells.ml-1 with 100 µm3 particles per cell in a 48 well tissue culture plate. The contents 
of each well were assessed using the ATP-liteTM luminescence detection assay and 
ELISA for quantitation of TNF-α at 12 and 24 hours post particle exposure. 
Viability of PBMNCs in agarose gel 
The viability of PBMNC’s (Figure 3.1) at all densities tested remained relatively 
constant over the three days, whereas cells cultured with DMSO (200 µl.ml-1) 
demonstrated a significant decrease in viability over the three days (ANOVA; p<0.05).  
 
Figure 3.1 Cell viability of PBMNC’s seeded at different densities in agarose 
gel over three days at 37°C in 5% (v/v) CO2 in air. Cells were seeded at 
densities of 1 x 104, 5 x 104 and 1 x 105 cells.ml-1 in a 48 well tissue 
culture plate. Cells plus DMSO (200 µl.ml-1) acted as a positive control. 
Cell viability was assessed using the ATP-liteTM luminescence detection 
assay. * designates a statistically significant data point relative to the 
seeding densities assessed (ANOVA, p<0.05). Error bars represent 
95% confidence intervals, n=6. 
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None of the treatments had a significant effect on the viability of PBMNC’s (Figure 
3.2A) compared to the cells only negative control at 12 hours post particle exposure 
(ANOVA; p>0.05). Cells cultured with 1 – 10 µm Ceridust®, 0.1 – 1 µm Ceridust® and 
0.2 µm FluoSpheres® exhibited significantly reduced viability when compared to the 
cells only control at 24 hours post particle exposure (ANOVA; p>0.05).  
TNF-α release from PBMNCs after exposure to model particles in agarose gels  
After 12 hours, cells cultured with >10 µm Ceridust®, 0.2 µm FluoSpheres® and LPS 
produced significantly elevated levels of TNF-α (Figure 3.2B) compared to the cells 
only negative control (ANOVA: p>0.05). None of the remaining Ceridust® treatments 
had any significant effect on TNF-α release.  
After 24 hours, only PBMNC’s treated with LPS (positive control) produced a 
significant release of TNF-α when compared to the cells only negative control 
(ANOVA: p<0.05). None of the Ceridust® or FluoSphere® particle treatments had a 
significant effect on the release of TNF-α. 
 
A) 
 
1	
10	
100	
1000	
10000	
100000	
1000000	
10000000	
Lo
g	
of
	m
ea
n	
lu
m
in
es
ce
nc
e	
co
un
t	p
er
	
se
co
nd
	+
/-
	9
5%
	C
L	
Particle	conditions	
12	hours	
24	hours	
* * *
- 85 - 
B) 
 
Figure 3.2– A) Cell viability and B) TNF-α release from PBMNC’s (donor 2) incubated 
with Ceridust® and FluoSpheres® model particles at a concentration of 100 µm3 
particles per cell in agarose gel at 12 and 24 hours post particle exposure at 
37°C in 5% (v/v) CO2 in air. Cells were seeded at a density of 1 x 105 cells.ml-1 
with particle treatments in a 48 well tissue culture plate. A cells only negative 
control and LPS positive control (200 ng.ml-1) were included in the conditions. * 
designates a statistically significant data point compared to the cells only 
negative control (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=4.  
 
3.5.1.2  Cell viability and response of PBMNCs to model particles in collagen 
gels 
The viability of PBMNCs (donor 2) at three seeding densities (1 x 104, 5 x 104 and 1 x 
105 cells.ml-) in collagen gel was assessed at days 0, 1, 2 and 3 using the ATP-liteTM 
luminescence detection assay. Isolated PBMNC’s were cultured with Ceridust® and 
FluoSpheres® model particles in collagen gel. Cells were seeded at 1 x 105 cells.ml-1 
with 100 µm3 particles per cell in 48 well tissue culture plates. The contents of each 
well was assessed using the ATP-liteTM luminescence detection assay and ELISA for 
TNF-α at 12 and 24 hours post particle exposure. 
The cell viability of PBMNC’s (Figure 3.3) at all cell seeding densities remained 
relatively constant over the three days whereas cells cultured with DMSO (200 µl.ml-1) 
demonstrated a significant decrease over three days (ANOVA; p<0.05).  
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Figure 3.3 Cell viability of PBMNC’s seeded at different densities in collagen 
gel over three days at 37°C in 5% (v/v) CO2 in air. Cells were seeded at 
densities of 1 x 104, 5 x 104 and 1 x 105 cells.ml-1 in a 48 well tissue 
culture plate. A cells plus DMSO (200 µl.ml-1) positive control was 
included in the conditions. Cell viability was assessed using the ATP-
liteTM luminescence detection assay. * designates a statistically 
significant data point compared to the seeding densities assessed 
(ANOVA, p<0.05). Error bars represent 95% confidence intervals, n=6. 
 
Viability of PBMNCs after exposure to model particles in collagen gels 
None of the treatments had a significant effect on the viability of PBMNC’s (Figure 
3.4A) compared to the cells only negative control at 12 and 24 hours post particle 
exposure with the exception of cells treated with LPS (200 ng.ml-1) at 24 hours post 
particle exposure (ANOVA; p<0.05). 
TNF-α release from PBMNCs after exposure to model particles in collagen gels  
After 12 hours, none of the treatments produced a significant release of TNF-α (Figure 
3.4B) when compared to the cells only negative control (ANOVA: p>0.05). 
After 24 hours, only PBMNC’s treated with the LPS (200 ng.ml-1) positive control 
produced a significant release of TNF-α (Figure 3.4B) when compared to the cells 
only negative control (ANOVA: p<0.05). None of the Ceridust® or FluoSphere® 
particle treatments had a significant effect on the release of TNF-α. 
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B) 
 
 
Figure 3.4 – A) Cell viability and B) TNF-α release from PBMNC’s (donor 2) incubated 
with Ceridust® and FluoSpheres® model particles at a concentration of 100 µm3 
particles per cell in collagen gel at 12 and 24 hours post particle exposure at 
37°C in 5% (v/v) CO2 in air. Cells were seeded at a density of 1 x 105 cells.ml-1 
with particle treatments in a 48 well tissue culture plate. A cells only negative 
control and LPS (200 ng.ml-1) positive control were included in the conditions. * 
designates a statistically significant data point compared to the cells only 
negative control (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=4. 
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3.5.2  Cell viability and inflammatory response of RAW 264.7 murine 
macrophages to model particles in agarose and collagen gels and inverted 
2D culture 
The viability of RAW 264.7 murine macrophages was assessed in both agarose and 
collagen gels over three days using the ATP-liteTM luminescence detection assay.  
RAW 264.7 murine macrophages were cultured with model particles, Ceridust® and 
FluoSpheres®, in agarose gel (1 x 105 cells.ml-1), collagen gel (1 x 105 cells.ml-1) and 
in inverted 2D culture (1 x 104 cells in 200 µl  of cell culture medium). The viability was 
measured at 12 and 24 hours using the ATP-liteTM luminescence detection assay. The 
supernatants at these time points were then used to assess the levels of TNF-α 
cytokine release using ELISA.  
3.5.2.1  RAW 264.7 murine macrophage cell viability and response to model 
particles in agarose gels 
The optimal cell seeding density of RAW 264.7 murine macrophages in 48 well tissue 
culture plates in 2D was initially assessed to provide a suitable range of seeding 
densities for use in the subsequent viability assays. The viability of RAW 264.7 murine 
macrophages at three seeding densities (1 x 104, 5 x 104 and 1 x 105 cells.ml-) in 
agarose gel was assessed at days 0, 1, 2 and 3 using the ATP-liteTM luminescence 
detection assay. RAW 264.7 murine macrophages were cultured with Ceridust® and 
FluoSpheres® model particles in agarose gels. Cells were seeded at 1 x 105 cells.ml-1 
with 100 µm3 particles per cell in a 48 well tissue culture plate. The contents of each 
well was assessed using the ATP-liteTM luminescence detection assay and ELISA for 
TNF-α at 12 and 24 hours post particle exposure. 
Viability of RAW 264.7 murine macrophages over time 
All cell seeding densities except 1 x 105 cells.ml-1 displayed a continual increase in 
viability for up to three days (Figure 3.5) and remained at a constant level of viability 
on day 5 (ANOVA; p<0.05). Cells seeded at 1 x 105 cells.ml-1 exhibited a significant 
increase in viability on day 1 and remained at a consistently high levels of viability 
throughout the course of the assay (ANOVA; p<0.05). The cells seeded at 2 x 105 
cells.ml-1 treated with DMSO (200 µl.ml-1) exhibited a significant decrease in viability 
every time point post seeding (ANOVA; p<0.05).  
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Figure 3.5 Cell viability of RAW 264.7 murine macrophages seeded at 
different densities over five days at 37°C in 5% (v/v) CO2 in air. Cells 
were seeded at densities of 5 x 103, 1 x 104, 5 x 104, 1 x 105 and 5 x 
105 cells.ml-1 in a 48 well tissue culture plate. A cells plus DMSO (200 
µl.ml-1) positive control was included in the conditions. * designates a 
statistically significant data point compared to the seeding densities 
assessed (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=6. 
 
RAW 264.7 murine macrophage viability in agarose gel 
The viability of RAW 264.7 murine macrophages in agarose gel was assessed using 
the ATP-liteTM luminescence detection assay. The assay was repeated both with and 
without a rinse step as it was observed, using light microscopy, that many cells were 
failing to penetrate the gel and were clumped together on the surface of the agarose 
gel. The rinse step removed the cells that had failed to penetrate the gel so that they 
would not affect subsequent experiments.   
RAW 264.7 murine macrophages cultured with no rinse step (Figure 3.6A) show a 
general increase in cell viability in agarose gels over three days, whereas the positive 
control, cells plus DMSO (200 µl.ml-1), showed a significant decrease in viability after 
day 0 (ANOVA; p<0.05 for day 0 and p>0.05 for days 1 and 3). However RAW 264.7 
murine macrophages cultured in agarose gel with a rinse step (Figure 3.6B) exhibited 
an increase in viability after 12 hours  until day 2, followed by a decrease in viability on 
day three (ANOVA; p<0.05).  
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B) 
 
Figure 3.6 Cell viability of RAW 264.7 murine macrophages seeded at 
different densities in agarose gel over three days at 37°C in 8% (v/v) 
CO2 in air. Cells were seeded at densities of 1 x 104, 5 x 104 and 1 x 
105 cells.ml-1 in a 48 well tissue culture plate. A cells plus DMSO (200 
µl.ml-1) positive control was included in the conditions. Cells viability 
was assessed using the ATP-liteTM luminescence detection assay both 
without (A) and with (B) a rinse step 12 hours post seeding to remove 
any cells that had not penetrated the gel. * designates a statistically 
significant data point compared to the seeding densities assessed 
(ANOVA, p<0.05). Error bars represent 95% confidence intervals, n=6. 
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None of the particle treatments had any effect on cell viability (Figure 3.7A) when 
compared to the cells only negative control (ANOVA; p<0.05). 
TNF-α release from RAW 264.7 murine macrophages after exposure to model 
particles in agarose gels  
After 12 hours, cells cultured with >10 µm Ceridust®, 0.2 µm FluoSpheres® and LPS 
produced significantly elevated levels of TNF-α (Figure 3.7B) compared to the cells 
only negative control (ANOVA; p>0.05). None of the remaining treatments had any 
significant effect on TNF-α release from RAW 264.7 murine macrophages (ANOVA; 
p<0.05).  
After 24 hours, cells cultured with LPS (200 ng.ml-1) produced significantly elevated 
levels of TNF-α (Figure 3.7B) compared to the cells only negative control (ANOVA; 
p>0.05). None of the remaining treatments had any significant effect on the TNF-α 
release of RAW 264.7 murine macrophages (ANOVA; p<0.05).  
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Figure 3.7 – A) Cell viability and B) TNF-α release from RAW 264.7 murine 
macrophages incubated with Ceridust® and FluoSpheres® model particles at a 
concentration of 100 µm3 particles per cell in agarose gel at 12 and 24 hours 
post particle exposure at 37°C in 8% (v/v) CO2 in air. Cells were seeded at a 
density of 1 x 105 cells.ml-1 with particle treatments in a 48 well tissue culture 
plate. A cells only negative control and  LPS (200 ng.ml-1) positive control were 
included in the conditions. * designates a statistically significant data point 
compared to the cells only negative control (ANOVA, p<0.05). Error bars 
represent 95% confidence intervals, n=4. 
 
3.5.2.2  RAW 264.7 murine macrophage cell viability and response to model 
particles in collagen gels 
The viability of RAW 264.7 murine macrophages in collagen gel was assessed using 
the ATP-liteTM luminescence detection assay. RAW 264.7 murine macrophages were 
cultured with Ceridust® and FluoSpheres® model particles in collagen gel. Cells were 
seeded at 1 x 105 cells.ml-1 with 100 µm3 particles per cell in a 48 well tissue culture 
plate. The contents of each well were assessed using the ATP-liteTM luminescence 
detection assay and ELISA for TNF-α at 12 and 24 hours post particle exposure. 
RAW 264.7 murine macrophage viability in collagen gels 
RAW 264.7 murine macrophages in collagen gel exhibit a general increase in cell 
viability (Figure 3.8) over three days with the exception of cells seeded at 1 x 105 
cells.ml-1, which declined in viability on day 3 (ANOVA; p<0.05). The positive control, 
cells plus DMSO (200 µl.ml-1), showed a significant decrease in viability beyond day 0.    
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Figure 3.8 Cell viability of RAW 264.7 murine macrophages seeded at 
different densities in collagen gel over three days at 37°C in 8% (v/v) 
CO2 in air. Cells were seeded at densities of 1 x 104, 5 x 104 and 1 x 105 
cells.ml-1 in a 48 well tissue culture plate. A cells plus DMSO (200 µl.ml-
1) positive control was included in the conditions. * designates a 
statistically significant data point compared to the range of seeding 
densities assessed (ANOVA, p<0.05). Error bars represent ± the 95% 
confidence level, n=6. 
 
Viability of RAW 264.7 murine macrophages after exposure to model particles in 
collagen gels  
Cells treated with 0.1 - 1 µm Ceridust®, 0.2 µm FluoSpheres® and LPS (200 ng.ml-1) 
exhibited a significant increase in cell viability at both 12 and 24 hours post particle 
exposure (Figure 3.9A) when compared to the cells only negative control (ANOVA; 
p<0.05). None of the remaining treatments had any effect on cell viability when 
compared to the cells only negative control (ANOVA; p<0.05).  
TNF-α release from RAW 264.7 murine macrophages after exposure to model 
particles in collagen gels  
After 12 hours, none of the treatments have any significant effect on the TNF-α 
release of RAW 264.7 murine macrophages (Figure 3.9B) except cells cultured with 
LPS (ANOVA; p>0.05). 
After 24 hours, cells cultured with >10 µm Ceridust® and LPS (200 ng.ml-1) produced 
a significantly elevated TNF-α (Figure 3.9B) compared to the cells only negative 
control (ANOVA; p>0.05). None of the remaining treatments had any significant effect 
on the TNF-α release of RAW 264.7 murine macrophages (ANOVA; p<0.05). These 
results were unexpected so this assay was repeated (Figure 3.9C and Figure 3.9D) 
which confirmed the same findings i.e. cells cultured with >10 µm Ceridust® and LPS 
1	
10	
100	
1000	
10000	
100000	
1000000	
10000000	
100000000	
1	x	10^4	 5	x	10^4	 1	x	10^5	 cells	plus	
DMSO	Lo
g	
of
	m
ea
n	
lu
m
in
se
ce
nc
e	
co
un
t	p
er
	
se
co
nd
	+
/-
	9
5%
	C
L	
No.	of	cells	per	well	
Day	0	
Day	1	
Day	2	
Day	3	
* *
*
- 94 - 
(200 ng.ml-1) produced a significantly elevated TNF-α (Figure 3.9B) compared to the 
cells only negative control (ANOVA; p>0.05). In addition, the repeated study showed 
that 0.2 µm FluoSpheres® also produced a significantly elevated TNF-α (Figure 3.9B) 
compared to the cells only negative control (ANOVA; p>0.05). 
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D) 
 
Figure 3.9 – A) Cell viability and B) TNF-α release from RAW 264.7 murine 
macrophages incubated with Ceridust® and FluoSpheres® model particles at a 
concentration of 100 µm3 particles per cell in collagen gel at 12 and 24 hours 
post particle exposure at 37°C in 8% (v/v) CO2 in air. Cells were seeded at a 
density of 1 x 105 cells.ml-1 with particle treatments in a 48 well tissue culture 
plate. A cells only negative control and LPS (200 ng.ml-1) positive control were 
included in the conditions. * designates a statistically significant data point 
compared to the cells only negative control (ANOVA, p<0.05). Error bars 
represent 95% confidence intervals, n=4. C) and D) show a repeat of the above 
in order to confirm the results were repeatable. 
 
3.5.2.3  Response of RAW 264.7 murine macrophage cells to model particles in 
an inverted culture model 
The optimal cell seeding density of RAW 264.7 murine macrophages in 96 well tissue 
culture plates in 2D was initially assessed over five days to provide a suitable range of 
densities for use in the subsequent inverted culture model. RAW 264.7 murine 
macrophages were cultured with Ceridust® and FluoSpheres® model particles in an 
inverted 2D culture model. Cells were seeded at 5 x 104 cells.ml-1 with 100 µm3 
particles per cell in a 96 well tissue culture plate. The contents of each well was 
assessed using the ATP-liteTM luminescence detection assay and TNF-α ELISA at 12 
and 24 hours post seeding. 
Viability of RAW 264.7 murine macrophages over time 
Cells seeded at densities of 1 x 103, 5 x 103 and 1 x 104 cells.ml-1 display a pattern of 
continual increase in viability (Figure 3.10) over the course of five days (ANOVA; 
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p<0.05). Cells seeded at densities of 5 x 104 and 1 x 105 cells.ml-1 displayed relatively 
constant levels of viability over two days, experienced a significant increase in viability 
on day 3 and then a significant decrease in viability on day 5 (ANOVA; p<0.05).  
 
 
Figure 3.10 Cell viability of RAW 264.7 murine macrophages seeded at different 
densities over five days at 37°C in 5% (v/v) CO2 in air. Cells were seeded at 
densities of 5 x 103, 1 x 104, 5 x 104, 1 x 105 and 5 x 105 cells.ml-1 in a 96 
well tissue culture plate. A cells plus DMSO (200 µl.ml-1) positive control was 
included in the conditions. * designates a statistically significant data point 
compared to the seeding densities assessed (ANOVA, p<0.05). Error bars 
represent 95% confidence intervals, n=6. 
 
Viability of RAW 264.7 murine macrophages after exposure to model particles in 
inverted 2D culture  
None of the treatments had a significant effect on the viability of RAW 264.7 murine 
macrophages (Figure 3.11A) compared to the cells only negative control at 12 hours 
post particle exposure, except cells cultured with >10 µm Ceridust®. The majority of 
treatments had no significant effect on the viability of RAW 264.7 murine 
macrophages compared to the cells only negative control at 24 hours post particle 
exposure except cells cultured with cells cultured with >10 µm Ceridust® and LPS 
(200 ng.ml-1) (ANOVA; p<0.05). 
TNF-α release from RAW 264.7 murine macrophages after exposure to model 
particles in inverted 2D culture 
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After 12 hours, none of the treatments have any significant effect on the TNF-α 
release (Figure 3.11B)  of RAW 264.7 murine macrophages (ANOVA; p>0.05). 
After 24 hours, none of the treatments have any significant effect on the TNF-α 
release (Figure 3.11B) of RAW 264.7 murine macrophages (ANOVA; p>0.05). 
 
 
A) 
 
B) 
 
Figure 3.11– A) Cell viability and B) TNF-α release from RAW 264.7 murine 
macrophages incubated with Ceridust® and FluoSpheres® model particles at a 
concentration of 100 µm3 particles per cell at 12 and 24 hours post particle 
exposure at 37°C in 8% (v/v) CO2 in air. Cells were seeded at a density of 1 x 
105 cells.ml-1 whilst inverted with particle treatments in a 48 well tissue culture 
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plate. A cells only negative control and LPS (200 ng.ml-1) positive control were 
included in the conditions. * designates a statistically significant data point 
compared to the cells only negative control (ANOVA, p<0.05). Error bars 
represent 95% confidence intervals, n=3. 
 
3.5.3  Cell viability and inflammatory response of U937 human histiocytes to 
model particles in agarose and collagen gels and inverted 2D culture 
The viability of U937 human histiocytes was assessed in both agarose and collagen 
gels over three days using the ATP-liteTM luminescence detection assay.  U937 
human histiocytes were cultured with model particles, Ceridust® and FluoSpheres®, 
in agarose gel, collagen gel and in inverted 2D culture. In agarose gel, only adherent 
cells were used as suspension cells are inappropriate in agarose gel as they do not 
penetrate or adhere to the gel. Similarly, in inverted 2D culture, only adherent cells 
were used as suspension cells are inappropriate for use in this context as they are 
incapable of adhering to the tissue culture plate prior to inversion. For the collagen 
gel, both adherent and suspension cells were assessed. The viability was measured 
at 12 (and 24 hours for the inverted model) using the ATP-liteTM luminescence 
detection assay. The supernatants at these time points were then used to assess the 
levels of TNF- α cytokine released using ELISA. Unfortunately, the data for U937 
human histiocytes in agarose and collagen gels with Ceridust® 24 hours post particle 
exposure was lost due to experimental error and the candidate made the decision not 
to repeat the assay for this time point due to time pressures and that this cell type was 
not being carried forward to the remaining parts of the study.  
 
3.5.3.1  U937 human histiocyte cell viability and response to model particles in 
agarose gels 
The viability of U937 human histiocytes was assessed in agarose gel over three days 
using the ATP-liteTM luminescence detection assay.  Transformed U937 human 
histiocytes were cultured with Ceridust® and FluoSpheres® model particles in 
agarose gel. Cells were seeded at 1 x 105 cells.ml-1 with 100 µm3 particles per cell in a 
48 well tissue culture plate. The contents of each well was assessed using the ATP-
liteTM cell viability assay (at 12 and 24 hours post particle exposure) and TNF-α ELISA 
(at 12 hours post particle exposure). Unfortunately, the data for U937 human 
histiocytes in agarose gels with Ceridust® 24 hours post particle exposure was lost 
due to experimental error and the candidate made the decision not to repeat the 
assay for this time point.  
Non-transformed U937 human histiocytes viability in agarose gel 
- 100 - 
Non-transformed U937 human histiocytes (i.e. untreated cells in a suspension culture) 
exhibited a general increase in cell viability over three days (Figure 3.12). Cell seeded 
at 5 x 104 and 1 x 105 cells.ml-1 remained constant in terms of their viability between 
days 1 and 3. Cells cultured with DMSO (200 µl.ml-1) demonstrated a significant 
decrease in viability from day 0 onwards (ANOVA; p<0.05). 
 
Figure 3.12 Cell viability of non-transformed U937 human histiocytes 
seeded at different densities in agarose gel over five days at 37°C in 
5% (v/v) CO2 in air. Cells were seeded at densities of 5 x 103, 1 x 104, 5 
x 104, 1 x 105 and 5 x 105 cells.ml-1 in a 48 well tissue culture plate. A 
cells plus DMSO (200 µl.ml-1) positive control was included in the 
conditions. * designates a statistically significant data point compared 
to the seeding densities assessed (ANOVA, p<0.05). Error bars 
represent 95% confidence intervals, n=6. 
 
Transformed U937 human histiocytes viability in agarose gel 
Transformed U937 human histiocytes (i.e. cells treated with PMA to become adherent 
and activated) exhibited a general increase in cell viability in agarose gel over three 
days (Figure 3.13) for all seeding densities (days 0 and 1 ANOVA; p<0.05, day 3 
ANOVA; p>0.05). 
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Figure 3.13 Cell viability of transformed U937 human histiocytes seeded at 
different densities in agarose gel over five days at 37°C in 5% (v/v) 
CO2 in air. Cells were seeded at densities of 5 x 103, 1 x 104, 5 x 104, 1 
x 105 and 5 x 105 cells.ml-1 in a 48 well tissue culture plate. A cells plus 
DMSO (200 µl.ml-1) positive control was included in the conditions. * 
designates a statistically significant data point compared to the seeding 
densities assessed (ANOVA, p<0.05). Error bars represent 95% 
confidence intervals, n=6. 
 
Viability of transformed U937 human histiocytes after exposure to model particles in 
agarose gels 
None of the treatments except LPS (200 ng.ml-1) (12 hours post particle exposure 
only) had a significant effect on the viability of transformed U937 human histiocytes 
(Figure 3.14A) compared to the cells only negative control at 12 and 24 hours post 
particle exposure (ANOVA; p<0.05). 
TNF-α release from transformed U937 human histiocytes after exposure to model 
particles in agarose gels  
After 12 hours, non-transformed U937 human histiocytes treated with 0.2 µm 
FluoSpheres® in addition to LPS (200 ng.ml-1) treated positive control cells produced 
significantly elevated levels of TNF-α (Figure 3.14B), when compared to the cells only 
negative control (ANOVA: p<0.05). None of the remaining Ceridust® particle 
treatments had a significant effect on the release of TNF-α. Unfortunately, the data for 
U937 human histiocytes in agarose gels with Ceridust® 24 hours post particle 
exposure was lost due to experimental error and the candidate made the decision not 
to repeat the assay for this time point. 
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B) 
 
Figure 3.14– A) Cell viability and B) TNF-α release from transformed U937 
human histiocytes incubated with Ceridust® and FluoSpheres® model 
particles at a concentration of 100 µm3 particles per cell in agarose gel 
at 12 hours post particle exposure at 37°C in 5% (v/v) CO2 in air. Cells 
were seeded at a density of 1 x 105 cells.ml-1 with particle treatments in 
a 48 well tissue culture plate. A cells only negative control and LPS (200 
ng.ml-1) positive control were included in the conditions. * designates a 
statistically significant data point compared to the cells only negative 
control (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=4. 
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3.5.3.2  U937 human histiocyte cell viability and response to model particles in 
collagen gels 
The viability of U937 human histiocytes was assessed in collagen gel over three days 
using the ATP-liteTM luminescence detection assay.  Transformed and non-
transformed U937 human histiocytes were cultured with Ceridust® and FluoSpheres® 
model particles in collagen gels. Cells were seeded at 1 x 105 cells.ml-1 with 100 µm3 
particles per cell in a 96 well tissue culture plate. The contents of each well was 
assessed using the ATP-liteTM luminescence detection assay (at 12 and 24 hours post 
particle exposure) and TNF-α ELISA (at 12 hours post particle exposure). 
Unfortunately, the data for U937 human histiocytes in collagen gels with Ceridust® 24 
hours post particle exposure was lost due to experimental error and the candidate 
made the decision not to repeat the assay for this time point. 
Transformed U937 human histiocytes 
Transformed U937 human histiocytes remain at a relatively constant level of cell 
viability at all densities in collagen gel (Figure 3.15) on days 0 and 1 however, on day 
3, a decrease in cell viability is observed although this is not significant (days 0 and 1 
ANOVA; p<0.05, day 3 ANOVA; p>0.05). Cells cultured with DMSO (200 µl.ml-1) 
exhibited a significant decrease in viability from day 0 onwards. 
 
Figure 3.15 Cell viability of transformed U937 human histiocytes  seeded at 
different densities in collagen gel over five days at 37°C in 5% (v/v) 
CO2 in air. Cells were seeded at densities of 5 x 103, 1 x 104, 5 x 104, 1 
x 105 and 5 x 105 cells.ml-1 in a 48 well tissue culture plate. A cells plus 
DMSO (200 µl.ml-1) positive control was included in the conditions. * 
designates a statistically significant data point compared to the seeding 
densities assessed (ANOVA, p<0.05). Error bars represent 95% 
confidence intervals, n=6. 
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Viability of transformed U937 human histiocytes after exposure to model particles in 
collagen gels 
All of the treatments except >10 µm Ceridust® had a significant effect on the viability 
of transformed U937 human histiocytes (Figure 3.16A) compared to the cells only 
negative control at 12 hours post seeding (ANOVA; p<0.05). 
TNF-α release from transformed U937 human histiocytes after exposure to model 
particles in collagen gels  
After 12 hours, non-transformed U937 human histiocytes treated with 0.2 µm 
FluoSpheres® in addition to LPS (200 ng.ml-1) treated cells produced a significantly 
higher level of TNF-α (Figure 3.16B) when compared to the cells only negative control 
(ANOVA: p<0.05). None of the remaining Ceridust® particle treatments had a 
significant effect on the release of TNF-α. Unfortunately, the data for U937 human 
histiocytes in collagen gels with Ceridust® 24 hours post particle exposure was lost 
due to experimental error and the candidate made the decision not to repeat the 
assay for this time point. 
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B) 
 
Figure 3.16– A) Cell viability and B) TNF-α release from transformed U937 
human histiocytes incubated with Ceridust® and FluoSpheres® model 
particles at a concentration of 100 µm3 particles per cell in collagen gel 
at 12 hours post particle exposure at 37°C in 5% (v/v) CO2 in air. Cells 
were seeded at a density of 1 x 105 cells.ml-1 with particle treatments in 
a 48 well tissue culture plate. A cells only negative control and LPS (200 
ng.ml-1) positive control were included in the conditions. * designates a 
statistically significant data point compared to the cells only negative 
control (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=4. 
 
Non-transformed U937 human histiocytes 
Transformed U937 human histiocytes showed a general increase in cell viability over 
three days in collagen gel (Figure 3.17) whereas cells cultured with DMSO 
demonstrated a significant decrease in viability over three days (ANOVA; p<0.05). 
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Figure 3.17 Cell viability of non-transformed U937 human histiocytes 
seeded at different densities in collagen gel over three days at 37°C in 
5% (v/v) CO2 in air. Cells were seeded at densities of 5 x 103, 1 x 104, 5 
x 104, 1 x 105 and 5 x 105 cells.ml-1 in a 48 well tissue culture plate. A 
cells plus DMSO (200 µl.ml-1) positive control was included in the 
conditions. * designates a statistically significant data point compared 
to the seeding densities assessed (ANOVA, p<0.05). Error bars 
represent 95% confidence intervals, n=6. 
 
Viability of non-transformed U937 human histiocytes after exposure to model particles 
in collagen gels 
All of the treatments had a significant effect on the viability of non-transformed U937 
human histiocytes (Figure 3.18A) compared to the cells only negative control at 12 
hours post particle exposure (ANOVA; p<0.05). 
TNF-α release from non-transformed U937 human histiocytes after exposure to model 
particles in collagen gels  
After 12 hours, non-transformed U937 human histiocytes treated with >10 µm 
Ceridust®, 0.2 µm FluoSpheres® in addition to LPS (200 ng.ml-1) treated positive 
control cells produced a significantly elevated release of TNF-α (Figure 3.18B) when 
compared to the cells only negative control (ANOVA: p<0.05). None of the remaining 
Ceridust® particle treatments had a significant effect on the release of TNF-α. 
Unfortunately, the data for U937 human histiocytes in collagen gels with Ceridust® 24 
hours post particle exposure was lost due to experimental error and the candidate 
made the decision not to repeat the assay for this time point. 
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B) 
 
Figure 3.18– A) Cell viability and B) TNF-α release from non-transformed 
U937 human histiocytes incubated with Ceridust® and FluoSpheres® 
model particles at a concentration of 100 µm3 particles per cell in 
collagen gel at 12 hours post particle exposure at 37°C in 5% (v/v) CO2 
in air. Cells were seeded at a density of 1 x 105 cells.ml-1 with particle 
treatments in a 48 well tissue culture plate. A cells only negative control 
and LPS (200 ng.ml-1) positive control were included in the conditions. * 
designates a statistically significant data point relative to the cells only 
negative control (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=4. 
 
3.5.3.3  Response of transformed U937 human histiocyte cells to model 
particles in an inverted culture model 
The optimal cell seeding density of U937 human histiocytes in 96 well tissue culture 
plates in 2D was initially assessed over five days to provide a suitable range of 
densities for use in the forthcoming inverted culture model. Transformed U937 human 
1	
10	
100	
1000	
10000	
100000	
1000000	
10000000	
Lo
g	
of
	m
ea
n	
lu
m
in
es
ce
nc
e	
co
un
t	
pe
r	s
ec
on
d	
+/
-	9
5%
	C
L	
Conditions	
0 
5 
10 
15 
20 
25 
30 
Cells Only >10 µm ceridust 1-10 µm 
ceridust 
0.1-1 µm 
ceridust 
0.2 µm 
fluospheres 
cells plus LPS 
TN
F-
α 
(p
g/
10
0 
µl
) 
Particle doses 
*
*
*
- 108 - 
histiocytes were cultured with Ceridust® and FluoSpheres® model particles in an 
inverted 2D culture model. Cells were seeded at 5 x 104 cells.ml-1 with 100 µm3 
particles per cell in a 96 well tissue culture plate. The contents of each well was 
assessed using the ATP-liteTM luminescence detection assay and TNF-α ELISA at 12 
and 24 hours post particle exposure. 
Viability of transformed U937 human histiocytes over time 
Cells seeded at densities of 1 x 103, 5 x 103 and 1 x 104 cells per ml displayed 
relatively constant levels of viability (Figure 3.19) over two days, experienced a 
significant increase in viability on day 3 and then a significant decrease in viability on 
day 5 (ANOVA; p<0.05). Cells seeded at densities of 5 x 104 and 1 x 105 cells.ml-1 
experienced a significant decrease in viability on day 1, remained constant on day 2, 
experienced a significant increase in viability on day 3 followed by a decrease in 
viability on day 5, although the latter was not significant (ANOVA; p<0.05).  
 
Figure 3.19–Cell viability of transformed U937 human histiocytes seeded at 
different densities over five days at 37°C in 5% (v/v) CO2. Cells were 
seeded at densities of 5 x 103, 1 x 104, 5 x 104, 1 x 105 and 5 x 105 
cells.ml-1 in a 48 well tissue culture plate. A cells plus DMSO (200 µl.ml-
1) positive control was included in the conditions. * designates a 
statistically significant data point compared to the seeding densities 
assessed (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=6. 
 
Viability of U937 human histiocytes after exposure to model particles in inverted 2D 
culture  
None of the Ceridust® treatments had a significant effect on the viability of U937 
human histiocytes (Figure 3.20A) compared to the cells only negative control at 12 
and 24 hours post particle exposure. However, cells cultured with 0.2 µm 
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FluoSpheres® and LPS (200 ng.ml-1) (positive control) did exhibit a significant 
reduction in viability 12 hours post particle exposure (ANOVA; p<0.05) but not at 24 
hours post particle exposure. 
TNF-α release from U937 human histiocytes after exposure to model particles in 
inverted 2D culture 
After 12 hours, transformed U937 human histiocytes treated with 0.2 µm 
FluoSpheres® in addition to LPS treated positive control cells produced a significant 
release of TNF-α (Figure 3.20B) when compared to the cells only negative control 
(ANOVA: p<0.05). None of the Ceridust® particle treatments had a significant effect 
on the release of TNF-α. 
After 24 hours, transformed U937 human histiocytes treated with 0.2 µm 
FluoSpheres® in addition to LPS (200 ng.ml-1) treated positive control cells produced 
a significant release of TNF-α (Figure 3.20B) when compared to the cells only 
negative control (ANOVA: p<0.05). None of the Ceridust® particle treatments had a 
significant effect on the release of TNF-α. 
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B) 
 
Figure 3.20 – A) Cell viability and B) TNF-α release from transformed U937 human 
histiocytes incubated with Ceridust® and FluoSpheres® model particles at a 
concentration of 100 µm3 particles per cell at 12 and 24 hours post particle 
exposure at 37°C in 5% (v/v) CO2. Cells were seeded at a density of 1 x 104 
cells.ml-1 whilst inverted with particle treatments in a 96 well tissue culture plate. 
A cells only negative control and LPS (200 ng.ml-1) positive control were included 
in the conditions. * designates a statistically significant data point compared to 
the cells only negative control (ANOVA, p<0.05). Error bars represent 95% 
confidence intervals, n=3. 
3.6  Discussion 
Aim of the present study 
The aim of the chapter was to develop a 3D in vitro model to assess the cellular 
response to model polyethylene particles in order to provide a more accurate 
representation of the periprosthetic environment in comparison to earlier 2D models.  
In vitro modelling of the biological response to polyethylene using gel encapsulation  
Green et al. (1998) encapsulated polyethylene particles (Ceridust®) in 1% (w/v) 
agarose gel and centrifuging the gel at 800 g to create a monolayer of polyethylene 
particle on the surface of the gel and seeding murine peritoneal macrophages on top 
of the gel (Green et al., 1998). This method was adapted and used by Liu (2012); the 
percentage of agarose in the gel was reduced from 1% to 0.4% (w/v) to increase 
porosity of the gel and the centrifugation step was removed, leaving polyethylene 
particles dispersed throughout the gel (Liu, 2012). Liu (2012) also used human 
PBMNC’s, rather than murine peritoneal macrophages. As both of these cell types are 
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primary, they demonstrate donor heterogeneity which can reduce the reliability and 
repeatability of the results obtained. Gowland (2014) also used this model and 
adapted it further by increasing the cell seeding density of PBMNC’s from 1 x 105 
cells.ml-1 to 2 x 105 cells.ml-1 and increasing the volume of particles used from 100 
µm3 particles.cell-1 to 500 µm3 particles.cell-1. This increased the proportion of 
polyethylene particles within the critical size range required to cause a biological 
response from macrophages. Gowland (2014) also trialled the use of transformed 
U937 human histiocytes in this setting and found their response comparable to 
PBMNC’s (Gowland, 2014). As U937 human histiocytes are a cell line, the issue of 
donor heterogeneity was removed, although Gowland (2014) did not continue their 
use.  
The agarose gel encapsulation method created a 2D culture system and overcame 
the issues associated with culturing cells with particles with a lower density than cell 
culture medium. However, as this is a 2D culture system, this model is not 
representative of the 3D periprosthetic environment.  
Development of a novel 3D model to measure cellular response to polyethylene wear 
debris  
In order to address the lack of a 3D model of the periprosthetic environment, this 
study sought to develop a novel 3D model to measure the cellular response to 
polyethylene wear debris to enhance reliability and repeatability of future studies. In 
order to improve the reliability of the model developed, alternative cell types and 
alternative gel types were investigated in different combinations in terms of their 
viability and ability to produce an inflammatory response when stimulated with model 
polyethylene wear debris. 
Initially the viability of PBMNC’s, U937 human histiocytes and RAW 264.7 murine 
macrophages in both agarose and collagen gels was examined using the ATP-liteTM 
luminescence detection assay. PBMNC’s were used as they represent the original 
primary cell type used in this model setting. U937 human histiocytes were chosen as 
they had been highlighted by a previous study by Matthews et al. (2001) as a human 
monocytic cell line capable of responding in a manner akin to PBMNC’s to 
polyethylene particles (Matthews et al., 2001). Moreover, Gowland (2014) briefly 
trialled their use and their responses to UHMWPE wear debris were promising 
(Gowland, 2014). Finally, RAW 264.7 murine macrophages were chosen as previous 
studies (Green et al., 1998; Matthews et al., 2000a) have routinely used murine 
peritoneal macrophages with success to model cellular response to UHMWPE wear 
debris. A cell line alternative, RAW 264.7 murine macrophages, as used in previous 
studies such as Musib and Saha (2010), was chosen in place of primary cells to avoid 
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donor heterogeneity. Agarose gel was chosen as it was the original type of gel used in 
this type of model. Collagen gel was chosen as previous studies by Lee (2016) and 
Smith (2016) had demonstrated its use in modelling cellular response to neural 
injuries in a 3D environment (Lee, 2016; Smith, 2016). Moreover, the gelation of 
collagen is pH dependent, allowing for simultaneous cell and particle encapsulation, 
whereas agarose gelation is heat dependent and it is therefore impossible to 
simultaneously encapsulate cells with particles as the high temperature required to 
plate the gel (>60°C) would adversely affect any cells present. Whereas, collagen gel 
allows for the simultaneous encapsulation of both cells and particles. Finally, agarose 
lacks cell attachment sites, such as RGD motifs, unlike collagen gel. The ATP-liteTM 
luminescence detection assay was chosen rather than the MTT viability assay as 
previous studies (Lee, 2016; Smith, 2016) found that MTT interacted with collagen gel, 
forming a brown precipitate; these authors instead used the live-dead assay to count 
viable cells in microscopic z stacks. The ATP-liteTM luminescence detection assay 
protocol was modified previously at the University of Leeds to account for its use with 
gels; the volume of reagents used was multiplied by four and the incubation and 
shaking times for each step were increased from 5 minutes to 20 minutes to allow the 
reagents sufficient time to penetrate the gels fully. A positive control, 1 x 105 cells.ml-1 
treated with DMSO (200 µl.ml-1), was included for comparative purposes. Additionally 
a medium only control was included to correct for background created by the cell 
culture medium itself. 
Neither the agarose or collagen gels adversely affected the viability of either the 
PBMNC’s, U937 human histiocytes or RAW 264.7 murine macrophages. This is 
consistent with previous studies carried out in agarose (Green et al., 1998, 2000; 
Matthews et al., 2001; Liu, 2012; Gowland, 2014) and collagen (Lee, 2016; Smith, 
2016). It was determined that the working cell seeding density for use in 48 well tissue 
culture plates was 1 x 105 cell.ml-1 as opposed to the increased cell seeding density, 2 
x 105 cells.ml-1, used by Gowland (2014); although it should be noted that Gowland 
(2014) used this cell seeding density in agarose gel rather than simple 2D culture on 
the base of a 48 well plate. When comparing the two seeding densities (1 x 105 
cell.ml-1 and 2 x 105 cells.ml-1) in simple 2D culture, there appeared to be a decrease 
in viability experienced by cells seeded at 2 x105 cells.ml-1 on day 1 which was not 
experienced by cells seeded at 1 x 105 cells.ml-1 on day 1. As cells were to be used 
within 24 hours, this seeding density was not carried forwards. When RAW 264.7 
murine macrophages were initially cultured in agarose gels, it was observed, using 
light microscopy, that the majority of cells were not penetrating the gel and were 
instead clumping together on the surface of the gel. The viability assay was therefore 
repeated with the addition of a rinse step after 12 hours to remove any cells that had 
failed to penetrate the gel. However the addition of this step resulted in significantly 
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lower cells numbers; too low for future studies so this step was discontinued. No 
images were obtained of each cell type in each gel type which would, in hindsight, 
have provided useful evidence whether the cells and particles in each type of gel had 
been able to penetrate the gel or not and, where penetration of the gel had occurred, 
how the cells and particles were distributed throughout the gel. For example, imaging 
the cells in the gels would have clearly shown the RAW 264.7 murine macrophages 
failing to penetrate the agarose gel and added evidence to the claims of this study. 
Once the viability of each cell type in each gel type had been established, the ability of 
each cell type to produce TNF-α in response to model particles, Ceridust® and 
FluoSpheres® in each gel environment was assessed using ELISA. The inflammatory 
response to model polyethylene particles of each combination tested is summarised in 
Table 3.1. TNF-α was chosen as the pro-inflammatory/osteolytic cytokine to assess as 
it has several roles in the inflammatory cascade and osteolysis. Moreover, it is one of 
the first cytokines to be released upon initial contact with a foreign material in the 
innate immune response (Janeway et al., 2001). It was decided not to use UHMWPE 
wear debris generated artificially using a wear simulator rig as the yield of particles 
can often be low and these particles were reserved for later inflammatory studies. 
Instead, it was decided to use model polyethylene particles, Ceridust®, as these had 
successfully been used previously to demonstrate the inflammatory and osteolytic 
response to polyethylene particles in both PBMNC’s (Matthews et al., 2000a; 
Matthews et al., 2001; Liu, 2012) and murine peritoneal macrophages (Green et al., 
1998). FluoSpheres® were also included as a particle control as these had also been 
proven to induce an inflammatory response in PBMNC’s (Liu, 2012; Gowland, 2014). 
LPS was included as a positive control as it is known to induce an extreme 
inflammatory response (Liu, 2012; Gowland, 2014). Cells were seeded in a 200 µl gel 
plug in a 48 well tissue culture plate rather than a 96 well tissue culture plate. 
Although, a 96 well tissue culture plate would be more economical in terms of the cell 
numbers and particle volumes required, the 1 ml of supernatant in a 48 well tissue 
culture plate would allow multiple ELISA’s to be performed from the supernatant of 
one experiment compared to 200 µl in 96 well plates. This would also preserve time 
and remove the need to set up multiple experiments to achieve the same results in 96 
well plates. Finally, it was also decided to report the cytokine data as pg.100 µl-1 rather 
than specific activity as this is consistent with previous studies by Liu (2012) and 
Gowland (2014) thus allowing a direct comparison between the data obtained in this 
study and the data obtained in the studies by Liu (2012) and Gowland (2014).  
The overall findings of this study were not consistent with previous studies conducted 
by Green et al. (1998) and Matthews et al. (2000a, 2001) which found that non-cross-
linked polyethylene particles (artificially generated GUR 1120 UHMWPE wear debris 
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and commercially available Ceridust®) between 0.1 and 10 µm generated a significant 
inflammatory cytokine response in comparison to particles greater than 10 µm  in both 
PBMNC’s (Matthews et al., 2000b), U937 human histiocytes (Matthews et al., 2001) 
and murine peritoneal macrophages (Green et al., 1998). This study only found an 
inflammatory response to Ceridust® particles  greater than 10 µm. It is not 
immediately clear why this was the case. This result was unexpected and the 
experiment was repeated for the cell type and gel type chosen to proceed with (RAW 
264.7 murine macrophages and collagen gel) in order to confirm repeatability. As the 
3D cell culture is very different to 2D cell culture, it is possible that this reproducible 
effect is valid rather than an error. It is hypothesised that the particles in the critical 
size range were trapped in the >10 µm particle fraction, as this did thickly coat the 
filter paper, and failed to fully pass through the filter paper membrane upon rinsing 
with ultrapure water however, since size distribution data was not obtained, it is not 
possible to verify this hypothesis. Unfortunately, neither size distribution data nor 
images were obtained of the Ceridust® particles obtained. Upon reflection, this was 
an oversight as it would have provided useful data as to the true size range of each 
Ceridust® particle fraction tested which may have accounted for the unexpected 
results. Similarly, the repeatability of this effect in other cell and gel combinations 
(PBMNC’s and agarose gel, RAW 264.7 murine macrophages and agarose gel and 
non-transformed U937 human histiocytes and collagen gel) ought to have been 
confirmed in order to validate the legitimacy of this effect in 3D culture. In most cases, 
all cell and gel combinations, except PBMNC’s in agarose, produced a significant 
TNF-α response to 0.2 µm FluoSpheres® in comparison to the cells only control. This 
was consistent with previous studies by Liu (2012) and Gowland (2014). It should be 
noted that the levels of TNF-α produced by the various cells types in response to >10 
µm Ceridust® and 0.2 µm FluoSpheres®, although statistically significant, were very 
low (only slightly higher than the cells only control) (Table 3.1). It is therefore difficult 
to assess the biological significance of these responses. The low levels of TNF-α 
produced in response to polyethylene wear debris is however consistent with previous 
studies by Liu (2012) and Gowland (2014); both of whom found it difficult to produce a 
significantly higher levels of TNF-α in PBMNC’s. For example, Liu (2012) produced 
values <100 pg.ml-1 from PBMNC’s treated with 100 µm3 0.2 µm FluoSpheres® and 
this study produced responses ranging from 20 to 120 pg.100 µl-1. Similarly, Gowland 
(2014) treated PBMNC’s with 100 µm3 GUR 1050 XL UHMWPE and GUR 1050 XL 
VE and produced TNF-α levels ranging between 3 and 19 pg.ml-1 (GUR 1050 XL) and 
1 and 9 pg.ml-1; none of which were significantly increased compared to the cells only 
control. All cell types in all gel types were able to produce significantly elevated levels 
of TNF-α in response to the LPS positive control. This was consistent with previous 
studies by Liu (2012) and Gowland (2014). In this study, both RAW 264.7 murine 
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macrophages and PBMNC’s produced between 400 and 500 pg.100 µl-1 of TNF-α in 
response to the LPS positive control. Although U937 human histiocytes did produce 
an increased TNF-α response, they failed to produce a significantly higher response 
consistent with previous studies so their use was discontinued. Gowland (2014) 
achieved TNF-α levels of around 1400 pg.ml-1 in response to the LPS positive control. 
In order to remove to issue of donor heterogeneity, the use of PBMNCs was 
discontinued. In order to create a 3D model, i.e. one allowing simultaneous 
encapsulation of cells and particles to ensure adequate cell-particle contact and allow 
for cell attachment to the gel, collagen gel was chosen to replace agarose gel as the 
encapsulation medium. Finally, as subsequent study examined the effect of 
antioxidants on inflammatory pathways such as the PKC pathway, RAW 264.7 murine 
macrophages were chosen rather than U937 human histiocytes as PMA, used to 
transform U937 human histiocytes, is an inhibitor of PKC. PMA is necessary to 
stimulate the differentiation of U937 human histiocytes into activated macrophages; 
without this stimulation, non-transformed U937 human histiocytes may not be an 
appropriate alternative to PBMNCs as their reactivity may be different to transformed 
U937 human macrophages. RAW 264.7 murine macrophages, however, do not 
require this chemical activation step. Overall, the combination of RAW 264.7 murine 
macrophages in collagen gels was chosen as the novel model and carried forward to 
subsequent chapters.  
Trialling an alternative inverted 2D culture with RAW 264.7 murine macrophages and 
U937 human histiocytes with model polyethylene particles 
An alternative inverted 2D culture method was developed at the University of Leeds 
by PDRA, Dr Saurabh Lal. PBMNC’s were seeded on the base of a 96 well tissue 
culture plate and UHMWPE wear debris was suspended in cell culture medium. The 
tissue culture plate was then inverted and the cells were then in contact with the 
model polyethylene particles at the cell culture medium interface. The cell culture 
medium was held in place by surface tension. As part of this study, the candidate 
trialled the use of RAW 264.7 murine macrophages and U937 human histiocytes in 
this novel inverted 2D culture model. RAW 264.7 murine macrophages failed to 
respond to any of the conditions, including the LPS positive control. The U937 human 
histiocytes produced significantly increased levels of TNF-α when treated with 0.2 µm 
FluoSpheres® and LPS in comparison to the cells only control. The inherent limitation 
and weakness of this novel method is that the plate itself is inverted and, if the plate is 
disturbed, the surface tension of the cell culture medium is destroyed and the cells will 
no longer be in contact with the particles or the medium. This may have been the case 
for RAW 264.7 murine macrophages. In comparison, the inverted cover slip method, 
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as carried out by Matthews et al. (2000a), is more robust as it is not sensitive to loss 
of surface tension and may be preferable to use for initial 2D culture studies.  
Table 3.1 Table of different cell and gel combinations treated with varying sizes of 
Ceridust® model polyethylene particles (>10 µm, 1 – 10 µm and 0.1 – 1 µm), 0.2 
µm FluoSpheres® and LPS to assess TNF-α release using ELISA. ✔ indicates a 
significant release of TNF-α and ✖ indicates no significant release of TNF-α in 
comparison to the cells only negative control.  
Cell and gel 
combination 
tested 
Particle treatment 
>10 µm 
Ceridust® 
1 – 10 µm 
Ceridust® 
0.1 – 1 µm 
Ceridust® 
0.2 µm 
FluoSpheres® 
LPS (200 
ng.ml-1) 
PBMNCs in 
agarose 
✔ 
<50 pg 
✖ ✖ ✔ 
<50 pg 
✔ 
550 pg 
PBMNCs in 
collagen 
✖ ✖ ✖ ✖ ✔ 
330 pg 
RAW cells in 
agarose 
✔ 
<50 pg 
✖ ✖ ✔ 
<50 pg 
✔ 
230 pg 
RAW cells in 
collagen 
✔ 
<50 pg 
✖ ✖ ✖ ✔ 
450 pg 
Transformed 
U937 cells in 
agarose 
✖ ✖ ✖ ✔ 
120 pg 
✔ 
<50 pg 
Transformed 
U937 cells in 
collagen 
✖ ✖ ✖ ✔ 
20 pg 
✔ 
<50 pg 
Non-
transformed 
U937 cells in 
collagen 
✔ 
20 pg 
✖ ✖ ✔ 
25 pg 
✔ 
20 pg 
 
3.7  Conclusions 
• This study showed that agarose and collagen gels do not cause any adverse 
effects on the viability of PBMNC’s, U937 human histiocytes and RAW 264.7 
murine macrophages.  
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• The combination of RAW 264.7 murine macrophages in collagen gel was 
chosen to proceed forwards with for further studies. RAW 264.7 murine 
macrophages were capable of responding to Ceridust® and FluoSphere® 
particles, do not require a donor or demonstrate donor heterogeneity and do 
not require chemical transformation. Collagen gel also simultaneously 
encapsulates cells and particles, allowing for a 3D model rather than a 2D 
model, in addition to providing cell attachment sites.  
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Chapter 4 
Generation, isolation and characterisation of antioxidant doped, 
highly cross-linked ultra-high molecular weight polyethylene wear 
debris  
4.1  Introduction 
Multidirectional reciprocating pin-on-plate (POP) wear simulator rigs have been 
successfully used to produce clinically relevant UHMWPE wear particles that 
resemble those found in vivo (Lancaster et al., 1997; Endo et al., 2001; Ingram et al., 
2004; Galvin et al., 2006; Affatato et al., 2008). In a multidirectional reciprocating POP 
wear simulator rig, the plate moves forwards and backwards whilst the pin rotates; this 
combination simulates the movement of the femoral head in the acetabulum of the hip 
joint. Both single and six station multidirectional reciprocal POP wear simulators are 
used at the University of Leeds. Galvin et al. (2006) produced clinically relevant cross-
linked and non-cross-linked UHMWPE wear debris using a six station multidirectional 
POP wear simulator rig operated using kinematics known to reproduce similar 
conditions to the hip in normal gait. Liu (2012) went on to use a six station 
multidirectional POP wear simulator rig to produce sterile nanometre sized UHMWPE 
wear debris. Ingram et al. (2004) used a single station multidirectional POP wear 
simulator aseptically to produce sterile, endotoxin-free UHMWPE wear debris. 
Multidirectional POP wear simulators may be used with rough (Ra 0.08 – 0.09 µm) or 
smooth (Ra 0.01 – 0.02 µm) CoCr plates. Smooth plates replicate the surface 
roughness of clinical implants in vivo, whereas rough plates are used to generate a 
large volume of wear debris for in vitro cell culture studies, as the wear factor is 
typically increased. The size distribution of particles produced differs between the 
types of plates: rough plates tend to produce larger particles (Endo et al., 2001). Both 
types of plates produce UHMWPE wear debris of similar particle size ranges and 
morphologies observed in retrieval studies (Endo et al., 2001; Ingram et al., 2004). 
The morphology and size and volume distribution of the particles generated was 
assessed at the University of Leeds using KOH digestion method developed by Tipper 
et al. (2000, 2006) with both retrieved periprosthetic tissue (Tipper et al., 2000) and 
simulator rig serum lubricants (Tipper et al., 2006) to isolate the particles which were 
then imaged using FEGSEM.  
The size and shapes of UHMWPE wear particles is important for in vitro studies in 
order to accurately assess the osteolytic cytokine production of representative cell 
types (usually macrophages) in response to UHMWPE wear debris. The size 
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distribution of wear particles is important for assessing the biological response to wear 
debris. Green et al. (1998) found the size range of polyethylene particles necessary to 
produce a biological response to be between 0.3 and 10 µm. Moreover, Ingham et al. 
(2000) found that polyethylene particles between 0.2 and 0.8 µm activated 
macrophages. The size of UHMWPE wear debris dictates how the body responds to 
it. Larger particles (>10 µm) are unable to be phagocytosed and are walled off by 
foreign body giant cells and granulomatous tissue. Local macrophages uptake 
UHMWPE particles less than 10 µm are uptaken and the macrophages attempt to 
phagocytose them. However, as polyethylene is chemically inert, phagocytosis is not 
possible and the macrophages become frustrated; releasing further pro-inflammatory 
cytokines and recruiting more macrophages to the periprosthetic tissue. The pro-
inflammatory cytokines (such as TNF-α, IL-1β and IL-6) stimulate osteoclastogenesis 
and an increase in osteoclastic activity. Osteoclasts begin to resorb bone surround the 
THR and, over time, the fixation of the implant is loosened. This results in pain and, 
ultimately, revision surgery. It is therefore important to have representative UHMWPE 
wear debris in order to accurately reproduce this effect in vitro.  
UHMWPE has been modified from the original virgin material to reduce the volume of 
wear debris produced and therefore the incidence of osteolysis. Cross-linked 
UHMWPE produces lower volumes of wear debris and exhibits lower wear factors 
than virgin (non-cross-linked) UHMWPE (Endo et al., 2001; Ingram et al., 2004). 
Antioxidant (vitamin E) doped, highly cross-linked UHMWPE does not exhibit a 
significantly different wear factor or a significantly different distribution of particle sizes 
in comparison to highly cross-linked UHMWPE (Gowland, 2014). The addition of 
antioxidants, such as vitamin E, does however quench free radicals and prevents the 
reduction in mechanical properties associated with oxidative embrittlement 
(Wannomae et al., 2006).  
The aim of this study was to produce UHMWPE wear debris from GUR 1020 XL, GUR 
1020 XL AOX, GUR 1050 XL, GUR 1050 XL VE using both the six and single station 
multidirectional wear simulators. The single station multidirectional POP wear 
simulator was used to generate the full range (nm to mm) of sterile UHMWPE wear 
debris that would be produced in vivo, whereas the six station multidirectional POP 
wear simulator was used to generate a greater volume of UHMWPE wear debris that 
was then filtered in to the critical size range specified by Matthews et al. (2001) as 
activating macrophages (0.1 to 1 µm) to produce osteolytic cytokines for later use in 
the novel in vitro model developed in Chapter 3. Rough (Ra 0.08 – 0.09 µm) ASTM 
1537 low carbon CoCr plates were used to produce a larger volume of UHMWPE over 
a short time frame (compared to smooth plates). The samples for each material on 
each type of wear simulator rig were then pooled and isolated using the digestion 
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method developed by Tipper et al. (2000, 2006) and modified by Richards et al. 
(2008). The particles were then imaged using FEGSEM and the images were 
analysed using Image J to assess the size and volume distribution of wear debris 
generated from each material on each type of rig in order to compare to previous 
studies.  
4.2  Aims and objectives 
4.2.1  Aims 
The overall aim of this chapter was to aseptically generate, isolate and characterise 
both highly cross-linked and antioxidant-doped, highly cross-linked UHMWPE wear 
debris using both the single and six station wear simulator rigs to culture with RAW 
264.7 murine macrophages in collagen gels to assess inflammatory and oxidative 
cellular response.  
4.2.2  Objectives 
The objectives of this chapter were as follows: 
• Generation of GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 
1050 XL VE UHMWPE wear debris using single and six station pin on plate 
wear simulator rigs under hip kinematic conditions for later use in in vitro 
studies throughout the subsequent chapters. 
• Microbiological and endotoxin testing of all wear debris samples obtained 
on each wear rig to confirm sterility in terms of whole organism and LPS 
contamination, which may have adversely affected later in vitro studies. 
• Isolation of a sample of wear debris from each material on each type of rig 
using the digestion method as previously validated by Tipper et al. (2000, 
2006) and Richards et al. (2008). 
• To image and characterise a full, unfractionated sample of wear debris from 
each material on each type of rig using FEGSEM to image the particles at 
various magnifications and ImageJ to analyse the subsequent images and 
characterise them according to size and volume frequency distribution. 
4.3  Materials 
The materials used throughout Chapter 4 are detailed below. 
4.3.1  Chemicals and reagents 
The chemicals and reagents used throughout Chapter 4 are listed in Table 4.1.  Any 
general chemicals and reagents used can be found in Chapter 2, Section 2.1.1.  
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Table 4.1  Chemicals and reagents used throughout Chapter 4.  
Chemicals and 
reagents 
Supplier Storage and 
preparation 
Bleach (<5% sodium 
hypochlorite) 
Tesco, Cheshunt, UK. Stored at room 
temperature (25°C). 
Carbon paste Agar Scientific, 
Stanstead, Essex, UK. 
Stored at room 
temperature (25°C). 
Chloroform VWR International Ltd, 
Poole, UK. 
Stored at room 
temperature (25°C). 
Ethanol absolute  Fisher Scientific UK, 
Loughborough, UK. 
Stored at room 
temperature (25°C). 
Heated blood agar 
(HBA) plates 
Fisher Scientific UK, 
Loughborough, UK. 
Stored at 4°C. 
Isopropanol (70% (v/v)) Acros Organics, Geel, 
Belgium. 
Prepared by adding 
100% (v/v) isopropanol 
to distilled water (7:3) 
and stored at room 
temperature (25°C). 
LAL chromogenic 
endotoxin quantitation 
kit 
ThermoFisher 
Scientific, Hemel 
Hempstead, UK. 
Stored at 4°C. 
Methanol Atom Scientific Ltd, 
Hyde, UK. 
Stored at room 
temperature (25°C). 
Nutrient agar (NA) 
plates 
Fisher Scientific UK,  
Loughborough, UK. 
Stored at 4°C. 
Nutrient broth powder Oxoid Limited, 
Basingstoke, 
Hampshire, UK. 
Stored at room 
temperature (25°C). 
Potassium hydroxide 
pellets 
Fluka Analytical, Buchs, 
Switzerland. 
Stored at room 
temperature (25°C). 
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Sabouraud dextrose 
agar (SAB) plates 
Fisher Scientific UK, 
Loughborough, UK. 
Stored at 4°C. 
Trigene (1% (v/v)) Scientific Laboratory 
Supplies Ltd, 
Nottingham, UK. 
Stored at room 
temperature (25°C) 
and a 1% solution is 
prepared by adding 
100% Trigene (v/v) to 
distilled water. 
Vaseline (petroleum 
jelly) – anti-fretting 
lubricant 
Unilever, Leatherhead, 
UK. 
Stored at room 
temperature (25°C). 
 
4.3.2  Consumables 
The consumables used throughout Chapter 4 are listed in Table 4.2.  Any general 
consumables used can be found in Chapter 2, Section 2.1.2.  
Table 4.2  Consumables used throughout Chapter 4.  
Materials and consumables Supplier 
Disposable aprons PAL International, Lutterworth, UK. 
Endotoxin free 1.5 ml 
microcentrifuge tubes	
Starlab, Milton Keynes, UK.	
Endotoxin free 96 well plates Associates of Cape Cod, 
Massachusetts, USA. 
Endotoxin free pipette tips Starlab, Milton Keynes, UK. 
Face masks Alpha Solway Ltd, Annan, UK. 
Foil packets Westfield Medical Ltd, Radstock, 
UK. 
Glass Pasteur pipettes Glassware Stores, School of 
Molecular and Cellular Biology, 
University of Leeds. 
Glass serological pipettes (10ml and MBL, UK. 
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25ml) 
Oversleeves PAL International, Lutterworth, UK. 
Short aluminium stubs  Electron Optics, School of Chemical 
and Process Engineering, University 
of Leeds. 
Sterile latex surgical gloves Bioclean™, Newmarket, UK.  
Tupperware box Tesco, Cheshunt, UK. 
 
4.3.3  Equipment 
The equipment used throughout Chapter 4 are listed in Table 4.3.  Any general 
equipment used can be found in Chapter 2, Section 2.1.3.  
Table 4.3  Equipment used throughout Chapter 4.  
Equipment and model (where 
relevant) 
Manufacturer 
Balance – XP26 Mettler Toledo, Ohio, USA. 
Bunsen burner Fisher Scientific UK, Loughborough, 
UK. 
Calibration load cell - 444N RDP Electronics  
 
Carbon coater – Quorum Q150T E Quorum, Lewes, UK. 
Centrifuge – Mistral 3000E Sanyo, Watford, UK. 
Compressed air dispenser Manufactured in house, School of 
Mechanical Engineering, University of 
Leeds. 
Field emission gun scanning electron 
microscope – Hitachi SU8230 Cold-
FEGSEM 
Hitachi, Maidenhead, UK. 
Heat sealer Hulme Martin Heat Sealers Ltd, 
Woking, UK. 
Heating block Eppendorf, Stevenage, UK. 
High speed Sorvall Evolution RC Thermo Scientific, Hemel 
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centrifuge and SLA-1500 rotor Hempstead, UK. 
Ignitor Fisher Scientific UK, Loughborough, 
UK. 
Infrared lamp Phillips, Guildford, UK. 
Plastic tweezers Mettler Toledo, Ohio, USA. 
Platinum inoculation loop and holder Fisher Scientific UK, Loughborough, 
UK. 
Single station pin on plate wear 
simulator 1 
Manufactured in house, School of 
Mechanical Engineering, University of 
Leeds. 
Single station pin on plate wear 
simulator 2 
Manufactured in house, School of 
Mechanical Engineering, University of 
Leeds. 
Six station pin on plate wear simulator 
B 
Manufactured in house, School of 
Mechanical Engineering, University of 
Leeds. 
Sonicator – RS Pro RS Components, Leeds, UK. 
Sorvall 250ml dry spin centrifuge 
bottles and sealing lids 
Thermo Scientific, Hemel 
Hempstead, UK. 
Stirrer bar Fisher Scientific UK, Loughborough, 
UK. 
Stirrer plate Stuart, Stone, UK. 
Stub storage and transport box Electron Optics, School of Chemical 
and Process Engineering, University 
of Leeds. 
Syringe driver Manufactured in house, School of 
Mechanical Engineering, University of 
Leeds. 
Timer Scientific Laboratory Supplies, 
Nottingham, UK 
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4.3.4  Pins and plates 
The UHMWPE pin and cobalt chromium (CoCr) plate materials used throughout 
Chapter 4 are listed in Table 4.4.  
Table 4.4  Pins and plates used throughout Chapter 4.  
Pins and plates Supplier 
GUR 1050 vitamin E (1000ppm) 
highly cross-linked (10 MRad) 
UHMWPE pins 
Bar stock supplied by Meditech 
medical polymers (Pennsylvania, 
USA). Machined in house, School of 
Mechanical Engineering, University 
of Leeds. 
GUR 1050 highly cross-linked (9.39 
MRad) UHMWPE pins 
Bar stock supplied by DePuy 
Synthes Joint Reconstruction (Leeds, 
UK; Warsaw, USA). Machined in 
house, School of Mechanical 
Engineering, University of Leeds. 
Pins sent for gamma irradiation 
treatment by Synergy Health PLC at 
a dose range of 9 – 11.5 MRad with 
an actual dose of 9.39 MRad. 
GUR 1020 AOX (hindered phenol -
700 ppm) highly cross-linked (8 
MRad) UHMWPE pins 
Bar stock supplied by DePuy 
Synthes Joint Reconstruction (Leeds, 
UK; Warsaw, USA). Machined in 
house, School of Mechanical 
Engineering, University of Leeds. 
GUR 1020 highly cross-linked (9.39 
MRad) UHMWPE pins 
Bar stock supplied by DePuy 
Synthes Joint Reconstruction (Leeds, 
UK; Warsaw, USA). Machined in 
house, School of Mechanical 
Engineering, University of Leeds. 
Pins sent for gamma irradiation 
treatment by Synergy Health PLC at 
a dose range of 9 – 11.5 MRad with 
an actual dose of 9.39 MRad. 
Rough (Ra 0.08 – 0.09 µm) ASTM 
1537 low carbon CoCr plates 
Raw material supplied by DePuy 
Synthes Joint Reconstruction (Leeds, 
UK; Warsaw, USA). Manufactured in 
- 126 - 
house, School of Mechanical 
Engineering, University of Leeds. 
4.3.5  Software 
The software used throughout Chapter 4 is detailed in Table 4.5. 
Table 4.5  Software used throughout Chapter 4.  
Software Supplier 
Image J Fiji – open source 
 
4.4  Methods 
The methods used throughout this study to generate, isolate and characterise wear 
debris from highly cross-linked UHMWPE pins with and without antioxidant doping are 
detailed in the following sections. 
4.4.1 Preparation of pins and plates for wear testing 
4.4.1.1  UHMWPE pin preparation 
4.4.1.1.1 Manufacture of UHMWPE pins 
The cylindrical UHMWPE pins were machined to be 12mm in diameter with a contact 
face of 10mm (Figure 4.1). 
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Figure 4.1  UHMWPE cylindrical pin dimensions. 
 
4.4.1.1.2 UHMWPE pin characteristics 
The details of the UHMWPE pins used throughout this study  are listed in Table 4.6.  
Table 4.6 UHMWPE materials used throughout this study; including details of resin, 
irradiation dose, antioxidant dose and supplier. 
Name Resin Gamma 
irradiation 
dose 
Antioxidant Supplier Abbreviation 
GUR 1050 
highly 
cross-
linked 
UHMWPE 
GUR 
1050 
9.39 MRad No DePuy 
Synthes 
GUR 1050 
XL 
GUR 1050 
highly 
cross-
linked 
vitamin E 
UHMWPE 
GUR 
1050 
10 MRad Vitamin E 
1000 ppm 
Meditech 
Polymers 
GUR 1050 
XL VE 
GUR 1020 
highly 
cross-
linked 
UHMWPE 
GUR 
1020 
9.39 MRad No DePuy 
Synthes 
GUR 1020 
XL 
GUR 1020 
highly 
cross-
linked AOX 
UHMWPE 
GUR 
1020 
8 MRad Hindered 
phenol  
700 ppm 
DePuy 
Synthes 
GUR 1020 
XL AOX 
 
4.4.1.1.3 Cleaning of UHMWPE pins for use in wear rig simulators 
All UHMWPE pins were cleaned by scrubbing with a toothbrush and household 
detergent with warm water. The pins were then transferred to sterile glass universals 
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containing bleach (>5% sodium hypochlorite) and placed on an orbital shaker at 180 
rpm for 20 minutes. Following this, in the presence of a Bunsen burner flame to 
maintain sterility, the pins were transferred to nutrient broth. The pins in nutrient broth 
were then incubated at 37ºC for 48 hours in order to confirm sterility. Once the pins 
were confirmed as sterile, the pins were either transferred to ethanol (70% (v/v)) if 
their use was imminent or to sterile ultrapure water for longer-term storage as carried 
out by Gowland (2014). 
4.4.1.2 Manufacture of rough cobalt chromium plates 
The low carbon CoCr alloy plates were prepared with a surface roughness of (0.08 – 
0.09 µm) (Figure 4.2).  
 
Figure 4.2 Schematic diagram of rough (Ra 0.08 – 0.09µm) low carbon (ASTM 1537) 
cobalt chromium plate. 
 
4.4.2 Determination of mass of UHMWPE pins  
In order to calculate the volume of wear debris generated, the UHMWPE pins were 
weighed before and after each test in the wear simulator. The pins were incubated in 
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the measurements lab for 48 hours prior to weighing in order to acclimatise to a 
constant temperature, pressure and humidity. The pins were then weighed at least 
five times to generate five measurements that were within 10 µg of each other. It was 
first necessary to take into account any increase in mass caused by the UHMWPE pin 
absorbing the lubricant. In order to do this, the additional mass was calculated using 
the soak control pin as follows: 𝑰𝒏𝒄𝒓𝒆𝒂𝒔𝒆 𝒊𝒏 𝒎𝒂𝒔𝒔 𝒅𝒖𝒆 𝒕𝒐 𝒔𝒐𝒂𝒌= 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒔𝒐𝒂𝒌 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 𝒑𝒊𝒏 𝒂𝒇𝒕𝒆𝒓 𝒓𝒖𝒏−𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒔𝒐𝒂𝒌 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 𝒑𝒊𝒏 𝒃𝒆𝒇𝒐𝒓𝒆 𝒓𝒖𝒏 
The amount of wear debris created (i.e. the mass lost) was then calculated as follows 
(allowing for the soak control correction): 𝑴𝒂𝒔𝒔 𝒐𝒇 𝒘𝒆𝒂𝒓 𝒅𝒆𝒃𝒓𝒊𝒔= 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒑𝒊𝒏 𝒃𝒆𝒇𝒐𝒓𝒆 𝒓𝒖𝒏+ 𝒊𝒏𝒄𝒓𝒆𝒂𝒔𝒆 𝒊𝒏 𝒎𝒂𝒔𝒔 𝒅𝒖𝒆 𝒕𝒐 𝒔𝒐𝒂𝒌−  𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒑𝒊𝒏 𝒂𝒇𝒕𝒆𝒓 𝒓𝒖𝒏 
The mass lost by the pin (or mass of wear debris) was used to calculate the volume 
generated as follows:  𝑽𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒘𝒆𝒂𝒓 𝒈𝒆𝒏𝒆𝒓𝒂𝒕𝒆𝒅 𝒎𝒎𝟑 =  𝒘𝒆𝒊𝒈𝒉𝒕 𝒍𝒐𝒔𝒔 𝒐𝒇 𝑼𝑯𝑴𝑾𝑷𝑬 𝒑𝒊𝒏𝒅𝒆𝒏𝒔𝒊𝒕𝒚 (𝒈.𝒎𝒎𝟑)  
Then the sliding distance was calculated as follows: 𝑺𝒍𝒊𝒅𝒊𝒏𝒈 𝒅𝒊𝒔𝒕𝒂𝒏𝒄𝒆 𝒎=  𝒐𝒑𝒆𝒓𝒂𝒕𝒊𝒐𝒏 𝒕𝒊𝒎𝒆 𝒉𝒐𝒖𝒓𝒔  𝒙 𝒅𝒊𝒔𝒕𝒂𝒏𝒄𝒆 𝒕𝒓𝒂𝒗𝒆𝒍𝒍𝒆𝒅 𝒃𝒚 𝒑𝒊𝒏 𝒊𝒏 𝒐𝒏𝒆 𝒄𝒚𝒄𝒍𝒆 𝟐 𝒙 𝟎.𝟎𝟐𝟖𝒎  𝒙 𝒇𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚 𝟏 𝑯𝒛  𝒙 𝟔𝟎 
Both the volume lost and the sliding distance were then used to calculate the wear 
factor for each material in each test as follows: 𝑾𝒆𝒂𝒓 𝒇𝒂𝒄𝒕𝒐𝒓 𝒎𝒎𝟑.𝑵𝒎!𝟏 =  𝑾𝒆𝒂𝒓 𝒗𝒐𝒍𝒖𝒎𝒆 (𝒎𝒎𝟑)𝒔𝒍𝒊𝒅𝒊𝒏𝒈 𝒅𝒊𝒔𝒕𝒂𝒏𝒄𝒆 𝒎 𝒙 𝒍𝒐𝒂𝒅 (𝑵) 
4.4.3 Generation of highly cross-linked and antioxidant doped, highly cross-
linked ultra-high molecular weight polyethylene wear debris 
In order to measure any response of relevant cells to wear debris that is generated by 
THR’s, it was first necessary to generate wear debris with which to dose cells for 
further study. Previous studies (Galvin et al., 2006) examined the size and volume 
distribution and morphology of UHMWPE particles produced and showed that 
clinically relevant wear debris can be generated using both single and six station pin 
on plate wear simulators. The single station multidirectional reciprocating POP wear 
simulator rig was operated under aseptic conditions at the kinematic conditions 
specified in Table 4.7 as the wear particles generated were to be used in future cell 
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studies and must therefore be free of any biological contaminants which may affect 
any results later obtained. 
Table 4.7 Kinematic conditions, to replicate hip conditions during normal gait, under 
which the single station wear simulator was run to create UHMWPE wear debris 
for cell culture studies. 
Wear simulator condition Hip kinematics value 
Stroke length 28 mm 
Rotation +/-30◦ 
Load 160 N 
Frequency 1 Hz 
 
4.4.2.1 Generation of highly cross-linked and antioxidant doped, highly cross-
linked ultra-high molecular weight polyethylene wear debris using single station 
pin-on-plate multidirectional wear simulator rigs 
The methods used to set up, maintain and disassemble both single station wear 
simulator rigs used (labelled 1 and 2 in this study) are detailed in the following 
sections. 
4.4.2.1.1 Preparation of single station pin-on-plate wear simulator components 
The single station wear simulator metal components (Figures 4.3 and 4.5) were 
prepared by scrubbing with a toothbrush in warm water and household detergent 
followed by sonicating in 70% (v/v) isopropanol for 20 minutes. The components were 
then rinsed with distilled water, dried and wrapped in foil before being placed into an 
oven at 190°C for 4 hours to sterilise the components and remove any endotoxin 
present. The vacuum tubing was by sterilised by autoclaving in a heat sealed packet. 
4.4.2.1.2 Setting up the single station pin-on-plate multidirectional wear 
simulator rig 
The methods used to set up each individual single station wear simulator rig (1 and 2) 
are detailed in the following sections. 
4.4.2.1.2.1 Single station pin-on-plate multidirectional wear simulator rig 1 
Prior to set up, stroke length and load were calibrated. Stroke length was measured 
with a ruler. Load was assessed by placing the load cell disc in the bridge (in place of 
the pin holder) and loading the cantilever arm with the 5.37 kg weight at a particular 
load (e.g. 160 N). The load was measured using the load cell to ensure accuracy 
between the load marked on the cantilever arm. The simulator, its components (Figure 
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4.3) and the class II laminar flow cabinet were all sterilised or cleaned before use. The 
simulator was assembled under sterile conditions using sterile gloves and sterile hex 
keys and components were held on sterile foil. The simulator was operated in a class 
II safety cabinet in order to maintain a sterile air flow and sterile environment. Prior to 
simulator assembly; the simulator (Figure 4.4) and the class II safety cabinet were 
cleaned with household detergent and warm water followed by 1% (v/v) Trigene and 
finally all components were sprayed with 70% (v/v) ethanol.  
 
Figure 4.3 Components of single station multidirectional reciprocating POP wear 
simulator 1 and components used to assemble the rig: Hex keys x 3 (used to 
assemble the rig), bath, toothed rack, medium sized spacers x 3, Screws (1 x 
grub, 2 x long (used to fix bath to rig), 2 x short (used to fix plate to bath) and 2 x 
thin (used to fix rack to bath)), tweezers (used to assemble the rig), collet, pin 
holder fastener, pin holder with attached cog, syringe driver delivery pipe and 
bearings. This image does not include the bridge, which remains with the rig 
itself. 
 
The simulator was then set up as follows: the plate was fixed to the bath using the two 
short screws and a hex key. The toothed rack was then fixed to the side of the bath 
using the two thin screws and a hex key. The bath was then fixed to the rig using the 
two long screws and a hex key. A metal spacer followed by the relevant UHMWPE pin 
(with the 10 mm contact face facing outwards) was placed into the collet using the 
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sterile tweezers. The collet was then placed into the cog in the correct alignment 
(ensuring the notch on the outside of the collet lined up with the notch on the inside of 
the pin holder) and tightened in place using the pin holder fastener. The pin was fixed 
into place in the pin holder ensuring that the pin was protruding at least 3-4 mm from 
the holder. The pin holder was inverted over a sterile surface to verify that the pin was 
securely in place before proceeding. The pin holder was placed into position in the 
bridge. A volume of 30 ml of previously prepared sterile RPMI 1640 cell culture 
medium containing 25% (v/v) FBS was placed into the bath using a sterile plastic 
syringe. The pin holder was lifted up slightly to allow the lubricant underneath the pin 
and then the bridge was secured in place. The bearings (lightly coated in anti-fretting 
lubricant) were placed into position atop the pin holder. Anti-fretting lubricant was also 
added to the toothed rack and cog attached to the pin holder. The cantilever arm was 
then lowered and the motor was switched on. A 5.37 kg weight was loaded at a set 
distance on the cantilever arm to provide a load of 160N and fixed in place. The stroke 
speed was adjusted to 7 on the motor – approximately 1 Hz (one complete cycle back 
and forth per second). The single station pin on plate wear simulator was operated 
under the kinematic conditions outlined in Table 4.7. A spare pre-weighed UHMWPE 
pin of the relevant material was placed into a sterile pot with 30ml RPMI 1640 cell 
culture medium with 25% FBS (v/v) to act as a soak control. 
 
Figure 4.4 Single station multidirectional reciprocating POP wear simulator rig 1 - 
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complete set up (photo kindly taken and used with permission of Pirkko-Liisa 
Muhonen). 
 
 4.4.2.1.2.2 Single station pin-on-plate multidirectional wear simulator rig 2 
The initial set up was identical to single station wear simulator rig 1. The components 
for single station wear simulator rig 2 are shown in Figure 4.5. 
Single station wear simulator rig 2 was set up in the same manner as single station 
wear simulator rig 1 with some minor differences.  The pin holder was assembled by 
placing the O-ring inside the pin holder followed by a metal spacer and the relevant 
UHMPWPE pin (with the 10 mm contact face facing outwards). The pin was fixed into 
place in the pin holder ensuring that the pin was protruding at least 3-4 mm from the 
holder and the pin holder screw was tightened using the smallest hex key. Anti-fretting 
lubricant was also placed on the rotating mechanism housing the pin holder.  
 
Figure 4.5 Components for single station multidirectional reciprocating POP wear 
simulator 2 and the components used to set up the wear rig: syringe driver 
delivery pipe, tweezers (used to set up the rig), bearings, medium sized spacers 
x 3, screws (left to right: 1 x grub, 2 x long (to fix bath to rig), 2 x short (to fix plate 
to bath)), hex keys, pin holder, collar, O ring and bath. Image also shows a CoCr 
plate. However the bridge holder is not shown as it is remains with the rig itself. 
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Figure 4.6 Single station multidirectional reciprocating POP wear simulator 2 – 
complete set up.  
 
4.4.2.1.2.3 Setting up the syringe driver 
The syringe driver is designed to deliver a constant supply of sterile water droplets to 
the bath via the delivery pipe to prevent total loss of lubricant through evaporation. 
The stainless steel delivery pipe was fixed to the rig using the grub screw. A 60 ml 
sterile plastic syringe was filled with water and attached to one end of the vacuum 
tubing whilst the other end of the vacuum tubing was attached to the stainless steel 
delivery pipe fixed to the rig. The syringe was fixed in place in the motorised syringe 
driver. The syringe was slowly depressed over time in order to replenish the bath and 
prevent evaporation of the lubricant. Finally, the speed of the syringe driver (the speed 
at which water is delivered to the lubricant bath) was set at 1 (the lowest speed). 
4.4.2.1.3 Maintenance of the single station pin-on-plate multidirectional wear 
simulator rig 
Each single station wear simulator rig was operated for up to five days in a sterile 
environment. The syringe driver was replenished every day with sterile ultrapure water 
and the motorised arm wound backwards such that the driver may have room to 
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depress the syringe plunger. The maintenance of sterility was verified throughout by 
daily microbiological testing.  
4.4.2.1.4 Disassembling the single station pin-on-plate multidirectional wear 
simulator rig 
After five days, the rig and syringe driver were switched off and disassembled. Sterility 
was maintained during disassembly until the lubricant and wear debris were contained 
within a sterile plastic container. Firstly, the lubricant was removed from the bath using 
a sterile plastic syringe and placed into a sterile plastic container along with 5 ml of 
ultrapure water that was used to rinse the remaining particles from the bath. The rig 
was washed with household detergent and warm water followed by 1% (v/v) Trigene 
and 70% (v/v) ethanol. The metal components of the simulator were washed with 
household detergent and warm water. The UHMWPE pins were cleaned with a paper 
tissue and placed into the metrology lab for 48 hours prior to weighing.  
4.4.2.2 Generation of highly cross-linked and antioxidant doped, highly cross-
linked ultra-high molecular weight polyethylene wear debris using six station 
pin-on-plate multidirectional wear simulator rig 
The methods used to prepare, set up, maintain and disassemble the six station pin-
on-plate wear simulator rig B under aseptic conditions are detailed in the following 
sections.  
4.4.2.2.1 Preparation of six station pin-on-plate multidirectional wear simulator 
rig components 
Prior to use, the stroke length and load were calibrated by a lab technician. Sterile 
gloves, oversleeves, a face mask and a disposable apron were worn throughout 
preparation and use of the six station wear simulator rig. All were sprayed with ethanol 
regularly and changed when necessary throughout. All rig components were 
immersed in warm water and household detergent for 15 minutes and then scrubbed 
individually with a toothbrush. The hex keys, plates, screws and ball bearings were 
sonicated for 10 minutes in 70% (v/v) isopropanol. All rig components (Figure 4.7) 
were then immersed in 1% (v/v) trigene for 30 minutes. The baths were assembled as 
follows: the plates were fixed onto the bath using the short screws and a hex key. The 
polymer baffles were then inserted into the baths and fixed in placed using the thin 
short screws. The stainless steel toothed rack were then fixed to the side of each bath 
using the thin, medium length screws and a hex key. The pin holders were assembled 
as follows: medium sized spacers followed by UHMWPE pins of the relevant material 
(with the 10 mm contact face facing outwards) were placed into the collet. The collet 
was then fitted into place in the pin holder – taking care to align the notches on the 
exterior of the collet and the interior of the pin holder. The pin holder was then fed 
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through the opening in the relevant numbered bridge and the pin fastener was 
screwed tightly in place to ensure the pin was securely held. The security of the pin 
was tested over a sterile surface. The assembled baths and bridges were then placed 
back into 1% (v/v) Trigene for a further 30 minutes. All components were then rinsed 
in deionised water and air-dried. The rig itself was cleaned using 1% (v/v) Trigene 
followed by 70% (v/v) ethanol.  
 
Figure 4.7 Components of six station multidirectional reciprocating POP wear 
simulator rig B (photo kindly taken and used with permission of Pirkko-Liisa 
Muhonen).  
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Figure 4.8 Complete set up of six station multidirectional reciprocating POP wear 
simulator rig (photo kindly taken and used with permission of Pirkko-Liisa 
Muhonen). 
 
4.4.2.2.2 Assembly of six station pin-on-plate multidirectional wear simulator rig 
Following sterile preparation, the six station wear simulator rig was assembled as 
follows. The baths were fixed to the rig using the thin, long screws and a hex key. The 
baths were placed on top of plastic sheets to protect the metal base from leaks. The 
baths were then filled with RPMI 1640 cell culture medium and bridges were then 
fixed in place. The white scotch yoke mechanisms were then screwed into place. The 
cantilever arms were then fixed to each station. The cycle counter was reset and the 
rig was switched on at low speed. The weights were loaded onto each cantilever arm 
at 160 N. The speed of the rig was then adjusted to 1 Hz (one complete cycle back 
and forth per second). A spare pre-weighed UHMWPE pin of the relevant material 
was placed into a sterile pot with 30 ml RPMI 1640 cell culture medium to act as a 
soak control. 
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4.4.2.2.3 Maintenance of six station pin-on-plate multidirectional wear simulator 
rig B 
Each day, the rig speed was slowed down and the baths were topped up with sterile 
ultrapure water using a sterile plastic syringe. The speed of the reciprocation of the 
paths was increased back to 1 Hertz. 
4.4.2.2.4 Disassembling the six station pin-on-plate multidirectional wear 
simulator rig B 
The six station wear simulator rig was disassembled as follows. The rig was slowed 
down and the weights were removed from the cantilever arms. The rig was then 
turned off completely. The cantilever arms were removed and the scotch yoke 
mechanisms disconnected. The bridges and pin holders were removed – the pin 
holders were disassembled and the pins removed and cleaned prior to weighing. The 
baths were unscrewed from the rig and the lubricant was removed using a sterile 
syringe and placed into sterile labelled pots. Aseptic conditions were maintained up 
until this point. All rig components were then cleaned with household detergent and 
warm water, soaked in 1% (v/v) Trigene for 10 minutes and rinsed with deionised 
water. All pins and plates were sonicated in isopropanol for 10 minutes, rinsed with 
deionised water and air-dried. All dry components were then replaced neatly in the rig. 
4.4.4 Microbiological testing of wear simulator lubricant 
A volume of 0.5 ml was taken daily from the lubricant in the bath (having first switched 
off the simulator) for use in microbiological tests to ensure sterility was maintained. 
The lubricant sample was streaked (Figure 4.9) onto three types of agar plates using a 
platinum innoculation loop in the presence of Bunsen burner flame (to main sterility). 
The agar plates used were: heated blood agar (HBA) (to test for fastidious, haemolytic 
bacteria), sabouraud dextrose agar (SAB) (to test for non-fastidous fungi and 
dermatophytes) and nutrient agar (NA) (to test for non-fastidious bacteria). The plates 
were incubated at 37°C (HBA and NA) and 30°C (SAB) for up to 5 days and assessed 
for contamination daily. 
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Figure 4.9 A schematic of a petri dish showing how a microbiological sample is 
streaked through the agar to test for biological contamination. 
 
4.4.5 Endotoxin testing of generated UHMWPE wear debris 
4.4.4.1 Endotoxin kit components 
Table 4.8 Endotoxin assay kit components 
Pierce LAL chromogenic endotoxin 
quantitation kit  contents 
Storage and preparation 
E. coli endotoxin standard (20 EU.ml-1) Stored at 4°C and reconstituted with 
20 ml endotoxin free water. 
LAL lyophilised 1.4 ml x 2 vials Stored at 4°C and reconstituted with 
1.4 ml endotoxin free water. 
Chromogenic substrate lyophilised 6.5 
ml 
Stored at 4°C and reconstituted with 
6.5 ml endotoxin free water. 
Endotoxin free water 30 ml Stored at 4°C. 
4.4.4.2 Sample preparation 
Each wear debris sample was defrosted and 500 µl from each sample was taken and 
placed in a labelled eppendorf whilst the remainder of the samples were returned to 
storage in the freezer. All eppendorfs were then heated to 75°C in a water bath for 30 
minutes. All eppendorfs were then vortexed for 1 minute and then centrifuged at 
13,000 g for 10 minutes. A volume of 0.5 µl supernatant in each eppendorf was 
transferred to a fresh labelled eppendorf and diluted with 49.5 µl endotoxin free water 
to achieve a 1:100 dilution as per the manufacturers instructions.  
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4.4.4.3 Reagent preparation 
The reagents of the endotoxin assay kit were prepared as described below. 
4.4.4.3.1 Endotoxin standard 
The endotoxin assay kit was equilibrated to room temperature (25°C). The endotoxin 
standard was reconstituted with 1 ml endotoxin free water and vortexed for 15 
minutes. This stock endotoxin standard was used to prepare standard as follows: 
• 1 EU.ml-1: 0.95 ml endotoxin free water + 50 µl stock 
• 0.5 EU.ml-1: 0.25 ml 1 EU.ml-1 standard + 0.25 ml endotoxin free water 
• 0.25 EU.ml-1:  0.25 ml 1 EU.ml-1 standard + 0.75 ml endotoxin free water 
• 0.1 EU.ml-1: 0.1 ml 1 EU.ml-1 standard + 0.9 ml endotoxin free water 
All standards were then vortexed for 1 minute at room temperature (25°C).  
4.4.4.3.2 Limulus Amebocyte Lysate reagent 
Limulus Amebocyte Lysate (LAL) was reconstituted by adding 1.4 ml endotoxin free 
water to the vial and the vial was swirled gently to mix.  
4.4.4.3.3 Chromogenic substrate 
Chromogenic substrate was reconstituted by adding 6.5 ml endotoxin free water to the 
vial which was kept at 37°C until use. 
4.4.4.3.4 Stop reagent 
25% (v/v) acetic acid was prepared by adding 1.5 ml 100% (v/v) glacial acetic acid to 
4.5 ml endotoxin free water. 
4.4.4.4 Assay procedure 
An endotoxin-free 96 well plate was placed in the incubator at 37°C. The safety 
cabinet and heating block were cleaned with 1% (v/v) Trigene followed by 70% (v/v) 
ethanol and the heating block was placed inside the class II safety cabinet. Sterile, 
empty labelled eppendorfs were placed in the heating block and heated to 37°C for 10 
minutes. A volume of 50 µl of either diluted sample, standard or blank (endotoxin free 
water only and RPMI 1640 medium only blanks were included) was added to an 
eppendorf. The timer was started and 50 µl of LAL reagent was added to each 
eppendorf tube. Once added, each tube was removed from the heating block briefly, 
tapped to mix and returned to the heating block. After 10 minutes, 100 µl chromogenic 
substrate was added to each tube. Again, once added each tube was removed, 
tapped to mixed and then returned to the heating block. After a total of 16 minutes, 
100 µl 25% (v/v) acetic acid was added to each tube and tapped to mix as before. The 
contents of each tube were then added to the corresponding labelled well in the 
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heated endotoxin free 96 well plate. The plate was then read at 405 nm using the 
Multiskan plate reader.  
4.4.4.5 Analysis 
The optical densities of the standards were plotted against EU.ml-1 (1, 0.5, 0.25 and 
0.1 EU.ml-1) to generate a standard curve. Linear regression was then used to 
calculate the concentration of endotoxin in each test sample. 
4.4.6 Long term storage of UHMWPE wear particles 
The wear debris generated in RPMI 1640 cell culture medium (with or without FBS) 
was stored in the freezer at -20°C until required for isolation or cell culture. 
4.4.7 Isolation of UHMWPE wear debris from wear test lubricants 
Each sample of wear debris in RPMI 1640 cell culture medium with 25% (v/v) FBS 
was taken from storage at -20°C and defrosted at room temperature. A small volume 
from each sample was taken and added to a sterile glass vial. The samples for each 
material from each type of rig (single and six station wear simulators) were pooled 
such that eight samples of at least 1 mm3 wear debris in total were isolated – wear 
debris from four different materials produced on two types of wear simulators. Pellets 
of potassium hydroxide (6.72 g per 10 ml of serum lubricant) were added to the sterile 
glass vials containing each sample to form a 12 M solution. The samples were then 
incubated in a water bath at 60°C for five days as the serum proteins were digested. 
The water level in the bath was topped up and each vial gently agitated each day. 
After five days, the vials were removed from the water bath and placed into the cold 
room at 4°C for a minimum of 30 minutes. The vials were removed from the cold room 
and 10 ml of chloroform:methanol (2:1) mixture was added to each vial using a glass 
pipette in a fumehood in order to separate the particles from any lipids present. The 
vials were then incubated at room temperature (25°C) in the fumehood for 48 hours. 
After 48 hours, the vials were then centrifuged at 2000 g for 20 minutes at room 
temperature. After centrifugation, the top layer was removed from each vial into a new 
vial using a glass Pasteur pipette. The separation process was repeated twice more. 
Upon the final separation, ice-cold 100% (v/v) ethanol (previously prepared by 
freezing at -20°C for several hours) was added to each vial containing the isolated top 
layer in order to precipitate any remaining proteins. The vials were then centrifuged at 
1000 g for 10 minutes at 4°C. The supernatants were decanted into a clean glass 
Duran bottle and an equal volume of ultrapure water was added. A stirrer bar was 
added to the bottle which was then placed on a stirrer plate in the cold room at 4°C 
overnight. The particle suspension was then decanted into a Sorvall bottle and 
centrifuged at 10,000 g at 4°C without the brake engaged for 2 hours. After 
centrifugation, the supernatant was decanted into a clean 1 litre glass Duran bottle 
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and an equal volume of ultrapure water was added. The sample was then stored at 
4°C until filtration. 
4.4.8 Filtration of isolated UHMWPE wear debris 
The methods for preparing the filtration equipment and carrying out the particle 
filtration are detailed below. 
4.4.8.1 Preparation of filtration units and filters 
All glass filtration equipment was washed thoroughly with household detergent and 
warm water before use, rinsed with distilled water followed by ultrapure water and 
dried at 180°C in the oven overnight (wrapped in foil). The plastic filter manifold was 
packaged and autoclaved before use. 
4.4.8.2 Filter coating for electron microscopy analysis 
The glass filtration equipment was assembled in a class I laminar flow cabinet and 
attached to the vacuum pump as below (Figure 4.10). Particular care was taken 
placing the filter paper correctly upon the plastic filter manifold (Figure 4.11).  
The particle suspension was filtered sequentially through 10 µm, 1 µm and 0.015 µm 
pore sized filter papers. Each filter paper was then carefully removed with tweezers 
and placed into a sterile petri dish. The filter papers were then placed under an infra-
red lamp for a minimum of 4 hours to dry.  
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Figure 4.10 UHMWPE particle filtration set up: vacuum flask, clamp, glass reservoir, 
plastic filtration disc, filter paper and tubing leading to vacuum pump. 
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Figure 4.11 UHMWPE particle filtration set up showing the candidate lifting the filter 
paper of the plastic filtration disc.  
 
4.4.9 Imaging 
The method for imaging the isolated UHMWPE wear particles using FEGSEM is 
detailed below. 
4.4.9.1 Imaging UHMWPE wear particles using Field Emission Gun Scanning 
Electron Microscopy 
The stubs for scanning electron microscope (SEM) analysis were prepared by cutting 
a small section from each filter paper and placing it on a SEM aluminium stub followed 
by sealing the edges with carbon paint. Prior to viewing, the stubs were coated with 
carbon (10 nm coating thickness). The stubs were then viewed using a field emission 
gun electron microscope (FEGSEM) (Hitachi SU8230 Cold-FEGSEM). For each stub, 
three random fields of view were captured over seven different magnifications (Table 
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4.9). A total of 62 images were taken for each material on each different rig (496 
images in total).  
Table 4.9 FEGSEM magnifications used to observe 10 µm, 1 µm and 0.015 µm pore 
sized filter stubs containing POP generated GUR 1020 XL, GUR 1020 XL AOX, 
GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris. 
Magnifications taken of 
10 µm pore sized filter 
stub 
Magnifications taken of 
1 µm pore sized filter 
stub 
Magnifications taken of 
0.015 µm pore sized 
filter stub 
400X 1500X 10kX 
700X 5kX 20kX 
1500X 10kX 30kX 
3kX 20kX 60kX 
8kX 30kX 70kX 
12kX 40kX 90kX 
15kX 60kX N/A 
 
4.4.10 Characterisation 
The methods for analysing the images of the UHMWPE wear debris using Image J 
software and utilising the resultant data to assess size and volume distribution are 
detailed in the following sections. 
4.4.10.1 ImageJ 
All images were then analysed using the Image J software package. Each UHMWPE 
wear particle was selected by the candidate and drawn around. For each material in 
each rig, approximately 100 random particles were analysed. The following 
measurements were calculated by the software for each particle: area, shape 
descriptors, perimeter, Ferets diameter (the longest dimension of the particle) and 
aspect ratio. The roundness was calculated manually from the equation below as set 
out in ASTM standard F1877-05 (2010) for particle isolation. A value of 1 indicates a 
perfectly round or circular particle.  𝑹𝒐𝒖𝒏𝒅𝒏𝒆𝒔𝒔 𝑹 = (𝟒𝑨)/(𝝅𝒅𝒎𝒂𝒙𝟐) 
Where A = aspect ratio and dmax = Ferets diameter.  
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4.4.10.2 Analysis 
The above data was then placed into an Excel spreadsheet and used to calculate size 
and volume distribution by placing each particle within a defined range (or bin) which 
included: 0 – 0.1µm, 0.1 - 1µm, 1 - 10 µm and >10 µm. 
4.5  Results 
Highly cross-linked and antioxidant doped, highly cross-linked UHMWPE wear debris 
(GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 Xl and GUR 1050 XL VE) was 
generated using single and six station multidirectional POP wear simulators under 
aseptic conditions. The serum lubricants were tested for microbiological and endotoxin 
contamination to ensure sterility prior to use in in vitro cell culture studies. Samples of 
the serum lubricants generated from each material and each type of wear simulator 
were pooled and the wear particles isolated using the digestion method. The resultant 
filter papers were imaged using FEGSEM and the images were analysed using Image 
J to generate size and volume distribution data in order to compare to previous 
studies.  
4.5.1 Microbiological testing of wear test lubricant from single and six station 
multidirectional Pin-On-Plate wear simulator rigs 
Samples of each serum lubricant were streaked onto NA, SAB and HBA plates in 
order to assess biological contamination from non-fastidious bacteria, fungi and 
fastidious, haemolytic bacteria respectively. Plates were incubated for up to five days 
to assess any potential contaminant growth.  
All agar plates used to test wear debris lubricant for the presence of any 
microbiological organisms were free of contamination. No signs of growth were 
present on any of the plates at any time point (Figure 4.12).  
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Figure 4.12  An example of nutrient agar (A), sabouraud dextrose agar (B) and 
heated blood agar (C) plates streaked with serum lubricant after five days 
showing no signs of microbial growth and therefore no biological contamination.  
 
4.5.2 Endotoxin testing of wear test lubricant 
The following section reports the results of the Pierce LAL endotoxin quantitation 
assay for both single and six station wear simulator rig generated wear debris for all 
materials. The optical density values for the standards were used to generate a 
standard curve (Figure 4.13). Linear regression of the equation for the standard curve 
was then used to calculate the endotoxin concentration in each test sample. Previous 
studies (Liu, 2012) and the pharmaceutical industry for injectable pharmaceuticals 
(FDA regulatory affairs, 1985) state that any value below 5 EU.ml-1 is considered 
acceptable.  
A) 
B) 
C) 
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Figure 4.13  Standard curve for the quantitation of endotoxin in wear simulator 
lubricant. The line of best fit was calculated using linear regression. The 
coefficient of determination (R2) and the line equation are reported on the graph. 
The line equation was then used to calculate the amount of endotoxin present in 
each sample analysed based on the optical density acquired.  
 
4.5.2.1 Determination of endotoxin concentration in single station pin-on-plate 
multidirectional wear simulator lubricant 
The endotoxin concentration values for each wear debris sample generated using the 
single station wear simulator rigs are shown in Table 4.10. All values were below the 
required standard of 5 EU.ml-1. 
Table 4.10 Endotoxin concentrations of wear debris samples generated with single 
station wear simulator rigs using GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 
XL and GUR 1050 XL VE UHMWPE. 
GUR	1020	XL	
optical	density	
at	405	nm	 EU.ml-1	
GUR	1020	XL	
AOX	optical	
density	at	
405	nm	 EU.ml-1	
0.087	 0.133	 0.09	 0.137	
0.082	 0.127	 0.127	 0.182	
0.09	 0.137	 0.078	 0.122	
0.084	 0.130	 0.087	 0.133	
y	=	0.8283x	-	0.0234	
R²	=	0.9806	
0	
0.1	
0.2	
0.3	
0.4	
0.5	
0.6	
0.7	
0.8	
0.9	
0	 0.2	 0.4	 0.6	 0.8	 1	 1.2	
N
et
	O
.D
.	a
t	4
05
	n
m
	
EU.ml-1		
- 149 - 
GUR	1050	XL	
optical	density	
at	405	nm	 EU.ml-1	
GUR	1050	XL	
VE	optical	
density	at	
405	nm	 EU.ml-1	
0.088	 0.135	 0.089	 0.136	
0.088	 0.135	 0.085	 0.131	
0.091	 0.138	 0.087	 0.133	
0.186	 0.253	 0.113	 0.165	
 
4.5.2.2 Determination of endotoxin concentration in six station pin-on-plate 
multidirectional wear simulator lubricant 
The endotoxin concentration values for each wear debris sample generated using the 
six station wear simulator rigs are shown in Table 4.11. All values were below the 
required standard of 5 EU.ml-1 previously used by Liu (2012) and Gowland (2014).  
Table 4.11 Endotoxin concentrations of wear debris samples generated with the six 
station wear simulator rig using GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 
XL and GUR 1050 XL VE UHMWPE. 
Rig	station	
number	
GUR	1020	XL	
optical	density	
at	405	nm	 EU.ml-1	
Rig	station	
number	
GUR	1020	XL	
AOX	optical	
density	at	
405	nm	 EU.ml-1	
B1	 0.098	 0.147	 B1	 0.089	 0.136	
B2	 0.109	 0.160	 B2	 0.12	 0.173	
B3	 0.086	 0.132	 B3	 0.088	 0.135	
B4	 0.083	 0.129	 B4	 0.198	 0.267	
B5	 -	 -	 B5	 0.087	 0.133	
B6	 0.109	 0.160	 B6	 0.096	 0.144	
Rig	station	
number	
GUR	1050	XL	
optical	density	
at	405	nm	 EU.ml-1	
Rig	station	
number	
GUR	1050	XL	
VE	optical	
density	at	
405	nm	 EU.ml-1	
B1	 0.092	 0.139	 B1	 0.095	 0.143	
B2	 0.091	 0.138	 B2	 0.088	 0.135	
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B3	 0.091	 0.138	 B3	 0.101	 0.150	
B4	 0.096	 0.144	 B4	 -	 -	
B5	 0.104	 0.154	 B5	 0.086	 0.132	
B6	 0.105	 0.155	 B6	 0.091	 0.138	
 
4.5.3 Calculation of volume of wear debris generated 
The primary aim of this chapter was to generate sterile UHMWPE (GUR 1020 XL, 
GUR 1020 XL AOX, GUR 1050 XL, GUR 1050 XL VE) wear debris using both the 
single and six station multidirectional wear simulator rigs. The volume of wear debris 
generated for each material was therefore reported as a primary output. Individual 
measurements from individual runs were combined to create a mean volume value 
and this was reported. The standard error with respect to the mean was reported to 
show the variation in the range of results obtained.  
4.5.3.1 Volume of wear debris generated in the single station pin-on-plate 
multidirectional wear simulators 
The UHMWPE wear debris volumes – range and mean – are reported in Table 4.12 
for all materials used in single station wear rig simulators 1 and 2. The mean wear 
debris volume values and the associated standard errors are reported in Figure 4.14. 
The antioxidant doped highly cross-linked UHMWPE materials generated the most 
debris in comparison to the highly cross-linked only materials and exhibited a large 
variation in range – this was particularly true of GUR 1020 XL AOX. Although 
statistical analysis revealed no significant difference between the mean wear debris 
volumes (ANOVA; p>0.05). Standard error of the mean (SEM) is reported. 
Table 4.12 UHMWPE wear debris volumes generated on single station wear rig 
simulators 1 and 2 - range and mean values alongside SEM are reported. 
UHMWPE pins (10 mm contact face) were articulated against rough (Ra 0.08 – 
0.09 µm) ASTM 1537 low carbon CoCr plates at 160 N load, 28 mm stroke 
length and +/- 30° rotation at a speed of 1 Hz over five days. 
Material  Range (mm3) Mean ± SEM (mm3) 
GUR 1020 XL 0.34 – 4.82 1.72 ± 1.06 
GUR 1020 XL AOX 8.45 – 95.11 37.48 ± 28.82 
GUR 1050 XL 0.47 – 1.52 0.94 ± 0.22 
GUR 1050 XL VE 0.47 – 14.79 9.61 ± 4.59 
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Figure 4.14 Mean wear debris volume ± SEM (mm3) from UHMWPE pins articulated 
against rough plates (Ra 0.08 – 0.09 µm) ASTM 1537 low carbon CoCr plates at 
160 N load, 28 mm stroke length and +/- 30° rotation at a speed of 1 Hz over five 
days in single station pin-on-plate wear simulator rigs for each material tested: 
GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE. The 
error bars represent +/- standard error; n=4. (ANOVA; p>0.05) 
4.5.3.2 Volume of wear generated in the six station pin-on-plate multidirectional 
wear simulator 
The volumes of UHMWPE wear debris (range and mean) are reported below (Table 
4.13) for all materials used in the six station POP multidirectional wear simulator. The 
mean wear debris volume values and the associated standard errors are reported 
below (Figure 4.15). The wear debris volumes were much greater than those 
generated on the single station rig for the same materials. In this case, the GUR 1020 
XL material generated the largest volume of wear debris, with the other materials 
generating similar lower volumes. Although statistical analysis revealed no significant 
differences between the mean wear debris volumes generated by the different 
materials (ANOVA; p>0.05). Standard error of the mean (SEM) is reported. 
Table 4.13 UHMWPE wear debris volumes generated on six station wear rig 
simulators B - range and mean values alongside SEM are reported. UHMWPE 
pins (10 mm contact face) were articulated against rough (Ra 0.08 – 0.09 µm) 
ASTM 1537 low carbon CoCr plates at 160 N load, 28 mm stroke length and +/- 
30° rotation at a speed of 1 Hz over three days. 
Material  Range (mm3) Mean  ± SEM (mm3) 
GUR 1020 XL 17.59 – 464.22 201.24 ± 74.69 
GUR 1020 XL AOX 41.00 – 148.13 99.56 ± 16.63 
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GUR 1050 XL 25.55 – 142.11 79.89 ± 20.58 
GUR 1050 XL VE 81.71 – 158.53 129.17 ± 13.72 
 
 
Figure 4.15 Mean wear debris volume (mm3) from UHMWPE pins tested in the six 
station pin-on-plate wear simulator rig for each material tested: GUR 1020 XL, 
GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE. The error bars 
represent +/- standard error; n=4. (ANOVA; p>0.05) 
4.5.4 Calculation of wear factors from each material tested on each type of wear 
simulator 
The wear factor is defined as an indication of how resistant a material is to wear – this 
is calculated as a function of volume lost, load and the sliding distance. Wear factor is 
reported in order to compare wear resistance between different types of material when 
assessing mechanical behaviour.  
4.5.4.1 Wear factors from each material tested on the single station pin-on-plate 
multidirectional wear simulators 
The UHMWPE wear factor values (range and mean) are reported below (Table 4.14) 
for all materials used in single station wear rig simulators 1 and 2. The mean wear 
factor values and the associated standard errors are reported below (Figure 4.16). 
The antioxidant doped highly cross-linked UHMWPE materials exhibited the highest 
wear factors in comparison to the highly cross-linked only materials and exhibited a 
large variation in range; this was particularly true of GUR 1020 XL AOX. Although 
statistical analysis revealed no significant differences between the mean wear factors 
(ANOVA; p>0.05). Standard error of the mean (SEM) is reported. 
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Table 4.14 UHMWPE wear factors generated on single station wear rig simulators 1 
and 2 - range and mean values alongside SEM are reported. UHMWPE pins (10 
mm contact face) were articulated against rough (Ra 0.08 – 0.09 µm) ASTM 1537 
low carbon CoCr plates at 160 N load, 28 mm stroke length and +/- 30° rotation 
at a speed of 1 Hz over five days.  
Material  Range (mm3.Nm-1) Mean ± SEM (mm3.Nm-1) 
GUR 1020 XL 5.9 x 10-7 – 1.2 x10-5 3.9 x 10-6± 2.7  x 10-6 
GUR 1050 XL 9.7 x 10-7 – 3.4 x 10-6 2.4 x 10-6± 4.9  x 10-5 
GUR 1020 XL AOX 1.8 x 10-5 – 1.7 x 10-4 6.7 x 10-5± 5.4  x 10-7 
GUR 1050 XL VE 6.9 x 10-7 – 3.5 x 10-5 2.1 x 10-5± 1.0  x 10-5 
 
 
 
Figure 4.16 Mean wear factors for UHMWPE pins articulated against rough (Ra 0.08 – 
0.09 µm) ASTM 1537 low carbon CoCr plates at 160 N load, 28 mm stroke 
length and +/- 30° rotation at a speed of 1 Hz over five days on single station pin-
on-plate wear simulator rigs for each material tested: GUR 1020 XL, GUR 1020 
XL AOX, GUR 1050 XL and GUR 1050 XL VE. The error bars represent +/- 
standard error; n=4. (ANOVA; p>0.05)  
4.5.4.2 Wear factors from each material tested on the six station pin-on-plate 
multidirectional wear simulators 
The UHMWPE wear factor values (range and mean) are reported in Table 4.15 for all 
materials used in six station rig B. The mean wear factor values and the associated 
standard errors are reported below (Figure 4.17). The wear factors were much greater 
than those generated using the single station POP multidirectional wear simulator for 
the same materials. In this case, the GUR 1020 XL material generated the highest 
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wear factor, with the other materials generating similar lower values. Although 
statistical analysis revealed no significant difference between the mean wear factors 
(ANOVA; p>0.05). Standard error of the mean (SEM) is reported. 
Table 4.15 UHMWPE wear factors generated on six station wear rig simulators B - 
range and mean values alongside SEM are reported. UHMWPE pins (10 mm 
contact face) were articulated against rough (Ra 0.08 – 0.09 µm) ASTM 1537 low 
carbon CoCr plates at 160 N load, 28 mm stroke length and +/- 30° rotation at a 
speed of 1 Hz over three days.  
Material  Range (mm3.Nm-1) Mean ± SEM (mm3.Nm-1) 
GUR 1020 XL 1.3 x 10-5 – 3.3 x 10-4 1.4 x 10-4 ± 5.3  x 10-5 
GUR 1020 XL AOX 3.1 x 10-5 – 1.1 x 10-4 7.5 x 10-5± 1.3  x 10-5 
GUR 1050 XL 2.1 x 10-5 – 1.2 x 10-4 6.5 x 10-5± 1.7  x 10-5 
GUR 1050 XL VE 7.7 x 10-5 – 1.5 x 10-4 1.2 x 10-4± 1.3  x 10-5 
 
 
Figure 4.17 Wear factors for UHMWPE pins articulated against rough (Ra 0.08 – 0.09 
µm) ASTM 1537 low carbon CoCr plates at 160 N load, 28 mm stroke length and 
+/- 30° rotation at a speed of 1 Hz over three days on all stations combined on 
six station pin-on-plate wear simulator rig for each material tested: GUR 1020 
XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE. The error bars 
represent +/- standard error; n=4. (ANOVA; p>0.05) 
4.5.5 Size and morphology of UHMWPE wear debris generated using the single 
and six station POP multidirectional wear simulators 
The following section includes a selection of images taken using FEGSEM of the wear 
debris generated from GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 
1050 XL VE UHMWPE pins using both the single and six station wear simulators. The 
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particles were isolated as reported in Section 4.4.7 and filtered onto three different 
sizes of filter papers (10 µm, 1 µm and 0.015 µm pore sized). Images were taken at 
varying magnifications from 400X to 90kX. Images display the range of morphologies 
found – typically UHMWPE can display morphologies including plates, flakes, fibrils 
and granules.  
4.5.5.1 Size and morphology of UHMWPE wear debris generated using the 
single station pin-on-plate multidirectional wear simulators 
A total of 62 images per material per rig were taken using FEGSEM. A selection of the 
images taken with the FEGSEM of GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL 
and GUR 1050 XL VE UHMWPE wear debris generated on the single station wear 
simulator rig against rough CoCr plates at 160 N, 28 mm stroke length and 30° 
rotation at 1 Hz over five days are reported in Figure 4.18: one image per material per 
rig. The UHMWPE wear debris was subsequently isolated, filtered and imaged as 
detailed in Sections 4.4.7, 4.4.8, 4.4.9 and 4.4.10 respectively.  
A number of the different morphologies possible for UHMWPE wear debris were 
observed such as large platelet shaped particles (Figure 4.18A and C), smaller 
granular particles (Figure 4.18B) and aggregated particles (Figure 4.18D). This 
assortment of images shows that the same range of shapes are generated by all the 
UHMWPE materials tested in this study. 
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Figure 4.18  A selection of images depicting UHMWPE wear debris generated against 
rough CoCr plates using single station multidirectional POP wear simulator rigs 1 
and 2. A1) GUR 1020 XL on a 10 µm pore sized filter paper taken at 400X 
magnification. Multiple large platelet shaped particles can clearly be seen. A2) 
GUR 1020 XL on a 1 µm pore sized filter paper taken at 30kX magnification. A3) 
GUR 1020 XL on a 0.015 µm pore sized filter paper taken at 20kX magnification. 
B1) GUR 1020 XL AOX on a 10 µm pore sized filter paper taken at 1.5kX 
magnification. B2) GUR 1020 XL AOX on a 1 µm pore sized filter paper taken at 
10kX magnification. B3) GUR 1020 XL AOX on a 0.015 µm pore sized filter paper 
taken at 10kX magnification. Two platelet shaped particles are visible along with 
several small granular particles. C1) GUR 1050 XL on a 10 µm pore sized filter 
paper taken at 400X magnification. Multiple large platelet shaped particles can 
clearly be seen. C2) GUR 1050 XL on a 1 µm pore sized filter paper taken at 
20kX magnification.  C3) GUR 1050 XL on a 0.015 µm pore sized filter paper 
taken at 90kX magnification. D1) GUR 1050 XL VE on a 10 µm pore sized filter 
paper taken at 700X magnification. D2) GUR 1050 XL VE on a 1 µm pore sized 
filter paper taken at 5kX magnification. D3) GUR 1050 XL VE on a 0.015 µm pore 
sized filter paper taken at 10kX magnification. One platelet shaped particle is 
visible on the right and a aggregate of small particles is visible on the left.  
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4.5.5.2 Size and morphology of UHMWPE wear debris generated using the six 
station pin-on-plate multidirectional wear simulators 
A selection of images taken with the FEGSEM of GUR 1020 XL, GUR 1020 XL AOX, 
GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris generated on the six 
station wear simulator rig against rough CoCr plates at 160 N, 28 mm stroke length 
and 30° rotation at 1 Hz over three days are reported in Figure 4.19. The UHMWPE 
wear debris was subsequently isolated, filtered and imaged as detailed in Sections 
4.4.7, 4.4.8, 4.4.9 and 4.4.10 respectively.  
A number of the different morphologies possible for UHMWPE wear debris were 
observed such as large platelet shaped particles (Figure 4.19D), groups of aggregated 
particles (Figure 4.19A) and small granule particles (Figure 4.19C). Figure 4.19C 
shows several of these morphologies. This assortment of images shows that the same 
range of shapes are generated by all the UHMWPE materials tested in this study. 
Some salt contamination was present on Figure 4.19B (long needle-like crystals on 
the left of the image). The isolation procedure is designed to remove salts as much as 
possible however occasionally there are some residual salt crystals present. 
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Figure 4.19 A selection of images depicting UHMWPE wear debris generated against 
rough CoCr plates using the six station multidirectional POP wear simulator: A1) 
GUR 1050 XL VE UHMWPE wear debris on a 10 µm pore sized filter paper taken 
at 8kX magnification. A large aggregated UHMWPE wear particle can clearly be 
seen in the centre of the image. The particle is approximately 4 µm in diameter. 
A2) GUR 1050 XL VE UHMWPE wear debris on a 1 µm pore sized filter paper 
taken at 10kX magnification. A3) GUR 1050 XL VE UHMWPE wear debris on a 
0.015 µm pore sized filter paper taken at 30kX magnification. B1) GUR 1050 XL 
UHMWPE wear debris on a 10 µm pore sized filter paper taken at 1.5kX 
magnification. B2) GUR 1050 XL UHMWPE wear debris on a 1 µm pore sized 
filter paper taken at 5kX magnification. In the centre a large platelet shaped 
particle is clearly visible – approximately 4 µm in diameter – which is surrounded 
by many much smaller granular particles. There are also some needle-like salt 
crystals visible on this filter paper. B3) GUR 1050 XL UHMWPE wear debris on a 
0.015 µm pore sized filter paper taken at 60kX magnification. C1) GUR 1020 XL 
AOX UHMWPE wear debris on a 10 µm pore sized filter paper taken at 1.5kX 
magnification. C2) GUR 1020 XL AOX UHMWPE wear debris on a 1 µm pore 
sized filter paper taken at 1.5kX magnification. This image shows a range of 
platelet shaped and granular particles. C3) GUR 1020 XL AOX UHMWPE wear 
debris on a 0.015 µm pore sized filter paper taken at 20kX magnification. D1) GUR 
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1020 XL UHMWPE wear debris on a 10 µm pore sized filter paper taken at 400X 
magnification. This image shows a range of large platelet shaped particles. D2) 
GUR 1020 XL UHMWPE wear debris on a 1 µm pore sized filter paper taken at 
10kX magnification. D3) GUR 1020 XL UHMWPE wear debris on a 0.015 µm pore 
sized filter paper taken at 70kX magnification. 
4.5.6 Characterisation of UHMWPE wear debris particles 
Using Image J, particle sizes and volumes were assessed. No statistical analysis was 
carried out as the samples for each material generated on each rig were pooled 
therefore n=1.  
4.5.6.1 Size distribution, volume distribution and roundness of UHMWPE wear 
debris generated using the single station multidirectional pin-on-plate wear 
simulator rigs 
Particles generated on the single station multidirectional wear simulator rigs displayed 
a range of sizes (Figure 4.20). GUR 1050 XL and GUR 1050 XL VE demonstrated 
particles in all size ranges. GUR 1050 XL particles were most commonly in the range 
>10 µm, whereas the most common size range of GUR 1050 XL VE particles was 0.1 
- 1 µm. For both materials, >10 µm particles represented the largest volume of 
particles. GUR 1020 XL particles however only exhibited particles in the size ranges 1 
– 10 µm and >10 µm with the latter representing the largest volume of particles; none 
of the particles analysed were in the size ranges <0.1 µm and 0.1 – 1 µm. GUR 1020 
XL AOX particles also only exhibited particles in the ranges 0.1 - 1 µm, 1 – 10 µm and 
>10 µm, with the latter representing the largest volume of particles; none of the 
particles analysed were found in the range <0.1 µm. 
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G) 
 
H) 
 
Figure 4.20 The percentage frequency and the percentage volume size distribution of 
GUR 1020 XL (A, B), GUR 1020 XL AOX (C, D), GUR 1050 XL (E, F) and GUR 
1050 XL VE (G, H) UHMWPE particle generated on the single station 
multidirectional POP wear simulator.  
The roundness of approximately 100 particles per material were calculated and an 
average value for each material was reported. A value of 1.0 indicates a perfectly 
circular particle. Table 4.16 shows that all materials generated particles of a similar 
roundness, suggesting that there is little difference in the morphology of particles 
between highly cross-linked UHMWPE wear particles and highly cross-linked, 
antioxidant doped UHMWPE wear particles.  
Table 4.16 Roundness values of UHMWPE wear debris generated on single station 
wear rig simulators 1 and 2 – approximately 100 particles per material were 
analysed and an average roundness value reported.  
Rig Material Roundness (average) 
SS GUR 1020 XL 0.67 
SS GUR 1020 XL AOX 0.63 
SS GUR 1050 XL 0.61 
SS GUR 1050 XL VE 0.65 
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4.5.6.2 Size distribution, volume distribution and roundness of UHMWPE wear 
debris generated using the six station multidirectional pin-on-plate wear 
simulator rig 
Particles generated on the six station multidirectional wear simulator rigs displayed a 
range of sizes (Figure 4.21). GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL 
VE demonstrated particles in all size ranges except >10 µm and 0.1 – 1 µm particles 
were the most common; with particles in the size range 1 – 10 µm representing the 
largest volume. GUR 1020 XL AOX particles however only exhibited particles in the 
size ranges <0.1 µm  and 0.1 – 1 µm with the latter representing the largest volume of 
particles; none of the particles analysed were found in the ranges 1 - 10 µm and >10 
µm.  
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The roundness of approximately 100 particles per material were calculated and an 
average value for each material was reported. A value of 1.0 indicates a perfectly 
circular particle. Table 4.17 shows that all materials generated particles of a similar 
roundness, suggesting that there is little difference in the morphology of particles 
between highly cross-linked UHMWPE wear particles and highly cross-linked, 
antioxidant doped UHMWPE wear particles.  
Table 4.17 Roundness values of UHMWPE wear debris generated on six station wear 
rig simulator B – approximately 100 particles per material were analysed and an 
average roundness value reported.  
Rig Material Roundness (average) 
6S GUR 1020 XL 0.59 
6S GUR 1020 XL AOX 0.55 
6S GUR 1050 XL 0.66 
6S GUR 1050 XL VE 0.59 
 
4.5.6.3 Comparison of size distribution, volume distribution and roundness of 
UHMWPE wear debris generated using the single and six station 
multidirectional pin-on-plate wear simulator rigs  
The above size distribution, volume distribution and roundness data for the UHMWPE 
wear particles generated using the single and six station wear rig simulators is 
  
Figure 4.21  The percentage frequency and the percentage volume size distribution of 
GUR 1020 XL (A, B), GUR 1020 XL AOX (C, D), GUR 1050 XL (E, F) and GUR 
1050 XL VE (G, H) UHMWPE particle generated on the six station 
multidirectional POP wear simulator.  
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summarised in Table 4.18. It can clearly be seen that the single station wear rig 
simulators generally produced wear particles over 1 µm (with the exception of GUR 
1050 XL VE) whereas the six station wear rig simulator typically produced particles 
less than 1 µm. Table 4.18 also shows that particles over 10 µm accounted for the 
largest volume of particles produced on the single station wear rig simulators whereas 
the particles between 1 and 10 µm accounted for the largest volume of particles 
produced on the six station wear rig simulator (with the exception of GUR 1020 XL).  
Table 4.18 Comparison of size distribution, volume distribution and roundness values 
of UHMWPE wear debris generated on single and six station wear rig simulators.  
	
Rig:	SS	
	
Material:	
% number of particles in size 
range: 
GUR	1020	
XL	
GUR	1020	XL	
AOX	
GUR	1050	
XL	
GUR	1050	XL	
VE	
<0.1 µm 0	 0	 0.8	 17.5	
0.1 - 1 µm 0	 33.3	 13.5	 61.7	
1 - 10 µm  43.5	 39.4	 42.1	 9.8	
>10 µm 56.5	 27.3	 43.6	 5.5	
% volume of particles in size 
range: 
	<0.1 µm 0	 0	 0	 0.2	
0.1 - 1 µm 0	 0.02	 0.02	 0.2	
1 - 10 µm  2.1	 0.48	 3	 10.6	
>10 µm 97.9	 99.5	 96.98	 89	
Roundness 0.67	 0.63	 0.61	 0.65	
	
Rig:	6S	
	
Material:	
% number of particles in size 
range: 
GUR	1020	
XL	
GUR	1020	XL	
AOX	
GUR	1050	
XL	
GUR	1050	XL	
VE	
<0.1 µm 57.3	 2.4	 2.8	 1.7	
0.1 - 1 µm 42.7	 78	 88.7	 79.3	
1 - 10 µm  0	 17.1	 8.5	 19	
>10 µm 0	 2.5	 0	 0	
% volume of particles in size 
range: 
	<0.1 µm 9.1	 0.2	 0.01	 0.02	
0.1 - 1 µm 90.9	 7.1	 20.9	 6.48	
1 - 10 µm  0	 60.3	 79.09	 93.5	
>10 µm 0	 32.5	 0	 0	
Roundness 0.59	 0.55	 0.66	 0.59	
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4.5.6.4 Comparison of size distribution, volume distribution and roundness of 
UHMWPE wear debris generated using the single and six station 
multidirectional pin-on-plate wear simulator rigs to literature values 
The size and volume distribution data from the UHMWPE wear debris produced using 
the single station wear rig simulator during this study was compared, where possible,  
to identical data achieved in previous study by Ingram et al. (2004). Unfortunately, the 
author was unable to obtain like-for-like data for all materials except one (GUR 1050 
XL). The study by Ingram et al. (2004) obtained size and volume distribution data for 
GUR 1050 XL 10 MRad against smooth (Ra ≈ 0.02 µm) and scratched (Ra ≈	1	µm) 
CoCr plates. As there was no rough plate (Ra ≈ 0.08 – 0.09 µm) data available for 
direct comparison so the data for scratched plates was used. The study by Ingram et 
al. (2004) generated GUR 1050 XL UHMWPE wear debris with the majority of 
particles between 0.1 and 1 µm however the present study generated the majority of 
particles between 1 and 10 µm and >10 µm therefore the wear debris generated in the 
present study was significantly larger than the previous study by Ingram et al. (2004).  
Table 4.19 Comparison of size distribution, volume distribution and roundness values 
of UHMWPE wear debris generated on single station wear rig simulators to 
literature values. In this case, N/A indicates that the data is not available. 
	
Rig:	SS	
	
Material:	
% number of particles in size 
range: 
GUR	1020	
XL	
GUR	1020	XL	
AOX	
GUR	1050	
XL	
GUR	1050	XL	
VE	
<0.1 µm 0	 0	 0.8	 17.5	
0.1 - 1 µm 0	 33.3	 13.5	 61.7	
1 - 10 µm  43.5	 39.4	 42.1	 9.8	
>10 µm 56.5	 27.3	 43.6	 5.5	
% volume of particles in size 
range: 
	<0.1 µm 0	 0	 0	 0.2	
0.1 - 1 µm 0	 0.02	 0.02	 0.2	
1 - 10 µm  2.1	 0.48	 3	 10.6	
>10 µm 97.9	 99.5	 96.98	 89	
Roundness 0.67	 0.63	 0.61	 0.65	
	
Literature	
	
Material:	
% number of particles in size 
range: 
GUR	1020	
XL		
GUR	1020	XL	
AOX	
GUR	1050	
XL	–	10	
MRad	–	
against	a	
scratched	
plate	
(Ingram	et	
GUR	1050	XL	
VE		
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al.,	2004)	
<0.1 µm N/A	 N/A	 0	 N/A	
0.1 - 1 µm N/A	 N/A	 87	 N/A	
1 - 10 µm  N/A	 N/A	 13	 N/A	
>10 µm N/A	 N/A	 0	 N/A	
% volume of particles in size 
range: 
	<0.1 µm N/A	 N/A	 0	 N/A	
0.1 - 1 µm N/A	 N/A	 7	 N/A	
1 - 10 µm  N/A	 N/A	 56	 N/A	
>10 µm N/A	 N/A	 37	 N/A	
Roundness N/A	 N/A	 N/A	 N/A	
 
The size and volume distribution data from the UHMWPE wear debris produced using 
the six station wear rig simulator during this study was compared to identical data 
achieved in a previous study by Gowland (2014). Unfortunately, Gowland (2014) only 
provided size and volume distribution for GUR 102 XL AOX and GUR 1050 XL VE so 
no comparative data was obtained for GUR 1020 XL and GUR 1050 XL. Table 4.20 
shows that GUR 1020 XL AOX materials in both studies yielded similar size and 
volume distribution data i.e. in both cases the majority of the particles were between 
0.1 and 1 µm. However, Table 4.20 shows that the majority of GUR 1050 XL VE wear 
debris produced by Gowland (2014) was <0.1 µm whereas, in the present study, the 
majority of the wear debris was between 0.1 and 1 µm. 
Table 4.20 Comparison of size distribution, volume distribution and roundness values 
of UHMWPE wear debris generated on six station wear rig simulators to 
literature values. In this case, N/A indicates that the data is not available. 
	
Literature	
	
Material:	
% number of particles in size 
range: 
GUR	1020	
XL	
GUR	1020	XL	
AOX	(Gowland,	
2014)	
GUR	1050	
XL	
GUR	1050	XL	
VE	(Gowland,	
2014)	
<0.1 µm N/A	 9	 N/A	 62	
0.1 - 1 µm N/A	 68	 N/A	 35	
1 - 10 µm  N/A	 22	 N/A	 3	
>10 µm N/A	 <1	 N/A	 <1	
% volume of particles in size 
range: 
	<0.1 µm N/A	 <1	 N/A	 <1	
0.1 - 1 µm N/A	 5	 N/A	 26	
1 - 10 µm  N/A	 62	 N/A	 57	
>10 µm N/A	 32	 N/A	 17	
Roundness N/A	 N/A	 N/A	 N/A	
	
Rig:	6S	
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Material:	
% number of particles in size 
range: 
GUR	1020	
XL	
GUR	1020	XL	
AOX	
GUR	1050	
XL	
GUR	1050	XL	
VE	
<0.1 µm 57.3	 2.4	 2.8	 1.7	
0.1 - 1 µm 42.7	 78	 88.7	 79.3	
1 - 10 µm  0	 17.1	 8.5	 19	
>10 µm 0	 2.5	 0	 0	
% volume of particles in size 
range: 
	<0.1 µm 9.1	 0.2	 0.01	 0.02	
0.1 - 1 µm 90.9	 7.1	 20.9	 6.48	
1 - 10 µm  0	 60.3	 79.09	 93.5	
>10 µm 0	 32.5	 0	 0	
Roundness 0.59	 0.55	 0.66	 0.59	
 
4.6  Discussion 
The aim of the chapter was to aseptically generate sterile UHMWPE wear debris 
(GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE) for use in a 
novel in vitro model developed in Chapter 3 in order to assess the inflammatory and 
oxidative response to highly cross-linked and antioxidant doped, highly cross-linked 
UHMWPE wear debris. The secondary aim of this chapter was to compare the particle 
morphology and size and volume distribution of the particles generated to previous 
studies. 
UHMWPE wear debris (GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 
1050 XL VE) was aseptically generated using single and six station multidirectional 
POP wear simulators. UHMWPE pins (10 mm contact face) were articulated against 
rough (Ra 0.08 – 0.09 µm) ASTM 1537 low carbon CoCr plates at 160 N load, 28 mm 
stroke length and +/- 30° rotation at a speed of 1 Hz over five and three days; for 
single and six station multidirectional POP wear simulators, respectively. Rough plates 
were used to increase the wear factor and therefore maximise the volume of wear 
debris available for in vitro studies. The single station multidirectional POP wear 
simulator was chosen to generate the full size range of UHMWPE particles possible 
with which to dose cells. The six station multidirectional POP wear simulator rig was 
chosen to maximise the volume of debris produced in order to filter the debris and 
obtain a sufficient volume of particles within the critical size range necessary to 
activate macrophages (0.1 – 1 µm). All serum lubricants were assessed for 
microbiological and endotoxin contamination to ensure sterility for in vitro studies. 
Samples from each serum lubricant were pooled for each material produced on each 
type of rig and isolated using the digestion method established by Tipper et al. (2000, 
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2006) and Richards et al. (2008). The particles were then filtered onto 10 µm, 1 µm 
and 0.015 µm pore sized filter papers which were then imaged using FEGSEM. The 
images were subsequently analysed with ImageJ to assess the size and volume 
distribution of the particles generated.  
Previous studies have shown that highly cross-linked UHMWPE materials produce 
significantly lower volumes of wear debris compared to their virgin, non-cross-linked 
counterparts (Endo et al., 2001). Moreover, Gowland (2014) found that there was no 
significant difference in the wear performance between highly cross-linked UHMWPE 
materials and the equivalent materials that have been doped with antioxidants. 
Gowland (2014) demonstrated that the presence of antioxidants had no impact on the 
resistance of the material to wear.  
Gowland (2014) generated UHMWPE using smooth (Ra <0.01 µm) CoCr plates in the 
six station multidirectional POP wear simulator. However, in order to maximise the 
volume of wear debris available for in vitro studies, this study utilised rough (Ra 0.08 – 
0.09 µm) plates in the six station multidirectional POP wear simulator. Although 
Gowland used the same UHMWPE materials (with the exception of GUR 1020 XL), a 
direct comparison between the two studies is not possible due to the difference in 
surface roughness of the plates used. However, Ingram et al. (2004) compared the 
wear factors produced by various UHMWPE materials articulated against scratched 
(Ra 1 µm) and smooth (Ra 0.02 µm) CoCr plates on a single station multidirectional 
POP wear simulator and found that the wear factor of GUR 1050 XL UHMWPE (10 
MRad) articulated against a scratched CoCr plate was 1 x 10-7 mm3.Nm-1. This wear 
factor is 10 times lower than the equivalent mean wear factor observed for GUR 1050 
XL against a rough (Ra 0.07 – 0.08 µm) plate on the single station multidirectional 
POP wear simulator. It is known that the use of rough rather than smooth plates 
increases the volume of wear debris produced and may impact the size and volume 
distribution of the particles produced (Endo et al., 2001). Additionally Endo et al. 
(2001) found that cross-linked UHMWPE produced significantly higher wear rates 
against rough CoCr plates than non-cross-linked UHMWPE.  
Previous studies have found that wear debris volumes and wear factors produced by 
the different UHMWPE materials on each type of rig were similar however this was not 
consistent with the values observed during this study. The volume of wear debris 
produced was higher than expected. This was particularly true for GUR 1020 XL AOX 
UHMWPE wear debris generated on the single station multidirectional POP wear 
simulator (mean 37.48 ± 28.82). This was also the case for all wear debris volumes for 
all materials generated on the six station multidirectional POP wear simulator, which 
were between 10 and 100 times higher than the volumes observed on the single 
station multidirectional POP wear simulator. There was no similarity or consistency 
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between the values for each material on different rigs or each material when 
compared to each other material; although there were no significant differences 
between the values from the single (ANOVA; p >0.05) and six station multidirectional 
POP wear simulators (ANOVA; p >0.05). The standard error bars on Figures 4.14 and 
4.15 were large and may account for this lack of significance. Similarly, the wear 
factors observed during this study were higher than expected and there was no 
similarity or consistency between the values for each material on different rigs or each 
material when compared to each other material. Again, there was a large margin of 
error for all mean wear factor values which may account for the lack of consistency. 
Gowland (2014) reported wear factor values between 1.9 and 2.5 x 10-7 mm3.Nm-1 for 
GUR 1050 XL, GUR 1050 XL VE and GUR 1020 XL AOX UHMWPE pins on smooth 
CoCr plates on the six station multidirectional POP wear simulator. This study 
demonstrated wear factors between 100 and 1000 times higher (1.2 x 10-4 and 7.5 x 
10-5 mm3.Nm-1) for UHMWPE pins on rough CoCr plates on the six station 
multidirectional POP wear simulator. The wear factor values obtained from the single 
station multidirectional POP wear simulator were lower than those obtained on the six 
station multidirectional POP wear simulator although these values were still between 
10 and 100 times higher (2.1 x 10-5 and 3.9 x 10-6 mm3.Nm-1) than those reported by 
Gowland (2014). It was not possible to compare wear factor values for GUR 1020 XL 
as Gowland (2014) did not include this material in the study due to lack of availability.  
Although statistical analysis showed that the differences between the wear debris 
volumes and wear factors of each material on each type of rig were not significantly 
different when compared to each other (ANOVA; p> 0.05), there is a large margin of 
error for each of the values. There are several possible explanations for the higher 
volumes of wear debris,  increased wear factors and large margins of error observed 
in this study.  
It is possible that there may have been some differences between the roughness of 
individual plates used in the study, however the range of surface roughness used was 
small, so this is unlikely. Surface roughness measurements were not obtained as the 
primary aim was to produce wear debris for in vitro studies rather than a detailed 
investigation into the mechanical properties of the materials involved. This was a 
potential oversight and such measurements may have contributed to an explanation 
for the unusual material behaviour observed in this study.  
The age and storage of the UHMWPE bar stock used to create the pins may have 
impacted the wear debris volumes and wear factors observed during this study. Since 
there was no industrial collaborator for this study, the bar stocks used to cut the pins 
were remnants of previous studies stored on the shelf in the Technicians Office in the 
School of Mechanical Engineering. Each material had been stored in air this way for 
- 173 - 
several years; for example, the GUR 1050 XL VE bar stock was sourced in 2009. 
Storage in air, i.e. oxidising conditions, is sub-optimal and may lead to oxidative 
embrittlement of the UHMWPE (Besong et al., 1997). Oxidative embrittlement reduces 
the wear resistance of UHMWPE, thus increasing the wear factor and volume of wear 
debris produced, as free radicals trapped within the polymer structure from cross-
linking irradiation, such as ROS, can cause polymer chain scission (Wannomae et al., 
2006). Bar stock stored this way may exhibit differences when pins are cut from the 
edge of the bar stock (exposed to the air) and the centre of the bar stock (somewhat 
protected from the air). UHMWPE bar stock should be vacuum packed and stored at – 
80 °C to prevent oxidation.  
As highly cross-linked GUR 1020 and GUR 1050 bar stock was not directly available 
for this study, the virgin, non-cross-linked GUR 1020 and GUR 1050 available was 
sent to be commercially irradiated to provide highly cross-linked UHMWPE materials. 
Pins were cut from the virgin bar stock and vacuum packaged at the University of 
Leeds prior to being sent to Synergy Health PLC for commercial gamma irradiation. 
The dose range was specified as 9 – 11.5 MRad and the pins received an 
approximate dose of 9.39 MRad in order to provide UHMWPE comparable to clinical 
materials GUR 1050 XL (10 MRad) and GUR 1020 XL (8 MRad). A food grade 
vacuum sealer was used to package the pins. As the apparatus was not adapted for 
this purpose, it was difficult for the candidate to achieve a good seal. This may have 
resulted in the presence of air during the irradiation process which may have lead to 
oxidation of the pins. Moreover, post-irradiation annealing or remelting was not carried 
out to remove any free radicals present. It was not known whether the GUR 1020 XL 
AOX and GUR 1050 XL VE materials underwent post-irradiation annealing or 
remelting. Remelting involves taking the UHMWPE above its melting point in order to 
allow the removal of any residual free radicals. Since the temperature is above the 
materials melting point, all the different regions of the polymer, including the crystalline 
regions, are melted and it is made certain that the polymer does not contain any free 
radicals (Wang et al., 2006). However this is at a detriment to the wear resistance of 
the material which is related to the level of crystallinity of the polymer. Whereas, 
annealing only exposes the polymer to temperatures below its melting point so does 
not have this detrimental impact on mechanical properties. However the crystalline 
regions remain during this process so any residual free radical trapped here will 
remain in the material and may continue to propagate and react oxidatively with the 
polymer after irradiation (Wang et al., 2006). Since, it is not known which of these 
processes, if any, the GUR 1020 XL AOX and GUR 1050 XL VE materials have been 
exposed to, it is difficult to pinpoint their effects. However it is clear that remelting 
impacts the mechanical properties of UHMWPE and therefore could impact the 
resistance to wear resulting in higher wear factors than expected. Additionally, 
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annealing preserves mechanical properties and therefore the resistance to wear but 
this may be negated by the continued existence of highly oxidising species within the 
polymers crystalline structure which can go on to react with polymer well beyond 
irradiation over the course of years of being stored on the shelf. The deterioration of 
the material in this way would also reduce the materials resistance to wear over time.  
Finally the differences between the wear debris volumes and wear factors from the 
same materials across the single and six station multidirectional POP wear simulators 
may be explained by the difference in lubrication regimes between the two types of 
simulators. The single station multidirectional POP wear simulator is run with RPMI 
cell culture medium with 25% (v/v) FBS. The presence of FBS mimics the proteins 
present in synovial fluid that coat wear particles. Whereas the six station 
multidirectional POP wear simulator is run with RPMI cell culture medium only; i.e. no 
proteins are added. Sodium azide is often added in such studies to prevent microbial 
contamination however sodium azide is highly toxic to cells and was not used during 
this study. Although it is not ideal for replicating conditions in vivo, UHMWPE wear 
debris was generated without FBS to allow fluorescent staining of the particles for 
microscopy. The presence of FBS changes the lubrication regime of the single station 
multidirectional POP wear simulator compared to the six station multidirectional POP 
wear simulator. In RPMI with 25% (v/v) FBS, proteins coat the UHMWPE pin and 
produce a protective effect i.e. the pin becomes more resistant to wear as the protein 
layer is sheared prior to the pins contact face (Fröhlich et al., 2014). This reduces the 
wear factor and volume of wear debris produced. Whereas the six station 
multidirectional POP wear simulator is operated without the presence of FBS so there 
is no protective effect created by protein adhesion to the pins. This results in larger 
volumes of wear debris produced and increased wear factors; similar to UHMWPE 
pins run in water (the UHMWPE pins become fractured and fatigued). This may 
account for the differences between the volumes of wear debris and wear factor 
values observed for each material on each different type of rig.  
All UHMWPE wear debris generated was free from microbiological contamination and 
contained sufficiently low levels of endotoxin (>0.5 EU.ml-1); >5 EU.ml-1 is 
recommended by FDA regulatory affairs (1985) for injectable pharmaceuticals to be 
declared endotoxin-free and sterile. This is consistent with previous studies that have 
operated both the single and six station multidirectional POP wear simulators under 
aseptic conditions to generate UHMWPE wear debris (Liu, 2012; Gowland, 2014) This 
step is necessary to ensure that any cellular response in vitro is caused by the 
particles only rather than any other contaminating material. Previous studies have 
shown that endotoxin contamination of orthopaedic particulates can induce an 
increased release of pro-inflammatory cytokines, such as TNF-α (Brooks, Wimhurst 
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and Rushton, 2002).  However, some of the optical density values were below the 
lowest endotoxin standard and should have been re-assayed in order to be certain 
that the wear debris produced was indeed free of endotoxin contamination. 
FEGSEM images of the UHMWPE wear particles produced on both the single and six 
station multidirectional POP wear simulators displayed various particle morphologies 
across all the different types of UHMWPE used: platelet-like particles, small granules 
and aggregated particles. The particle morphologies observed were consistent from 
both types of wear simulators. These particle morphologies were consistent with those 
observed in the previous study by Gowland (2014) using both wear simulators and 
identical UHMWPE materials (except GUR 1020 XL). Although the particle 
morphologies observed in this study are consistent with the particle morphologies 
observed by Tipper et al. (2000) in UHMWPE wear debris from retrieved Charnley hip 
prostheses, the full range of different shapes demonstrated by Tipper et al. (2000) 
was not observed. For example, no fibril particles were observed. Most materials used 
to generate particles on the single station multidirectional wear simulator rig 
demonstrated particles in all size ranges as was demonstrated by Tipper et al (2000) 
in the retrieval study of Charnley prostheses, however no particles were found in the 
ranges <0.1 and 0.1 -1 µm for the GUR 1020 XL material. Similarly, no particles were 
found in the range <0.1 µm for the GUR 1020 XL AOX material. This lack of 
representation of these size ranges indicates that the samples may not be 
representative of the wide range of particles sizes produced in vivo.  Endo et al. 
(2001) demonstrated that UHMWPE pins articulated against rough CoCr plates 
produced larger particles which may explain why the materials used generated less or 
no particles in the smaller size ranges. Particles generated on the six station 
multidirectional wear simulator rig also demonstrated a lack of >10 µm particles for all 
materials except GUR 1020 XL AOX and a lack of 1 – 10 µm particles for GUR 1020 
XL. Since particles generated using the six station multidirectional wear simulator rig 
went on to be filtered into the range 0.1 – 1 µm, the lack of representation for larger 
sizes was not a relevant issue. It is not clear why larger particle sizes were not 
observed using the six station multidirectional wear simulator rig compared to the 
single station multidirectional wear simulator rig which demonstrated a lack of smaller 
particles. It is possible that the difference in lubrication regime between the rigs was a 
contributory factor.  The single station multidirectional wear simulator rig used RPMI 
medium and 25% (v/v) FBS whereas the six station multidirectional wear simulator rig 
used RPMI medium only. The presence of proteins in FBS change the lubrication 
regime as discussed before and may contribute to the size of particles produced 
(Fröhlich et al., 2014). 
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There were a number of limitations to this study. Since the primary objective of this 
chapter was not to determine wear performance data for the materials used, certain 
measurements were not obtained. The surface roughness of the CoCr plates used 
were not obtained using Talysurf before and after runs. This may have provided 
further insight as to the unusually high wear debris volumes and wear factors 
observed during this study. Moreover, EDX analysis of the UHMWPE wear debris was 
not performed when obtaining FEGSEM images of the particles. The primary 
limitations to this study were the age and storage conditions of the UHMWPE 
materials used. The shelf aging in oxidative conditions over several years could have 
decreased the wear resistance of the UHMWPE materials and resulted in the high 
volume of wear debris and large wear factors observed. It would have been useful to 
compare the wear volumes of the UHMWPE pins used in this study before and after 
irradiation treatment, in order to assess whether the irradiation treatment contributed 
to the high wear volumes or not.  Similarly, it would have been useful to compare wear 
volumes generated using rough and smooth CoCr plates in order to assess the impact 
of plate roughness on the high wear volumes seen in this study. Future studies would 
be improved by obtaining fresh UHMWPE bar stock or pins from industrial 
collaborators. Additionally, the correct storage of UHMWPE materials in vacuum 
packaging at -80°C to prevent oxidation would remove shelf aging and oxidation as a 
potential variable in future studies.  
The size and volume distribution values generated by each material on each type of 
rig simulator were compared, where possible, to data available in the literature or 
previous studies for wear debris from the same materials on the same type of rig 
simulator. However, much of the necessary comparative data was not available; 
meaning a full comparison was not always possible and thus it was difficult to 
ascertain a full picture of how the wear debris produced in this study compared to 
previous work. In order to assess the clinical relevance of the wear debris produced in 
this study, it would be necessary to compare the wear debris produced here to the 
wear debris from identical materials isolated during retrieval studies. However, as both 
cross-linked and (in particular) antioxidant doped cross-linked UHMWPE are relatively 
new clinically and retrieval studies are long term (>10 years), the necessary retrieval 
data is not available for comparison. As such, it is not possible to comment on the 
clinical relevance of the wear debris produced in this study.  
4.7  Conclusions 
• Sufficient volumes of GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and 
GUR 1050 XL VE UHMWPE wear debris were generated using both the single 
and six station multidirectional POP wear simulator rigs for use in the in vitro 
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cell culture studies to be performed later in the study. This was confirmed by 
the high volumes of wear debris and large wear factors reported in Section 4.5.  
• Microbiological and endotoxin testing of the serum lubricants produced 
confirmed particle sterility, i.e. the particles did not exhibit any biological or 
endotoxin contamination.  
• A pooled sample of each material (GUR 1020 XL, GUR 1020 XL AOX, GUR 
1050 XL and GUR 1050 XL VE) from each rig was isolated and imaged to 
assess particle morphology. Typical particle morphologies, such as large 
platelets, small granules and aggregate particles, were observed across all 
samples although all possible morphologies found in previous retrieval studies 
were not found during this study. Particles produced on the single station 
multidirectional wear simulator were generally larger than those produced on 
the six station multidirectional wear simulator although larger particles 
represented a significant volume of the particles produced in both cases. The 
size and volume distribution of the particles produced in this study did not 
match the literature values of equivalent materials (where possible to obtain). 
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Chapter 5 
Assessing the anti-inflammatory and antioxidant effects of 
antioxidant doped, highly cross-linked ultra-high molecular weight 
polyethylene wear debris using a novel 3D in vitro model 
5.1  Introduction 
Metal on polyethylene (MOP) remains the gold standard THR to the present day and 
represent 30.4% of all primary THR’s (National Joint Registry, 2017). It is well 
documented that the biological response to polyethylene wear debris produced by 
MOP THR’s is linked to osteolysis and, ultimately, aseptic loosening which is 
responsible for 50.1% of all revision surgeries in 2017 (National Joint Registry, 2017). 
Polyethylene has since been modified by cross-linking in order to reduce the volume 
of wear debris produced (Galvin et al., 2006). Antioxidants, such as vitamin E and 
hindered phenols, can also be added to quench free radicals and remove the need for 
remelting or annealing which can reduce the mechanical properties (such as strength 
and fatigue resistance) of polyethylene (Oral, Malhi and Muratoglu, 2006). Vitamin E is 
known for its well documented anti-inflammatory effects in cardiovascular disease 
(Devaraj, Li and Jialal, 1996) and rheumatoid arthritis (De Bandt et al., 2002). Singh 
and Jialal (2004) showed that treatment of monocytes with vitamin E reduced the 
release of pro-inflammatory cytokines linked to osteolysis; TNF-α, IL-1β, IL-6. Another 
study by Devaraj and Jialal (1999) examined the effects of vitamin E on the production 
of common inflammatory mediators, LTB4 and PGE2, in PBMNC’s. Devaraj and Jialal 
(1999) showed that the presence of vitamin E significantly reduced the production of 
LTB4 but had no effect of the production of PGE2 in LPS-stimulated PBMNC’s. 
Devaraj and Jialal (1999) utilised Calphostin C, Bisindolylmaleimide I, Indomethacin, 
MK 886 and REV 5901 to examine the effects of vitamin E on the inhibition of IL-1β 
production via the interaction with one of three possible inflammatory pathways: 
cyclooxygenase (COX), lipooxygenase (5-LO) or protein kinase C (PKC). COX and 5-
LO are enzymes involved the production of prostaglandins and leukotrienes, 
respectively, which are mediators in the cascade of reactions that constitute 
inflammation. Similarly PKC, which is a family of enzymes that catalyse 
phosphorylation, also has a role in inflammation (Devaraj and Jialal, 1999). Calphostin 
C and Bisindolylmaleimide I are inhibitors of PKC, Indomethacin is an inhibitor of COX 
and MK 886 and REV 5901 are inhibitors of 5-LO. 
Bladen et al. (2013b) showed that the release of TNF-α, IL-1β and IL-6 were 
significantly increased (there was no significant effect on the release of IL-8) in 
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PBMNC’s in response to GUR 1050 non-cross-linked UHMWPE compared to the cells 
only control. However, the release of these cytokines was significantly reduced in 
response to GUR 1050 VE (3000 and 30,000 ppm) UHMWPE wear debris when 
compared to GUR 1050 UHMWPE wear debris. However, Bladen et al. (2013a) used 
non-clinical doses of vitamin E to assess cytokine release. Bladen et al. (2013b) 
subsequently showed that GUR 1050 VE (1000 ppm), a clinically relevant dosed 
material, did exhibit the same reduction in TNF-α however the effect on IL-1β and IL-6 
was not assessed with the clinically relevant dose of vitamin E. Moreover, Bladen et 
al. (2013a) did not test highly cross-linked material so it is unclear whether these 
responses would be repeated with a clinically relevant GUR 1050 XL VE material 
(1000 ppm). Bladen et al. (2013b) also stimulated both PMA-activated U937 human 
histiocytes and PBMNC’s with LPS and, after 3 hours, treated the cells with 
antioxidant compounds vitamin E (800 µM) and hindered phenol (25 µM) to observe 
the effect on TNF-α release. Bladen et al. (2013a) found that both vitamin E and 
hindered phenol significantly reduced the release of TNF-α in U937 human histiocytes 
but only vitamin E significantly reduced the release of TNF-α in PBMNC’s. This study 
demonstrated the potential of antioxidant compounds to exhibit anti-inflammatory 
activity in a periprosthetic environment however, this study used the antioxidant 
compounds in isolation rather than blended or diffused UHMWPE as is clinically 
revelant. There is some debate as to whether vitamin E is freely available in blended 
UHMWPE (as it is added prior to consolidation and can be grafted into the polymer 
backbone) in addition to how much vitamin E is capable of leaching from a diffused 
UHMWPE material (as the consolidated UHMWPE is soaked in a concentrated 
vitamin E solution). 
This study has developed a novel 3D in vitro model (RAW 264.7 murine macrophages 
simultaneously encapsulated with polyethylene particles in collagen gel) as a more 
accurate representation of the periprosthetic environment than previous 2D models. 
The novel model requires comparison to the outcomes of previous studies in order to 
attempt to assess how much value it has for future studies. Liu (2012) used UHMWPE 
wear debris in the size range 0.1 – 0.6 µm to produce significant TNF-α release in 
PBMNC’s which was consistent with the critical size range necessary for macrophage 
response demonstrated by Green et al. (1998) whereas Gowland (2014) used the full 
size range of particles generated as this was more clinically representative of the 
particles found in the in vivo periprosthetic environment (Tipper et al., 2000). The aim 
of this study was to challenge the novel 3D model with both representations of particle 
sizes: the full size range generated using the single station multidirectional POP wear 
simulator known to successfully produce representative, sterile UHMWPE wear debris 
(Ingram et al., 2004) and particles filtered into the critical size range 0.1 – 1 µm, 
known to activate macrophages, generated using the six station multidirectional POP 
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wear simulator known to successfully produce representative, sterile UHMWPE wear 
debris (Liu, 2012). This study aimed to assess the impact of both of these particle size 
ranges on known inflammatory and osteolytic mediators: TNF-α, IL-1β, IL-6, IL-8 (KC), 
LTB4 and PGE2. Mice do not express IL-8 but they do express a homologue known as 
keratinocyte derived chemokine (KC) which was measured instead. This study also 
aimed to assess the impact of both of these particle size ranges on the intracellular 
concentrations of ROS. Additionally, this study intended to compare the ability of RAW 
264.7 murine macrophages to uptake and sequester UHMWPE wear particles to the 
known ability of PBMNC’s to uptake and sequester UHMWPE particles around the 
nucleus. Finally, the study aimed to use the novel model to assess the effect of 
inflammatory pathway inhibitors (Calphostin C, Bisindolylmaleimide I, Indomethacin, 
MK 886 and REV 5901) and antioxidant compounds (Vitamin E and Pentaerythritol 
tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate)) on the release of osteolytic 
mediators: TNF-α, IL-1β, IL-6, LTB4 and PGE2 in order to ascertain by which pathway 
any potential anti-inflammatory activity, displayed in previous studies, may be acting.  
5.2  Aims and objectives 
5.2.1  Aims 
The overall aim of this chapter was to use the novel 3D in vitro model generated in 
Chapter 3 (RAW 264.7 murine macrophages in collagen gel) to measure the cellular 
response to antioxidant doped, highly cross-linked ultra-high molecular weight 
polyethylene wear debris and compare this data to data generated using previous 2D 
in vitro models. The model was tested in a number of circumstances from previous 
studies in order to ascertain whether the model was capable of reproducing their 
effects and may therefore be of future use. 
5.2.2  Objectives 
The objectives of this chapter were as follows: 
• To assess the production of TNF-α, IL-1β, IL-6, IL-8 (KC), LTB4 and PGE2 in 
response to the full range of particle sizes of antioxidant-doped, highly cross-
linked UHMWPE generated on the single station wear simulator rig and 
antioxidant-doped, highly cross-linked UHMWPE particles generated on the six 
station wear simulator rig which had been filtered into the critical size range 
necessary for macrophage activation (0.1 µm – 1 µm).  
• To assess the cellular oxidative stress response to the full range of particle 
sizes of antioxidant-doped, highly cross-linked UHMWPE generated on the 
single station wear simulator rig and antioxidant-doped, highly cross-linked 
UHMWPE particles generated on the six station wear simulator rig which had 
- 181 - 
been filtered into the critical size range necessary for macrophage activation 
(0.1 µm – 1 µm).  
• To stimulate the novel in vitro model with LPS and then, after 3 hours, dose the  
novel in vitro model with inhibitors of the COX pathway (indomethacin), 5-LO 
pathway (MK 886 and REV 5901) and PKC pathway (Calphostin C and 
Bisindolylmaleimide I) and antioxidant compounds (Vitamin E and 
Pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)) in order to 
assess the resultant cytokine output of TNF-α, IL-1B, IL-6, LTB4 and PGE2. 
• To assess the internal sequestration of UHMWPE wear debris in RAW 264.7 
murine macrophages in the novel in vitro model compared to PBMNC’s used in 
the previous model. 
5.3  Materials 
The materials used throughout Chapter 5 are detailed in the following section. Any 
general materials used are listed in Chapter 2.  
5.3.1  Chemicals and reagents 
The chemicals and reagents used throughout Chapter 5 are detailed in Table 5.1. Any 
general chemicals and reagents are detailed in Chapter 2, Section 2.1.1. 
Table 5.1 Chemicals and reagents used throughout Chapter 5. 
 
Chemical/reagent Supplier Storage and 
preparation 
Bisindolylmaleimide I AdipoGen life sciences, 
California, USA. 
Stored at -20°C and 
prepared by dissolving 
1 mg in 1 ml DMSO. 
Calphostin C Santa Cruz 
Biotechnology Inc., 
Texas, USA. 
Stored at -20°C and 
prepared by dissolving 
100 µg in 1 ml DMSO. 
DCFDA cellular ROS 
detection assay kit 
Abcam, Cambridge, 
UK. 
Stored at 4°C. 
DMEM – phenol red free Sigma Aldrich, Dorset, 
UK. 
Stored at 4°C. 
Hoechst® 33342 ThermoFisher Scientific 
UK, Loughborough, UK. 
Stored at -20°C and 
prepared by dissolving 
100 mg in 10 ml 
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deionised water. 
Indomethacin Sigma Aldrich, Dorset, 
UK. 
Stored at 25°C and 
prepared by dissolving 
10 mg in 1 ml DMSO. 
Lysotracker red DND-99 ThermoFisher Scientific 
UK, Loughborough, UK. 
Stored at -20°C. 
MK 886 Cayman chemical, 
Michigan, USA. 
Stored at -20°C and 
prepared by dissolving 
1 mg in 1 ml DMSO. 
Pentaerythritol 
tetrakis(3,5-di-tert-butyl-
4-
hydroxyhydrocinnamate) 
Sigma Aldrich, Dorset, 
UK. 
Stored at 25°C. 
RayBio® Mouse KC 
ELISA kit – 1 x 96 well 
plate 
RayBio®, Georgia, 
USA. 
Stored at -20°C. 
R&D® Parameter ™ 
LTB4 assay – 1 x 96 well 
plate 
R&D® Systems, 
Minneapolis, USA. 
Stored at -20°C. 
R&D® Parameter ™ 
PGE2 assay – 1 x 96 
well plate 
R&D® Systems, 
Minneapolis, USA. 
Stored at -20°C. 
REV 5901 Cayman chemical, 
Michigan, USA. 
Stored at -20°C and 
prepared by dissolving 
5 mg in 1 ml DMSO. 
Sodium fluorescein Santa Cruz 
Biotechnology Inc., 
Texas, USA. 
Stored at room 
temperature (25°C). 
Vitamin E – dl- α-
tocopherol acetate – 
500 mg/ml 
Merck, Germany Stored at 25°C. 
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5.3.2  Consumables 
The consumables used throughout Chapter 5 is detailed in Table 5.2. Any general 
consumables are detailed in Chapter 2, Section 2.1.2. 
Table 5.2 Consumables used throughout Chapter 5. 
 
Consumable Size Supplier 
Corning cell culture 
spatulas 
N/A Fisher Scientific UK, 
Loughborough, UK. 
Glass cover slips 22 mm Menzel Gläser, Gerhard 
Menzel GmbH, 
Germany. 
Glass slides 76 x 26 mm Menzel Gläser, Gerhard 
Menzel GmbH, 
Germany. 
 
5.3.3  Equipment 
The equipment used throughout Chapter 5 is detailed in Table 5.3. Any general 
equipment is detailed in Chapter 2, Section 2.1.3. 
Table 5.3 Equipment used throughout Chapter 5. 
 
Equipment Supplier 
Zeiss Axio Imager M2 Carl Zeiss, UK. 
 
5.3.4  Software 
The software used throughout Chapter 5 is detailed below in Table 5.4. 
Table 5.4 Software used throughout Chapter 5. 
 
Software Supplier 
Zen lite Carl Zeiss, UK. 
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5.4  Methods 
5.4.1  Reagents and solutions preparation 
5.4.1.1  Antioxidant compounds 
5.4.1.1.1 Pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) 
Stock solution 
A stock solution of Pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) 
was prepared by adding 10 mg Pentaerythritol tetrakis(3,5-di-tert-butyl-4-
hydroxyhydrocinnamate) to 1 ml DMSO. This stock solution was kept at -20°C 
between uses. This was filter sterilised as described in Chapter 2, Section 2.2.1.5. 
5.4.1.2  Inflammatory pathway inhibitors 
5.4.1.2.1 Bisindolylmaleimide I 
Stock solution 
A stock solution of Bisindolylmaleimide I was prepared by adding 1 mg 
Bisindolylmaleimide I to 1 ml DMSO. This stock solution was kept at -20°C between 
uses. This was filter sterilised as described in Chapter 2, Section 2.2.1.5. 
5.4.1.2.2 Calphostin C 
Stock solution 
A stock solution of Calphostin C was prepared by adding 100 µg Calphostin C to 1 ml 
DMSO. This stock solution was kept at -20°C between uses. This was filter sterilised 
as described in Chapter 2, Section 2.2.1.5. 
5.4.1.2.3 Indomethacin 
Stock solution 
A stock solution of Indomethacin was prepared by adding 10 mg Indomethacin to 1 ml 
DMSO. This stock solution was kept at -20°C between uses. This was filter sterilised 
as described in Chapter 2, Section 2.2.1.5. 
5.4.1.2.4 MK 886 
Stock solution 
A stock solution of MK 886 was prepared by adding 1 mg MK 886 to 1 ml DMSO. This 
stock solution was kept at -20°C between uses. This was filter sterilised as described 
in Chapter 2, Section 2.2.1.5. 
5.4.1.2.5 REV 5901 
- 185 - 
Stock solution 
A stock solution of REV 5901 was prepared by adding 5 mg REV 5901 to 1 ml DMSO. 
This stock solution was kept at -20°C between uses. This was filter sterilised as 
described in Chapter 2, Section 2.2.1.5. 
5.4.1.3  Fluorescent microscopy stains 
5.4.1.3.1 Hoechst® 33342 
Stock solution 
A stock solution of Hoechst 33342 was prepared by weighing out 10 mg of Hoechst 
33342 and adding to 1 ml DPBS. This was covered in foil and kept at -20°C in 
between uses. This was filter sterilised as described in Chapter 2, Section 2.2.1.5. 
Working solution 
A working solution of Hoechst 33342 was prepared by adding 1 µl of 10 mg.ml-1 stock 
solution to 1999 µl DPBS to create a 1:2000 working solution. 
5.4.1.3.2 Lysotracker red DND-99 
Working solution 
A working solution of Lysotracker red (75 nM) was created by adding 0.75 µl 
lysotracker red to 10 ml complete DMEM. This was filter sterilised as described in 
Chapter 2, Section 2.2.1.5.  
5.4.1.3.3 Sodium fluorescein 
Stock solution 
A stock solution (1 mg.ml-1) of sodium fluorescein was prepared by adding 10 mg of 
sodium fluorescein to 10 ml sterile ultrapure water. This was filter sterilised as 
described in Chapter 2, Section 2.2.1.5. 
5.4.2 Cytokine release in RAW 264.7 murine macrophages in response to 
UHMWPE wear debris in collagen gel 
RAW 264.7 murine macrophages were passaged and counted as described in 
Chapter 2, Sections 2.2.5.4 and 2.2.8.3. The doses of single and six station generated 
UHMWPE wear debris (GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 
1050 XL VE) and FluoSphere® particle control  were calculated as described in 
Chapter 2, Sections 2.2.6.2 and 2.2.6.3. RAW cells were seeded at 1 x 105 cells.ml-1 
with 100 µm3.cell-1 particles in collagen gels in 48 well tissue culture plates as 
described in Chapter 2, Section 2.2.7.2. The gels were allowed to set and the plates 
were incubated at 37°C and 8% (v/v) CO2 in air. The ATP-liteTM viability assay was 
carried out at 12 and 24 hours. After 12 and 24 hours, the supernatant was removed 
- 186 - 
and placed in the corresponding wells of a Nunc F uncoated plate which was frozen at 
-80°C until use in ELISA. The ATP-liteTM viability assay was then carried out as 
described in Chapter 2, Section 2.2.8.1. The supernatants were later defrosted and 
used to carry out TNF-α, IL-1β, IL-6, KC, LTB4 and PGE2 ELISA as described in 
Chapter 2, Section 2.2.8.2.  
5.4.3 Cytokine release of LPS-stimulated RAW 264.7 murine macrophages in 
response to inflammatory pathway inhibitors and antioxidant compounds 
in collagen gel 
Inhibitor growth curve 
RAW 264.7 murine macrophages were passaged and counted as described in 
Chapter 2, Sections 2.2.5.4 and 2.2.8.3. RAW cells were seeded at 5 x 104 cells.ml-1 
in a 96 well tissue culture plate. Each well was filled with 200 µl complete DMEM 
containing the following concentrations of inflammatory pathway inhibitors (n=3): 
Bisindolylmaleimide I (0.1, 1, 10 and 100 µmol.L-1), Calphostin C (100 nmol.L-1, 250 
nmol.L-1, 500 nmol.L-1, 1 µmol.L-1), Indomethacin (0.1, 1, 10 and 100 µmol.L-1), MK 
886 (0.1, 1, 10 and 100 µmol.L-1) and REV 5901 (1, 10, 100 and 1000 µmol.L-1). The 
plates were incubated at 37°C and 8% (v/v) CO2 in air and the ATP-liteTM viability 
assay was carried out at days 0, 1 and 3 as described in Chapter 2, Section 2.2.8.1. 
Antioxidant growth curve 
RAW 264.7 murine macrophages were passaged and counted as described in 
Chapter 2, Sections 2.2.5.4 and 2.2.8.3. RAW cells were seeded at 5 x 104 cells.ml-1 
in a 96 well tissue culture plate. Each well was filled with 200 µl complete DMEM 
containing the following concentrations of antioxidants (n=3): Vitamin E (400 µmol/L, 
800 µmol.L-1, 1 mmol.L-1, 2 mmol.L-1, 3 mmol.L-1 and 5 mmol.L-1) and Pentaerythritol 
tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (12.5, 25, 50, 100, 300 and 500 
µmol.L-1). The plates were incubated at 37°C and 8% (v/v) CO2 in air and the ATP-
liteTM viability assay was carried out at days 0, 1 and 3 as described in Chapter 2, 
Section 2.2.8.1. 
LPS stimulated RAW 264.7 murine macrophages in collagen gel dosed with 
inflammatory pathway inhibitors and antioxidant compounds 
RAW 264.7 murine macrophages were passaged and counted as described in 
Chapter 2, Sections 2.2.5.4 and 2.2.8.3. RAW cells were seeded at 1 x 105 cells.ml-1 
in collagen gels in 48 well tissue culture plates as described in Chapter 2, Section 
2.2.7.2. Each well was then filled with 200 µl complete DMEM containing LPS (200 
ng.ml-1). Cells only (no LPS), medium only and cells plus DMSO (200 µl.ml-1) (no LPS) 
controls were included. Gels were allowed to set and the plates were placed in the 
incubator at 37°C and 8% (v/v) CO2 in air for 3 hours. After 3 hours, the plates were 
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removed from the incubator and the following inflammatory pathway inhibitors and 
antioxidant compounds were added (n=3): Calphostin C (250 and 500 nmol.L-1), 
Bisindolylmaleimide I (0.1 and 1 µmol.L-1), Indomethacin (0.1, 1, 10 and 100 µmol.L-1), 
MK 886 (0.1, 1, 10 and 100 µmol.L-1), REV 5901 (1, 10, 100 and 1000 µmol.L-1), 
Vitamin E (800 µmol.L-1) and Pentaerythritol tetrakis(3,5-di-tert-butyl-4-
hydroxyhydrocinnamate) (25 µmol.L-1). The plates were incubated at 37°C and 8% 
(v/v) CO2 in air for 24 hours. After 24 hours, the supernatants were removed from 
each well and placed in the corresponding wells of a Nunc F uncoated plate which 
was stored at -80°C until use in ELISA. The ATP-liteTM viability assay was then carried 
out as described in Chapter 2, Section 2.2.8.1. The supernatants were later defrosted 
and used to carry out TNF-α, IL-1β, IL-6, LTB4 and PGE2 ELISA as described in 
Chapter 2, Section 2.2.8.2 .  
5.4.4 Detection of cellular reactive species in RAW 264.7 murine macrophages 
in response to UHMWPE wear debris in collagen gel 
Table 5.5 Abcam DCFDA cellular ROS detection assay kit components storage and 
preparation details. 
Abcam DCFDA cellular ROS detection 
assay kit components 
Storage and preparation 
DCFDA in DMSO (20 mM) – 35 µl Diluted 20 µl of DCFDA (20 mM) with 
3980 µl 1X buffer to create 100 mM 
DCFDA working solution. Stored at 4°C. 
10X buffer - 10 ml Diluted 10 ml 10X buffer with 90 ml 
deionised water to created 1X buffer. 
Stored at 4°C. 
TBHP (55 mM) – 50 µl A working solution (5 mM) of DCFDA was 
assembled by diluting 13.6 µl TBHP with 
136.4 µl 1X buffer. Stored at 4°C. 
 
RAW 264.7 murine macrophages were passaged and counted as described in 
Chapter 2, Sections 2.2.5.4 and 2.2.8.3. Single and six station multidirectional POP 
wear simulator generated UHMWPE wear debris particle doses were calculated as 
described in Chapter 2, Section 2.2.6.2 and 2.2.6.3. RAW cells were seeded at 1 x 
105 cells.ml-1 with 100 µm3 particles.cell-1 in collagen gels in 96 well tissue culture 
plates with a 50 µl gel plug per well as described in Chapter 2, Section 2.2.7.2. Cells 
plus FluoSpheres® (100 µm3.cell-1), cells only, cells plus DMSO (200 µl.ml-1), cells 
plus LPS 200 ng.ml-1) and cells plus TBHP (5 mM) controls were also included. After 
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20 hours (4 hours prior to measurement), 11 µl of TBHP working solution (5 mM) was 
added to each well of the cells plus TBHP (250 µM) control. After 23 hours 15 minutes 
(45 minutes prior to measurement), 50 µl of DCFDA working solution (100 µM) was 
added to each well (25 µM). After 24 hours, the contents of the well plate were then 
immediately read at 535 nm using a Multiskan plate reader. The results were analysed 
relative to the cells only control.  
5.4.5 Fluorescent microscopy imaging of RAW 264.7 murine macrophages 
incubated with UHMWPE wear debris in collagen gel 
Six station generated UHMWPE wear debris (GUR 1020 XL, GUR 1020 XL AOX, 
GUR 1050 XL and GUR 1050 XL VE) was filtered into the size range 0.1 – 1 µm as 
described in Chapter 2, Section 2.2.6.3. The resultant filter papers were placed into 
sterile glass vials and the wear particles resuspended in 5 ml complete DMEM. The 
required volume for 200 µg particles (for each material) was taken and 2 ml of the 
stock solution of sodium fluorescein was added to each vial in addition to 2 ml of 
bicarbonate buffered saline solution. The particle suspensions were incubated with the 
sodium fluorescein solution overnight at 4°C. Each suspension was then passed 
through a 25 mm diameter 0.015 µm pore sized filter to remove any remaining 
unbound sodium fluorescein. The filter papers were then dispersed in 1 ml complete 
DMEM and sonicated prior to cell culture.  
RAW 264.7 murine macrophages were passaged and counted as described in 
Chapter 2, Sections 2.2.5.4 and 2.2.8.3. RAW cells were seeded at 1 x 105 cells.ml-1 
with 100 µm3 particles.cell-1 in collagen gels in 48 well tissue culture plates as 
described in Chapter 2 Section 2.2.7.2. Cells with FluoSpheres® were also included 
as a control: the particle dose of FluoSpheres® were calculated as described in 
Chapter 2, Section 2.2.6.2. 
After 48 hours, the plates were removed from the incubator. The supernatant was 
aspirated and replaced with lysotracker red loading solution (75 nmol). The plate was 
returned to the incubator at 37°C and 8% (v/v) CO2 in air for 30 minutes, after which 
the lysotracker red loading solution was replaced with Hoechst 33342 loading solution 
(5 ng.ml-1). The plate was returned to the incubator at 37C and 8% (v/v) CO2 in air for 
10 minutes. The supernatant was then removed and each gel plug was removed 
using a cell spatula and placed onto a glass cover slip. A glass cover slip was allowed 
to settle on top of each gel prior to imaging. Each gel plug, containing GUR 1020 XL, 
GUR 1020 XL AOX, GUR 1050 XL, GUR 1050 XL VE or FluoSphere® particles, was 
imaged as detailed Chapter 2, Section 2.2.2.2.  
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5.5  Results 
The following section reports the pro-inflammatory and osteolytic cytokine release 
(TNF-α, IL-1β, IL-6, KC, LTB4 and PGE2) and cellular reactive oxygen species levels 
produced by RAW 264.7 murine macrophages in collagen gel developed (in Chapter 
3) in response to single and six station wear simulator rig generated GUR 1020 XL, 
GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris. 
Additionally, the cells were stimulated with LPS followed by treatment with various 
inflammatory pathway inhibitors (Indomethacin, Calphostin C, Bisindolylmaleimide I, 
MK 886 and REV 5901) and the antioxidants (Vitamin E and and Pentaerythritol 
tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)) to assess the subsequent effect 
on the production of pro-inflammatory and osteolytic cytokines (TNF-α, IL-1β, IL-6, 
KC, LTB4 and PGE2) in order to elucidate by what mechanism or pathway any 
potential anti-inflammatory action of antioxidants added to orthopaedic polyethylene 
might be acting. Finally, the ability of the novel model to uptake the generated 
UHMWPE wear debris and sequester them in the lysosomes (perinuclear) was 
assessed by staining the particles, cell nucleus and lysosomes to determine whether 
the particles and lysosomes are co-localised using fluorescence microscopy. 
5.5.1  Cytokine release in response to treatment with highly cross-linked and 
highly cross-linked, antioxidant doped UHMWPE wear debris 
The following section reports the pro-inflammatory and osteolytic cytokine release 
(TNF-α, IL-1β, IL-6, KC, LTB4 and PGE2) produced by RAW 264.7 murine 
macrophages in collagen gel in response to single and six station wear simulator rig 
generated GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE 
UHMWPE wear debris. Cells treated with LPS (200 ng.ml-1) were included as a 
positive control. RAW 264.7 murine macrophages, 1 x 105 cells.ml-1, were treated with 
particles from each material (100 µm3.cell-1) and cytokine release was assessed at 12 
and 24 hours post seeding using ELISA. Cell viability was assessed using the ATP-lite 
viability assay was also assessed at 12 and 24 hours post seeding.  
5.5.1.1 Full size range of UHMWPE wear debris 
5.5.1.1.1 Cell viability assay of RAW 264.7 murine macrophages in collagen gel 
stimulated with the full size range of UHMWPE wear debris 
All of the treatments had a significant effect on the viability of RAW 264.7 murine 
macrophages compared to the cells only negative control at 12 and 24 hours post 
particle exposure (ANOVA; p<0.05) except the LPS (200 ng.ml-1) positive control. 
RAW 264.7 murine macrophages incubated with all particle treatments had a 
significantly higher cell viability  than the cells only control (Figure 5.1A). However, 
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RAW 264.7 murine macrophages cultured with DMSO had a significantly lower cell 
viability compared to the cells only control (ANOVA; p<0.05).   
5.5.1.1.2 ELISA of RAW 264.7 murine macrophages in collagen gel stimulated 
with the full size range of UHMWPE wear debris 
TNF-α cytokine release on stimulation with the full size range of UHMWPE wear 
debris 
At 12 and 24 hours post particle exposure, none of the full size range UHMWPE 
particle treatments stimulated a significantly increased release of TNF-α however the 
positive control, RAW 264.7 murine macrophages treated with LPS, exhibited 
significantly elevated  TNF-α release when compared to the cells only control 
(ANOVA; p<0.05). 
IL-1β cytokine release on stimulation with the full size range of UHMWPE wear debris 
At 12 hours post particle exposure, GUR 1050 XL and GUR 1050 XL VE full size 
range UHMWPE particle treatments stimulated a significant decrease in the release of 
IL-1β when compared to the cells only control (ANOVA; p<0.05). However, at 24 
hours particle exposure, none of the particle treatments or controls elicited a 
significant elevated or reduced release of IL-1β compared to the cells only control 
(ANOVA: p>0.05). 
IL-6 cytokine release on stimulation with the full size range of UHMWPE wear debris 
At 12 and 24 hours post particle exposure, none of the full size range UHMWPE 
particle treatments stimulated a significantly increased release of IL-6 however the 
positive control, RAW 264.7 murine macrophages treated with LPS, exhibited 
significant IL-6 release when compared to the cells only control (ANOVA; p<0.05). 
KC chemokine release on stimulation with the full size range of UHMWPE wear debris 
At 12 and 24 hours post particle exposure, none of the full size range UHMWPE 
particle treatments or the positive control, LPS (200 ng.ml-1), stimulated a significantly 
elevated release of KC however the 0.2µm FluoSphere® particle control did exhibit 
significant KC release when compared to the cells only control (ANOVA; p<0.05).  
LTB4 mediator release on stimulation with the full size range of UHMWPE wear debris 
At 24 hours post particle exposure, RAW 264.7 murine macrophages incubated with 
GUR 1020 XL and GUR 1020 XL AOX UHMWPE wear particles exhibited a significant 
decrease in the release of LTB4 in comparison to the cells only control (ANOVA; 
p<0.05). RAW 264.7 murine macrophages stimulated with LPS (200 ng.ml-1) exhibited 
significantly increased release of LTB4 in comparison to the cells only control 
(ANOVA; p<0.05). 
- 191 - 
PGE2 mediator release on stimulation with the full size range of UHMWPE wear debris 
At 24 hours post particle exposure, RAW 264.7 murine macrophages incubated with 
GUR 1020 XL and GUR 1020 XL AOX UHMWPE wear particles exhibited a 
significantly decreased release of PGE2 in comparison to the cells only control 
(ANOVA; p<0.05). RAW 264.7 murine macrophages stimulated with LPS (200 ng.ml-1) 
exhibited a significantly increased release of PGE2 in comparison to the cells only 
control (ANOVA; p<0.05).  
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Figure 5.1– A) Cell viability, B) TNF-α release, C) IL-1β release, D) IL-6 release E) 
KC release, F) LTB4 release and G) PGE2 release from RAW 264.7 murine 
macrophages incubated with full size range UHMWPE particles at a 
concentration of 100 µm3 particles per cell in collagen gel at 12 and 24 hours 
post particle exposure at 37°C in 8% (v/v) CO2 in air. RAW 264.7 murine 
macrophages were seeded at a density of 1 x 105 cells per well with particle 
treatments in a 48 well tissue culture plate. RAW 264.7 murine macrophages 
were exposed to the full size range of particles generated from GUR 1020 XL, 
GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE UHMWPE. A cells only 
negative control and 200 ng.ml-1 LPS positive control were included in the 
conditions. * designates a statistically significant data point (ANOVA, p<0.05). 
Error bars represent 95% confidence intervals, n=4.  
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5.5.1.2  0.1 - 1 µm UHMWPE wear debris 
5.5.1.2.1 Cell viability assay of RAW 264.7 murine macrophages in collagen gel 
stimulated with 0.1 – 1 µm UHMWPE wear debris 
None of the UHMWPE particles treatment had a significant effect on the viability of 
RAW 264.7 murine macrophages compared to the cells only at 12 hours post particle 
exposure (ANOVA; p<0.05). However, cells cultured with 0.2 µm FluoSpheres® and 
DMSO (positive control) did exhibit a significant effect on the viability compared to the 
cells only control 12 hours post particle exposure (ANOVA; p<0.05). The cell viability 
of RAW 264.7 murine macrophages cultured with FluoSpheres® was significantly 
higher than the cells only control, whereas the cell viability of cells cultured with 
DMSO was significantly lower than the cells only control (Figure 5.2A). At 24 hours 
post particle exposure, all conditions except cells treated with LPS elicited a significant 
effect on cell viability compared to the cells only control. All particle treatments 
significantly increased cell viability compared to the cells only control, whereas 
treatment with DMSO significantly decreased the cell viability compared to the cells 
only control (Figure 5.2A).  
5.5.1.2.2 ELISA of RAW 264.7 murine macrophages in collagen gel stimulated 
with 0.1 - 1 µm UHMWPE wear debris 
TNF-α cytokine release on stimulation with 0.1 - 1 µm UHMWPE wear debris 
At 12 hour post particle exposure, all of the particle treatments and positive control, 
except GUR 1020 XL, stimulated a significantly reduced release of TNF-α compared 
to the cells only control (ANOVA; p<0.05) (Figure 5.2B). However the positive control, 
cells treated with LPS (200 ng.ml-1), exhibited significantly increased production of 
TNF-α compared to the cells only control (ANOVA; p<0.05). At 24 hour post particle 
exposure, all of the particle treatments and positive control, except FluoSpheres®, 
stimulated a significantly reduced release of TNF-α compared to the cells only control 
(ANOVA; p<0.05). All particle treatments significantly reduced the production of TNF-α 
compared to the cells only control (Figure 5.2B). However the positive control, cells 
treated with LPS (200 ng.ml-1), significantly increased production of TNF-α compared 
to the cells only control (ANOVA; p<0.05). 
IL-1β cytokine release on stimulation with 0.1 - 1 µm UHMWPE wear debris 
At 12 hours post particle exposure, GUR 1020 XL 0.1 - 1 µm UHMWPE particle 
treatments stimulated a significantly increased release of IL-1β when compared to the 
cells only control (ANOVA; p<0.05). However, by 24 hours post particle exposure, the 
level had decreased so that it was not significantly different compared to the cells only 
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control. None of the particle treatments or controls elicited a significantly elevated or 
reduced release of IL-1β when compared to the cells only control (ANOVA: p>0.05). 
IL-6 cytokine release on stimulation with 0.1 - 1 µm UHMWPE wear debris 
At 12 and 24 hours post particle exposure, none of the 0.1 - 1 µm UHMWPE particle 
treatments stimulated a significantly increased release of IL-6, however the positive 
control, cells treated with LPS, exhibited significantly elevated levels of IL-6 when 
compared to the cells only control (ANOVA; p<0.05). 
KC chemokine release on stimulation with 0.1 - 1 µm UHMWPE wear debris 
At 12 and 24 hours post particle exposure, none of the 0.1 - 1 µm UHMWPE particle 
treatments or the positive control, LPS (200 ng.ml-1), stimulated a significant release 
of KC however the 0.2 µm FluoSphere® particle control did exhibit significant KC 
release when compared to the cells only control (ANOVA; p<0.05).  
LTB4 mediator release on stimulation with 0.1 - 1 µm UHMWPE wear debris 
At 24 hours post particle exposure, none of the cells incubated with particle treatments 
exhibited a significant effect on the release of LTB4 in comparison to the cells only 
control (ANOVA; p<0.05). Cells stimulated with LPS (200 ng.ml-1) exhibited a 
significantly increased release of LTB4 in comparison to the cells only control 
(ANOVA; p<0.05). 
PGE2 mediator release on stimulation with 0.1 - 1 µm UHMWPE wear debris 
At 24 hours post particle exposure, none of the cells incubated with particle treatments 
exhibited a significant effect on the release of PGE2 in comparison to the cells only 
control (ANOVA; p<0.05). Cells stimulated with LPS (200 ng.ml-1) exhibited a 
significantly increased release of PGE2 in comparison to the cells only control 
(ANOVA; p<0.05). 
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Figure 5.2– A) Cell viability, B) TNF-α release, C) IL-1β release, D) IL-6 release, E) 
KC release, F) LTB4 release and G) PGE2 release from RAW 264.7 murine 
macrophages incubated with 0.1 - 1 µm UHMWPE wear debris at a 
concentration of 100 µm3 particles per cell in collagen gel at 12 (left) and 24 
(right) hours post particle exposure at 37°C in 8% (v/v) CO2 in air. RAW 264.7 
murine macrophages were seeded at a density of 1 x 105 cells per well with 
particle treatments in a 48 well tissue culture plate. RAW 264.7 murine 
macrophages were exposed to 0.1 - 1 µm GUR 1020 XL, GUR 1020 XL AOX, 
GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris. A cells only 
negative control and 200 ng.ml-1 LPS positive control were included in the 
conditions. * designates a statistically significant data point (ANOVA, p<0.05). 
Error bars represent 95% confidence intervals, n=4.  
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5.5.2 Cytokine release of LPS-stimulated RAW 264.7 murine macrophages in 
response to treatment with inflammatory pathway inhibitors and 
antioxidant compounds 
The following section reports the pro-inflammatory and osteolytic cytokine release 
(TNF-α, IL-1β, IL-6, LTB4 and PGE2) produced by LPS (200 ng.ml-1) stimulated RAW 
264.7 murine macrophages in response to inflammatory pathway inhibitors 
(CalphostinC, Bisindolylmaleimide I, Indomethacin, MK 886 and REV 5901) and 
antioxidant compounds (Vitamin E and Pentaerythritol tetrakis(3,5-di-tert-butyl-4-
hydroxyhydrocinnamate)). Cells treated with LPS only (200 ng.ml-1) and cells only 
were included as negative controls. RAW 264.7 murine macrophages, 1 x 105 cells.ml-
1, were treated with inhibitor and antioxidant compounds and cytokine release  was 
assessed at 12 and 24 hours post particle exposure using ELISA (24 hours only for 
LTB4 and PGE2). Cell viability was assessed using the ATP-liteTM luminescence 
detection assay was also assessed at 12 and 24 hours post seeding. Cell viability 
assays for RAW 264.7 murine macrophages incubated with four concentrations of 
each inhibitor and antioxidant compounds were carried out to assess the most 
appropriate concentrations for use.  
5.5.2.1 Cell viability in response to treatment with inflammatory pathway 
inhibitors and antioxidant compounds 
The range of concentrations used in this study were based on those used by Deveraj 
and Jialal (1999) with higher and lower concentrations included either side of the 
previous values. The highest concentrations of each inhibitor treatment had a 
significant effect on the viability of RAW 264.7 murine macrophages compared to the 
cells only control at days 0, 1 and 3 (ANOVA; p<0.05). RAW 264.7 murine 
macrophages treated with Indomethacin (100 µmol.L-1), REV 5901 (100 µmol.L-1 and 
1000 µM.L-1), MK 886 (100 µmol.L-1), Bisindolylmaleimide I (10 µmol.L-1 and 100 
µmol.L-1) and Calphostin C (500 nmol.L-1 and 1 µmol.L-1) reduced the viability 
significantly below that exhibited by the cells only control and to the viability levels 
demonstrated by the cells plus DMSO (200 µl.ml-1) positive control (Figure 5.3). The 
remaining concentrations, Calphostin C (100 and 250 nmol.L-1), Bisindolylmaleimide I 
(0.1 and 1 µmol.L-1), Indomethacin (0.1, 1 and 10 µmol.L-1), MK 886 (0.1, 1 and 10 
µmol.L-1) and REV 5901 (1 and 10 µmol.L-1), had no significant adverse effect on the 
viability of RAW 264.7 murine macrophages over days 0, 1 and 3 (Figure 5.3). The 
following concentrations of each inhibitor were carried forward: Calphostin C (250 and 
500 nmol.L-1), Bisindolylmaleimide I (0.1 and 1 µmol.L-1), Indomethacin (10 µmol.L-1), 
MK 886 (1 µmol.L-1) and REV 5901 (10 µmol.L-1). These concentrations of inhibitors 
were used in a previous study by Deveraj and Jialal (1999) and the dose response 
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study carried out by the candidate showed that these concentrations did not adversely 
affect cell viability of RAW 264.7 murine macrophages over the 24 hour time period.  
 
Figure 5.3 Cell viability of RAW 264.7 murine macrophages in collagen gel treated 
with Bisindolylmaleimide I (0.1, 1, 10 and 100 µmol.L-1), Calphostin C (100 
nmol.L-1, 250 nmol.L-1, 500 nmol.L-1, 1 µmol.L-1), Indomethacin (0.1, 1, 10 and 
100 µmol.L-1), MK 886 (0.1, 1, 10 and 100 µmol.L-1) and REV 5901 (1, 10, 100 
and 1000 µmol.L-1) over three days at 37°C in 8% (v/v) CO2 in air. Cells were 
seeded at a density 5 x 104 cells.ml-1 in a 96 well tissue culture plate. A cells plus 
DMSO (200 µl.ml-1) positive control was included in the conditions. Cells viability 
was assessed using the ATP-liteTM luminescence detection assay. * designates a 
statistically significant data point (ANOVA, p<0.05). Error bars represent 95% 
confidence intervals, n=6.  
The highest concentrations of each antioxidant treatment had a significant effect on 
the viability of RAW 264.7 murine macrophages compared to the cells only control at 
days 0, 1 and 3 (ANOVA; p<0.05). RAW 264.7 murine macrophages treated with 
Vitamin E (2, 3 and 5 mmol.L-1) and Pentaerythritol tetrakis(3,5-di-tert-butyl-4-
hydroxyhydrocinnamate) (300 and 500 µmol.L-1) reduced the viability significantly 
below that exhibited by the cells only control and to the viability levels demonstrated 
by the cells plus DMSO (200 µl.ml-1) positive control (Figure 5.4) on days 0, 1 and 3. 
The remaining concentrations of antioxidants, Vitamin E (400 and 800 µmol.L-1 and 1 
mmol.L-1) and Pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (300 
and 500 µmol.L-1) did not have a significant adverse effect on cell viability. The 
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following concentrations of each antioxidant were carried forward based on a previous 
study by Bladen et al. (2013b): Vitamin E (800 µmol.L-1) and Pentaerythritol 
tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (25 µmol.L-1).   
 
 
Figure 5.4  Cell viability of RAW 264.7 murine macrophages in collagen gel treated 
with Vitamin E (400 µmol.L-1, 800 µmol.L-1, 1 mmol.L-1, 2 mmol.L-1, 3 mmol.L-1 
and 5 mmol.L-1) and Pentaerythritol tetrakis(3,5-di-tert-butyl-4-
hydroxyhydrocinnamate) (12.5, 25, 50, 100, 300 and 500 µmol.L-1) over three 
days at 37°C in 8% (v/v) CO2 in air. Cells were seeded at a density 5 x 104 
cells.ml-1 in a 96 well tissue culture plate. A cells plus DMSO (200 µl.ml-1) 
positive control was included in the conditions. Cells viability was assessed using 
the ATP-liteTM luminescence detection assay. * designates a statistically 
significant data point (ANOVA, p<0.05). Error bars represent 95% confidence 
intervals, n=6. 
5.5.2.2 Cell viability of RAW 264.7 murine macrophages in collagen gel 
stimulated with inflammatory inhibitors and antioxidant compounds 
Treatment with Calphostin (250 and 500 µmol.L-1) and DMSO (200 µl.ml-1) (positive 
control) significantly decreased the viability of LPS stimulated RAW 264.7 murine 
macrophages compared to the LPS stimulated cells only control at 12 hours post 
seeding (ANOVA; p<0.05). No other treatments exhibited a significantly adverse effect 
on cell viability at 12 hours post seeding. Treatment with Calphostin (250 and 500 
µmol.L-1), Vitamin E (800 µmol.L-1) and DMSO (200 µl.ml-1) (positive control) 
significantly decreased the viability of LPS stimulated RAW 264.7 murine 
macrophages (Figure 5.4A) compared to the LPS stimulated cells only control at 24 
hours post seeding (ANOVA; p<0.05).  
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5.5.2.3 ELISA of RAW 264.7 murine macrophages in collagen gel stimulated with 
inflammatory inhibitors and antioxidant compounds 
TNF-α cytokine release on stimulation with inflammatory inhibitors and antioxidant 
compounds 
At 12 hours post seeding, LPS stimulated cells treated with Calphostin C (250 and 
500 µmol.L-1), Bisindolylmaleimide I (1 µmol.L-1), Vitamin E (800 µmol.L-1) and 
Pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (25 µmol.L-1) 
exhibited significantly decreased levels of TNF-α production (Figure 5.5B) compared 
to the LPS stimulated cells only control (ANOVA; p<0.05). At 24 hours post seeding, 
LPS stimulated cells treated with Calphostin C (250 µmol.L-1) and Vitamin E (800 
µmol.L-1) exhibited significantly decreased levels of TNF-α production compared to the 
LPS stimulated cells only control (ANOVA; p<0.05). 
IL-1β cytokine release on stimulation with inflammatory inhibitors and antioxidant 
compounds 
At 12 hours post seeding, LPS stimulated cells treated with Calphostin C (250 and 
500 µmol.L-1), Bisindolylmaleimide I (1 µmol.L-1), Indomethacin (10 µmol.L-1), MK 886 
(1 µmol.L-1), REV 5901 (10 µmol.L-1), Vitamin E (800 µmol.L-1) and Pentaerythritol 
tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (25 µmol.L-1) exhibited significantly 
decreased levels of IL-1β production (Figure 5.5C) compared to the LPS stimulated 
cells only control (ANOVA; p<0.05). At 24 hours post seeding, LPS stimulated cells 
treated with Calphostin C (250 µmol.L-1), Bisindolylmaleimide I (0.1 µmol.L-1), 
Indomethacin (10 µmol.L-1), REV 5901 (10 µmol.L-1) and Vitamin E (800 µmol.L-1) 
exhibited significantly decreased levels of IL-1β production compared to the LPS 
stimulated cells only control (ANOVA; p<0.05). 
IL-6 cytokine release on stimulation with inflammatory inhibitors and antioxidant 
compounds 
At 12 hours post seeding, LPS stimulated cells treated with Calphostin C (250 and 
500 µmol.L-1) and Vitamin E (800 µmol.L-1) exhibited significantly decreased levels of 
IL-6 production (Figure 5.5D) compared to the LPS stimulated cells only control 
(ANOVA; p<0.05). At 24 hours post seeding, LPS stimulated cells treated with 
Calphostin C (250 and 500 µmol.L-1), Bisindolylmaleimide I (0.1 and 1 µmol.L-1), 
Vitamin E (800 µmol.L-1) and Pentaerythritol tetrakis(3,5-di-tert-butyl-4-
hydroxyhydrocinnamate) (25 µmol.L-1) exhibited significantly decreased levels of IL-6 
production compared to the LPS stimulated cells only control (ANOVA; p<0.05). 
LTB4 cytokine release on stimulation with inflammatory inhibitors and antioxidant 
compounds 
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At 24 hours post seeding, LPS stimulated cells treated with Calphostin C (250 nmol.L-
1) and Bisindolylmaleimide I (0.1 µmol.L-1) released significantly lower levels of LTB4 
(Figure 5.5.E) in comparison to the LPS stimulated cells only control (ANOVA; 
p<0.05).  
PGE2 cytokine release on stimulation with inflammatory inhibitors and antioxidant 
compounds 
At 24 hours post seeding, LPS stimulated cells treated with Calphostin C (250 nmol.L-
1) and Bisindolylmaleimide I (0.1 µmol.L-1) released significantly lower levels of PGE2 
in comparison to the LPS stimulated cells only control (ANOVA; p<0.05).  
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F) 
 
Figure 5.5– A) Cell viability, B) TNF-α release, C) IL-1β release, D) IL-6 release, E) 
LTB4 release and F) PGE2 release from LPS stimulated RAW 264.7 murine 
macrophages in collagen gel treated with Bisindolylmaleimide I (0.1 and 1 
µmol.L-1), Calphostin C (250 and 500 nmol.L-1), Indomethacin (10 µmol.L-1), MK 
886 (1 µmol.L-1), REV 5901 (10 µmol.L-1) Vitamin E (800 µmol.L-1) and 
Pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (25 µmol.L-1) 
after three hours at 12 (left) and 24 (right) hours post seeding at 37°C in 8% (v/v) 
CO2 in air. LTB4 and PGE2 was only measured after 24 hours. RAW 264.7 
murine macrophages were seeded at a density of 1 x 105 cells per well in a 48 
well tissue culture plate. Cells only and LPS stimulated cells only negative 
controls were included. A cells plus DMSO (200 µl.ml-1) positive control was 
included in the cell viability assay. * designates a statistically significant data 
point (ANOVA, p<0.05). Error bars represent ± the 95% confidence level, n=4.  
5.5.3 Reactive oxygen species production for RAW 264.7 murine macrophages 
in response to full size range and 0.1 – 1 µm GUR 1020 XL, GUR 1020 XL 
AOX, GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris 
RAW 264.7 murine macrophages were cultured with full size range and 0.1 – 1 µm 
UHMWPE wear debris (GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 
1050 XL VE) in collagen gel (Section 5.4.4). The particles generated using the six 
station multidirectional POP wear simulator were filtered in to the size range 0.1 – 1 
µm prior to cell culture. The production of reactive oxygen species (ROS) in response 
to the particulates was assessed using the Abcam cellular reactive oxygen species 
assay.  
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At 24 hours post particle exposure, none of the full size range and 0.1 – 1 µm 
UHMWPE particle treatments resulted in significant production of cellular reactive 
oxygen species in comparison to the cells only control (ANOVA; p<0.05). However, 
the FluoSphere® particle control (0.2 µm), cells treated with DMSO, cells treated with 
LPS and cells with TBHP positive control elicited significantly elevated levels of 
cellular reactive oxygen species (ANOVA: p>0.05).  
A) 
 
B) 
 
Figure 5.6  Cellular reactive oxygen species concentration (proportional to the level of 
fluorescence) of RAW 264.7 murine macrophages in response to GUR 1020 XL, 
GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris 
produced using A) single station and B) six station multidirectional POP wear 
simulator. A cells only negative control, FluoSpheres® particle control and cells 
plus LPS (200 ng.ml-1), cells plus DMSO (200 µl.ml-1) and cells plus TBHP (250 
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µM) positive controls were included. Error bars represent ± the 95% confidence 
level, n=4.   
 
5.5.4 Visualising internal particle sequestration of 0.1 – 1 µm GUR 1020 XL, GUR 
1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris in RAW 
264.7 murine macrophages encapsulated in collagen gels 
RAW 264.7 murine macrophages were cultured with 0.1 – 1 µm filtered fluorescein 
stained UHMWPE wear debris (GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL 
and GUR 1050 XL VE)  in collagen gels for 48 hours. The cells were then stained with 
lysotracker red (locates to the lysosomes) and Hoechst 33342 (stains the nucleus) 
and the gel plugs were imaged using fluorescent microscopy to observe particle 
internalisation and localisation of the particles within the cells. 
Issues were experienced with the fluorescent labelling of the UHMWPE wear debris 
and, as such very few particles were visible in Figure 5.7A/B/C/D. However, those few 
particles that were visible were located around the nucleus. FluoSpheres® were 
included as a particle control (no fluorescein staining was necessary as the particles 
are tagged with FITC) and the images taken of cells cultured with FluoSpheres® more 
clearly show the co-localisation of uptaken particles with the lysosomes around the 
cell nucleus.  
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Figure 5.7  Fluorescence microscopy images of RAW 264.7 murine macrophages 
incubated with fluorescein tagged particles: A) GUR 1020 XL, B) GUR 1020 XL 
AOX, C) GUR 1050 XL, D) GUR 10150 XL VE and E) FluoSpheres®. The cell 
nucleus was stained with Hoechst 33342 and the lysosomes were stained with 
Lysotracker red.  Images A to D were taken at 40X magnification (red scale bar 
represents 10 µm) and Image E was taken at 20X magnification (white scale bar 
represents 50 µm). White arrows indicate perinuclear particles; in the case of 
fluorospheres colocalised with lysosomes.  
5.6  Discussion 
The aim of this part of the study was to compare the novel 3D in vitro model 
developed in Chapter 3 to the outcomes of previous studies; measuring the production 
of osteolytic cytokines and reactive oxygen species (ROS) in response to treatment 
with UHMWPE wear debris, comparing particle uptake and sequestration of the novel 
3D in vitro collagen gel encapsulation model to the previous 2D agarose gel model 
and treating cells with inflammatory pathway inhibitors and antioxidant compounds 
and assessing the release of pro-inflammatory, osteolytic mediators in LPS stimulated 
cells in order to elucidate which inflammatory pathways are affected by the anti-
inflammatory activity of antioxidant doped, highly cross-linked UHMWPE. This 
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comparison was necessary to assess the use of the novel 3D in vitro model 
developed herein for future studies.  
Singh and Jialal (2004) showed that treatment of LPS stimulated human mononuclear 
cells with vitamin E significantly reduced the release of pro-inflammatory cytokines, 
TNF-α, IL-1β and IL-6.  Van Tits et al. (2000) also confirmed this and found that 
treatment of LPS stimulated human mononuclear cells with vitamin E significantly 
reduced the release of pro-inflammatory chemokine, IL-8. Deveraj and Jialal (1999) 
also found that treatment of LPS stimulated human mononuclear cells with vitamin E 
significantly reduced the release of LTB4 but had no effect on the release of PGE2. 
The present study aimed to assess whether these effects were reproducible in the 
novel 3D in vitro model developed in Chapter 3 in order to elucidate which 
inflammatory pathways may be affected by the presence of antioxidants, such as 
vitamin E. The present study found that all of the 0.1 – 1 µm UHMWPE wear debris 
treatments had no effect on the production of LTB4 and PGE2 in RAW 264.7 murine 
macrophages, whereas treatment with the full size range of GUR 1020 XL and GUR 
1020 XL AOX UHMWPE wear debris reduced the levels of LTB4 and PGE2 produced 
by RAW 264.7 murine macrophages. This is not consistent with the findings of Singh 
and Jialal (2004), Van Tits et al. (2000) and Devaraj and Jialal (1999). However, a 
direct comparison between this study and the highlighted previous studies is not 
possible as the previous studies were examining the effect of vitamin E treatment on 
LPS stimulated PBMNC’s whereas this study did not treat LPS stimulated cells with 
UHMWPE wear debris, the cell type used was different (murine cell line rather than 
human primary) and the antioxidants used were contained within UHMWPE wear 
debris. Additionally, a negative value for LTB4 was obtained for cells cultured with the 
full size range of GUR 1020 XL in the present study – this value is less than the 
background and should have been repeated. This finding may therefore not be an 
accurate finding. This study did go onto treat LPS stimulated RAW 264.7 murine 
macrophages with antioxidant compounds (vitamin E and hindered phenol) alone 
(alongside inflammatory inhibitors). This study did find that LPS-stimulated RAW 
264.7 murine macrophages did exhibit reduced levels of TNF-α, IL-1β and IL-6 upon 
treatment with vitamin E, which was consistent with Singh and Jialal (2004). Similarly, 
this study also found that LPS stimulated RAW 264.7 murine macrophages treated 
with PKC inhibitors, Calphostin C and Bisindolylmaleimide I, also significantly reduced 
the release of TNF-α, IL-1β, IL-6, LTB4 and PGE2. This is also consistent with Singh 
and Jialal (2004) and suggests that antioxidants, such as vitamin E, may achieve their 
anti-inflammatory behaviour through the inhibition of PKC phosphorylation in the 
prostaglandin and leukotriene synthesis reaction pathway. Again, a negative value for 
LTB4 was obtained for LPS stimulated cells cultured with Calphostin C – this value is 
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less than the background and may not be accurate and so should have been 
repeated. 
In the context of orthopaedic UHMWPE wear debris, Bladen et al. (2013a) found that 
PBMNC’s incubated with GUR 1050 VE  UHMWPE wear debris (3000 and 30,000 
ppm) (non-cross-linked) exhibited significantly reduced levels of TNF-α, IL-1β and IL-6 
compared to PBMNC’s incubated with GUR 1050 virgin UHMWPE wear debris. 
Bladen et al. (2013a) showed that PBMNC’s incubated with GUR 1050 VE  UHMWPE 
wear debris (3000 and 30,000 ppm) (non-cross-linked) exhibited no significant 
reduction in production IL-8 in comparison to PBMNC’s incubated with GUR 1050 
virgin UHMWPE wear debris. Bladen et al. (2013a) also showed that PBMNC’s 
incubated with GUR 1050 VE (1000 ppm) produced significantly lower levels of TNF-α 
in comparison to PBMNC’s incubated with GUR 1050 virgin UHMWPE wear debris. 
The results of the present study were not consistent with the results presented by 
Bladen et al (2013). The present study did not find evidence distinguishing between 
the effects of UHMWPE with and without antioxidant doping on cytokine release. The 
dosing regime of the particles was the same between studies; 100 µm3 particles.cell-1. 
However there were a number of limitations in both studies. Bladen et al. (2013a) 
used only non-cross-linked UHMWPE materials. Antioxidants, such as vitamin E, are 
typically added to quench the free radicals associated with the cross-linking process. 
Moreover, cross-linked UHMWPE exhibits a significantly reduced rate of wear in 
comparison to non-cross-linked, virgin UHMWPE (Galvin et al., 2006) so virgin 
UHMWPE is used less often in the present day. Additionally, Bladen et al. (2013a) 
used doses of vitamin E that are not clinically relevant (3000 and 30,000 ppm) to show 
a reduction in the output of TNF-α, IL-1β and IL-6. Bladen et al. (2013a) did show that 
a clinically relevant dosage of 1000 ppm vitamin E in UHMWPE did produce a 
significant reduction in TNF-α output but failed to do the same for IL-1β and IL-6. The 
present study did use clinically relevant materials, i.e. highly cross-linked and with 
clinically relevant doses of antioxidant. The present study also compared the output of 
antioxidant doped, highly cross-linked to highly cross-linked as opposed to virgin 
UHMWPE wear debris. However, the present study did experience a number of 
issues with the storage and treatment of the UHMWPE bar stock used to cut pins from 
to create UHMWPE wear debris. The suboptimal storage conditions and irradiation 
treatment could have caused oxidative embrittlement of the polymer which may have 
affected the overall behaviour of the material in vitro. Additionally, the length of time 
the bar stock was aged on the shelf may have allowed the antioxidant compounds 
present to degrade over time; meaning at the time of testing a sufficient dose of 
antioxidant was not present to create a significant anti-inflammatory response in vitro. 
There is no direct evidence in the current literature that vitamin E or hindered phenols 
degrade over time however the candidate could not find any studies that directly 
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assess this rather than the overall oxidative stability of the UHMWPE material 
assessed. However, all studies examined do preserve their samples in vacuum sealed 
bags and store them frozen in order to reduce unintentional degradation or aging 
between studies (Berlin et al., 2011) therefore it is acknowledged that UHMWPE 
and/or antioxidant degradation is possible in suboptimal storage conditions. The 
present study did however find that the presence of highly cross-linked UHMWPE 
wear debris, whether antioxidant doped or not, did not affect the levels of KC (a 
homologue of IL-8 in mice) produced. However, this may not necessarily be a reliable 
result if the suboptimal storage conditions and irradiation treatment reduced the 
clinical relevance of the materials tested.  
Gowland (2014) treated PBMNC’s with aseptic highly cross-linked and highly cross-
linked, antioxidant-doped UHMWPE wear debris generated on the single station 
multidirectional POP wear simulator and assessed the effect on the release of pro-
inflammatory and pro-osteolytic cytokine, TNF-α. The particles were not filtered 
according to size prior to incubation with cells and resembled the wide range of 
particle sizes that would be found in vivo. When PBMNC’s seeded at 1 x 105 cells.ml-1 
were dosed with 100 µm3 particles.cell-1, Gowland (2014) found that there was no 
significant effect on the release of TNF-α for any of the particle treatments. However, 
when Gowland (2014) increased the number of cells per well to 2 x 105 cells.ml-1 and 
the particle dosage to 500 µm3 particles.cell-1, PBMNC’s treated with GUR 1050 XL 
VE and GUR 1020 XL AOX UHMWPE wear debris exhibited a significant reduction in 
the release of TNF-α in comparison to PBMNC’s treated with GUR 1050 XL UHMWPE 
wear debris. The present study found that there was no significant effect on release of 
TNF-α when RAW 264.7 murine macrophages were treated with any of the full size 
range UHMWPE wear debris which was consistent with the initial findings of Gowland 
(2014). The present study did not replicate the findings of Gowland (2014) at a higher 
dosing regime. There were a number of differences between the two studies and 
limitations to both. Gowland (2014) increased the particle dose per cell in order to 
increase the percentage of particles within the critical size range known to activate 
macrophages however it was not possible to increase the particle dose used in this 
study. The increased volume of lubricant required would have affected the ratio of 
components in the collagen gel, reducing the integrity of the gel and resulting in the 
gel being unable to set. In retrospect, it may have been possible to filter the particles 
and resuspend them in a smaller volume to achieve a higher dose. However this study 
did account for this by including UHMWPE wear debris generated using the six station 
multidirectional POP wear simulator and filtering the debris into the critical size range 
of 0.1 – 1 µm. RAW 264.7 murine macrophages incubated with 0.1 – 1 µm UHMWPE 
debris did exhibit a significantly reduced output of TNF-α, however this was the case 
for all materials tested (highly cross-linked and antioxidant doped, highly cross-linked). 
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There was no distinct anti-inflammatory effect observed for GUR 1050 XL VE and 
GUR 1020 XL AOX. Gowland (2014) included GUR 1050 XL as a control to compare 
the in vitro effects of GUR 1050 XL VE and GUR 1020 XL AOX but was unable to 
include GUR 1020 XL as a control due to lack of material availability. This study did 
address this weakness by including GUR 1020 XL as a control material however, as 
discussed in Chapter 4, significant issues with the storage and irradiation treatment of 
the UHMWPE materials may have affected accuracy of the in vitro outcomes of the 
study. 
Gowland (2014) also compared the intracellular concentration of ROS produced in 
response to GUR 1050 XL and GUR 1050 XL VE wear debris and found that 
PBMNC’s treated with GUR 1050 XL VE UHMWPE wear debris exhibited significantly 
decreased levels of ROS in comparison to PBMNC’s treated with GUR 1050 XL. The 
present study did not find any significant effects on the production of ROS in RAW 
264.7 murine macrophages in response to any of the particle treatments compared to 
the cells only control. This was not consistent with the findings of Gowland (2014). 
Gowland (2014) used the ImageIt LIVE cellular ROS quantitation kit which provided 
Intracellular ROS levels in addition to fluorescent images showing the sites of 
oxidation within the cell, whereas this study used the Abcam DCFDA cellular ROS 
detection assay kit which only provided cellular ROS levels. The previously outlined 
issues with UHMWPE bar stock (i.e. shelf aging) could have allowed the antioxidants 
to degrade over time thus a sufficient volume of antioxidants may not have been 
present in the wear debris to produce a reduction in cellular ROS during this study. 
Future studies would repeat this assay over 3 or 5 days in order to assess whether a 
longer time frame is needed to observe the presence of ROS. Additionally, future 
studies would include cells plus TBHP plus particle treatment conditions in order to 
assess whether the antioxidants present (or not) in the UHMWPE wear debris quench 
ROS synthesis and reduce the levels of ROS observed. Additionally, future studies 
could have viewed the plate using microscopy to provide qualitative images showing 
intracellular ROS levels.  
Finally, Liu (2012) imaged the uptake of GUR 1020 UHMWPE wear debris in 
PBMNCs and was able to co-localise the particles with the lysosomes around the 
nucleus. Liu (2012) stained the particles with sodium fluorescein, the cell nucleus with 
Hoechst 33342 and the lysosomes with CD 63. Gowland (2014) took this further by 
imaging the uptake of GUR 1050 XL UHMWPE wear debris and FluoSpheres® in 
PBMNC’s. The particles were imaged in the cytoplasm around the nucleus. Gowland 
(2014) stained the particles with sodium fluorescein and the cell nucleus with Hoechst 
33342 however did not include a lysosome specific dye to co-localise the particles in 
the lysosomes. The present study imaged the uptake and sequestration of both highly 
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cross-linked and antioxidant doped highly cross-linked UHMWPE: GUR 1020 XL, 
GUR 1050 XL, GUR 1020 XL AOX and GUR 1050 XL VE (in addition to FluoSpheres® 
as a control). These materials were chosen in order to assess whether there was any 
difference in uptake and storage between materials. Unlike Gowland (2014), the 
present study included lysotracker red to co-localise the particles as Liu (2012) did. 
The present study was able to ascertain that all particles, irrespective of the material, 
were located around the nucleus; this was consistent with the findings of Liu (2012) 
and Gowland (2014). Unfortunately, the UHMWPE wear debris was unable to be 
clearly co-localised with the lysotracker red dye conclusively as very few fluorescently 
tagged particles were visible, whereas the FluoSpheres®, already fluorescently 
tagged, clearly showed co-localisation within the cells lysosomes. It is not clear why 
so few fluorescein stained UHMWPE particles were visible; it is possible that some 
particles were lost in the experimental process as there are multiple filtration steps 
and transfers between vessels. 
Overall, the 3D model developed in Chapter 3 was not successful in reproducing the 
findings of previous studies. There were a number of issues associated with it; notably 
inadequate development of the model in Chapter 3 and poor quality UHMWPE bar 
stock used for wear debris development. The overall success of the model will be 
discussed in more detail in Chapter 6. 
There are number of ways in which the present study could be developed further. 
FluoSpheres® were included as a positive particle control based on the standard 
practice of previous studies however, in this study, FluoSpheres® did not produce a 
reliable positive response. During the model development in Chapter 3, >10 µm 
Ceridust® repeatedly generated a significant release of TNF-α. Although this was 
unexpected and not consistent with previous studies, this may be a genuine effect in 
3D studies and may have provided a more reliable positive particle control than 
FluoSpheres®. An additional study treating LPS stimulated RAW 264.7 murine 
macrophages with GUR 1020 XL, GUR 1050 XL, GUR 1020 XL AOX and GUR 1050 
XL VE UHMWPE wear debris to assess any reduction in cytokine release could be 
carried out in order to compare to the reduction in cytokine release by LPS stimulated 
cells treated with inflammatory pathway inhibitors and antioxidant compounds. 
Furthermore, other cytokines, MCSF and GM-CSF, which are implicated in osteolysis 
could have been assessed in response to treatment with UHMWPE wear debris. A 
potential weakness of the novel in vitro model is the use of a mouse cell line which is 
less representative than human primary cells. The use of U937 human histiocytes in 
this model could be developed further. Additionally, differentiated osteoclasts could be 
trialled in the model which could then be used to assess osteolysis directly using 
relevant assays, such as the TRAP assay.  
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Table 5.6 Summary table of different UHMWPE materials cultured with the 3D in vitro 
model and the subsequent cytokine (TNF-α, IL-1β, IL-6, KC, LTB4 and PGE2) 
and ROS release. ↑ indicates a significant increase in cytokine release. ↓ 
indicates a significant decrease in cytokine release and ✖ indicates no significant 
release of cytokine or ROS in comparison to the cells only negative control. 
 TNF-α IL-1β IL-6 KC LTB4 PGE2 ROS 
SS 1020 XL X X X X ↓  ↓  X 
SS 1020 XL 
AOX 
X X X X ↓  ↓  X 
SS 1050 XL X ↓  X X X X X 
SS 1050 XL 
VE 
X ↓  X X X X X 
6S 1020 XL ↓  ↑  X X X X X 
6S 1020 XL 
AOX 
↓  X X X X X X 
6S 1050 XL ↓  X X X X X X 
6S 1050 XL 
VE 
↓  X X X X X X 
Table 5.7 Summary table of different inhibitors and antioxidants cultured with the 3D 
in vitro model and the subsequent cytokine (TNF-α, IL-1β, IL-6, LTB4 and PGE2) 
release. ↑ indicates a significant increase in cytokine release. ↓ indicates a 
significant decrease in cytokine release and ✖ indicates no significant release of 
cytokine or ROS in comparison to the cells only negative control. 
 TNF-α IL-1β IL-6 LTB4 PGE2 
Calphostin C 250 ↓  ↓  ↓  ↓  ↓  
Calphostin C 500 ↓  ↓  ↓  X X 
Bisindolylmaleimide I 0.1 X ↓  ↓  ↓  ↓  
Bisindolylmaleimide I 1 ↓  ↓  ↓  X X 
MK 886 1 X ↓  X X X 
REV 5901 10 X ↓  X X X 
Indomethacin 10 X ↓  X X X 
Vitamin E ↓  ↓  ↓  X X 
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Hindered phenol ↓  ↓  ↓  X X 
 
5.7  Conclusion 
• GUR 1050 XL and GUR 1050 XL VE UHMWPE wear debris (full range of 
particle sizes) significantly reduced the release of IL-1β from RAW 264.7 
murine macrophages in collagen gel. GUR 1020 XL and GUR 1020 XL AOX 
UHMWPE wear debris (full range of particle sizes) significantly reduced the 
release of LTB4 and PGE2 from RAW 264.7 murine macrophages in collagen 
gel. The full size range of UHMWPE wear debris produced on the single station 
POP wear simulator rig (GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and 
GUR 1050 XL VE) had no significant effect on the release of TNF-α, IL-6 and 
KC from RAW 264.7 murine macrophages in collagen gel. This was not 
consistent with previous studies and it is difficult to ascertain the potential anti-
inflammatory effects (and their mechanism) of vitamin E and hindered phenols 
in an orthopaedic context from the data generated in this study.  
• GUR 1020 XL UHMWPE wear debris (0.1 – 1 µm) significantly elevated the 
release of IL-1β. GUR 1050 XL, GUR 1050 XL VE and GUR 1020 XL AOX 
UHMWPE wear debris (0.1 – 1 µm)  significantly reduced the release of TNF-α. 
UHMWPE wear debris filtered into the size range 0.1 – 1 µm (GUR 1020 XL, 
GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE) had no significant 
effect on the release of IL-6, KC, LTB4 and PGE2 from RAW 264.7 murine 
macrophages. This was not consistent with previous studies and it is difficult to 
ascertain the potential anti-inflammatory effects (and their mechanism) of 
vitamin E and hindered phenols in an orthopaedic context from the data 
generated in this study. 
• Treatment with Calphostin C and Bisindolylmaleimide I significantly reduced the 
release of TNF-α, IL-1β, IL-6, LTB4 and PGE2 in LPS stimulated RAW 264.7 
murine macrophages. Treatment with Vitamin E and Pentaerythritol tetrakis 
(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) significantly reduced the release of 
TNF-α, IL-1B, and IL-6 in LPS stimulated RAW 264.7 murine macrophages. 
Treatment with Indomethacin, MK 886 and REV 5901 significantly reduced the 
release of IL-1B in LPS stimulated RAW 264.7 murine macrophages. It is 
possible that vitamin E and Pentaerythritol tetrakis (3,5-di-tert-butyl-4-
hydroxyhydrocinnamate) exhibit anti-inflammatory behaviour by interacting with 
the PKC pathway in order to reduce the release of TNF-α and IL-6 whereas the 
antioxidants may act via a more general mechanism to reduce the release of 
IL-1β.   
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• GUR 1020 XL, GUR 1020 XL AOX, GUR 1050 XL and GUR 1050 XL VE 
UHMWPE wear debris created using the full size range and 0.1 – 1 µm did not 
produce a significant amount of ROS within RAW 264.7 murine macrophages 
in collagen gel in 24 hours.   
• Fluorescent imaging showed that highly cross-linked, antioxidant doped and 
highly cross-linked UHMWPE wear debris particles are uptaken by RAW 264.7 
murine macrophages and are located around the nucleus within the cytoplasm. 
Further imaging showed the co-localisation of FluoSpheres® within the 
lysosomes around the cell nucleus. The uptake and co-localisation of 
UHMWPE wear particles (and FluoSpheres®) is consistent with previous 
studies, which implies the presence of antioxidant compounds in the 
polyethylene structure does not affect the uptake and storage mechanism.  
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Chapter 6 
General discussion 
6.1  Original project aims 
The overall aim of this study was to develop a novel 3D in vitro model to assess 
cellular responses to UHMWPE wear debris that could aid with determining whether 
the presence of antioxidants, such as vitamin E and hindered phenols, in highly cross-
linked UHMWPE can reduce the release of osteolytic cytokines. 
Chapter 3 aimed to develop a novel 3D in vitro model to assess the cellular response 
to model polyethylene particles in order to address the problems associated with 
donor variation and dependence on cell penetration associated with the existing 2D 
method in order to enhance the reliability and repeatability of the model. 
Chapter 4 aimed to aseptically generate both highly cross-linked and antioxidant-
doped, highly cross-linked UHMWPE wear debris using both the single and six station 
wear simulator rigs to culture with the novel 3D in vitro model.  
Chapter 5 aimed to measure the cellular response to antioxidant doped, highly cross-
linked UHMWPE wear debris in the novel 3D in vitro model and compare the results to 
previous studies.  
6.2  Overall discussion 
Chapter 3 trialled various combinations of three cell types (PBMNCs, U937 human 
histiocytes and RAW 264.7 murine macrophages) in two different types of gel 
(agarose and collagen) in terms of the viability of each type of cell in each type of gel 
and the ability of each cell in each type of gel to release a significantly elevated 
amount of TNF-α upon stimulation with model polyethylene particles, Ceridust®, and 
FluoSpheres®; both of which have been shown to induce such a response in 
PBMNCs, U937 human histiocytes and murine peritoneal macrophages in previous 
studies by Green et al. (1998) and Matthews et al. (2000). This study found that none 
of the cell types experienced a reduction in cell viability upon culture in either agarose 
or collagen gel over 3 days. This study also found that not all cell and gel 
combinations tested were able to produce a significantly elevated release of TNF-α. 
Interestingly, the none of the cell types produced a significantly elevated release of 
TNF-α in response to model polyethylene particles in the critical size range 0.1 – 10 
µm (Green et al., 1998). Only >10 µm Ceridust® particles stimulated a significantly 
elevated release of TNF-α in PBMNCs in agarose, RAW 264.7 murine macrophages 
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in both agarose and collagen and non-transformed U937 human histiocytes in 
collagen. It is not clear why the critical size range of Ceridust® particles failed to 
stimulated a significant release of TNF-α as previous studies suggested they would. It 
is possible that the some critical size Ceridust® particles were trapped in the >10 µm 
fraction however characterisation studies were not carried out on the Ceridust® 
particles so it is not possible to evidence this either way. The primary objective of this 
chapter was to develop a novel in vitro model in order to address the issues of donor 
heterogeneity and cell penetration dependence associated with the previous model. 
To that effect, the use of PBMNCs were discontinued to remove donor heterogeneity. 
Additionally, the use of agarose gel was discontinued to allow the simultaneous 
encapsulation of cells and particles and remove the need for cells to penetrate the gel 
to access the particles. Finally, RAW 264.7 murine macrophages were chosen over 
U937 human histiocytes as the PMA treatment required to transform U937 human 
histiocytes into activated U937 human macrophages also inhibits the PKC pathway 
which was of interest in Chapter 5.  
Chapter 4 aseptically generated highly cross-linked and antioxidant doped, highly 
cross-linked UHMWPE wear debris for use in cell culture studies in Chapter 5. This 
was carried out using both single and six station multidirectional POP wear simulators. 
The particles generated were then isolated, imaged using FEGSEM and characterised 
according to size and volume distribution. Additionally, the particles and wear test 
lubricants were tested for microbiological and endotoxin contamination. All particles 
tested were free of microbiological and endotoxin contamination. The particles 
generated using the single station multidirectional POP wear simulator were used 
directly in cell culture studies to represent the full size range of particles found in vivo 
which range from several mm to 10 nm (Tipper et al., 2000). Prior to this a pooled 
sample of particles from each material generated on both types of wear simulator 
were isolated, imaged and characterised. All particle samples demonstrated the 
morphologies seen previously by studies such as Tipper et al. (2000); such as plate-
like particles and particle aggregates. The wear debris volumes and wear factors 
measured, especially for the materials tested on the six station multidirectional POP 
wear simulator, were very high; several times higher than demonstrated by Gowland 
(2014). This was attributed to the lack of optimal storage conditions; allowing the 
materials to undergo oxidative embrittlement after shelf aging. The size and volume 
distribution data revealed little similarity between particles of the same material 
generated using different wear simulator. Particles tended to be larger when 
generated using the single station rather than the six station multidirectional POP 
wear simulator. This difference in particle size was attributed to the difference in 
lubrication regimes between the two wear simulators. The particles generated using 
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the six station multidirectional POP wear simulator were filtered into the critical size 
range of 0.1 – 1 µm prior to cell culture.  
Chapter 5 assessed the release of inflammatory, osteolytic cytokines, chemokines 
and mediators in response to the UHMWPE wear debris generated (both the 
unfiltered, full size range and a filtered, critical size range of 0.1 - 1 µm) and treatment 
with inflammatory pathway inhibitors and antioxidant compounds from the novel in 
vitro model. Additionally, the release of ROS in response to the UHMWPE wear debris 
generated (both the unfiltered, full size range and a filtered, critical size range of 0.1 - 
1 µm) from the novel in vitro model was measured. Finally, the internal sequestration 
of the UHMWPE wear debris generated (filtered into the critical size range of 0.1 – 1 
µm) and FluoSpheres® within RAW 264.7 murine macrophages in collagen gel. 
Treatment of the novel in vitro model with all size ranges of UHMWPE wear debris 
produced no significant release of inflammatory, osteolytic cytokines, chemokines and 
mediators. This was not consistent with previous studies by Green et al. (1998), 
Matthews et al. (2000a, 2001) and Gowland (2014). Green et al. (1998) treated 
murine peritoneal macrophages with Ceridust® particles therefore the two studies are 
not necessarily directly comparable as the former used a different cell type and model 
low density polyethylene particles rather than UHMWPE wear debris. Similarly, both 
Matthews et al. (2000a, 2001) and Gowland (2014) used different cell types, PBMNCs 
and U937 human histiocytes, which may not be directly comparable with RAW 264.7 
murine macrophages. However all three previous studies are consistent with one 
another, suggesting that the model and particles used in the present study may be the 
outlier in terms of the inflammatory response observed. It is possible that the unusual 
material behaviour of UHMWPE (possibly owing to shelf aging) contributed to the 
observed release of inflammatory cytokines, chemokines and mediators.  
Treatment of LPS stimulated RAW 264.7 murine macrophages in collagen gel with 
Calphostin C, Bisindolylmaleimide I, Vitamin E and Pentaerythritol tetrakis (3,5-di-tert-
butyl-4-hydroxyhydrocinnamate) significantly reduced the release of TNF-α, IL-1β, IL-
6, LTB4 and PGE2 compared to LPS stimulated cells with no treatments; implying that 
antioxidants may achieve their anti-inflammatory activity through inhibition of the PKC 
pathway. This was consistent with previous studies by Devaraj and Jialal (1999) and 
Singh and Jialal (2004).  
Treatment of RAW 264.7 murine macrophages in collagen gels with all size ranges of 
UHMWPE wear debris produced no significant release of ROS. Gowland (2014) was 
able to show that the amount of intracellular ROS was less for PBMNCs treated with 
GUR 1050 XL VE in comparison to GUR 1050 XL however the present study was able 
to make no such distinction as all materials uniformly produced no significantly 
elevated levels of ROS. The present study carried out a quantitative ROS assay 
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whereas Gowland (2014) carried out a qualitative imaging study so it is difficult to 
directly compare the two studies. It is possible that imaging in the present study may 
have revealed more information. Additionally, a longer study i.e 3 or 5 days, may have 
been more appropriate to allow for maximum ROS production. It is possible that the 
suboptimal UHMWPE materials used may have impacted the intracellular ROS levels. 
Fluorescent imaging of UHMWPE wear debris internalised by RAW 264.7 murine 
macrophages in collagen did show that particles are perinuclear which is consistent 
with the findings of Gowland (2014). The present study was able to take this a step 
further by co-localising FluoSpheres® with lysosomes in RAW 264.7 murine 
macrophages.  
Overall the novel in vitro model developed during this study did not produce data 
consistent with previous cell-particle studies. This could  be due to the potential shelf 
aging issues associated with the UHMWPE materials used. It is also possible that the 
model itself is unsuitable for this particular application.  The effect of aged UHMWPE 
material is more likely to account for the inconsistent observations rather than lack of 
model suitability as the model did generate inflammatory responses consistent with 
previous studies by Singh and Jialal (2004) when treated with inflammatory inhibitors 
and antioxidant compounds rather than generated UHMWPE particles. It is possible 
that non-transformed U937 human histiocytes in collagen gel may have performed 
better in this context however these cells were not chosen owing to uncertainty 
regarding the maturity of the cells – non-transformed U937 human histiocytes are not 
true macrophages as they are at a more immature stage whereas RAW 264.7 murine 
macrophages are a more mature phenotype. 
6.3  Further work 
There were numerous areas in which this study could have been developed further 
with additional time and resources. In particular, the in vitro model chosen could have 
been improved further and the assays and reagents used to assess anti-inflammatory 
and antioxidant behaviour could have been optimised further. 
6.3.1  Development of a novel 3D in vitro model for measuring cellular 
responses to model polyethylene particles 
This study did have several limitations. Primarily, there was no data for U937 human 
histiocytes treated with model particles after 24 hours in either agarose or collagen 
gel. Unfortunately, this data was lost due to experimental error and the candidate 
made the decision not to repeat the assay for this time point due to time pressures 
and that this cell type was not being carried forward to the remaining parts of the 
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study. Future studies would repeat this time point to give a fuller picture as to how 
U937 human histiocytes in either agarose or collagen gel functions as a potential 
novel 3D model to measure cellular response to UHMWPE wear debris. Viability 
studies of PBMNC’s, U937 human histiocytes and RAW 264.7 murine macrophages in 
agarose and collagen gel could have been supplemented with live/dead staining and 
fluorescent imaging. This would have added an additional layer of confidence to the 
overall findings in addition to showing the distribution of cells throughout each type of 
gel (or lack of in some cases of agarose gel use).  
An additional limitation of this study was that no characterisation data, i.e. size and 
volume distribution, was obtained for the Ceridust® model polyethylene particles 
used. This was an oversight and would have provided more detail on the true size 
range of the particle fractions (>10 µm, 1 – 10 µm and 0.1 – 1 µm) used. It may have 
revealed why cells were producing TNF-α in response to >10 µm Ceridust® rather 
than those sizes in the critical size range determined by Green et al. (1998) which 
failed to generate a significant TNF-α response in any cell type. Future studies would 
obtain this characterisation data. It is possible that producing an inflammatory 
response to >10 µm Ceridust® particles rather than the expected critical size range of 
0.1 - 10 µm is a legitimate effect in a 3D model as opposed to 2D. The effect was 
certainly reproducible with RAW 264.7 murine macrophages in collagen gel however it 
would be prudent for all experiments showing this effect to be reproduced to assess 
its validity. 
Initial trials of the cell types and gel types used to create a novel in vitro model could 
have been conducted using artificially generated UHMWPE wear debris rather than 
model polyethylene particles. Moreover, the panel of cytokines tested could have 
been expanded to include IL-1β and IL-6, which are also common pro-inflammatory, 
osteolytic cytokines and may further inform which model is a more robust choice for 
use in this context. Further cell types, such as MG-63 osteoblasts (Vermes et al., 
2001) and macrophage cells that have been chemically transformed into osteoclasts, 
could have been trialled in these models to infer more direct information on the 
osteolytic pathway.  
Future studies could trial the use of non-transformed U937 human histiocytes in 
collagen gel (as treatment with PMA to transform them into activated macrophages 
inhibits the actions of PKC which may interfere with anti-inflammatory studies). Non-
transformed U937 human histiocytes could be treated with UHMWPE wear debris and 
compared to transformed U937 human macrophages for the production of a panel of 
inflammatory cytokines so assess whether they are capable of responding in the same 
manner to UHMWPE particles. The cell type is human and therefore preferable to a 
murine cell line for increased clinical accuracy however they remain immature without 
- 227 - 
treatment with PMA. It is also possible to use this model with PBMNC’s that have 
been magnetically cell sorted (MACS) using CD 14 and CD 68 macrophage markers 
in order to separate out the relevant phagocytic fraction (usually around 6% (Liu, 
2012)). 
In hindsight, in order to construct a suitable 3D in vitro model, the existing model 
should have been stripped back and each feature examined and optimised. This was 
attempted in the present study in terms of trialling new types of gel and new cell types 
however, upon reflection, this was not detailed enough. The optimal cell seeding 
density and particle doses in 3D should have been examined in addition to optimising 
the time points used for ELISA analysis. It is possible that longer culture times were 
needed for the 3D model to show any effects in terms of inflammatory cytokine and 
chemokine release. The present study used the cell seeding density established in the 
existing 2D in vitro model however the volume of the gel ought to have been 
accounted for (rather than simply the 2D area). Since the present study used a cell 
seeding density of 1 x 105 cells in an area of 0.95 cm2, this ought to have been 
multiplied by itself and the depth of the well (0.2 cm) in order to estimate a cell 
seeding density (1.9 x 109 cells per well). 
6.3.2  Generation, isolation and characterisation of antioxidant doped, highly 
cross-linked ultra-high molecular weight polyethylene wear debris 
There were a number of limitations to this study. Since the primary objective of this 
chapter was not to determine wear performance data for the materials used, certain 
measurements were not obtained. The surface roughness of the CoCr plates used 
were not obtained using Talysurf before and after each test. Future studies would 
obtain these measurements as they may have provided further insight, such any 
potential differences between individual plates, as to the unusually high wear debris 
volumes and wear factors observed during this study. Moreover, EDX analysis of the 
UHMWPE wear debris was not performed when obtaining FEGSEM images of the 
particles. Future studies would perform EDX analysis as this may reveal any usual 
elemental peaks that may relate to the oxidation of the bar stock. The main limitations 
to this study were the age and storage conditions of the UHMWPE materials used. 
The shelf aging in oxidative conditions over several years could have decreased the 
wear resistance of the UHMWPE materials and resulted in the high volume of wear 
debris and large wear factors observed. Future studies would be improved by 
obtaining fresh UHMWPE bar stock or pins from industrial collaborators. Additionally, 
the correct storage of UHMWPE materials in vacuum packaging at -80°C, to prevent 
oxidation, would remove shelf aging and oxidation as a potential variable in future 
studies. Similarly, there was a lack of highly cross-linked UHMWPE bar stock so virgin 
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UHMWPE bar stock was sent for commercial irradiation treatment. The dose (9.39 
MRad) was slightly different from the 10 MRad GUR 1050 XL and 8 MRad GUR 1020 
XL clinical materials. This slight difference is unlikely to have accounted for the high 
wear debris volumes and wear factors however irradiating already aged UHMWPE 
may have increased the deterioration of the materials. In addition, any air trapped in 
the vacuum packaging may have contributed to this deterioration. As before, future 
studies would source already cross-linked and sterilised UHMWPE material to ensure 
these processes had taken place under optimal conditions so as not to influence any 
future data. Additionally, obtaining industrial materials would provide the necessary 
information on whether the bar stock had been remelted or annealed following 
irradiation and also whether the antioxidant was blended or diffused. These processes 
can also affect the mechanical behaviour of UHMWPE and may have influenced the 
results obtained in this study.  
The size and volume distribution of the particles generated in this study were 
compared to existing data from previous studies, where possible, in order to validate 
the particles produced. However, much of the necessary data does not exist as highly 
cross-linked, antioxidant doped UHMWPE materials are still relatively new. There is 
data concerning the wear rates of such material but not the specifics regarding the 
size and volume distribution of the particles. It would have been even more useful to 
compare the size and volume distribution data of the particles produced in this study 
to similar data obtained from retrieval studies of identical materials however, as highly 
cross-linked, antioxidant doped UHMWPE materials are still relatively new and clinical 
studies often take upwards of 10 years, such data is not yet in existence.  
Future studies would trial the generation of sterile UHMWPE wear debris using the six 
station multidirectional POP wear simulator with lubricant containing FBS in order to 
maintain a constant lubrication regime between simulators. Moreover, retrieved 
UHMWPE wear debris is typically coated with adhered proteins which can affect the 
inflammatory response to the particles therefore the addition of FBS to debris 
generated using the six station multidirectional POP wear simulator would increase 
the relevance of the particles tested. 
Virgin UHMWPE (GUR 1020 and GUR 1050) could be included in future studies as a 
further control to distinguish between the biological response to cross-linked and non-
cross-linked UHMWPE.  
Additionally, it would be useful to assess experimental antioxidant doped UHMWPE 
materials, such as anthocyanin doped UHMWPE (acquired through collaboration), 
alongside clinically available vitamin E and hindered phenol UHMWPE. 
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Finally, future studies would assess the size and volume distribution of the filtered, 
critical size range (0.1 – 1 µm) in addition to the pre-fractionated particles in all size 
ranges in order to obtain the true size and volume distribution of the fractionated 
particles used with which to greater elucidate the in vitro response to such particles. 
6.3.3  Assessing the anti-inflammatory and antioxidant effects of antioxidant 
doped, highly cross-linked ultra-high molecular weight polyethylene wear 
debris using a novel 3D in vitro model 
Overall, it was not clear whether the model developed in this study was appropriate to 
take forward in to future work. In order to assess this, further developments could be 
made to the model. The particle dose could be increased to 500 µm3 which may result 
in a significant increase or reduction in the production of inflammatory cytokines. 
Gowland (2014) demonstrated that PBMNCs treated with 500 µm3 of UHMWPE wear 
debris were more likely to release a significant amount of TNF-α than those treated 
with 100 µm3 of UHMWPE wear debris. The present study was not able to treat cells 
with an increased dose of UHMWPE particles as the volume of lubricant required was 
too large and would have reduced the integrity of the collagen gels used to 
encapsulate the particles. In hindsight, a higher dose of particles could have been 
achieved by re-filtering the particles into a smaller volume although this would risk loss 
of particles when transferring between vessels. Moreover, it is difficult to resuspend 
UHMWPE in very small volumes as the UHMWPE particles are hydrophobic so all 
particles may not be incorporated into the cell culture medium. Future work could 
develop an approach to allow the encapsulation of larger volumes of UHMWPE wear 
debris without negatively impacting the collagen gel integrity. The test time on the 
wear simulators could be increased and the volume of lubricant allowed to evaporate 
towards the end of the test in order to increase the particle concentration whilst 
reducing the volume of lubricant present. It is possible that the lack of inflammatory 
response to the critical size range of UHMWPE particles and occasional response to 
particles greater than 10 µm was a real effect of the 3D model as opposed to the 2D 
model; in which case, fresh clinical material ought to be sought and the experiments 
repeated to validate the effect and remove any concern than a lack of response is due 
to the aging of the material.  
An additional study treating LPS stimulated RAW 264.7 murine macrophages with 
GUR 1020 XL, GUR 1050 XL, GUR 1020 XL AOX and GUR 1050 XL VE UHMWPE 
wear debris to assess any reduction in cytokine release could be carried out in order 
to compare to the reduction in cytokine release by LPS stimulated cells treated with 
inflammatory pathway inhibitors and antioxidant compounds. Furthermore, other 
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cytokines, such as MCSF and GM-CSF, which are implicated in osteolysis could have 
been assessed in response to treatment with UHMWPE wear debris.  
It is clear that this study would have benefitted from further optimisation of the assays 
used to assess anti-inflammatory and antioxidant behaviour of UHMWPE wear debris 
used to treat the in vitro model developed herein. Future studies would repeat the 
ROS assay over 3 and 5 days in order to assess whether a longer time frame is 
needed to observe the presence of ROS in RAW 264.7 murine macrophages following 
UHMWPE particle treatment. Additionally, future studies would include cells plus 
TBHP plus particle treatment conditions in order to assess whether the antioxidants 
present (or not) in the UHMWPE wear debris quench ROS synthesis and reduce the 
levels of ROS observed. Moreover, future studies could have viewed the plate using 
microscopy to provide qualitative images showing intracellular ROS levels. Future 
studies would assess multiple concentrations of sodium fluorescein used to 
fluorescently tag the UHMWPE wear debris. The concentration used in this study may 
not have been sufficient hence the lack of visible UHMWPE wear debris in the 
microscopy images. Finally, ELISA was used to assess the production of inflammatory 
cytokines at 12 and 24 hour post particle treatment. Additional time points, such as 36 
and 48 hours, could have been introduced in order to assess cytokine production over 
longer periods of time. Furthermore, LPS was used as a positive control in ELISA 
studies however, in several instances, RAW 264.7 murine macrophages treated with 
LPS failed to produce significantly increased release of inflammatory cytokine, 
chemokine or mediator. Future studies would trial LPS alongside other possible 
positive control substances, such as Camptothecin, to assess which compound was 
able to perform most effectively as a positive control.  
A potential weakness of the novel in vitro model is the use of a mouse cell line which 
is less representative than human primary cells. This could be addressed by trialling 
the use of non-transformed U937 human histiocytes as discussed previously. It is also 
possible to use human PBMNC’s differentiated into osteoclasts (although donor 
heterogeneity would still be problematic) or RAW 264.7 murine macrophages 
differentiated into murine osteoclasts. The model could then be used to assess 
osteolysis directly using relevant assays, such as the TRAP assay.  
A novel 3D in vitro model could also be used to assess the potential anti-inflammatory 
effect of antioxidant doped UHMWPE at the genetic level using PCR to assess the 
downstream effect on genetic expression of inflammatory cytokines, such as TNF-α. 
Moreover, the antioxidant effect could also be assessed at the genetic level by 
assessing the up or down regulation of common oxidative damage genes; HIF-1α, 
SOD 1/2/3 and OXR 1/2.  
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Finally, it would be useful to use the novel 3D in vitro model developed during this 
study for the basis of an in vitro model to directly assess osteolysis by culturing 
osteoclasts (transformed macrophage cells – primary or cell line) onto calcium 
hydroxyapatite discs and treating with UHMWPE wear debris. The discs could be 
assessed with micro-CT to account for volumetric changes in the disc which could 
inform how osteolytic different types of UHMWPE are.  
6.4  Conclusion 
• This study began to develop a 3D representation of local macrophages in the 
periprosthetic environment to model the cellular response to UHMWPE wear 
debris.  
• The novel model developed in this study attempted to encapsulate UHMWPE 
wear debris with RAW 264.7 murine macrophages to create a 3D in vitro model 
composed of ECM material; collagen.  
• RAW 264.7 murine macrophages were able to take up and sequester 
UHMWPE wear debris and FluoSpheres® in the lysosomes as demonstrated in 
PBMNC’s in previous studies by Gowland (2014) and Liu (2012). 
• The novel model developed in this study demonstrated the link between 
proposed anti-inflammatory behaviour of Vitamin E and hindered phenol 
compounds and the PKC inflammatory pathway.  
• However, issues with suboptimal storage and treatment of UHMWPE bar stock 
prior to wear generation resulted in a skewed distribution of larger particles. 
• Cells incubated with generated UHMWPE wear debris failed to produce the 
patterns of cytokine release observed in a previous study by Gowland (2014). 
• The model developed requires significant optimisation; particularly transitioning 
from 2D into 3D, the cell seeding density, particle dose and culture times 
require further optimisation.  
• Fresh clinical UHMWPE material would also be required for future studies in 
order to ensure the UHMWPE particles produced were clinically relevant and 
add confidence to any response or lack thereof being a true and accurate effect 
of the 3D model. 
• Culturing LPS stimulated cells with generated UHMWPE wear debris in this 
model could further strengthen any potential link between the anti-inflammatory 
behaviour of antioxidant doped, highly cross-linked UHMWPE and the PKC 
inflammatory pathway.  
• Furthermore, this model could be adapted to include osteoclasts for direct 
osteolysis studies; for example the TRAP assay. 
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• 3D in vitro collagen gel models, allowing simultaneous cell and particle 
encapsulation, could provide valuable insight into the chemical and genetic 
mechanisms of the potential anti-inflammatory and antioxidant behaviour of 
antioxidant doped, highly cross-linked UHMWPE which may further inform 
UHMWPE material development with alternative antioxidant compounds.  
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